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Summary 
 
Obesity is a complex condition associated with an increased risk of multiple comorbidities 
and endocrine abnormalities, including thyroid dysfunction. Recently, there has been 
increasing interest toward the association between thyroid function and obesity. 
Therefore, this thesis aims to investigate the complex metabolic phenotypes of obesity on 
one side and thyroid disorders on the other, then converging to the study of the crosstalk 
between these conditions. 
Severe obesity is characterized by highly variable degrees of metabolic dysfunction. 
Insulin resistance is a common factor that, per se, predisposes to metabolic abnormalities 
and a chronic proinflammatory state. Beyond the well-known detrimental effects of 
chronic inflammation on cardio-metabolic health, our interest primarily focused on the 
characterization of multiple molecules and we documented a new role for ANGPTL8, 
vitamin D, uric acid and oxytocin in association with the metabolic setting and 
comorbidities related to obesity. 
There is consistent evidence that adipose tissue accumulation and fat partitioning 
potentially interfere with thyroid tumorigenesis and function. In studying exogenous and 
endogenous factors involved in differentiated thyroid cancers (DTC) phenotypes, our 
analysis on two geographically distinct populations with DTCs show that many 
environmental factors could influence thyroid cancer histopathological features and 
clinical behaviour. Subsequently, in assessing the role of metabolic determinants on DTC 
features in the general population, we also obtained preliminary evidence of a potential 
key role for insulin resistance and pro-inflammatory adipokines on clinical profile of DTCs.  
We then addressed the association between obesity and thyroid function in multiple 
ways, and showed that the metabolic milieu of obesity, as well as body weight changes, 
can significantly impact thyroid hormone levels via interactions with body composition. 
Retrospective analyses also allowed us to evaluate the effect of obesity on thyroid 
replacement therapy in obese hypothyroid patients, confirming the complex interplay 
linking obesity and thyroid function, both in health and in disease. 
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All the above-mentioned results were published or are submitted for publication in 
international peer-reviewed scientific journals, hoping to contribute to expand current 
knowledge on the crosstalk between obesity and the thyroid gland. 
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Sommario 
 
L͛oďesità è uŶa ĐoŶdizioŶe clinica complessa, associata ad un rischio aumentato di 
sviluppare numerose comorbidità e disfunzioni endocrine, tra cui quelle tiroidee. 
Recentemente si è sviluppato un cresceŶte iŶteƌesse ĐiƌĐa l͛assoĐiazioŶe tƌa fuŶzioŶe 
tiroidea e obesità. Pertanto, questa tesi ha lo scopo di indagare, da un lato, la complessità 
dei diǀeƌsi feŶotipi ŵetaďoliĐi assoĐiati all͛oďesità e, dall͛altƌo, le patologie tiroidee, per 
poi studiare l͛associazione fra le due condizioni. 
L͛oďesità seǀeƌa è Đaƌatteƌizzata da diversi gradi di alterazioni ŵetaďoliĐhe. L͛iŶsuliŶo-
resistenza è un fattore comune che, di per sé, predispone a disordini metabolici e ad uno 
stato pro-infiammatorio cronico. Oltre che sui Ŷoti effetti daŶŶosi dell͛iŶfiaŵŵazioŶe 
cronica sulla salute cardio-metabolica, il nostro interesse si è focalizzato principalmente 
sulla caratterizzazione di diverse molecole attribuendo un nuovo ruolo ad ANGPTL8, 
vitamina D, acido urico e ossitocina nell͛interazione con il profilo metabolico e le 
comorbilità associate all͛oďesità. 
Esistono prove consistenti del fatto che l'accumulo di tessuto adiposo e la sua 
distribuzione siano potenzialmente in grado di interferire con la tumorigenesi e la 
funzione tiroidea. Nello studio di fattori esogeni ed endogeni coinvolti nei fenotipi del 
carcinoma differenziato della tiroide (CDT), le nostre analisi su due popolazioni di pazienti 
geograficamente distinte, affette da CDT, mostrano che diversi fattori ambientali possono 
influenzare le caratteristiche istopatologiche e il comportamento clinico dei tumori 
tiroidei. 
Successivamente, nel valutare il ruolo dei determinanti metabolici sulle caratteristiche del 
CDT nella popolazione generale, abbiamo ottenuto risultati preliminari circa il potenziale 
ruolo chiave dell'insulino-resistenza e delle adipochine pro-infiammatorie nel 
determinare il profilo clinico dei CDT. 
Abbiamo poi studiato l'associazione tra obesità e funzione tiroidea su diversi livelli, 
dimostrando che il setting metabolico dell'obesità, così come le variazioni del peso 
corporeo, possono avere un impatto significativo sui livelli degli ormoni tiroidei attraverso  
molteplici interazioni con la composizione corporea. 
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Alcune analisi retrospettive ci hanno inoltre consentito di valutare l'effetto dell'obesità 
sulla terapia sostitutiva con LT4 in pazienti obesi ipotiroidei, confermando l͛esisteŶza di 
una complessa interazione tra obesità e funzione tiroidea, sia in condizioni normali che 
patologiche. 
Tutti i risultati sopra menzionati sono stati pubblicati o sono in fase di pubblicazione su 
riviste scientifiche internazionali, ĐoŶ l͛iŶteŶto di contribuire ad ampliare le conoscenze 
attuali sull͛assoĐiazioŶe tra obesità e tiroide. 
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General Introduction 
 
Obesity is one of the most important health risks of our time. The prevalence of obesity 
has increased worldwide since the mid 1970s. Obesity is associated with an increased risk 
of diabetes, dyslipidemia, cardiovascular disease, sleep apnea, cancer and all-cause 
mortality (Golden 2009). Moreover, severe obesity is an important cause of premature 
mortality among middle-aged adults (Mehta 2009). Importantly, obesity, especially 
central obesity, is linked to many endocrine abnormalities (Kokkoris 2003), including 
thyroid dysfunction (Reinehr 2010). 
Recently, there has been increasing interest toward the association between thyroid 
function and obesity. Based on the notion that triiodothyronine (T3) controls metabolic 
and energy homeostasis influencing body weight, thermogenesis, lipolysis and 
metabolism of cholesterol, and that thyroid-stimulating hormone (TSH) induces 
differentiation of preadipocytes into adipocytes and adipogenesis, thyroid function has 
been extensively investigated in obese adults (Laurberg 2012, Biondi 2010). An elevated 
level of TSH with normal peripheral thyroid hormone concentration, potentially 
suggesting the occurrence of subclinical hypothyroidism, has been consistently found in 
obese subjects. Several mechanisms leading to hyperthyrotropinemia in obesity have 
been hypothesized, including subclinical hypothyroidism caused by iodine deficiency, 
autoimmune thyroiditis, mutations in TSH-R gene or stimulatory effects of leptin, the 
main adipocytokine, on TRH secretion (Santini 2014). Moreover, several metabolic 
outcomes have been related to TSH elevation. In fact, TSH increase was shown to be 
associated with increased cholesterol and triglycerides and with decreased HDL-C. 
Moreover, thyroid hormones are important determinants of glucose homeostasis. In fact, 
increased thyroid hormone levels impair the ability of insulin to suppress hepatic glucose 
production and increase glucose uptake in muscles (Mullur 2014). The presence of insulin 
resistance, which is a major component of obesity, was found to be associated with an 
increased thyroid volume and is an independent risk factor for thyroid nodule formation 
(Rezzonico 2008, Ayturk 2009, Yasar 2011). Furthermore, the prevalence of insulin 
resistance is reckoned as a potential risk factor for thyroid tumorigenesis (Rezzonico 2009, 
Marcello 2014), as well as for some non-thyroid cancers (Djiogue 2013). 
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The increased TSH levels and concomitant changes in thyroid hormone levels, with FT3 
levels that are usually in the upper normal range and FT4 levels in the lower normal range 
of obese subjects, may reflect an adaptation process aiming to increase energy 
expenditure and control further weight gain (Reinehr 2010). Therefore, the changes of 
thyroid hormones concentration may be regarded as a consequence rather than a cause 
of obesity.  
 
Aim of this thesis 
 
Reflecting the doctoral research activity in the fields of obesity, thyroid diseases and their 
two-way interaction, this thesis aims to describe the results of studies on: 
- Phenotypes, complications and treatments of obesity and metabolic disorders. 
- Thyroid dysfunction and cancer in relation to metabolic setting and risk factors. 
- The crosstalk between obesity and thyroid function.  
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CHAPTER 1 
 
Obesity and metabolic disorders:  
Phenotypes, complications and treatments 
 
SEVERE OBESITY: 
METABOLIC FEATURES, PHENOTYPES AND COMPLICATIONS 
 
Introduction 
 
The prevalence of obesity has increased dramatically in the last decades and is now 
considered a major health problem (Flegal 2010). In fact, the current epidemic of obesity 
has been reported as the leading cause for the decreased life expectancy forecast for the 
next generation (Lavie 2009). Worldwide, the prevalence rate for being overweight or 
obese between 1980 and 2013 increased 27.5% for adults and 47.1% for children, for a 
total of 2.1 billion individuals considered overweight or obese (Ng 2014). Body mass index 
(BMI), which is weight in kilograms divided by height in meters squared, is used to 
identify obesity. For adults, a BMI of 25.0 to 29.9 kg/m2 is defined as overweight and a 
BMI of 30 kg/m2 or higher is defined as obese (Jensen 2014). For every 5-unit increase in 
BMI above 25 kg/m2, overall mortality increases by 29%, vascular mortality by 41%, and 
diabetes-related mortality by 210% (Whitlock 2009). 
Patients with obesity are at increased risk of morbidity from hepatic steatosis,  
hypovitaminosis D,  dyslipidemia, type 2 diabetes, hypertension, cardiovascular diseases, 
respiratory problems, sleep apnea, osteoarthritis, and some cancers (Jensen 2014). 
 
Aiming to explore the metabolic features, phenotypes and complication of severe obesity, 
the doctoral activity was focused on the following subjects: 
- ANGPTL8 and liver steatosis in obesity and the Prader Willi syndrome (PWS) 
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- A role for adiponectin oligomers in modulating Vitamin D effects on glucose 
homoeostasis and insulin sensitivity in obesity 
- Uric acid as a potential new marker of positive energy states in obesity  
- Circulating oxytocin across menopause in the lean and obese state 
- A rare case of endocrine-dependent obesity and related therapeutic strategies. 
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Abstract 
 
Background. ANGPTL8 is a liver-derived protein related to insulin-sensitivity. Its 
relationship with obesity and liver function in Prader-Willi syndrome (PWS) is unknown. 
The present study investigated circulating ANGPTL8 in PWS and controls with common 
obesity, assessing its association to liver steatosis. 
 
Methods. For this purpose, 20 obese PWS and 20 controls matched for body mass index 
(BMI), sex and age underwent analysis of ANGPTL8 levels, glucose and lipid metabolism. 
Liver function tests and degree of liver steatosis by ultrasonography (US), fat-free mass 
(FFM) and fat mass (FM) by dual-energy x-ray absorptiometry (DEXA) were also assessed. 
 
Results. In comparison to controls, obese PWS showed lower values of FFM (p<0.0001) 
and higher FM (p=0.01), while harbouring higher HDL cholesterol, lower triglycerides and 
OGTT-derived insulin levels, as well as a lower prevalence and severity of liver steatosis. 
With respect to obese controls, ANGPTL8 levels were significantly lower in PWS (p=0.007) 
and overall correlated with transaminase levels and the severity of liver steatosis, as well 
as FFM (p<0.05 for all). By a stepwise multivariable regression analysis, ANGPTL8 levels 
were independently predicted by PWS status (p= 0.01) and liver steatosis (p<0.05). 
 
Conclusions. ANGPTL8 levels are lower in PWS than obese controls and are inversely 
associated with the severity of liver steatosis. Further studies should investigate the 
potential genetic basis for this observation. 
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Background 
 
Prader-Willi syndrome (PWS) is an imprinted neurobehavioral condition caused by the 
lack of expression of genes located on the paternal chromosome 15q11.2-q13. There are 
three main genetic subtypes in PWS: paternal 15q11-q13 deletion (65–75% of cases), 
maternal uniparental disomy of chromosome 15 (UPD15) (20–30% of cases), and 
imprinting defects (1–3%) (Angulo 2015). The smallest deletions discovered to date 
demonstrate that the SNORD116 snoRNA gene cluster can explain much of the PWS 
phenotype (Hasan 2016). Clinically, PWS is characterized by neonatal hypotonia and 
failure to thrive, cognitive and behavioural disorders, endocrine defects such as short 
stature and hypogonadism, autonomic dysregulation. PWS is tipically associated with a 
lack of satiety, which generates obsessive craving for food and results in extreme obesity 
by the adult age (Cassidy 2009). 
Adult patients with PWS show peculiar body and metabolic features. Compared to BMI-
matched controls, PWS patients harbour a predominant accumulation of subcutaneous 
adipose tissue, with lower accumulation of visceral adipose tissue than that observed in 
patients with common obesity (Goldstone 2001, Goldstone 2002, Tanaka 2013). In 
addition, lean body mass and muscle function is impaired (Lafortuna 2014), and results in 
reduced resting energy expenditure (REE) and decreased voluntary activity (Butler 2007). 
Despite this unfavourable body composition, the metabolic phenotype of PWS is 
characterized by lower insulin levels and higher insulin sensitivity as opposed to obese 
controls (Talebizadeh 2005, Schuster 1996), while dyslipidaemia rarely occurs in PWS 
(Sanchez-Ortiga 2012). Although the molecular mechanisms driving this peculiar 
metabolic profile are not well understood, it can be hypothesized that the elevation of 
orexigenic hormones, such as ghrelin (Goldstone 2004, Prodam 2009), and different 
expression of adipocytokines (Pagano 2005), particularly adiponectin (Kennedy 2006), 
could intervene to regulate the metabolic profile of PWS adults (Lacroix 2015). 
A recently identified liver protein, angiopoietin-like 8 (ANGPTL8), has been described to 
be involved in different metabolic pathways related to glucose and lipid metabolism 
(Tseng 2014a, Tseng 2014b, Rong Guo 2016). As summarized by Tseng et al., several 
researchers have investigated the subcellular localization of ANGPTL8, demonstrating that 
its cytoplasmic vesicle-like distribution is likely involved in the lipid regulation pathway 
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(Tseng 2014a). Serum ANGPTL8 has been detected in sera from humans and mice, with 
its levels found to be positively correlated with triglycerides (TG) and very low-density 
lipoprotein (VLDL) levels (Tseng 2014b). Intracellular ANGPTL8 is associated with lipid 
droplets, suggesting that ANGPTL8 may serve as a lipoprotein and could be secreted or 
taken up with a lipid-associated compartment (Tseng 2014b). 
Regarding its function/s in glucose homeostasis, ANGPTL8 might be key in regulating 
postprandial glucose metabolism. In fact, liver ANGPTL8 over-expression in mice increases 
insulin-mediated synthesis of glycogen (Rong Guo 2016). Moreover, it is able to promote 
the suppression of key enzymes involved in gluconeogenic pathways, thereby improving 
insulin resistance (Rong Guo 2016). 
To date, the metabolic significance of ANGPTL8 in human obesity and obese patients with 
PWS is unknown. As such, this study was designed to investigate the relationship 
between ANGPTL8 levels and adiposity, metabolic homeostasis and liver steatosis in 
association with obesity and the PWS condition. 
 
Methods 
 
Patients 
 
This study enrolled 40 patients, consisting of 20 PWS adults with obesity (10 F/10 M; age, 
34.2±7.6 years; BMI, 45.5±9.4 kg/m2) and 20 BMI-matched control subjects (10 F/10 M; 
age, 35.0±8.3 years; BMI, 48.6±10.2 kg/m2), referred to our institution for work-up and 
rehabilitation of obesity and its comorbidities. All PWS individuals received a diagnosis 
based on typical syndromic features confirmed by molecular genetic studies of 
chromosome 15, including 15q11-q13 deletion in 16 (10 males and 6 females) and UPD15 
in the remaining 4 females. Exclusion criteria included any liver disease except for newly 
diagnosed steatosis, kidney failure, autoimmune diseases, uncontrolled hypothyroidism 
and/or diabetes mellitus, exposure to glucocorticoids or alcohol consumption. With 
respect to hormone replacement therapy in PWS, 9 patients were treated with rhGH, 2 
female patients with estrogens and 2 patients with levothyroxine. Four PWS patients 
were treated with psychotropic medications. The experimental procedure was approved 
by the ad hoc Ethical Research Committee of the Istituto Auxologico Italiano, Verbania, 
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Italy. A written informed consent was obtained from the PWS patients and their parents 
or guardians, and from the obese participants. The study protocol conformed to the 
guidelines of the European Convention on Human Rights and Biomedicine concerning 
biomedical research. 
 
Body measurements and instrumental tests  
 
All subjects underwent body measurements wearing light underwear, in fasting 
conditions after voiding. Weight and height were measured to the nearest 0.1 kg and 0.1 
cm, respectively, using standard methods. BMI was expressed as body mass (kg)/height 
(m)2. Obesity was defined for any BMI over 30 kg/m2 (WHO 2000). Waist circumference 
(WC) was measured midway between the lowest rib and the top of the iliac crest after 
gentle expiration; hip measurements were taken at the greatest circumference around 
the nates. 
A dual-energy x-ray absorptiometry (DEXA; GE Lunar, Madison, WI, USA) was performed 
for the assessment of body mass. This was expressed as lean body mass in kilograms and 
fat body mass as the percentage of total body mass. 
The REE was expressed in kilocalories/24 h and determined in a thermoregulated room 
(22–24°C) by computed open-circuit indirect calorimetry, measuring resting oxygen 
uptake and resting carbon dioxide production by a ventilated canopy (Sensormedics, 
Milan, Italy) at 1-min intervals for 30 min, expressed as 24 h value. 
In order to assess the presence and severity of liver steatosis, liver US was performed by 
the same operator who was blinded to the laboratory and clinical data at the time of the 
procedure, using a high-resolution US system (LOGIQ 7, GE Healthcare, Waukesha, WI, 
USA). The degree of hepatic steatosis was assessed semi-quantitatively on the basis of 
hepatorenal echo contrast, liver brightness, deep attenuation and vascular blurring. Liver 
steatosis was established by a validated method of US grading (categorized as: 
G0=absent; G1=mild; G2=moderate, G3=severe steatosis) (Shannon 2011), to accomplish 
for the subjective difficulties of PWS patients to undergo invasive or radiological 
assessment (MRI) where patieŶts͛ ĐollaďoƌatioŶ ǁas Ŷeeded. 
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Laboratory tests 
 
Blood saŵples ǁeƌe dƌaǁŶ uŶdeƌ fastiŶg ĐoŶditioŶs, ĐeŶtƌifuged, aŶd stoƌed at −ϴϬ °C 
until required. 
Serum ANGPTL8 levels were assessed using a commercially available human EIA kit 
(Phoenix Pharmaceutics, Inc, Burlingame, CA, USA). The assay procedure was performed 
in accordance ǁith the ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtions. All samples were analyzed in 
duplicate. Intra-assay CV and inter-assay CV of ANGPTL8 were less than 10% and 15% 
respectively. Minimum detectable concentration was 0.12 ng/mL. Furthermore, the EIA 
was specific for human ANGPTL8. In addition, quality controls were included in all EIA 
measurements with the results within the expected range. 
Routine laboratory data included levels of C-reactive protein, alkaline phosphatase, 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl 
transpeptidase (GGT), glucose, total cholesterol, high-density (HDL) and low-density 
lipoprotein (LDL) cholesterol, triglycerides (TG) and glycated haemoglobin (HbA1c), 
measured by enzymatic methods (Roche Diagnostics, Mannheim, Germany). Levels of 
insulin were measured using a Cobas Integra 800 Autoanalyzer (Roche Diagnostics, 
Indianapolis, IN, USA). Ultrasensitive C-reactive protein (CRP) was measured by CRP 
(latex) HS Roche kit. 
Glucose homeostasis was evaluated by oral glucose tolerance test (OGTT) in all subjects 
and glucose tolerance was expressed, according to ADA recommendations (ADA 2012), as 
normal fasting plasma glucose (FPG) if <100 mg/ dl (5.6 mmol/l); impaired FPG (IFG) if 
FPG was 100–125 mg/dl (6.9 mmol/l); impaired glucose tolerance (IGT) if 2-h post-OGTT 
plasma glucose was 140–199 mg/dl (7.8–ϭϭ.Ϭ ŵŵol/lͿ; TϮDM if FPG ǁas шϭϮϲ ŵg/dl ;шϳ 
mmol/l) two days apart, or if 2-h post-OGTT plasŵa gluĐose ǁas шϮϬϬ ŵg/dl ;шϭϭ.ϭ 
mmol/l). HbA1c values of 5.7 and 6.5% were considered as the threshold of normal 
glucose metabolism and T2DM, respectively. 
Matsuda (Matsuda 1999, De Fronzo 2010) and Stumvoll (Stumvoll 2000) indexes were 
used to measure insulin sensitivity obtained from plasma glucose and insulin 
concentrations during the oral glucose tolerance test (OGTT). The Matsuda index provides 
a reasonable index of whole-body insulin sensitivity (Matsuda 1999, De Fronzo 2010) and 
was calculated using the following formula: 10,000/square root of [(fasting glucose × 
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fasting insulin) × (glucose × insulin at time 120 min during OGTT)]. The Stumvoll index is a 
pƌediĐtoƌ of iŶdiǀidual͛s iŶsuliŶ seŶsitiǀitǇ aŶd β-cell function (Stumvoll 2000) and was 
calculated using the following formula: Ϭ.ϭϱϲ − ;Ϭ.ϬϬϬϬϰϱϵ × iŶsuliŶ at tiŵe ϭϮϬ ŵiŶ 
duƌiŶg OGTTͿ − ;Ϭ.ϬϬϬϯϮϭ × fastiŶg iŶsuliŶͿ − ;Ϭ.ϬϬϱϰϭ × gluĐose at tiŵe ϭϮϬ ŵin during 
OGTT). 
Insulin resistance was calculated by the homeostatic model of insulin resistance (HOMA-
IR) index: insulin (mIU/L) × [glucose (mmol/L)/22.5] (Matthews 1985). A HOMA-IR value 
greater than 2.0 was considered indicative of insulin resistance, as obtained in a sample 
of the Italian population (Bonora 2000). The hoŵeostatiĐ ŵodel of β Đell fuŶĐtioŶ ;HOMA-
B) was used to describe the functionality of pancreatic beta cells and calculated using the 
folloǁiŶg foƌŵula: ϮϬ × [iŶsuliŶ ;ŵIU/LͿ/gluĐose ;ŵŵol/LͿ − ϯ.ϱ] (Matthews 1985). 
 
Data analysis 
 
Statistical analysis was performed using SPSS version 18 (Somers, NY, USA). Values are 
expressed as means ± standard deviation (SD). For comparative analysis, ANOVA between 
the 2 groups and paired-T test intra-groups were used. For comparative analysis of 
ANGPTL8 levels across liver steatosis categories, Kruskall-Wallis test ǁith DuŶŶ͛s 
ĐoƌƌeĐtioŶ ǁas used. PeaƌsoŶ͛s ĐoƌƌelatioŶ aŶalǇsis aŶd the Chi sƋuaƌe ǁeƌe used to 
identify significant associations between variables of interest. Stepwise multivariate 
regression analysis was used to evaluate the independent association of variations in 
ANGPTL8 with metabolic, anthropometric or biochemical parameters. The multilinear 
model included PWS status (no PWS=0; PWS=1), liver steatosis or ALT levels, age, gender 
and BMI as independeŶt ǀaƌiaďles. β ĐoeffiĐieŶts aŶd ƌelated sigŶifiĐaŶĐe ǀalues oďtaiŶed 
from the models are reported. P< 0.05 was considered as statistically significant. 
 
Results 
 
A summary of anthropometric and biochemical data is reported in Tables 1 and 2 (pag. 
23, 24), and Figure 1 (pag. 26). BMI values were comparable between the two groups and 
ranged, collectively, between 31.5–73.3 kg/m2. Severe obesity (BMI > 40 kg/m2) was 
present in 67.5% of cases (13 PWS and 14 obese patients). Abnormal glucose metabolism 
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was detected in 50% of PWS and 55% of obese controls (T2DM in 25% of PWS and 20% of 
obese subjects, IGT in 20% of PWS and 35% of obese controls, IFG in 5% of PWS and no 
controls). 
Anthropometric parameters differed between groups. PWS showed lower values of REE 
(p<0.0001) and FFM (p<0.0001), and higher %FM (p=0.01) with respect to obese controls. 
Nevertheless, in the PWS group we observed lower OGTT-derived insulin (p=0.02), higher 
HDL (p=0.02 for all) and lower TG (p=0.01) and urate levels (p=0.004), which was 
suggestive of a better metabolic profile in PWS compared to obese controls. 
Liver function tests and liver steatosis evaluated by US resulted less impaired in PWS than 
obese controls. In fact, transaminases levels were high (>40 U/L) in 3 PWS and in 7 obese 
patients (15% vs. 35%), while US documented liver steatosis in 14 PWS and 18 obese 
ĐoŶtƌols ;ϳϬ% ǀs. ϵϬ%; χ2=12.5, p<0.001). According to the grading of liver steatosis, PWS 
had a higher pƌeǀaleŶĐe of GϬ ;ϯϬ% ǀs. ϳ%; χ2=17.5, p<0.0001), a similar prevalence of G1 
(20% vs. 20%, respectively) and G2 (30% vs. 33%, respectively), and a lower prevalence of 
Gϯ sĐoƌe ;ϮϬ% ǀs. ϰϬ%; χ2=9.5, p<0.01), when compared with obese controls. 
Analysis of circulating ANGPTL8 showed overall significantly lower levels in PWS 
compared to obese controls (Figure 2, pag. 27). ANGPTL8 levels were only modestly 
overlapping between populations and were less variable in PWS than obese subjects. The 
greater dispersion around the mean of ANGPTL8 values in the obese group likely reflected 
differences in liver function, as confirmed by an elevation of AST and ALT levels in both 
outliers of the obese group of controls (Figure 2, pag. 27). Corroborating these findings, 
correlation analysis in the two groups as a whole (Table 3, pag. 25) showed significant 
positive correlations between ANGPTL8 and AST (r=0.35, p<0.05), ALT (r=0.38, p=0.01), as 
well as with the grading of liver steatosis (r=0.36, p<0.05). These relationships were 
further substantiated by the observation of parallel increases of ANGPTL8 levels with the 
severity of liver steatosis (p=0.01 by repeated measures ANOVA) (Figure 3, pag. 28), and 
by association observed between ANGPTL8 levels and liver steatosis in the group of obese 
controls (r=0.53, p<0.05). Of note, a significant association was also seen between 
ANGPTL8 levels and REE (r=0.32, p=0.05) as well as FFM (r=0.31, p<0.05), while only in 
PWS ANGPTL8 levels were inversely associated with %FM (r=−0.46, p<0.05). Significant 
correlations obtained on the entire dataset were lost after controlling for PWS status, 
theƌeďǇ ĐoŶfiƌŵiŶg the ďluŶtiŶg effeĐt of PW“ oŶ ANGPTLϴ leǀels ;ƌ=−0.42, p<0.01). There 
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were no differences in ANGPTL8 levels and liver steatosis when PWS group was analysed 
according to GH treatment or genotype (data not shown). 
Stepwise multivariable regression analysis documented that ANGPTL8 levels were 
ŶegatiǀelǇ pƌediĐted ďǇ PW“ status ;staŶdaƌdized β=−Ϭ.ϰϭ, p=Ϭ.ϬϭͿ. Afteƌ the ƌeŵoǀal of 
PW“ status fƌoŵ the ƌegƌessioŶ eƋuatioŶ, ALT leǀels ;staŶdaƌdized β=Ϭ.ϯϵ, p=Ϭ.Ϭ1) or the 
sĐoƌe of liǀeƌ steatosis ;staŶdaƌdized β=Ϭ.ϯϱ, p<Ϭ.ϬϱͿ, aĐted as iŶdepeŶdeŶt pƌediĐtoƌs of 
ANGPTL8 levels. 
 
Discussion 
 
The present study analysed the association between ANGPTL8 levels and adiposity, 
metabolic profile and liver steatosis in relation to the adult PWS condition and obesity. 
Our results show that PWS patients harbor lower ANGPTL8 levels than obese controls and 
that ANGPTL8 levels are more closely associated with liver steatosis, than with body 
composition and metabolic homeostasis. 
The metabolic phenotype of PWS is different as compared to common obesity and some 
metabolic complications typically related to obesity, such as insulin resistance and 
reduced hepatic insulin extraction, are less severe than expected for the degree of fat 
accumulation (Grugni 2016). In addition, PWS is associated with peripheral rather than 
central distribution of body fat (Goldstone 2001), less severe metabolic signatures in 
adipocytes (Lacroix 2015), and abnormalities in growth hormone secretion, ghrelin levels 
and adipokine patterns, when compared to common obesity (Goldstone 2004, Pagano 
2005, Kennedy 2006, Lacroix 2015). From a clinical viewpoint, factors influencing these 
discrepancies are incompletely understood. 
ANGPTL8 is a liver and adipose tissue-produced protein, involved in the regulation of 
triglyceride and glucose metabolism. Its activity involves the ability of reducing serum 
triglyceride clearance and improving insulin resistance (Tseng 2014a, Quagliarini 2012, 
Ren 2012, Zhang 2012, Fu 2013, Zhang 2013). In the current study, we observed lower 
circulating levels and less interindividual variability of ANGPTL8 in PWS when compared 
to subjects with common obesity. While insulin resistance and whole-body insulin 
sensitivity index did not greatly differ between PWS and obese controls, several 
anthropometric and metabolic differences existed between the two populations. 
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Particularly, PWS patients showed higher HDL cholesterol and lower TG levels than their 
control counterpart. Previous studies have suggested that PWS is characterized by a more 
efficient triglyceride storage likely due to an increase of adipose tissue lipoprotein lipase 
(LPL) activity, suggesting an altered pathway of fat mobilization and oxidation (Meaney 
1989). Noteworthy, ANGPTL8 shows the ability to suppress triglyceride clearance through 
the inhibition of LPL, thus increasing serum triglycerides (Zhang 2013). Therefore, we 
speculate that the decreased serum ANGPTL8 levels in PWS could contribute in explaining 
the lower triglyceride levels seen in PWS when compared to obese controls. In our study 
groups, the role of circulating ANGPTL8 on glucose homeostasis and insulin resistance 
appeared to be of little relevance compared to data in the literature (Rong Guo 2016). In 
fact, no correlations between ANGPTL8 and glucometabolic parameters were observed. 
These results do not disagree with recent data, but rather suggest that ANGPTL8 is not as 
ƌoďustlǇ iŶǀolǀed iŶ β-cell proliferation as originally proposed (Cox 2016), at least in our 
study populations. 
In the search for mechanisms to explain our observations, we noted that circulating 
ANGPTL8 paralleled the behaviour of crucial determinants of metabolic health, such as 
liver steatosis. In fact, circulating ANGPTL8 levels were negatively associated with indices 
of liver steatosis, i.e. transaminases and US-derived scores of steatosis, which are 
recognized non-invasive markers of liver impairment in obesity (Clark 2003, Bedogni 
2014, Marchesini 2003). While liver biopsy is the gold-standard method for the accurate 
staging of non-alcoholic liver steatosis, several previous studies demonstrated a strong 
correlation between US findings and the degree of liver steatosis documented by biopsy 
(Shannon 2011, Dasarathy 2009, Saadeh 2002). Bearing in mind the limitation of our 
approach, current data confirm that liver steatosis is less severe in PWS than in common 
obesity (Bedogni 2014), and substantiates the emerging role of liver steatosis on 
circulating ANGPTL8 in severe obesity, which is further strengthened by the results of 
correlation analyses and multivariable regression analyses. Being a primarily liver-
produced protein, ANGPTL8 is positively associated with biochemical indices of liver injury 
and steatosis in overweight and obese individuals (Guo 2015). In hepatoma cells, Tseng 
YH et al. demonstrated that ANGPTL8 is mainly localized in the cytoplasm with a vesicle-
like distribution (Tseng 2014b), possibly implying that hepatocyte lysis linked to steatosis 
could promote the leakage of ANGPTL8 vesicle in the bloodstream, thus helping to 
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explain our findings. Complementing literature data (Guo 2015, Lee 2016), our results 
suggest that ANGPTL8 levels could act as a novel surrogate biomarker for liver steatosis in 
non-PWS obese individuals. As certain adipokines can predict the severity of liver 
steatosis (Jamali 2016), however, studies are required to clarify the association between 
adipocytokines and ANGPTL8 levels in steatosis. 
 
Conclusions 
 
In conclusion, ANGPTL8 levels are lower in PWS than obese controls and, overall, they 
seem to reflect the severity of liver steatosis. Further studies should investigate the 
potential genetic basis of these findings. 
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Tables 
 
Table 1. Summary of anthropometric data obtained in PWS subjects and obese controls. 
Data are expressed as mean ± SD. Comparison between populations was performed by 
ANOVA test. Significant differences are shown in bold characters.  
 
Variables PWS (n= 20) Obese (n= 20) P Value 
Males/females 10/10 10/10 — 
Age (years) 34.2 ± 7.6 35.0 ± 8.3 0.7 
BMI (kg/m2) 45.5 ± 9.4 48.6 ± 10.2 0.3 
Weight (Kg) 105.9 ± 23.5 137.6 ± 27.2 <0.001 
Height (cm) 152.6 ± 8.1 168.5 ± 10.5 <0.0001 
Waist (cm) 124.8 ± 15.2 132.6 ± 12.8 0.09 
Hip (cm) 130.1 ± 16.8 140.4 ± 18.8 0.08 
Waist-to-hip ratio 0.96 ± 0.08 0.95 ± 0.11 0.7 
FM (%) 53.7 ± 6.1 47.5 ± 8.1 0.01 
FFM (Kg) 47.8 ± 11.6 70.2 ± 13.7 <0.0001 
REE (kcal/day) 1607.5 ± 281.3 2198.6 ± 402.1 <0.0001 
 
BMI, body mass index; FM, fat mass; FFM, fat free mass; REE, resting energy expenditure. 
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Table 2. Summary of biochemical data obtained in PWS subjects and obese controls. Data 
are expressed as mean ± SD. Comparison between populations was performed by ANOVA 
test. Significance is shown in bold characters.  
 
Variables PWS (n= 20) Obese (n= 20) P Value 
ANGPTL8 (ng/mL) 0.58 ± 0.21 0.93 ± 0.50 0.007 
Glucose OGTT0 (mg/dL) 100.6 ± 31.6 90.6 ± 10.0 0.1 
Glucose OGTT120 (mg/dL) 125.1 ± 44.9 142.2 ± 47.8 0.3 
Insulin OGTT0 (mIU/L) 10.7 ± 5.0 13.5 ± 6.2 0.1 
Insulin OGTT120 (mIU/L) 53.4 ± 28.1 106.6 ± 86.5 0.02 
C- Peptide ;μg/LͿ 2.3 ± 0.9 3.2 ± 0.9 0.002 
Matsuda 6.39 ± 6.37 3.51 ± 2.25 0.06 
Stumvoll 0.077 ± 0.029 0.051 ± 0.045 0.05 
HOMA-IR 2.6 ± 1.6 3.0 ± 1.5 0.4 
HOMA-B 149.4 ± 57.0 194.9 ± 109.3 0.1 
HbA1c (%) 5.8 ± 1.0 5.7 ± 0.5 0.5 
AST (U/L) 18.9 ± 6.7 29.1 ± 15.1 0.01 
ALT (U/L) 25.0 ± 16.9 40.5 ± 29.9 0.02 
GGT (U/L) 36.9 ± 50.0 34.0 ± 26.6 0.8 
ALP (U/L) 77.1 ± 19.6 73.7 ± 14.9 0.5 
CHO (mg/dL) 178.6 ± 42.6 186.9 ± 25.2 0.4 
LDL CHO (mg/dL) 118.9 ± 39.3 120.4 ± 21.9 0.8 
HDL CHO (mg/dL) 48.9 ± 11.1 41.1 ± 9.2 0.02 
TG (mg/dL) 97.3 ± 35.1 131.6 ± 45.1 0.01 
Urate (mg/dL) 5.4 ± 1.0 6.5 ± 1.1 0.004 
CRP (mg/dL) 1.2 ± 1.3 1.1 ± 0.7 0.7 
 
OGTT, Oral Glucose Tolerance Test; OGTT0 and OGTT120, OGTT at time 0 min and 120 min; HOMA-IR, 
homeostatic model of insulin resistance; HOMA-B, hoŵeostatiĐ ŵodel of β Đell fuŶĐtioŶ; HďAϭĐ, glǇĐated 
haemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl 
transpeptidase; ALP, alkaline phosphatase; CHO, total cholesterol; LDL CHO, low density lipoprotein 
cholesterol; HDL CHO, high density lipoprotein cholesterol; TG, triglycerides; CRP, C-reactive protein. 
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Table 3. PeaƌsoŶ͛s ĐoƌƌelatioŶ aŶalǇsis ďetǁeeŶ ANGPTLϴ leǀels aŶd aŶthƌopoŵetƌiĐ aŶd 
biochemical parameters in the study populations as a whole. For obese status: PWS = 1, 
common obese = 0. Significance is shown in bold characters.  
 
 
Parameters 
ANGPTL8 levels 
r p-value 
Age (years) 0.04 0.7 
Status −Ϭ.ϰϮ 0.007 
BMI (kg/m2) −Ϭ.Ϭϰ 0.7 
FM (%) −Ϭ.Ϯϲ 0.1 
FFM (kg) 0.31 0.04 
REE (kcal/day) 0.32 0.05 
Glucose OGTT0 (mg/dL) −Ϭ.ϭϬ 0.5 
Glucose OGTT120 (mg/dL) 0.30 0.08 
Insulin OGTT0 (mIU/L) 0.09 0.5 
Insulin OGTT120 (mIU/L) 0.30 0.08 
C- Peptide ;μg/LͿ 0.30 0.07 
AST (U/L) 0.35 0.02 
ALT (U/L) 0.38 0.01 
Liver steatosis score 0.35 0.03 
 
BMI, body mass index; FM, fat mass; FFM, fat free mass; REE, resting energy expenditure; OGTT, Oral 
Glucose Tolerance Test; OGTT0 and OGTT120, OGTT at time 0 min and 120 min; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase. 
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Figures 
 
Figure 1. OGTT-derived glucose levels (mg/dl) (A) and insulin levels (mIU/L) (B) obtained 
at time 0 min and 120 min in PWS and controls. Intra-groups differences were assessed 
by paired T-test. Inter-group analyses were performed by ANOVA. For significance: *p< 
0.0001 by paired T-test; §p= 0.02 by ANOVA. 
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Figure 2. Individual values of circulating ANGPTL8 levels obtained in PWS patients and 
obese controls. Lines represent mean and standard deviation values in the two 
populations. 
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Figure 3. Histogram illustrating the prevalence (%) of liver steatosis in PWS and obese 
controls, and the corresponding ANGPTL8 levels across liver steatosis scores as obtained 
in the two population as a whole. Significance is expressed as obtained by ANOVA. Inter-
group differences are listed in the Results section. 
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Abstract 
 
Obesity predisposes to vitamin D deficiency (VDD) and glucose abnormalities. It is 
currently debated if vitamin D administration may improve glucose homeostasis by 
interacting with modulators of insulin sensitivity, such as adiponectin and its oligomers. In 
a 4-week inpatient study on a metabolic rehabilitation program, consisting of 
individualized caloric restriction and aerobic physical exercise in obese subjects with VDD, 
we assessed the acute effects of 600,000 IU cholecalciferol given per os VD group, 12 
subjects; body mass index (BMI) 42.7±1.3 kg/m2) or placebo per os (PL group, 12 subjects, 
BMI 39.8±0.9 kg/m2) on high (HWM-A), medium (MMW-A), and low molecular weight 
adiponectin (LMW-A), as quantified by western immunoblot (WIB) and ELISA. During the 
4-week study, dieting promoted a similar magnitude of weight loss in VD and PL groups. 
Compared to the PL group, cholecalciferol administration increased 25(OH)Vit D levels 
(p<0.001) and promoted a significant increase of HMW-A expression analyzed by WIB 
(p=0.02). In parallel, a significant decrease of leptin/HMW-A ratio (p<0.05), a biomarker of 
metabolic homeostasis, was observed. During the study, changes of MMW-A and LMW-A 
occurred independently of cholecalciferol administration, and were likely explained by 
weight loss. At odds with these findings, the ELISA assessment of adiponectin oligomers 
showed no modifications in the VD group or PL group. Current findings suggest that acute 
cholecalciferol administration selectively modifies HMW-A and the leptin/HMW-A ratio. 
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Background 
 
Vitamin D is a fat-soluble secosteroid hormone that has an established physiological role 
in mineral and bone homeostasis. Its precursor vitamin D3, or cholecalciferol, is 
synthesized by 7-dehydrocholesterol in the skin during sun exposure, and it is 
hydroxylated first in the liver to form 25-hydroxycholecalciferol (calcidiol, or 25(OH)Vit D), 
and then in the kidney to generate the bioactive form 1,25(OH)2 Vit D, the actions of 
which are mediated by the vitamin D nuclear receptor (VDR). Notably, the VDR is widely 
expressed in human tissues, where it likely mediates the pleiotropic functions of vitamin 
D (Holick 2007). It has long been shown that serum 25(OH)Vit D concentrations are 
inversely correlated with body mass index (BMI), as well as with several anthropometric 
or biochemical surrogates of adiposity (Ding 2012). Vitamin D deficiency (VDD) affects up 
to 95% of patients with severe obesity (Bellan 2014), and an associative network relates 
VDD and obesity to low grade inflammatory state, insulin resistance, metabolic syndrome, 
and type 2 diabetes mellitus (T2DM) (Bellan 2014, McGIll 2008, Palomer 2008). Evidence 
collected in case-control and observational studies led to the hypothesis that 
cholecalciferol administration could improve glucose tolerance, pancreatic beta-cell 
function, insulin and C-peptide responses, as well as insulin sensitivity (Mathieu 2005, 
Baziar 2014, Breslavsky 2013). However, the possibility that vitamin D3 supplementation 
may help to prevent the risk of T2DM has been challenged, and the ability of vitamin D3 
supplementation to improve fasting glucose, HbA1c levels, or insulin resistance in 
patients with impaired glucose tolerance (IGT), gestational diabetes, or T2DM is openly 
debated (Krul-Poel 2017). 
Being a source of adipokines, white adipose tissue (WAT) is actively involved in regulating 
many endocrine and metabolic functions related to energy storage, glucose homeostasis, 
and cardio-metabolic health (Athyros 2010). In particular, adiponectin is a WAT-derived 
adipokine that acts as an insulin-sensitizer and is capable of yielding anti-inflammatory 
and anti-atherogenic effects (Matsuzawa 2005). Because the secretion of adiponectin is 
negatively regulated by adiposity, particularly visceral fat accumulation (Han 2007), 
adiponectin levels are reduced in overweight/obese and insulin resistant states (Shibata 
2009), and increase upon bodyweight reduction (Bobbert 2005). It has long been shown 
that adiponectin circulates as three isoforms with largely different molecular weights. The 
32 
 
high molecular weight adiponectin isoform (HMW-A) is the recognized major determinant 
of insulin-sensitizing effects of adiponectin in liver, muscle, and endothelial tissue, as 
compared to medium (MMW-A) and low molecular weight adiponectin (LMW-A) (Kaser 
2008, Antoniades 2009). In previous investigations, serum HMW-A expression was 
positively associated with indices of insulin sensitivity and high density lipoprotein (HDL) 
cholesterol, while being negatively associated with BMI, central body fat, 
hyperinsulinemia, and T2DM (Lara-Castro 2006, Tschritter 2003, Basu 2007). In obesity, 
HMW-A levels are significantly decreased but increase during weight loss (Mai 2014, 
Polak 2007). Cross-sectional studies found a positive association between circulating 
adiponectin and 25(OH)Vit D levels (Liu 2009, Vaidya 2012, Al-Daghri 2013), as well as 
between VDD and hypoadiponectinemia (Gannagè-Yared 2009, Nimitphong 2009). While 
meta-analytic data failed to prove stimulatory effects of cholecalciferol supplementation 
on total adiponectin concentrations (Dinca 2016), it has been shown in obese children 
that VDD is associated with lower expression of adiponectin isoforms, particularly HMW-
A, while 1 year supplementation with cholecalciferol was shown to upregulate HMW-A 
expression independent of changes in BMI (Walker 2014). Pediatric studies also found 
that the increase in HMW-A levels was correlated with improvements in insulin sensitivity 
(Gueugnon 2012, Martos-Moren 2010). Finally, cholecalciferol supplementation in 
children was shown to decrease the value of the leptin-to-adiponectin ratio (L/A) 
(Belenchia 2013), a marker of metabolic disease (Satoh 2004, Kotani 2005), which is 
better correlated with insulin resistance than the levels of each single peptide (Inoue 
2005, Inoue 2006). 
Based on the evidence that cholecalciferol may improve insulin sensitivity, we sought to 
explore the effect of 25(OH)Vit D on glucose homoeostasis in non-diabetic obese subjects 
with VDD through analysis of indirect mediators of insulin sensitivity, such as adiponectin 
oligomers. We therefore undertook a placebo-controlled investigation to explore if the 
administration of a large dose of cholecalciferol in severely obese individuals could 
acutely modify the profile of adiponectin oligomers measured by western immunoblot 
and ELISA, in relation to anthropometric measures, indices of insulin resistance, and the 
leptin-to-(multimeric) adiponectin ratio. 
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Methods 
 
Subjects 
 
The study enrolled 24 obese patients (13 males/11 females; age 37.5±1.9 years; BMI 
41.3±0.8 kg/m2) who were referred to our institution for work-up and rehabilitation of 
obesity and its comorbidities. All patients were enrolled between July 2014 and February 
2015 after biochemical demonstration of VDD status and were distributed during the 
three subsequent seasons. Written consent was obtained from all patients after full 
explanation of the purpose and nature of the study. The investigation was approved by 
the local ethical committee (Comitato Etico, Istituto Auxologico Italiano, Milano, Italy, 
18F101_2011), and was developed in accordance with the 3rd edition of the Guidelines 
on the Practice of Ethical Committees in Medical Research. 
Patients were otherwise healthy, and exclusion criteria included T1DM or T2DM, 
autoimmune or inflammatory diseases, kidney or cardiac disorders, chronic steroid 
treatment, any therapy capable of influencing calcium metabolism, vitamin D treatment, 
and comorbidities affecting 25(OH)Vit D metabolism, and menopause. Patients had not 
been prescribed any pharmacological therapies, diet therapy, dietary supplements, or 
anti-obesity compounds for at least 3 months prior to entering the study. Obese subjects 
were studied at baseline upon admission and following a four-week inpatient metabolic 
rehabilitation consisting of individualized caloric restriction equivalent to 75% of basal 
resting energy expenditure measured by indirect calorimetry, physical exercise 
comprising three sessions per week of aerobic activity, supported by a nutrition and 
lifestyle action program consisting of three 1-h classes per week dedicated to an 
educational approach on dietary behavior, nutrition knowledge, and motor activity. A 
standard inpatient hypocaloric diet consisting of 30% lipids, 50% carbohydrates, and 20% 
proteins was administered during the study, and the average caloric deficit was 488±79 
kcal/day for the VD group and 485±83 kcal/day for the PL group. Neither supplements nor 
anti-obesity therapies were used during the study period. 
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Study Design 
 
On admission, patients underwent routine analysis and assessment of VDD considered as 
25(OH) Vit D levels <20 ng/mL (Holick 2011). Subsequently, patients were randomly 
allocated to a single blind, placebo–controlled study. The starting study population 
included 26 subjects with VDD, two of whom dropped out during the study. The 
remaining 24 patients were divided between the vitamin D group (VD group; 6 males/6 
females; age 38±2.4 years; BMI 42.7±1.3 kg/m2) and the placebo group (PL group; 7 
males/5 females; age 37±3 years; BMI 39.8±0.9 kg/m2). An effort was made to include 
patients with comparable age, gender, and BMI in the two groups. Patients of the VD 
group underwent administration of an oral dose of commercially available oily solution 
containing 600,000 IU of cholecalciferol. Patients of the PL group were administered an 
equivalent volume of certified cholecalciferol-free olive oil. Following administration, 
fasting blood samples were collected for analysis at baseline and after 3, 7, 14, and 28 
days post-administration in each group. 
 
Body Measurements 
 
All subjects underwent body measurement wearing light underwear in fasting conditions 
after voiding. Weight and height were measured to the nearest 0.1 kg and 0.1 cm 
respectively. BMI was expressed as body mass (kg)/height (m)2. Obesity was defined for 
any BMI over 30 kg/m2. Waist circumference was measured midway between the lowest 
rib and the top of the iliac crest after gentle expiration; hip circumference was measured 
as the greatest circumference around the nates. Anthropometric data were expressed as 
the mean of two measurements and were assessed at study entry and at study end. At 
baseline, all subjects underwent dual-energy X-ray absorptiometry (GE-Lunar, Madison, 
WI, USA) for measurement of lean and fat body mass the morning after an overnight 
fasting and after voiding. 
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Western Immunoblot (WIB) of Multimeric Adiponectin 
 
Blood samples were drawn in fasting conditions, then they were centrifuged, separated, 
aliƋuoted, aŶd kept at −80◦C until assays in single batches. As previously published  
(Walker 2014), for WIB all serum samples were size-fractionated on 10% Sodium Dodecyl 
Sulphate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) under non-reducing (NR) 
conditions and electro-transferred to immuno-blot polyvinylidene difluoride (PVDF) 
membranes (BioRad, Hercules, CA, USA). Membranes were incubated with monoclonal 
anti-adiponectin (Adipogen, Incheon, Korea) and detected with the appropriate 
horseradish peroxidase-conjugated secondary antibody (Chemicon Millipore, Temecula, 
CA, USA). 
Immunoreactive proteins were detected using enhanced chemiluminescence (Pierce 
Biotechnology, Rockford, IL, USA) with image capture performed using a CCD-camera 
linked to ChemiTouch (BioRad). The results were quantified using Image Lab software 
(BioRad). Values are presented as arbitrary units (AU) normalized to total protein 
determined by Ponceau S staining (Sigma Aldrich, St. Louis, MO, USA). 
 
Adiponectin Immunoassay 
 
Serum total adiponectin and adiponectin multimeric forms were determined as 
previously published (Mai 2014), using the Adiponectin (Multimeric) Enzyme 
IŵŵuŶoassaǇ ;ALPCO DiagŶostiĐs, “aleŵ, NH, U“AͿ, aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ͛s 
instructions. Assay sensitivity is 0.019 ng/mL, the limit of detection performed is 0.0196 
ng/mL; as reported by the manufacturer, overall intra- and inter-assay coefficient of 
variations (CV) for total, HMW, and MMW + HMW are 5.4–5.0%, 5.0–5.7%, and 5.0–6.0%, 
respectively. Total adiponectin and HMW-A were measured directly from the assay 
plates, whereas MMW-A and LMW-A were calculated; MMW-A was obtained by 
subtracting the concentration of HMW-A from the combined concentration of MMW-A 
and HMW-A (measured directly), and LMW-A was obtained by subtracting the combined 
concentration of MMW-A and HMW-A (measured directly) from the total concentration 
of adiponectin. In parallel to sample preparation, duplicate P1 (protease one of the kit) 
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digestions were also prepared for WIB under non-reduced conditions according to the 
ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶs. 
 
Biochemistry 
 
Laboratory data were obtained in a central laboratory. Blood glucose and HbA1c were 
measured by enzymatic methods (Roche Molecular Biochemicals, Mannheim, Germany). 
HbA1c values of 6.5% were considered diagnostic for T2DM. Insulin (CVs, 0.8–1.5% and 
2.4–4.9%) was measured using a Cobas Integra 800 Autoanalyzer (Roche Diagnostics, 
Indianapolis, IN, USA). In both groups, insulin resistance was calculated by the 
homeostatic model of insulin resistance (HOMA-IR) index as insulin (mU/L) × (glucose 
(mmol/L)/22.5). 25(OH)Vit D levels were determined by an Agilent HP1100 series HPLC 
system equipped with a Variable Wavelength Detector; the detector wavelength was set 
at 265 nm. 25(OH)-Vit D was determined using an analysis kit from Chromsystems 
(Chromsystems Instruments & Chemicals GmbH, Gräfelfing, Germany). Calibration was 
performed using a lyophilized serum calibrator NIST traceable of known concentration. 
Low and high concentration lyophilized sera samples were used as quality controls. 
Samples, Đaliďƌatoƌs, aŶd ƋualitǇ ĐoŶtƌols ǁeƌe pƌepaƌed aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ͛s 
instructions. Assay sensitivity was 1.4 µg/L and the inter- and intra-assay coefficients of 
variations were 0.9–3.0% and 2.3–3.3%, respectively. Serum leptin levels were measured 
using a Leptin Human ELISA kit (Mediagnost, Ruetlingen, Germany) with a sensitivity of 
0.2 ng/mL, and inter- and intra-assay coefficients of variability below 10%, as reported by 
the manufacturer. 
 
Statistics 
 
Data are expressed as the mean ± SEM. Statistical analyses were carried out by GraphPad 
Prism 5 (GraphPad Software, La Jolla, CA, USA) using unpaired and paired two-tailed 
“tudeŶt͛s t-test to compare baseline characteristics of the two groups and within the 
obese population at the different time-points. One-way ANOVA for repeated measures 
was used to assess within-group modifications of measured variables during the study. 
Two-way ANOVA was performed to analyze the effect of time, treatment, and time 
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treatment. Assessments of differences between groups were additionally assessed by the 
χ2 test. LiŶeaƌ ƌegƌessioŶ peƌ PeaƌsoŶ͛s aŶalǇsis ǁas peƌfoƌŵed to deteƌŵiŶe ĐoƌƌelatioŶ 
coefficients between different parameters. p<0.05 was considered as statistically 
sigŶifiĐaŶt. PeƌĐeŶt ∆ ǀalue ǁas ĐalĐulated as the fiŶal ǀalue − ďaseliŶe ǀalue/ďaseliŶe 
value × 100. 
 
Results 
 
Metabolic Effects of Cholecalciferol Supplementation 
 
The characteristics of the 24 participants enrolled in the two study groups are shown in 
Table 1 (pag. 43). We found no difference in anthropometric variables between the VD 
group and the PL group at baseline, including BMI and body weight. A slight but non-
significant difference in BMI (p=0.08) and percent fat mass (p=0.07) occurred between 
groups. Baseline levels of 25(OH)Vit D were similar across groups, and all subjects were 
25(OH)Vit D deficient, considered as 25(OH)Vit D <20 ng/mL. Metabolic analysis showed 
baseline glucose levels in the diabetic range in one patient in the VD group. Baseline 
values of leptin and total adiponectin, as well as their ratio, were comparable between 
groups. Figure 1 (pag. 45) shows changes in 25(OH)Vit D levels following cholecalciferol or 
placebo administration in the study populations. 
Figure 1 (pag. 45) shows the changes in serum 25(OH)Vit D levels induced by 
cholecalciferol or placebo supplementation in the studied populations. A significant 
change in 25(OH)Vit D levels occurred throughout the entire observation period only in 
the VD group, and analysis by repeated measures ANOVA showed that this change was 
significant (p<0.001). In particular, a sharp and significant increase in 25(OH)Vit D levels 
was observed as soon as after 3 days following administration and persisted at 
significantly higher levels than baseline throughout the study period. By contrast, there 
was no modification in 25(OH)Vit D levels in the PL group. The interaction between 
cholecalciferol treatment and time was significant (p<0.0001). At the end of the 
treatment period, obese patients treated with cholecalciferol lost 6±0.7% of their body 
weight (Table1, pag. 43), which did not statistically differ from the 5.5±0.5% weight loss 
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observed in the PL group. Overall changes of immunoassayable total adiponectin levels 
were negligible, whereas leptin levels significantly decreased in both groups. Hence, a 
significant reduction was also documented in the L/A ratio in both groups. 
 
Analysis of Multimeric Adiponectin 
 
Sera obtained from obese subjects undergoing the two treatment arms were processed 
by WIB to assess whether cholecalciferol treatment influenced adiponectin 
multimerization as compared to placebo. Despite a visual difference in baseline MMW-A 
values, analysis of multimeric adiponectin at study entry showed no difference between 
groups in the expression levels of HMW-A, MMW-A, and LMW-A. During the study, 
individual HMW-A profiles displayed a progressive increase in 71% of patients treated 
ǁith ĐholeĐalĐifeƌol Đoŵpaƌed to ϯϲ% of those of the PL gƌoup ;χ2=24.6, p<0.0001). A 
cumulative increase in HMW-A expression, depicted in Figures 2 and 3 (pag. 46, 47), was 
only evident for the  VD group but reached statistical significance 14 days following 
cholecalciferol administration (p<0.05 vs. baseline, 3 and 7 days). Inversely, we failed to 
document any significant interaction between time and treatment, probably due to the 
low sample number. An incremental trend was also observed for MMW-A and LMW-A, 
but this occurred in both groups, regardless of cholecalciferol treatment. Specifically, a 
significant change in MMW-A and LMW-A expression was achieved at 28-day when 
compared to the day 3 time-point (p<0.05), thus likely suggesting a diet-related effect. 
Based on WIB analysis, we then sought to corroborate results obtained at baseline and 
after 14 and 28 days by multimeric adiponectin immunoassays. As shown in Table 2 (pag. 
44), we failed to document significant increments in HMW-A in the VD group, while in the 
PL group there was a slight decrease of HMW-A at 28-day. By contrast, MMW-A and 
LMW-A did not appear to consistently change in either group during the experimental 
period. For all three adiponectin oligomers, we did not document significant effects of 
cholecalciferol administration, time of treatment, and their interaction by two-way 
ANOVA. Overall, one-way ANOVA for repeated measures also showed no significant 
difference. When the leptin/HMW-A ratio was used as a surrogate measure of the 
bioactive adiponectin multimerization, a decrease was only documented in the VD group 
(Table 1, pag. 43). 
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No correlation was observed when we analyzed the effect of vitamin D3 treatment in 
relation to adiponectin isoforms, body weight, and measures of insulin resistance, when 
assessed as both absolute values and incremental changes. 
 
Discussion 
 
Recent research has demonstrated that 25(OH)Vit D modulates the secretion of 
adipokines such as leptin and adiponectin (Walker 2014, Abbas 2017). In particular, the 
most bioactive form of adiponectin, HMW-A, was found to be down-regulated in obese 
children with VDD, and to increase following cholecalciferol supplementation (Walker 
2014). Current results suggest that oral administration of a high dose of cholecalciferol to 
obese adults with VDD did not significantly impact total adiponectin concentrations but 
promoted a selective increase of the HMW-A oligomer, which was independent of initial 
body weight, insulin resistance, and amount of body weight lost on diet. Because HMW-A 
is a putative modulator of insulin homeostasis, and its changes were specific to 
cholecalciferol treatment, it seems conceivable that cholecalciferol may intervene on 
molecular intermediates of glucose homeostasis and influence insulin sensitivity. 
Obesity is a global health problem and an important risk factor for diabetes, cancer, heart 
disease, and hypertension. Obesity and the metabolic syndrome have a high impact on 
the current epidemic of VDD (Holick 2005). Owing to its pleiotropic actions, 
supplementation with vitamin D3 and its congeners is hypothesized to act beneficially on 
several markers of chronic diseases (Autier 2014). It has been shown that serum 
25(OH)Vit D concentrations are inversely correlated with body mass index (BMI), fat 
mass, or percentage of body fat, as well as waist circumference (Ding 2012). It is not clear 
whether this association is due to increased storage in the adipose tissue, sedentary 
lifestyle, low sunlight exposure, true vitamin D deficiency, genetic changes in vitamin D 
metabolism, or unknown factors (Holick 2005). Interventional studies investigating 
25(OH)Vit D action on weight gain (Caan 2007), glucose abnormalities (Pittas 2007), and 
lipid profiles (Major 2007) failed to provide reproducible results. However, problems 
remain with the daily amount of vitamin D3 supplementation, which was in these studies 
lower than the vitamin D intake considered to be appropriate for adults (Vieth 2007, Aloia 
2008). Current evidence collected from randomized trials does not support an effect for 
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short-term vitamin D supplementation on glucose control in a heterogeneous population 
with type 2 diabetes, whereas a favorable effect of vitamin D on fasting glucose was seen 
in patients with poorly controlled diabetes (Krul-Poel 2017). In overweight and obese 
subjects, high dose vitamin D3 supplementation was also reported to amplify the 
beneficial effect  of weight loss on traditional and non-traditional cardiovascular disease 
risk markers, independent of changes in body weight, fat mass, and abdominal fat mass 
(Zittermann 2009). In agreement with previous findings (Cipriani 2010, Camozzi 2016), 
our study observed that administration of a high cholecalciferol dose in VDD obese 
subjects caused a prompt and sustained increase of 25(OH)Vit D levels for the 28-day 
study period. The main finding of our study was the statistically significant incremental 
modification of HMW-A expression detected by western immunoblot after cholecalciferol 
administration but not after placebo. This increment appeared slightly delayed as 
compared to the peak of 25(OH)Vit D levels in the circulation, thus the peak 25(OH)Vit D 
levels occurred after 7 days while HMW adiponectin peaked after 14 days post-
administration, thus suggesting a possible genomic effect. By two-way ANOVA, however, 
there was no time × treatment interaction, likely due to the small sample. We found a 
similar incremental effect exerted by cholecalciferol and placebo on MMW-A and LMW-A 
profiles, which was likely consequent to the diet-induced weight loss. While it should be 
noted that the placebo group tended to have slightly milder baseline measures of severe 
obesity and metabolic dysfunction compared to the vitamin D group, these differences 
were not statistically significant and, thus, we hypothesize that this divergence played a 
negligible effect on the main findings of this study. In support of our findings obtained by 
WIB on cholecalciferol and placebo,  previous studies showed that supplementation  with 
vitamin D3 at therapeutic doses did not impact total adiponectin concentrations (Dinca 
2016), but it selectively increased HMW-A levels in obese adolescents treated for 1 year 
with cholecalciferol (Walker 2014). While our study and other studies failed to record 
associations between short-term increases of HMW-A and improvements in insulin 
sensitivity (Mai 2014, Polak 2007), long-term studies documented a significant correlation 
between modifications of HMW-A and insulin sensitivity (Gueugnon 2012, Martos-Moren 
2010, Swarbrick 2006). Based on our study and long-term clinical data, we hypothesize an 
insulin-sensitizing effect of vitamin D supplementation through HWM-A. 
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At odds with results obtained by WIB, our investigation on multimeric adiponectin 
quantitated by ELISA failed to capture modifications of HWM-A related to cholecalciferol 
administration, nor did it detect the increases of MMW-A and LMW-A identified by WIB in 
both groups. There are no comparative data in the literature that fully address this issue, 
and it cannot be excluded that it may depend on the performance of the methodologies 
herein used. We, thus, speculate that this discrepancy may reflect intrinsic differences 
between qualitative/semiquantitative (western immunoblot) and quantitative (ELISA) 
analyses. This incongruence has been previously noted in a study by Polack and 
colleagues, where an increase in all three types of adiponectin multimeric complexes was 
identified by western immunoblot but it was not accompanied by significant changes in 
total plasma adiponectin levels measured by ELISA (Polak 2007). Finally, such a 
discrepancy could also reflect different binding capacities of the different monoclonal 
antibodies used by the two methods. 
From a mechanistic viewpoint, adipose tissue is indeed a major site of vitamin D storage, 
and both the VDR and vitamin D metabolizing enzymes are expressed in adipocytes. 
Partly contradictory results exist on the adipogenic effect of 1,25(OH)2Vit D (Abbas 2017), 
which was shown to inhibit adipogenesis in 3T3-L1 mouse preadipocyte cell lines 
(Blumberg 2006), while promoting adipogenesis and increasing adiponectin expression in 
primary mouse and human subcutaneous preadipocytes (Nimitphong 2012). Similarly, 
treatment with 1,25(OH)2Vit D in 3T3-L1 cells was found to stimulate the synthesis of 
adiponectin and its multimeric forms (Dinca 2016). Moreover, a key regulator of folding 
and assembly of adiponectin, the endoplasmatic reticulum (ER) chaperon DsbA-L, was 
found to be upregulated by 1,25(OH)2Vit D, which suggests that vitamin D regulation of 
adiponectin may involve post-transcriptional mechanism/s (Walker 2014). Alternatively, 
no effect of 1,25(OH)2Vit D on adiponectin expression was found in human adipocyte 
cultures (Sun 2007), suggesting that the effect of vitamin D on adiponectin secretion is on 
open field and warrants  further studies. 
Our findings also indicate that, in the short term, vitamin D3 supplementation had no 
additional effect on the magnitude of weight loss compared to placebo, which agrees 
with previous evidence that vitamin D3 supplementation does not promote 
improvements in the degree of obesity (Mallard 2016). On the other hand, we also 
observed that weight loss obtained without Vitamin D3 supplementation did not modify 
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circulating 25(OH)Vit D levels, which agrees with the inference that loss of adipose tissue 
does not promote the release of 25(OH)Vit D release from fat into the bloodstream 
(Piccolo 2013). Although vitamin D3 supplementation does not act synergistically on 
adiponectin and leptin levels (Duggan 2015), we found a reduction of the 
leptin/adiponectin ratio in both groups, while a reduction of the leptin/HMW-A ratio was 
only obtained in the VD group. Based on the predictive role of these measures on 
metabolic health (Satoh 2004, Kotani 2005, Inoue 2005, Inoue 2006) and response to anti-
diabetic therapy (Lilja 2012), such a result may add strength to the metabolic role of 
vitamin D3 administration, independent of changes in body weight. This suggestion is 
substantiated in studies on obese adolescents, where a 6-month cholecalciferol 
supplementation (4000 IU/day) significantly decreased the leptin/adiponectin ratio in the 
absence of changes in BMI or waist circumference (Belenchia 2013). 
As limitations of our study, we acknowledge that the small sample size may hamper the 
clinical significance of our observations. However, the randomized placebo-controlled 
design of the study is a potential point of strength in addition to the tight monitoring of 
study effects during the inpatient dieting program. As all participants received a weight 
loss intervention leading to similar outcomes between groups, we could discriminate 
independent effects of vitamin D3 supplementation in our experimental conditions. 
Indeed, the duration of the study and the obese sample does not allow for insights to be 
gained on the long-term effects vitamin D3 supplementation, or extend our findings  to 
lean populations and different clinical settings. Finally, our study cannot provide insights 
on translational and post-translational mechanisms involved in modifications of 
adiponectin oligomers. 
 
Conclusions 
 
In conclusion, we found that an acute dose of cholecalciferol in obese VDD subjects 
promoted changes of HMW-A independent of changes in body weight and insulin 
resistance. We observed a decrease in the ratio between leptin and adiponectin or HMW-
A. These results could not be confirmed by immunoassay procedures. Further studies are 
needed to clarify the mechanisms underlying these effects. 
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Tables 
 
Table 1. Summary of anthropometric and metabolic data in the two populations obtained at baseline and at the end of the study. 
 
 Vitamin D Group (n=12) Placebo Group (n=12) p Value 
 Baseline At the end of the study Δ ;%Ϳ Baseline 
At the end of 
the study Δ ;%Ϳ Time Treatment 
Time x 
Treatment 
Male/Females 6/6 - - 7/5 - - - - - 
Age (years) 38±2.4 - - 37±3.0 - - - - - 
BMI (kg/m2) 42.7±1.3 40.1±1.2** -6.0±0.7 39.8±0.9 37.6±0.7** -5.5±0.5 <0.0001 0.07 0.41 
Body Weight (kg) 115.9±4.4 109.2±4.9** -5.8±0.4 112.7±4.7 106.4±4.3** -5.5±0.5 <0.0001 0.64 0.65 
Fat mass (%) 44.8±1.6 - - 40.4±1.6 - - - - - 
Free fat mass (kg) 63.4±2.9 - - 66.7±3.3 - - - - - 
Waist (cm) 126.2±3.5 - - 119.0±4.0 - - - - - 
Glucose (mg/dL) 97.0±7.1 90.2±3.1 -7.1±4.1 88.5±3.2 83.0±1.6* -5.5±2.1 0.07 0.45 0.10 
Insulin (mU/L) 13.9±2.5 14.5±1.7 5.9±12.7 17.5±2.2 14.1±1.3 -18.5±8.1 0.06 0.17 0.30 
HbA1c (%) 5.5±0.1 5.7±0.3 0.7±3.2 5.6±0.6 5.3±0.2* -4.7±1.3 0.21 0.53 0.07 
HOMA-IR 3.9±0.6 3.3±0.4 -3.2±11.3 3.7±0.5 3.0±0.2 -9.7±8.3 0.11 0.67 0.99 
25(OH) Vit D (ng/mL) 14.2±1.9 35.0±3.2#,** 191.0±39.6 14.5±1.9 14.8±1.6 7.2±6.3 <0.0001 <0.0001 <0.0001 
Total adiponectin (µg/mL) 3.6±0.5 3.5±0.4 0.2±5.9 4.0±1.1 3.9±1.0 1.9±9.1 0.39 0.75 0.89 
Leptin (ng/mL) 44.1±7.2 31.6±5.9* -27.3±5.4 41.1±4.6 9.8±4.1** -29.9±4.0 <0.0001 0.75 0.72 
Leptin/Adiponectin 15.9±4.3 10.5±2.7* -23.6±5.4 14.8±2.5 10.3±1.6 -21.2±12.9 <0.01 0.86 0.73 
Leptin/HMW-A 49.1±12.0 24.7±4.2* -26.8±10.6 37.4±7.4 35.5±9.9 -6.9±12.8 <0.05 0.96 <0.05 
 
Data are presented as mean SEM. p-values refer to the effect of time, treatment, and time treatment assessed by two-way ANOVA. For significance:  a paired t-test was 
performed  in each group between baseline and study-end assessment (**p < 0.001, *p < 0.05); an unpaired t-test was performed between the two groups at baseline and at 
the end of the study (#p < 0.01). For abbreviations: BMI, Body Mass Index; HbA1c, Glycated Haemoglobin; HOMA-IR, Homeostatic Model of Insulin resistance; 25(OH)Vit D, 
25-hydroxycholecalciferol; HMW-A, High MoleĐulaƌ Weight AdipoŶeĐtiŶ; ∆ ;%Ϳ, peƌĐeŶt delta ǀalue ;listed as ŵeaŶ ± “EMͿ. 
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Table 2. Biochemical evaluation of multimeric adiponectin by ELISA. 
 
 Vitamin D Group (n=12) Placebo Group (n=12) p Value 
 Baseline 14 Days 28 Days Baseline 14 Days 28 Days Time Treatment Time x Treatment 
Total Adiponectin (µg/mL) 3.6±0.5 3.7±0.4 3.5±0.4 4.0±1.1 3.9±0.9 3.8±1.0 0.94 0.51 0.99 
HMW-A (µg/mL) 1.6±0.4 1.6±0.2 1.5±0.2 2.1±0.8 1.9±0.5 1.8±0.7 0.92 0.38 0.97 
MMW-A (µg/mL) 0.7±0.1 0.6±0.1 0.7±0.1 0.5±0.2 0.4±0.2 0.8±0.2 0.63 0.93 0.87 
LMW-A (µg/mL) 1.5±0.2 1.5±0.2 1.4±0.2 1.5±0.3 1.8±0.4 1.5±0.4 0.64 0.51 0.74 
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Figures 
 
Figure 1. Effect of cholecalciferol or placebo administration on serum 25(OH)Vit D levels. 
Data are presented as mean ± SEM. For significance: *p<0.001 vs. baseline within group,  
as calculated by repeated measures one-ǁaǇ ANOVA; ΐp<0.0001 between groups by 
unpaired t-test. Two-way ANOVA was also performed to test the effect of time, 
treatment, and time × treatment interaction, and results are summarized in the text and 
Table 1. 
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Figure 2. Effect of cholecalciferol or placebo administration on serum adiponectin 
oligomer expression levels measured by western immunoblot. Data are presented as 
mean ± SEM. Values are presented as arbitrary units (AU) normalized to total protein 
determined by Ponceau S staining.  
 
 
 
 
 
 
 
 
Two-way ANOVA was also performed to test the effect of time, treatment, and time × 
treatment interaction, and results are summarized in the text.  
(a) High molecular weight 
adiponectin (HMW-A): 
for significance in the VD group: 
*p<0.05 vs. baseline, 3 and 7 days 
after treatment (repeated measures 
one-way ANOVA), no difference 
between groups by unpaired t-test 
(b) medium molecular weight 
adiponectin (MMW-A): 
for significance: *p<0.05 vs. 3 days 
iŶ the VD gƌoup; ΐp<Ϭ.Ϭϱ ǀs. ϳ daǇs 
in PL group (repeated measures 
one-way ANOVA), no difference 
between groups by unpaired t-test 
(c) low molecular weight 
adiponectin (LMW-A):  
for significance: *p<0.05 vs. 3, 7, 
and 14 days in the VD group; 
ΐp<Ϭ.Ϭϱ ǀs. ϯ, ϳ daǇs iŶ the PL 
group (repeated measures one-way 
ANOVA), no difference between 
groups by unpaired t-test. 
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Figure 3. Representative immunoblots of high (HMW-A), medium, (MMW-A), and low 
molecular weight adiponectin (LMW-A) changes obtained at baseline and after 3, 7, 14, 
and 28 days following cholecalciferol or placebo administration in obese subjects. 
Representative western immunoblot (WIB) analyses under non-reduced conditions are 
displayed. HMW-A and MMW-A were analyzed following P1 digestion, while LMW-A was 
analyzed directly (for description see text). MW = molecular weight. 
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Abstract 
 
Purpose. Uric acid (UA) is a byproduct of the high-energy purine metabolism that is 
conventionally regarded as a marker of cardio-metabolic impairment. Its potential 
relationship with energy homeostasis is indeterminate. 
 
Methods. We performed a cross-sectional study on 121 otherwise healthy obese and 99 
sex- and-age-matched lean subjects to analyze UA levels in relation to metabolic health, 
inflammatory markers, respiratory quotient (RQ) and resting energy expenditure (REE) 
assessed by indirect calorimetry, fat mass (%FM) and fat-free mass (FFM) measured by 
bioimpedance analysis. 
 
Results. Obese and lean subjects differed as expected in BMI, glucolipid homeostasis, 
leptin and insulin levels, inflammatory markers, %FM and FFM (p<0.001 for all). Obese 
had higher UA levels (p<0.001) and higher rates of hyperuricaemia (40.5% vs 3.0%, 
p<0.0001) than controls. Indirect calorimetry revealed that obesity increased REE and 
decreased RQ significantly (p<0.001). Beyond expected metabolic correlates, correlation 
analysis both in individual and merged datasets revealed that UA was associated 
negatively with RQ and positively with REE (p<0.0001 for both). In multivariable 
regression analysis, significant independent predictors of UA were REE, RQ, BMI, and sex. 
When BMI was replaced by measures of body composition, FFM emerged as only 
significant predictor of serum UA (p<0.0001). 
 
Conclusions. The associative link between serum UA and REE reveals a potential role for 
UA in managing obesity energy homeostasis. 
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Background 
 
Most mammals excrete UA, a byproduct of purine degradation (Wu 1989), upon 
conversion to soluble allantoin by the liver enzyme urate oxidase (uricase) (Hayashi 
2002). In humans, the lack of uricase causes UA accumulation (Richette 2010) and 
promotes hyperuricemia under the influence of inappropriate dietary and life-style 
factors (Choi 2004). Upon urate super-saturation, crystalline monosodium urate becomes 
susceptible to precipitation leading to potentially serious complications, such as gout and 
kidney disease (Doherty 2009). Non-crystalline soluble component of UA possesses a 
unique amphipathic action (Sautin 2008) and exerts pro-oxidant effects in vascular cells 
mediated by lipid oxidation, which can lead to endothelial dysfunction and cardiovascular 
disease (Kanellis 2005, Sánchez-Lozada 2006). On the other hand, soluble UA acts as a 
powerful antioxidant that scavenges oxygen singlets and oxygen radicals, peroxynitrite, 
and chelates transition metals, thus protecting the cell membrane and DNA from 
oxidative damage (So 2010, Kuzkaya 2005, Ames 1981). 
Physiologically, UA levels are higher in men than women, increase with age and 
menopause, and change under the influence of antiuricosuric drugs, such as thiazide 
diuretics (Mikuls 2006, Rho 2011). With the gradual progression of obesity and diabetes 
mellitus, UA accumulation has been increasingly referred to as a proxy of the so-called 
metabolic syndrome (Yang 2012, Modan 1987), due to its robust association with obesity, 
visceral adipose tissue (VAT) accumulation, insulin resistance, systemic inflammation and 
muscle loss (Onat 2006, Ogbera 2010, Matsuura 1998, Tamba 2008, Hikita 2007, Huang 
2013). Obesity-associated hyperuricaemia is prompted by a number of mechanisms, 
including the following: overexpression of xanthine oxidoreductase in adipose tissue, 
which results in enhanced purine catabolism and increased production of UA (Tsushima 
2013); hyperinsulinaemia and insulin resistance, which decrease renal UA excretion 
(Facchini 1991); 3) VAT accumulation, which promotes fatty acid (FA) output in the portal 
vein (Chen 2007, Clausen 1998) and, as a result of the excessive metabolic outflow, 
promotes de novo synthesis of purine from NADPH in the pentose phosphate pathway 
and increased UA production (Matsuura 1998, Fabregat 1987, Matsubara 1989); 
increased consumption of purine-rich food, especially meat and to a lesser extent fish, 
alcoholic drinks and soft drinks rich in fructose (Wallace 2004, Choi 2008). Blood UA 
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reflects the balance between purine dietary uptake, production and catabolism of 
purines, and production and excretion of UA. Although purine turnover is relatively 
constant at 300-400 mg/day, dietary factors accelerate purine nucleotide depletion and 
rates of de novo purine synthesis, thus potentiating UA production (Choi 2010). De novo 
purine biosynthesis is a high-energy process that leads to the conversion of 
phosphoribosyl pyrophosphate (PRPP) to inosine monophosphate (IMP) through 10 
enzymatic activities and consumption of 6 ATP molecules, whereas only one ATP 
molecule is required for the purine salvage pathway consumption (Buchanan 1994, 
Seegmiller 1975, Becker 1993). Thus, production and excretion of UA in humans reflects 
energy utilization and could act as a surrogate measure of fuel utilization and energy 
homeostasis. On this basis, we sought to investigate if UA could reflect energy storage 
and explored the relationship between circulating UA and the components of energy 
metabolism, e.g. respiratory quotient (RQ) and resting energy expenditure (REE), in a 
cross-sectional analysis in lean and obese adult individuals. 
 
Methods 
 
Patients 
 
This study enrolled 121 obese patients (52 males; age 18-58 yr; body mass index (BMI), 
43.1±7.1 kg/m2) referred to our Institution for work-up and rehabilitation of obesity and 
its comorbidities, and 99 matched lean subjects (34 males; age 19-53 yr; BMI, 22.5±2.5 
kg/m2). All women were premenopausal, as assessed by personal history of regular 
menses. Exclusion criteria for both groups included medications interfering with UA levels 
and hypertriglyceridaemia. Patients were also excluded if suffering from autoimmune 
diseases, tumors, polycythemia, hemolysis, diabetes, liver or kidney diseases, smoke and 
alcohol consumption. The investigation was approved by the ad hoc Ethical Research 
Committee of Istituto Auxologico Italiano, functioning according to the 3rd edition of the 
Guidelines on the Practice of Ethical Committees in Medical Research. Written consent 
was obtained from all patients and controls, after full explanation of the purpose and 
nature of the study. 
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Body measurements 
 
All subjects underwent body measurements wearing light underwear, in fasting 
conditions after voiding. Weight and height were measured to the nearest 0.1 kg and 0.1 
cm, respectively, using standard methods. BMI was expressed as body mass (kg)/height 
(m)2. Obesity was defined for any BMI over 30 kg/m2.  
The respiratory quotient (RQ; VO2/VCO2) and resting energy expenditure (REE; kcal/24 h) 
were determined in a thermoregulated room (22-24°C) by computed open-circuit indirect 
calorimetry, measuring resting oxygen uptake and resting carbone dioxide production by 
a ventilated canopy (Sensormedics, Milan, Italy) at 1-min intervals for 30 minutes and 
expressed as a 24-h value. The test consists of making each patient lie down relaxed on a 
comfortable armchair, with the head under a transparent hood connected to a pump, 
which applies an adjustable ventilation through it. Exhaled gas dilutes with the fresh air 
ventilated under the hood and a sample of this mixture is conveyed to the analysers, 
through a capillary tube and analysed. Ambient and diluted fractions of O2 and CO2 are 
measured for a known ventilation rate, and O2 consumption (VO2) and CO2 production 
(VCO2) are determined. Energy expenditure was calculated according to the Weir 
equation (Weir 1949): EE = 5.68 VO2 + 1.59 VCO2 – 2.17 Nu. As short-term urinary 
collections to assess total nitrogen excretion (Nu) may not be representative of the 
protein oxidized during the measurement itself, they were not be obtained in this study, 
and assumed to be 13g/24h (Frayn 1983). The predicted REE (pREE) was calculated by the 
Harris-Benedict formula and allowed to test for metabolic efficiency, calculated as the 
ratio between measured/predicted REE values, as previously reported (Marzullo 2004).  
Percent fat body mass (FM) and lean body mass (FFM) were determined by bioelectrical 
impedance analysis (BIA) (model BIA 101/S Akern, Florence, Italy). Patients with fluid 
overload according to vectorial analysis were excluded to minimize errors in estimating 
FM and FFM in severe obesity (Piccoli 1998). 
 
Assays 
 
Blood samples were drawn under fasting conditions (8-12 h). For each participant was 
required to avoid physical activity, caffeine and dietary supplements 24 h prior to testing. 
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Blood levels of UA, glucose, total cholesterol, high-density (HDL) and low-density (LDL) 
lipoprotein cholesterol and triglycerides were measured by enzymatic methods (Roche 
Diagnostics, Mannheim, Germany). Serum insulin levels were measured using a Cobas 
Integra 800 Autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA). Ultrasensitive C-
reactive protein was measured by CRP (latex) HS Roche kit. 
Insulin resistance was calculated by the homeostasis model of assessment-insulin 
resistance (HOMA-IR) approach, calculated as insulin (microunits per milliliter) x blood 
glucose (millimoles per liter)/22.5. Serum leptin levels were measured by enzyme-linked 
immunosorbent assay (Human Leptin ELISA, Mediagnost, Reutlingen, Germany). The 
minimum detectable concentration was 0.2 ng/mL. The intra-assay and inter-assay 
coefficients of variation were <10%. 
 
Statistical analysis 
 
Statistical analysis was performed using SPSS version 21 (Somers, NY, USA). Values are 
expressed as means ± standard deviation (SD). Continuous variables were log 
transformed if distribution resulted skewed by the Shapiro-Wilk normality test. 
Comparative analyses within and between groups were performed by Mann-Whitney U 
test or two-tailed uŶpaiƌed “tudeŶt͛s t test afteƌ WelĐh͛s ĐoƌƌeĐtioŶ, ǁheŶ appƌopƌiate. 
The simple chi-square test was used for associations between categorical variables. 
“peaƌŵaŶ͛s ĐoƌƌelatioŶ aŶalǇsis ǁas used to ideŶtifǇ sigŶifiĐaŶt assoĐiatioŶs ďetǁeeŶ 
variables of interest. Stepwise multivariable regression analysis was used to evaluate the 
independent association of variations in UA with metabolic, anthropometric or 
bioĐheŵiĐal paƌaŵeteƌs. β ĐoeffiĐieŶts aŶd ƌelated sigŶifiĐaŶĐe ǀalues oďtaiŶed fƌoŵ the 
models are reported. P<0.05 was considered as statistically significant. 
 
Results 
 
A summary of anthropometric, metabolic an biochemical data is reported in Table 1 (pag. 
59). As predicted, obese and lean subjects differed for measures of adiposity, glucose and 
lipid metabolism, inflammatory markers, and leptin levels. Compared to lean individuals, 
obese patients had higher REE and lower RQ values. Obese subjects showed higher UA 
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levels, and hyperuricemia was documented in 40.5% of obese and 3.0% of lean subjects 
;χϮ=ϰϬ.ϲ, p<Ϭ.ϬϬϬϭͿ. CoƌƌelatioŶ aŶalǇsis ďetǁeeŶ UA aŶd ǀaƌiaďles of iŶteƌest iŶ the 
population as a whole and in the two groups separately (Table 2, pag. 60) showed an 
expected inverse correlation between UA and female gender, while a positive association 
related UA to impaired glucolipid metabolism, inflammatory markers, body composition 
and anthropometric variables related to visceral adiposity. A strong correlation was 
observed between serum UA and FFM in separate and merged groups. All correlations 
obtained in the entire dataset were lost after controlling for gender, age and BMI. When 
serum UA was plotted against the components of energy homeostasis, RQ and REE, 
divergent associations emerged. As such, an overall negative association related serum 
UA to RQ values in merged dataset, while it fail to reach statistical significance in separate 
groups. This association persisted after controlling for gender, age and BMI. Oppositely, 
UA levels were positively associated with REE (Figure 1, pag. 61) and this association 
persisted when REE was normalized by FFM (rho=0.13, p<0.05). After controlling for BMI, 
age and gender as individual covariates, the association between REE and UA remained 
significant, whereas it was abrogated when these variables were included collectively in 
analysis. Alternatively, the correlation between UA and either the predicted REE or the 
measured/predicted REE ratio, a surrogate measure of metabolic efficiency, was null.  
Based on correlations obtained between groups, a number of stepwise regression models 
were performed between UA and metabolic, anthropometric and body composition 
parameters. With the purpose of avoiding collinearity, a general model was created that 
comprised either BMI or FFM and %FM, either RQ or REE, as well as sex (0=males, 
1=females), HOMA-IR, HDL and triglycerides. When BMI and RQ were introduced with the 
otheƌ ǀaƌiaďles, the oŶlǇ pƌediĐtoƌs ǁeƌe BMI ;β=Ϭ.ϲϬ, p<Ϭ.ϬϬϬϭͿ, seǆ ;β=-0.37, p<0.0001) 
aŶd ‘Q ;β=Ϭ.ϭϭ, p<Ϭ.ϬϱͿ ǁith aŶ adjusted ‘Ϯ ǀalue of Ϭ.ϱϴ. IŶ a ŵodel ǁith ‘EE, this ǁas 
eǆĐluded aŶd the oŶlǇ pƌediĐtoƌs ǁeƌe BMI ;β=Ϭ.ϱϵ, p<Ϭ.ϬϬϬϭͿ aŶd seǆ ;β=-0.37, 
p<0.0001) with an R2 of 0.58. Replacement of BMI with FFM and %FM in a model that 
had ‘Q aŶd the otheƌ ǀaƌiaďles shoǁed that pƌediĐtoƌs of UA ǁeƌe FFM ;β=Ϭ.ϯϰ, 
p<Ϭ.ϬϬϬϭͿ, %FM ;β=Ϭ.ϯϵ, p<Ϭ.ϬϬϬϭͿ, seǆ ;β=-Ϭ.ϯϮ, p<Ϭ.ϬϬϬϭͿ aŶd ‘Q ;β=Ϭ.ϭϬ, p<Ϭ.ϬϱͿ 
with a R2 value of 0.56. REE instead of RQ had no statistical value, with the only 
pƌediĐtoƌs ďeiŶg FFM ;β=Ϭ.Ϯϵ, p<Ϭ.ϬϬϬϭͿ, %FM ;β=Ϭ.ϯϲ, p<Ϭ.ϬϬϬϭͿ, seǆ ;β=-0.32, 
p<Ϭ.ϬϬϬϭͿ aŶd tƌiglǇĐeƌides ;β=Ϭ.ϭϭ, p<Ϭ.ϬϱͿ, ǁith a ‘Ϯ ǀalue of Ϭ.ϱϱ. IŶteƌestiŶglǇ, 
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analysis of the effect of FFM and %FM on UA showed that FFM was a stronger predictor 
of UA ;β=Ϭ.ϲϭ, p<Ϭ.ϬϬϬϭͿ thaŶ %FM ;β=Ϭ.Ϯϰ, p<Ϭ.ϬϬϬϭͿ aŶd the ‘Ϯ ǀalue ǁas Ϭ.ϱϭ. 
 
Discussion 
 
The results of our study show that serum UA, in addition to reflect metabolic 
derangement, is a surrogate index of the resting energy state in lean and obese subjects. 
We observed that UA levels were inversely associated with values of RQ and increased 
with increasing values of REE. Multivariate analysis found that UA was an independent 
predictor of REE. This finding suggests that UA may be involved in the regulation of 
substrate availability and energy stores. 
UA is a recognized marker of metabolic derangement widely used for its ability to predict 
the risk of cardio-metabolic morbidity (Abdelmalek 2012, Yamashita 1986). Dietary 
excess, fat accumulation and insulin resistance are all known causes of increased UA, 
which enhance the risk of gout and kidney disease. Among the NHANES participants, a 
1.3–1.5 times greater than normal prevalence of gout was found in overweight individuals 
after adjustment for serum UA, while the prevalence ratio was 1.8 for class I obesity and 
2.2–2.4 for class II or III obesity (Juraschek 2013). Epidemiologic studies have repeatedly 
manifested the ability of serum UA to associate with cardio-metabolic disorders, e.g. 
hypertension, coronary artery disease, cerebrovascular disease, and kidney disease, not 
just if overt hyperuricemia occurs but also when serum UA approaches the high-normal 
range (Feig 2008). Such unfavourable link is herein confirmed by the clustering of UA 
levels with variables related to obesity and derived indexes, i.e. metabolic setting, fatty 
body composition and abdominal adiposity. One novel finding was a divergent association 
observed between UA levels and components of fuel use. Our obese cohort had lower RQ 
values than lean controls, a finding that originates from the effects of the fat mass on the 
rate of FA oxidation (Rossow 2014). RQ values were linearly and inversely associated with 
UA levels, and this relationship was not influenced by hyperuricaemia, i.e. subjects with 
hyperuricaemia did not show lower RQ levels that those without. However, the 
correlation lost significance disappeared in separate group, likely due to the narrow 
regression of RQ values. RQ, which represents the moles of carbon evolved per mole of 
oxygen consumed, reflects macronutrients metabolism (Widmaier 2016) and RQ values of 
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0.7, 0.8 and 1.0 are conventionally used in humans to identify the prominent oxidation of 
lipids, proteins and carbohydrates, respectively (Widmaier 2016). Previous evidence has 
showed that UA production and lipid metabolism are related in gout (Matsubara 1989), 
and obese adipose tissue is characterized by active FA synthesis (Spiegelman 1996) and 
de novo purine synthesis through the activation of the pentose phosphate pathway 
(Leyva 1998), which could contribute to increase UA synthesis and excretion (Becker 
2002). On the other hand, also lipolysis is up-regulated in obese adipose tissue 
(Greenberg 2011) and a high content of FA may flow into the liver directly through the 
portal vein in subjects with visceral fat accumulation, thereby accelerating TG synthesis in 
the liver and ultimately promoting hypertriglyceridemia (Bjmtorp 1990). According to this 
flow, we too observed that UA associated with plasma TG and abdominal adiposity. 
Hence, it can be hypothesized that UA could signal the rate of FA oxidation, e.g. the 
switch from glycolysis to lipolysis. 
Another result worth of mention was the positive association between serum UA and REE 
values, which was evident in single-group and whole-group analysis. At the multivariable 
regression analysis, REE was excluded from the equation, suggesting that anthropometric 
variables maintain greater control of UA levels. It remains difficult to conceptualize on 
these results based on the lack of data in the literature, with the exception of an abstract 
reporting on a correlation between serum UA and REE in a study on obese women 
(Kerksick 2009). It has long been shown that energy expenditure varies among people 
independent of body size and composition, and that skeletal muscle metabolism is the 
main determinant of metabolic rate, such that differences in resting muscle metabolism 
can produce differences in metabolic rates among individuals (Zurlo 1990, Bosy-Westphal 
2004). While it can be argued that the link between UA and REE could depend on the 
effect of fat-free mass between obese and lean individuals, we found the same 
correlation when REE was adjusted for FFM, suggesting that FFM was not involved in the 
association. It should be stated, however, that body composition was herein measured by 
BIA, which per se is less informative than DXA due to the potential effect of fluid 
overload. Literature data suggests that UA, as a marker of cell metabolism, can increase in 
conditions associated with high REE such as hyperthyroidism (Sato 1995), HIV-related 
infection (Walker 2006, Hommes 1990), and hypoxia from chronic obstructive pulmonary 
disease or sleep apnea (Creutzberg 1998, Garcia-Pachon 2007). As we did not assess sleep 
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apnea in our obese patients, this issue remains open. When adipose tissue accumulation 
is accounted for, there is evidence that adipocyte differentiation upregulates intracellular 
accumulation of triglyceride and UA secretion, suggesting that the activation of the 
pentose phosphate pathway related to FA synthesis is associated with the activity of 
xanthine oxidoreductase and production of UA (Tsushima 2013). Purines are endogenous 
modulators of energy metabolism and signal transduction, and play important roles in the 
physiology of platelets, muscles and neurotransmission (Maiuolo 2016). De novo purine 
biosynthesis is a high-energy event that leads to the conversion of phosphoribosyl 
pyrophosphate (PRPP) to inosine monophosphate (IMP) through a process requiring 10 
enzymatic activities and 6 ATP molecules, while only one ATP molecule is required for the 
purine salvage pathway (Buchanan 1994, Seegmiller 1975). Bearing in mind that UA 
production provides an indirect estimate of ATP degradation, and because any increase in 
energy expenditure for a given amount of substrate requires either increased ATP 
hydrolysis or decreased ATP synthesis (Ricquier 2005), UA could be involved in signalling 
ATP availability, hence the energy state to other organs or apparatuses. As independent 
factor, UA has been already shown to mediate its effects by inducing oxidative stress, 
inflammation, endothelial dysfunction and activation of the renin angiotensin aldosterone 
system, which play a role in the pathogenesis of cardiovascular disease (Kanbay 2013).  
Our study has some important limitations that should be mentioned. Firstly, the 
retrospective, cross-sectional design of the study limits our ability to determine excretion 
of UA in the urine, that could allow a comparison between the excretion rate and 
circulating UA levels. This could possibly explain the retention of UA in obese vs lean 
individuals. Secondly, we did not measure ATP levels, which could allow us to discuss the 
role of UA as an indirect measurement of ATP degradation. Finally, we cannot assess a 
͞oŶe-to-oŶe͟ ŵatĐhiŶg of paƌteĐipaŶts aŶalǇsis ďeĐause of the ƌetƌospeĐtiǀe desigŶ of ouƌ 
study. Notwithstanding these limitations, this study has important strengths, including 
the accurate analysis of REE, the inclusion of pre-menopausal women and the evaluation 
multiple anthropometric and biochemical parameters. 
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Conclusions 
 
In summary, UA could be one of those factors that signal the systemic oxidative 
phosphorylation and are able to fine tune the energy state required for cell 
differentiation and metabolic requirements. Further studies are warranted to clarify if the 
relationship between UA and REE reflects a functional link or acts as an adaptive 
physiological response to abnormal substrates oxidation. 
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Tables 
 
Table 1. Summary of anthropometric, metabolic and biochemical parameters in lean 
subjects and obese patients. Significance between groups was calculated by Mann-
Whitney test for continuous variables or the chi-square for categorical variables. 
 
Parameters Obese  subjects 
Lean  
subjects P 
Males/Females 52/69 34/65 0.2 
Age (years) 35.1±9.1 35.3±7.9 0.8 
BMI (Kg/m2) 43.1±7.1 22.5±2.5 <0.001 
WC (cm) 121.0±26.5 63.0±10.8 <0.001 
FM (%) 45.0±6.7 24.9±6.4 <0.001 
FFM (kg) 66.7±17.7 47.6±8.5 <0.001 
RQ (VO2/VCO2) 0.84±0.08 0.90±0.12 <0.001 
REE (Kcal/24 h) 2054±432 1577±255 <0.001 
pREE (Kcal/24 h) 2119±471 1469±203 <0.001 
REE/pREE 0.98±0.10 1.08±0.13 <0.001 
UA (mg/dL) 6.49±1.51 4.32±1.19 <0.001 
CHO (mg/dL) 200.9±35.2 198.6±36.7 0.6 
HDL CHO (mg/dL) 46.9±15.7 63.8±15.9 <0.001 
LDL CHO (mg/dL) 135.4±32.6 131.6±83.8 0.6 
TG (mg/dL) 154.8±78.5 93.6±43.2 <0.001 
Insulin (mIU/mL) 14.2±7.3 9.7±8.8 <0.001 
Glucose (mg/dL) 84.6±13.6 86.0±14.5 0.4 
HOMA-IR 3.05±1.78 1.94±1.42 <0.001 
CRP (mg/dL) 0.93±0.96 0.19±0.32 <0.001 
Fibrinogen (mg/dL) 407.7±66.9 305.5±67.8 <0.001 
Leptin (mg/mL) 33.92±15.18 8.95±7.83 <0.001 
 
For abbreviations: BMI, body mass index; WC, waist circumference; TBW, total body water; FM, fat mass; 
FFM, free fat mass; RQ, Respiratory Quotient; REE, resting energy expenditure; pREE, predicted resting 
energy expenditure; UA, uric acid; CHO, total cholesterol; HDL, high density lipoprotein; LDL, low density 
lipoprotein; TG, triglycerides; HOMA-IR, homeostatic model of insulin resistance; CRP, C-reactive protein. 
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Table 2. “peaƌŵaŶ͛s Đorrelation analysis between serum UA levels and variables of 
interest in merged groups (whole), obese patients and lean subjects. For significance: a, 
p<0.05; b, p<0.01; c, p<0.001; d, p<0.0001. 
 
Parameters Whole population Obese subjects Lean controls 
Age (years) -0.07 -0.15 0.04 
BMI (Kg/m2) 0.64d 0.25b 0.38d 
WC (cm) 0.74d 0.44d 0,57d 
FM (%) 0.43d -0.34d -0.12 
FFM (kg) 0.73d 0.50d 0.60d 
RQ (VO2/VCO2) -0.32d -0.02 -0.11 
REE (Kcal/24 h) 0.66d 0.46d 0.47d 
CHO (mg/dL) 0.11 0.14 0.11 
HDL CHO (mg/dL) -0.54d -0.29c -0.34d 
LDL CHO (mg/dL) 0.24d 0.14 0.23a 
TG (mg/dL) 0.43d 0.27b 0.16 
Insulin (mIU/mL) 0.44d 0.38d 0.04 
Glucose (mg/dL) 0.05 0.05 0.36d 
HOMA-IR 0.44d 0.36d 0.11 
PCR  0.47d 0.02 0.06 
Fibrinogen (mg/dL) 0.34d -0.03 -0.11 
Leptin (mg/mL) 0.36d 0.23a 0.39d 
 
For abbreviations: BMI, body mass index; TBW, total body water; FM, fat mass; FFM, free fat mass; RQ, 
Respiratory Quotient; REE, resting energy expenditure; CHO, total cholesterol; HDL, high density lipoprotein; 
LDL, low density lipoprotein; TG, triglycerides; HOMA-IR, homeostatic model of insulin resistance; CRP, C-
reactive protein 
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Figures 
 
Figure 1. Bivariate correlation analysis between serum UA levels and RQ (upper panel) or 
REE (lower panel) in merged datasets from obese subjects and lean controls. Open circles 
and dashed line: obese subjects; closed circles and broken line: lean controls. 
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Abstract 
 
Objective. In addition to its standard neurohypophyseal functions, oxytocin is under 
investigation for its role in the control of energy balance. Its relationship with obesity and 
menopause, a critical stage for bodyweight changes, is unknown. 
 
Methods. This cross-sectional study enrolled 56 subjects with obesity (OB) (28 
premenopausal and 28 postmenopausal; medium BMI 46±4.5 kg/m2) and 53 normal-
weight (NW) women (27 premenopausal and 26 postmenopausal; medium BMI 23±3 
kg/m2). Measurements included oxytocin, and adipokines leptin and adiponectin levels; 
menopause-related hormones; glucose and lipid homeostasis. Percent fat mass (%FM) 
and fat-free mass (FFM, kg) were measured by DXA. 
 
Results. Oxytocin levels were significantly lower in OB than NW group both in pre- and 
postmenopausal conditions (p<0.001 for both), with 3 OB women having levels below the 
assay detection limit. In both study groups, menopause was associated with lower 
oxytocin compared to premenopausal levels (NW, p<0.05; OB, p=0.005). Multivariable 
analysis showed that both menopause and obesity, or their derived measures, acted as 
pƌediĐtoƌs of oǆǇtoĐiŶ leǀels ;BMI, β=-Ϭ.ϱϭ, p<Ϭ.ϬϬϬϭ; ŵeŶopause, β=-0.28, p<0.001), 
while their interaction was not significant (F=0.34, p=0.5). 
 
Conclusions. Both obesity and menopause significantly reduced impair oxytocin levels, 
but their effects are independent. Our findings may contribute to understanding the 
hormonal changes involved in weight modifications at menopause. 
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Background 
 
Body weight gain and consequent onset of associated diseases affect a growing 
proportion of the adult population and represent one of the most pressing worldwide 
public health problems (WHO 2015). Modifications in hormonal homeostasis, body 
composition and bone mass are associated with aging, in particular for women aged 55-
65 years (Zain 2015). Obesity is a major risk factor for a variety of chronic conditions 
(Stevens 2002), and changes in the hormonal milieu at menopause can impact fat 
partitioning and overall body composition (Karvonen-Gutierrez 2016), critical for the 
onset of type 2 diabetes mellitus (T2DM) and cardio-metabolic disease (Lobo 2014). While 
energy imbalance and genetic susceptibility are leading causes for overweight and 
obesity, the mechanisms underlying weight gain at menopause are not completely 
understood. Estrogens and the estrogen receptor (ER)-α aƌe esseŶtial ĐoŵpoŶeŶts of the 
central network that controls appetite, meal size, food intake and body weight, and they 
significantly impact neural circuits controlling food intake and energy expenditure 
(Schwartz 2000). Evidence has accumulated that oxytocin, a neurohypophyseal hormone 
physiologically implicated in labor (den Hertog 2001) and psycho-neural functions 
(MacDonald 2010), also intervenes in controlling food intake and energy balance in 
concert with leptin (Cai 2013), although their interplay is not completely understood 
(Perello 2013). At the central level, oxytocin expression is predominantly located within 
the hypothalamic parvocellular neurons of the paraventricular nucleus (PVN) and 
magnocellular neurons of both the PVN and supraoptic nucleus, but small amounts of 
oxytocin are also synthesized in the gastrointestinal tract in rodents and humans (Ohlsson 
2006, Welch 2009). In parallel, the oxytocin receptor is widely expressed in relevant areas 
of the central nervous system (CNS) involved in food intake (Schwartz 2000), as well as in 
several peripheral tissues, including adipocytes (Yi 2015) and gastrointestinal tract  
(Monstein 2004). Reduced oxytocin signaling associates with obesity and mice deficient in 
oxytocin or oxytocin-receptors are prone to develop late-onset obesity (Camerino 2009, 
Takayanagi 2008). On the other hand, peripheral oxytocin administration to obese rats 
reduced food intake and bodyweight, while preventing the typical reduction of energy 
expenditure caused by weight loss (Morton 2012). Recently, intranasal oxytocin in obese 
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subjects, reduced caloric intake, resulting in a shift from carbohydrate to fat utilization 
and improving insulin sensitivity (Lawson 2015).  
Modifications of circulating oxytocin in relation to pathophysiological events following 
menopause, is to date only a hypothesis (Breuil 2014), with only a limited number of 
studies investigating the overall changes of oxytocin levels in patients with obesity and 
T2DM (Qian 2014), as well as premenopausal women with T1DM (Kujack 2015). To date, 
oxytocin physiology remains overlooked with menopause, while its contribution in energy 
homeostasis is a burgeoning area of research with its use having interesting potentials as 
a therapeutic strategy to treat the metabolic disease. In this study, we aimed to 
determine the levels of plasma oxytocin and its relationship with biochemical, hormonal 
and indices of adiposity in menopause of both lean and obese state. 
 
Methods 
 
Study participants 
 
The study included women in premenopausal and postmenopausal stage selected from 
obese subjects referred to our institution for work-up and rehabilitation for obesity with 
no known systemic comorbidities. Control women were selected from the hospital staff. 
All study participants were recruited between January 2011 and September 2015. 
between January 2014 and September 2015. Diagnosis of physiological menopause was 
based on clinical criteria in women over 45 years who did not report a period for at least 
12 months and were not using hormonal contraception, independent of menopausal 
symptoms (Sarri 2015). For this study, the age limits were arbitrarily set between 40-50 
years for premenopausal and 51-60 years for postmenopausal women. The original 
samples comprised 120 women equally divided between several over-weight (OB) and 
normal-weight (NW) women, and complete datasets according to criteria herein used 
were available for 56 severely OB women (28 pre- and 28 post-menopausal) and 53 NW 
control women (27 pre and 26 post-menopausal). All women in premenopausal stage 
reported regular menses and were not taking estrogens or other hormone therapies. 
Exclusion criteria for both groups included history of menstrual irregularities, previous or 
current treatment for osteoporosis, use of hormone therapy, menopause age <45 years, 
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previous major gynecological surgery, autoimmune diseases, thyroid disorders, previously 
known and/or treated T2DM. Informed consent was obtained from each participant 
before inclusion into the study. The study was approved by the Clinical Research Ethics 
Committee of our Institute, according to the Declaration of Helsinki. 
 
Clinical examination and body composition analysis 
 
Height and weight were measured with standardized techniques. BMI was expressed as 
kilograms per square meter. Participants were told to avoid stressful activities (sports and 
physical exercise) for at least three days before blood sampling. Information collected by 
each participant included the following data: age, age at menarche, age at menopause, 
number of pregnancies, current treatments, past medical history. Dual-energy x-ray 
absorptiometry (DXA) (GE Lunar Corp. Madison, WI, USA) was used for the assessment of 
body mass, expressed as lean body mass in kilograms and fat body mass as the 
percentage of total body mass, as well as for the assessment of the regional percentage 
of trunk fat mass.  
 
Biochemical parameters 
 
Blood samples were withdrawn from an antecubital vein after 10 hours overnight fast, in 
follicular phase for premenopausal women. Blood samples were separated by 
centrifugation after clotting, and aliquots of serum or plasma supernatants were 
processed for routine measurements and stored at -80°C until assayed for the hormones 
of interest. Analysis included measurement of glucose, insulin, HbA1c, total cholesterol 
(TC), high-density (HDL-C) and low-density lipoprotein (LDL-C) cholesterol, triglycerides 
(TGL), AST, ALT, total estradiol (E2), total testosterone, FSH, LH, prolactin (PRL), leptin, 
adiponectin and oxytocin levels. Obese patients underwent an oral glucose tolerance test 
(OGTT) for the determination of glucose and insulin levels, with the diagnosis of T2DM 
determined according to the latest ADA guidelines (ADA 2016). HbA1c was determined by 
a turbidimetric immunologic inhibition assay (TINIA; Boehringer-Mannheim, Germany); 
HbA1c values of 6.5% were also considered diagnostic for T2DM. Insulin resistance was 
calculated by the homeostatic model of insulin resistance (HOMA-IR) index as insulin 
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(mU/L) x [glucose (mmol/L)/22.5]. A two-site, solid-phase chemiluminescent 
immunometric assay or competitive immunoassay was used for insulin, E2, total 
testosterone, FSH, LH and PRL levels (Immulite 2000 Analyzer; DPC, Los Angeles, CA). 
Blood glucose and the lipid profile were measured by enzymatic assays (Roche 
Diagnostics GmbH, Mannheim, Germany). Serum adiponectin levels (µg/mL) were 
determined by an enzyme-linked immunoabsorbent assay (DRG Instruments GmbH, 
Marburg, Germany), the detection limit was 1.56–100 ng/mL, having sensitivity of 0.2 
ng/mL and inter- and intra-assay coefficients of variations (CVs) of 2.4-8.4 and 0.9-7.4%, 
respectively. Serum leptin concentrations were quantified using a commercially available 
ELISA kit (Mediagnost GmbH, Reutlingen, Germany) with sensitivity of 0.2 ng/mL and 
overall inter- and intra-assay CVs of 6.8-8.3 % and 5.5-6.9% respectively. Plasma oxytocin 
EIA (Phoenix Pharmaceutical Europe GmbH, Karlsruhe, Germany) was performed 
aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶs. Plasŵa speĐiŵeŶs ǁeƌe eǆtƌaĐted to 
eliminate interfering molecules and concentrate the sample before analysis. Sample 
extraction was performed using a solid-phase extraction recommended by EIA kit assay 
manufacturers and as described by Szeto et al (Szeto 2011). The lowest calibrator for this 
EIA kit was 0.01 ng/mL and the minimum detectable concentration was 0.06 ng/mL. The 
inter- and intra-assay CVs were 5.2-14.5 % and 8.7-9.1% respectively. 
 
Statistical analysis 
 
Statistical analyses were performed using the SPSS version 18.0 software. All data are 
summarized as mean and standard deviations. Continuous variables with skewed 
distribution were logarithmically transformed for statistical analyses. Inter-group and 
intra-gƌoup ĐoŵpaƌisoŶs ǁeƌe peƌfoƌŵed ďǇ ANOVA. PeaƌsoŶ͛s ĐoƌƌelatioŶ ĐoeffiĐieŶts 
were calculated to evaluate the associations between serum oxytocin and clinical and 
laboratory measurements. Partial correlation was used to determine the associations 
after adjusting for the effects of BMI, menopause and age. The effects of covariates and 
covariate interactions with oxytocin were studied by the general linear model and by 
stepwise multiple linear regressions. Statistical tests were 2-tailed with p<0.05 as the 
threshold level of significance. 
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Results 
 
Data summaries for anthropometric and biochemical variables are reported in Table 1 
and 2 (pag. 72, 73). Compared to NW, OB women reported earlier menarche and more 
pregnancies. They also harbored lower FSH and LH levels, and higher estradiol and 
testosterone concentrations. Within the OB group, pre- and postmenopausal women 
differed for age at menarche, parity and total number of pregnancies. Compared to their 
postmenopausal counterpart, premenopausal women from each group showed greater 
values of FFM values, while %FM values were seemingly overlapping across stages. 
Adiposity-related measures, lipid profile and parameters of glucose homeostasis were 
expectedly different between OB and NW groups and 25% of OB women (7 pre- and 7 
postmenopausal) were diabetic. Higher adiponectin levels were seen in postmenopausal 
women within each group, with significance only observed in the OB group.  
Analysis of circulating oxytocin documented a significant blunting effect of menopause 
and high bodyweight. In the OB group as a whole, oxytocin levels were 3.5-fold lower 
than NW women, whereas stage-dependent differences accounted for 2.7-fold difference 
before menopausal and 5.8-fold difference after menopausal between NW and OB group 
(Figure 1, pag. 75). In OB group, oxytocin levels were below 0.1 ng/ml in 10 cases, all 
being postmenopausal except for one, while values were below the lowest detection limit 
in 3 OB cases (1 in premenopausal and 2 in postmenopausal group, respectively). In single 
group analyses, for both NW and OB groups, oxytocin levels were significantly lower in 
postmenopausal than premenopausal stage, with differences being more striking in obese 
conditions. As one of the postmenopausal woman from the NW group showed 
unexpectedly elevated oxytocin levels, the results were re-analyzed after omitting this 
subject from the dataset, however the differences remained unchanged (data not 
shown). 
Bivariate analysis on the two groups as a whole showed associations between oxytocin 
and age at menarche, as well as menopausal status (Table 3, pag. 74), while age at 
menopause, menopause duration or menopause-related hormone levels showed no 
influence (data not shown). In our study, the association between oxytocin and age 
demonstrated a borderline significant (p=0.07). Strong inverse associations were seen 
between oxytocin and adiposity indices (Figure 2), i.e. leptin levels, bodyweight, BMI, 
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FFM, %FM and %FM Trunk, whereas associations relating oxytocin to measures of glucose 
homeostasis, lipids and adiponectin were feeble (Figure 2, pag. 76). Corroborating the 
dominant role of menopause and obesity on circulating oxytocin in our dataset, the 
aforementioned correlations disappeared in partial correlation analyses after controlling 
for such variables, either as single or aggregate covariates. Inclusion of age and/or 
estradiol levels as covariates did not influence the observed results. Separate correlation 
analyses in NW and OB subgroups showed correlations between oxytocin and age (NW: 
r=-0.32, p<0.05; OB: r=-0.33, p<0.05) and menopause (NW: r=-0.28, p<0.05; OB: r=-0.37, 
p<0.05). In covariate analysis, such correlations were independent of BMI. An association 
between oxytocin and estradiol levels (r=0.28, p<0.05) was only recorded in OB women. 
By multivariate regression analyses, the only variables entering the regression equation 
foƌ oǆǇtoĐiŶ ǁeƌe BMI ;β=-Ϭ.ϱϭ, p<Ϭ.ϬϬϬϭͿ aŶd ŵeŶopause ;β=-0.28, p<0.001), with a 
cumulative adjusted R2 value of 0.32. Confirming their inter-independent effects, the P 
for interaction between the effect of obesity and menopause on oxytocin was not 
significant (F=0.34, p=0.5). The same result was obtained when BMI, leptin levels, fat 
mass or estradiol levels were introduced as alternative covariates. 
 
Discussion 
 
Oxytocin is a labor-related hypothalamic peptide involved in social bonding, and recently 
has been characterized for its involvement in the regulation of energy homeostasis in 
animals and humans. In the present study, we documented that menopause and obesity 
can independently influence circulating oxytocin levels. Regardless of obesity, oxytocin 
levels were lower in post- than premenopausal women, while obesity was per se 
associated with reduced oxytocin levels, and further amplified the negative effect elicited 
by menopause. In our scenario, the effect of menopause and obesity appeared to be 
inter-independent. Together, these findings may contribute in shedding light on the 
mechanisms involved in weight modifications at menopause.  
Mid-life period is critical for many women, with transition into menopause posing a 
higher risk for changes in bodyweight, visceral fat accumulation and cardio-metabolic 
health (WHO 2015, Karvonen-Gutierrez 2016, Palmer 2015). At this stage, the physiology 
underlying weight accrual is important in efforts focused on the prevention of subsequent 
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metabolic disorders. Oxytocin governs mammary and uterine functions at labor 
(Arrowsmith 2014) and is emerging for its regulatory effects on social behavior, skeletal 
health, body composition and feeding habits in other stages of life (MacDonald 2010). 
Previous studies have shown that circulating oxytocin decreases with increasing age 
(Elabd 2014) and is reportedly unchanged between genders (Qian 2014). Rodent studies 
have shown that ovarian hormone deprivation is critical for changes in oxytocin activity 
and its expression in the PVN (De Melo 2016), while gain in bodyweight and intra-
abdominal fat accumulation in ovariectomized mice was hampered by oxytocin 
administration (Beranger 2014). Circulating oxytocin levels, and its hypothalamic 
expression, was also found to be associated with fasting-feeding cycles (Deblon 2011), 
whereas loss of expression of oxytocin or its receptors promoted obesity (Camerino 2009, 
Takayanagi 2008). Finally, low hypothalamic expression of oxytocin was found in animal 
models of genetic obesity, such as single-minded 1 (Sim1) haplo-insufficiency or MAGED1 
deficient mice (Holder 2000, Dombret 2012), and their human homologs (Swaab 1995). 
Our investigation provides novel evidence that menopause is associated with lower 
oxytocin levels regardless of obesity, and that this relationship is amplified by obesity. The 
magnitude in the difference between oxytocin levels in obese and lean women recorded 
after menopause nearly doubled that seen prior to menopause. While no hormonal, 
metabolic or anthropometric variable emerged as unconditional mediators of menopause 
effect on oxytocin, this latter was associated with estradiol levels in the obese group, 
possibly due to the enhanced aromatase activity (Palmer 2015). Similarly, previous 
reports showed that estradiol increases oxytocin levels in women (Chiodera 1991), and 
both oxytocin and its receptors are positively regulated by estrogens in the central 
nervous system (McCarthy 1995). We are therefore inclined to consider estradiol 
variations as the potential main regulator of oxytocin levels across menopause. Notably, 
oxytocin dynamics paralleled modifications of fat-free mass across the menopause more 
tightly than other body or metabolic measures. While the significance of this finding 
remains unclear, it is worth mentioning that oxytocin plays a role in muscle tissue 
regeneration and homeostasis, while inhibition of oxytocin signaling or genetic lack of 
oxytocin alters muscle regeneration and causes premature sarcopenia (Elabd 2014). 
Further studies are required to clarify this issue. 
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One key finding of our study resides in the evidence that oxytocin concentrations were 
significantly affected by obesity and, overall, it decreased by 3.5-fold in obese compared 
to lean women. As mentioned earlier, this difference was particularly robust after 
menopause. Several indices of bodyweight were also found to strongly associate with 
oxytocin levels, including BMI, FM, leptin levels and, less significantly, glucose and lipid 
homeostasis. Our findings agree with previous results obtained in obese patients and 
T2DM (Qian 2014), but disagree with results obtained in obese subjects undergoing 
gastric binding where oxytocin levels were higher than in controls (Stock 1989). However, 
we are inclined to explain this latter divergence as the result of technical drawbacks. Our 
procedures of extraction, in fact, enabled us to prevent the detection of nonspecific 
immunoreactive molecules, thus increasing analytical accuracy (Breuil 2014, Szeto 2011). 
In the search for potential explanatory mechanisms related to obesity, we noted a strong 
inverse relationship between oxytocin and leptin levels in both groups as a whole, but not 
in single study groups. This relationship is currently argued (Perello 2013, Ott 2013), and 
was shown to be positive in overweight premenopausal women with T1DM (Kujack 2015) 
and non-obese postmenopausal women with osteoporosis (Breuil 2014). Although leptin 
and oxytocin act centrally to inhibit food intake (Ott 2013), and leptin effects are partly 
mediated by oxytocin-expressing neurons within the PVN (Blevins 2004), animal and 
human studies have demonstrated that obesity impairs the hypothalamic interplay 
between these peptides (Morton 2012, Chiodera 2000). Oxytocin administration to diet-
induced obese mice or obese humans was shown to bypass leptin resistance and reduce 
caloric intake without affecting leptin levels (Lawson 2015, Fenselau 2017, Thienel 2016). 
These and our results prompt evidence that oxytocin signals bodyweight independent of 
the leptin-sensitive circuitry. 
 
Conclusions 
 
In summary, this is the first study to show that oxytocin undergoes the negative effect of 
obesity and menopause, and that this regulation is inter-independent. Further studies are 
warranted to clarify if menopause intervenes to regulate the energy-regulating actions of 
oxytocin, and thus contribute to explain oxytocin involvement in weight modifications at 
menopause. 
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Tables 
 
Table 1. Anthropometric characteristics in normal weight women and women with 
obesity, after stratification in the pre-menopausal (Pre) and post-menopausal (Post) 
subgroups. 
 
 
Results are expressed as mean ± standard deviation (SD). For statistical significance: ns, not significant; *, 
p<0.05 and §, p<0.001 between normal weight and obese groups. 
For abbreviations: BMI body mass index; FM fat mass; FFM fat-free mass; FM Trunk is indicated as the 
regional percentage of fat mass of trunk. 
  
 
Normal weight women 
(N=53) 
 
Obese women 
(N=56) 
 
  Menopause status   
Parameters  Pre (N=27) 
Post 
(N=26) P 
Pre 
(N=28) 
Post 
(N=28) P 
Age (yrs) 47.6±3.6 56.7±2.7 <0.001 44.7±3.9* 55.5±3.8 <0.001 
Age at menarche (yrs) 12.6±1 12.5±1.6 ns 11.9±1.8 11.1±0.4* <0.05 
Number of pregnancies 1.33±0.9 1.27±0.87 ns 1.25±1.2 2.25±1.4* <0.05 
Weight (Kg) 62.52±9.6 57.5±6.4 0.03 116.8±9.6§ 113.2±13.6§ ns 
Height (cm) 159.3±6.7 158.1±8.0 ns 158.8±7.2 157±6.2 ns 
BMI (kg /m2) 23.4±3.2 21.9±2.8 ns 46±4.2§ 46.1±4.7§ ns 
FFM (kg) 38.5±5.2 35.6±3.4 <0.05 53.3±5.1 49.8±6.7§ <0.05 
FM (%) 37.7±6.6 36.4±8.4 ns 51.8±3.4§ 53.2±3.1* ns 
FM Trunk (%) 36.1±8.6 35.3±9.9 ns 51.2±4.5* 53.5±4.3* ns 
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Table 2. Baseline hormone and metabolic characteristics in normal weight (NW) and 
obese (OB) study groups, after stratification in the pre-menopausal (Pre) and post-
menopausal (Post) subpopulations. 
 
Results are expressed as mean ± standard deviation (SD). For statistical significance: ns, not significant; 
*p<0.05 and §p<0.001 between normal weight and obese groups.  
For abbreviations: HOMA-IR, homeostatic model of insulin resistance; TC, total cholesterol; LDL, low density 
lipoprotein; HDL, high density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
FSH, follicle stimulating hormone; LH, luteinizing hormone; PRL, prolactin; E2, total estradiol. 
  
 
 
Normal weight women 
(N=53) 
 Obese women 
(N=56) 
 
  Menopause status   
   Parameters Pre (N=27) 
Post 
(N=26) P 
Pre 
(N=28) 
Post 
(N=28) P 
Oxytocin (pg/mL) 3.5±2.1 2.3±1.9 <0.05 1.31±1.5§ 0.4±0.6§ 0.005 
Leptin (ng/mL) 21.5±11.7 16.5±10.9 ns 75.5±21.8§ 78.8±29.7§ ns 
Adiponectin (µg/mL) 17.4±9.0 21.8±9.7 ns 8.11±3§ 11.2±5.3§ 0.01 
Glucose (mg/dL) 88.59±11.5 87.88±8.8 ns 102±16* 111.9±32* ns 
Insulin (mg/dL) 8.3±4.8 7.1±3.7 ns 14.8±8.4* 14.1±8.5* ns 
HOMA-IR 1.86±1.3 1.56±0.88 ns 3.8±2.4§ 3.8±2.3§ ns 
HbA1c (%) 5.34±0.26 5.37±0.24 ns 6.1±0.5§ 6.5±1.4§ ns 
TC (mg/dL) 206±37 214±29.7 ns 211±39.6 199±37.6 ns 
HDL-C (mg/dL) 65±16.5 71.7±17.4 ns 41±9.3§ 42.5±8.4§ ns 
LDL-C (mg/dL) 130.6±34.7 131±29.4 ns 139.2±36.1 126±34.3 ns 
TGL (mg/dL) 90.7±46 94±41 ns 151.5±69.8§ 149.7±54* ns 
AST (U/L) 14.8±5.7 16.9±6.7 ns 28.1±14.4§ 26.4±11.1* ns 
ALT (U/L) 16.7±2.9 19.2±4.3 ns 23.4±10.3§ 20.8±5.4 ns 
FSH (U/L) 21.48±30.5 89.5±23.9 <0.001 6.5±5.4* 45.7±22.3§ <0.001 
LH (U/L) 14.1±14.9 43.8±13.1 <0.001 5.04±4.3* 25.9±10.7§ <0.001 
PRL (mcg/L) 18.2±10.2 11.2±4.9 0.003 21.5±11.3 13.4±8.8   0.005 
E2 (ng/L) 101.4±62.9 28.9±8.1 <0.001 110.2±80 40.2±12.3§ <0.001 
Testosterone (nmol/L) 0.8±0.2 0.9±0.5 ns 1.1±0.5* 1.2±0.6  ns 
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Table 3. Bivariate correlation analysis between oxytocin concentrations and parameters 
of interest in the population as a whole and sub-grouped as normal weight and obese 
women. 
 
Parameters related by significant associations are indicated in bold character. For abbreviations: BMI, body 
mass index; FM, fat mass; FFM fat-free mass; FM Trunk is indicated as the regional percentage of fat mass 
of trunk; HOMA-IR, homeostatic model of insulin resistance; TC, total cholesterol; LDL, low density 
lipoprotein; HDL, high density lipoprotein; TGL, triglycerides; E2, total estradiol. 
  
 Whole 
Population 
(N=109) 
 
Normal-weight 
women 
(N=53) 
 
Obese 
women 
(N=56) 
  Parameters r p  r p  r p 
Age (yrs) -0.17 0.07  -0.32 0.02  -0.33 0.01 
Age at menarche (yrs)  0.31 0.001   0.165 ns   0.13 ns 
Menopausal status -0.26 0.005  -0.28 0.04  -0.37 0.005 
Weight (kg) -0.48 0.001  -0.08 ns   0.17 ns 
BMI (kg/m2) -0.50 0.001  -0.09 ns   0.05 ns 
FFM (kg) -0.40 0.001   0.01 ns   0.1 ns 
FM (%) -0.49 0.001   0.01 ns   0.06 ns 
FM Trunk (%) -0.48 0.001  -0.17 ns  -0.13 ns 
Glucose (mg/dL) -0.24 0.013   0.26 ns  -0.21 ns 
Insulin (mg/dL) -0.19 0.04   0.04 ns   0.09 ns 
HOMA-IR -0.23 0.016   0.07 ns   0.04 ns 
TC (mg/dL)  0.17 0.07   0.16 ns   0.19 ns 
HDL-C (mg/dL)  0.41 0.001   0.08 ns  -0.01 ns 
LDL-C (mg/dL)  0.12 ns   0.15 ns   0.20 ns 
TGL (mg/dL) -0.228 0.017  -0.005 ns   0.09 ns 
E2 (ng/L)  0.132 ns  -0.16 ns   0.28 <0.05 
Leptin (ng/mL) -0.45 0.001  -0.13 ns   0.005 ns 
Adiponectin (µg/mL)  0.22 0.02  -0.06 ns  -0.18 ns 
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Abstract 
 
Purpose. Benign insulinoma is the most common functioning neuroendocrine tumor of 
the pancreas. The gold-standard therapeutic approach for insulinoma is surgery, which 
allows for tumor removal, histology and immunochemical analyses. If surgery is not 
feasible, minimally invasive ablative procedures performed by interventional radiology 
can lead to partial or complete remission of hormone hypersecretion and tumor control 
in insulinoma patients. 
 
Methods. We performed a review of existing literature on non-chemotherapeutic/ 
radioactive ablative techniques employed for the treatment of benign, otherwise 
inoperable, pancreatic insulinoma. For this purpose, feasibility, effectiveness and safety of 
ablative treatments for pancreatic insulinoma were reviewed from literature data 
published from 1982 to date. 
 
Results. A total of 44 insulinoma cases treated with non-surgical ablative techniques were 
desumed, and divided as follows: 7 cases of tumor embolization, 26 ethanol ablations, 7 
radiofrequency ablations, 2 high intensity focused ultrasound ablation, 1 irreversible 
electroporation and 1 percutaneous microwave ablation. Most cases involved single 
insulinoma, predominantly located in the pancreas head and body. In the majority of 
patients, ablation was chosen instead of surgery due to severe comorbidities. After an 
average follow-up of 16 months, the overall success rate of non-surgical ablative 
treatments of insulinoma was 84%, the recurrence/persistence rate was 16%, and 
transient adverse events were noted in 23% of cases. Adverse events were usually self-
limiting and medically manageable. 
 
Conclusions. Non-surgical ablation is a feasible, safe and repeatable procedure in patients 
with pancreatic insulinoma, who are not candidate to surgery or refuse it. Partial or 
complete control of symptoms and tumor growth is experienced by the majority of 
patients. 
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Background 
 
Insulinoma is the most common functioning neuroendocrine tumor of the pancreas 
(pNET), and accounts for 20–30% of all pNETs (Service 1991). Insulinoma is usually 
sporadic and develops as a benign solitary intrapancreatic lesion, whereas ectopic or 
aggressive insulinoma is rare (Grant 2005, Mehrabi 2014). The clinical hallmark of 
iŶsuliŶoŵa is the Whipple͛s tƌiad, ǁhiĐh tǇpiĐallǇ iŶĐludes glucose-responsive 
hypoglycaemia with neuroglycopenia (Pourmotabbed 2001). Because snacking reliefs 
recurrent hypoglycaemic episodes, insulinoma patients may increase calorie ingestion 
and increment their bodyweight or develop obesity in up to 40% of cases, thus mimicking 
the subtle course of the metabolic syndrome (Dizon 1999, Goldin 2008, Inadera 1993). 
Upon radiological identification and localization (Morera 2016), surgery by enucleation or 
distal pancreatectomy represent the therapeutic mainstay in nearly 98% of insulinoma 
cases (Mehrabi 2014). Nevertheless, postsurgical complications can develop in 16–43% of 
patients, particularly if these are abdominally obese (Grant 2005, Arnold 2007, Solcia 
1997). Pharmacological options, such as diazoxide, calcium channel blockers, 
hydrochlorothiazide and somatostatin analogues can aid disease management in patients 
who are inoperable, show persistent postsurgical disease, or necessitate clinical 
improvement to undergo surgery safely (Tucker 2006). Unresponsiveness or intolerance 
to medical therapies usually prompt to explore alternative therapies for insulinoma. 
According to the European Neuroendocrine Tumor Society guidelines (Falconi 2016), the 
use of non-surgical ablative therapies, such as ethanol injection or radiofrequency, can be 
successfully attempted in patients with localized insulinoma who are not candidate to 
surgery. These procedures employ the endoscopic or percutaneous approach, and can be 
assisted by endoscopic ultrasonography (EUS) or CT guidance. To date, there is sparse 
evidence on the feasibility, effectiveness and safety of non-surgical ablative therapies for 
insulinoma (Davì 2017). In this review, we sought to summarize the literature collected 
between 1982 and 2017 on non-surgical ablative approaches in patients with benign 
insulinoma. The search for relevant original publications and case reports in English was 
performed using PubMed, Embase and Google Scholar. The ablative procedures included 
trans-catheter arterial embolization (TAE), ethanol ablation (EA), radiofrequency ablation 
(RFA), high intensity focused ultrasound ablation (HIFU), percutaneous microwave 
80 
 
ablation (PMA) and irreversible electroporation (IRE). An overall summary of data 
published so far is reported in Table 1 (pag. 87, 88). As an index case, we illustrate the 
outcome of trans-catheter embolization in an elderly obese patient with multiple 
comorbidities. 
 
Trans‑catheter arterial embolization 
 
Trans-catheter arterial embolization with particles coated with chemo- or radio-
therapeutic agents is usefully employed in several confined malignant diseases (Huo 
2015). In vascular, urogenital and non-malignant endocrine conditions, TAE has been 
proven as a useful alternative to surgery to achieve partial or definitive cure (Ginat 2010). 
Between 1982 and 2014, TAE has been reportedly performed in six insulinoma-bearing 
patients (Table 1, pag. 87, 88) having an average age of 51 years (range 30–84 years) 
(Moore 1982, Uflacker 1992, Rott 2008, Peppa 2009, Balawejder 2014). Reasons for TAE 
included refusal or failure of surgery or emergency procedure. No pre-intervention 
cytology was reported in any of the cases. The success rate of TAE was 67% while disease 
recurrence was documented in two cases, one of whom suffered from MEN-1. Post-
procedure complications included abdominal pain, increase in liver enzymes, mild 
pancreatitis and transitory mild diabetes. 
In our index case, TAE was performed in 2007 by dedicated interventional radiologists (BD 
and VT) on a 72-year old female patient bearing an isolated cephalo-pancreatic 1.7 × 1.5 
cm insulinoma (Figure 1, pag. 90). This patient presented with incoercible obesity, 
unstable hypertension with hypertrophic cardiomyopathy, moderate ventilatory failure 
and obstructive sleep apnea, and was unresponsive to octreotide and mildly responsive 
to high-dose diazoxide (800 mg daily). Selective trans-catheter embolization was 
performed using tris-acryl gelatin-Đoated ϰϬ μŵ ŵiĐƌospheres on two separate steps, one 
year apart (Figure 1, pag. 90). The procedure was well tolerated and led to partial tumor 
necrosis with near-complete recovery from hypoglycemia. After 10 year follow-up, this 
patient has achieved a marked clinical improvement (Table 2, pag. 89), despite a mild 
residual disease which is well controlled by low-dose diazoxide therapy (200 mg daily). 
Regular CT scans performed during follow-up did not show significant dimensional 
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changes of the pancreatic lesion, showing a size of 1.6 × 1.3 cm at the last CT scan 
performed in March 2017. 
Considering also this index case, the final success rate of TAE was 57%. Based on ours and 
otheƌs͛ eǆpeƌieŶĐe, TAE ƌepƌeseŶts a feasiďle aŶd ƌepeataďle pƌoĐeduƌe in severely 
complicated patients with insulinoma, and can be associated with transient and self-
limiting adverse events. 
 
Ethanol ablation 
 
Ethanol ablation is a minimally invasive approach successfully used to treat benign 
lesions, to achieve neurolysis in chronic pain, and to control growth of unresectable 
malignancies (Zhang 2013). Recently, EA by EUS guidance has been shown to treat safely 
and effectively localized pancreatic tumors in patients who are poor candidates to surgery 
(Zhang 2013). 
A total of 26 insulinoma cases have been treated so far by EA (Table 1, pag. 87, 88) 
(Jurgensen 2006, Deprez 2008, Vleggaar 2011, Levy 2012, Lee 2013, Qin 2014, Yang 2015, 
Paik 2016, Trikudanathan 2016, Burghardt 2017, Lages 2017). The aǀeƌage patieŶts͛ age 
was 63 years, and nearly 40% of patients were aged >75 years. Reasons for EUS-guided EA 
included morbid obesity, clinical impairment for comorbidities, intraoperative 
complications, surgery refusal and elective therapy. EUS-FNA or biopsy with cytological 
and immunohistochemical analysis was only assessed in eight cases. Overall success rate 
of EA was 85% and disease recurrence was only observed in 15% of patients. Of note, 
successful treatment was achieved in two cases bearing multiple insulinomas (one of 
whom suffered from MEN-1). Literature data shows variability on the final ethanol 
concentration, ranging between 95 and 99%, and on the injected volume of ethanol, 
which should be not greater than half of the tumor volume per single interventional 
session (Qin 2014). Post-procedure complications included localized abdominal pain, 
pseudocysts, and mild elevation of pancreatic enzymes in 19% of cases. However, 
symptoms typically subsided within 48 h following the procedure. Rare but medically 
manageable complications included late occurrence of hematoma and duodenal 
ulceration (Deprez 2008). A relationship between occurrence of complications and the 
opeƌatoƌ͛s eǆpeƌieŶĐe has ďeeŶ suggested (Qin 2014). Together, current literature 
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documents that EA of insulinoma is clinically effective, minimally invasive and at low 
complication risk when compared to surgical treatment (Jurgensen 2006, Deprez 2008, 
Vleggaar 2011, Levy 2012, Lee 2013, Qin 2014, Yang 2015, Paik 2016, Trikudanathan 
2016, Burghardt 2017, Lages 2017). Potential limitations or caveats to account for are 
constituted by small lesions, proximity to blood vessels, and risk of haemorrhage (Qin 
2014). 
 
Radiofrequency ablation 
 
Radiofrequency ablation is a well-established minimally invasive procedure that is usually 
performed under local anaesthesia and mild sedation, and is successfully used to ablate 
dysplastic and neoplastic tissue via local thermal coagulative necrosis (Rustagi 2017). 
Despite its widespread application for the treatment of malignancies, RFA has been rarely 
used to treat pancreatic diseases due to an intrinsic risk of complications derived from an 
increased sensitivity of pancreatic tissue to thermal injury and the proximity to vascular 
and biliary structures (Rustagi 2017). 
Seven case reports have been so far published of insulinomas treated by RFA (Table 1, 
pag. 87, 88), 5 of which by EUS-guided RFA (Limmer 2009, Prochàzka 2012, Waung 2016, 
Lakhtakia 2016, Bas-Cutrina 2017). Aǀeƌage patieŶts͛ age ǁas ϲϬ Ǉeaƌs, aŶd ŵost ǁeƌe 
suffering from clinical comorbidities such as obesity, ischemic cardiomyopathy, atrial 
fibrillation, chronic pancreatitis or concomitant neoplasms. EUS-FNA with cytological and 
immunohistochemical analysis was performed in two cases. The overall success rate of 
RFA was 100%, and no case of disease recurrence was noted. Post-procedure 
complications included transitory diabetes in one case (Prochàzka 2012). Although limited 
by the small sample size, current studies suggest that RFA is a technically feasible, safe 
and highly effective therapeutic methodology in selected patients with insulinoma, in 
whom surgery is not an option (Limmer 2009, Prochàzka 2012, Waung 2016, Lakhtakia 
2016, Bas-Cutrina 2017). There is growing interest on pancreatic RFA, yet a few 
theoretical concerns and limitations should be reckoned, such as the lack of 
standardization and the need for dose–effect dosimetry studies. Sorting out these issues 
could help to clarify the relationship between energy delivery, duration of application and 
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the zone of ablation produced to safely and effectively ablate pancreatic insulinoma 
(Rustagi 2017). 
  
High intensity focused ultrasound ablation 
 
High intensity focused ultrasound ablation has been recently introduced for the 
treatment of pancreatic cancer (Wu 2005) and is receiving increasing interest for the 
treatment of several primary tumors and metastasis (Orgera 2010). Wu et al. reported 
that HIFU is safe and feasible for the treatment of patients with pancreatic cancer, 
without the evidence of post-procedural complications (Wu 2005). HIFU achieves ablation 
by means of focused US energy from an external source that is targeted within the body, 
resulting in thermally induced localized necrosis (Orgera 2011). Orgera et al. described 
the use of HIFU for ablation of two insulinomas, demonstrating that this technique is a 
clinically successful procedure capable of improving disease control and quality of life in 
inoperable patients (Orgera 2011). In one case, benignity was defined through biopsy 
with histological examination. An important limitation of this methodology is the need for 
general anaesthesia in most cases. Therefore, this therapeutic approach should reserved 
for the treatment of patients whose symptoms cannot be controlled by medical therapy 
and who are not candidates to surgery or any other minimally invasive treatment (Orgera 
2011). 
 
Percutaneous microwave ablation 
 
Percutaneous microwave ablation has been used as a palliative treatment modality for 
locally advanced pancreatic cancer (Lygidakis 2007). Tissue-specific advantages of PMA 
have been identified in the liver, kidney, lung, and bone, while experience in the 
treatment of pancreatic lesions is limited. Among thermal ablative techniques, PMA 
shows several potential advantages over RFA when applied to pancreatic mass ablation, 
including faster heating over a larger volume of tissue with less susceptibility to heat sink 
effects and high impedance tissues, ability to use multiple applicators, and independence 
from grounding pads (Chen 2015, Lubner 2010). 
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Its employment for the treatment of insulinoma has been described only in the case of a 
60-year old patient, who underwent PMA because of complicated obesity (Chen 2015). 
Benignity was established on the basis of EUS-FNA with cytological and 
immunohistochemical analysis. In this patient, the procedure was successful and no 
recurrence nor post-procedure complication was reported (Table 1, pag. 87, 88). Indeed, 
larger studies and extended follow-up are needed to determine the effectiveness of this 
treatment for insulinoma. 
 
Irreversible electroporation 
 
Irreversible electroporation is a novel non-thermal ablative technique mainly used for 
treating liver tumors and pancreatic adenocarcinomas in patients who are not eligible to 
surgical or conventional ablative treatments (Dunki-Jacobs 2014). This technique uses 
high-voltage electric pulses directed to tumor cells resulting in the creation of nano-pores 
within the phospholipid bilayer of cell membrane, ultimately inducing apoptotic cell death 
(Ierardi 2014, Scheffer 2015, Philips 2013). It is considered superior to other ablative 
methods because it preserves vital structures such as vessels, nerves or ducts (Scheffer 
2015, Philips 2013, Paiella 2015). IRE yields potential benefit in locoregional palliation and 
overall survival in the locally advanced, non-metastatic pancreatic cancer (Moir 2014). 
Complications include bleeding, bile/pancreatic leak, portal vein thrombosis, duodenal 
perforation, pancreatitis and cardiac arrhythmias (Martin 2013). The employment of this 
method for the treatment of benign insulinoma has been described only in the case of a 
29-year old patient, who underwent IRE and developed mild pancreatitis after the 
procedure, which was treated conservatively (Papamichail 2016). Benignity was 
established on the basis of EUS-FNA with cytological and immunohistochemical analysis. 
In this patient, resolution of the insulinoma-related symptoms occurred without disease 
recurrence. Indeed, larger studies and extended follow-up are needed to confirm the 
effectiveness and safety of this type of treatment for benign insulinoma. 
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Conclusions 
 
Islet cells are surrounded by a rich blood supply and receive about 10–15% of the 
pancreatic blood flow (Horton 2006), therefore, insulinoma is a suitable target for non-
surgical ablative approach for the treatment of patients who are at increased 
anesthesiological/surgical risk, or at high risk of post-surgical complications. In terms of 
success and adverse  events, most cases of non-surgical ablation described so far have 
focused on isolated and, rarely, multiple insulinomas, with diameter up to 75 mm, mostly 
located in the pancreas head and body. Benignity was reportedly established on the basis 
of endoscopic ultrasound (EUS)-fine-needle aspiration (FNA) or biopsy with cytological 
and immunohistochemical analysis only in 13 cases, thus that the lack of cytological 
verification of benignity remains an issue. 
There are currently insufficient comparative data to discriminate which, among the non-
surgical ablative techniques, achieves the best clinical outcome for the treatment of 
insulinoma. Collectively, EA and RFA seem to offer greater success in terms of disease 
remission. However, it should be borne in mind that some of the mentioned studies are 
possibly ongoing, and far more patients have been treated than those published; likely, 
this approach could be preferred over a Whipple͛s procedure when this is necessary 
because of the tumor location. Although the overall rate of complete disease control is 
84%, a true success rate cannot be assessed because of the short duration of follow-up of 
most cases described to date (Davì 2017). PatieŶt͛s ĐliŶiĐal ĐoŶditioŶs aŶd tuŵoƌ 
characteristics (e.g., location, dimension, distance from the pancreatic duct and 
vascularization pattern) may support the clinician in selecting the candidate patients and 
the most pertinent ablative procedure. Obesity per se does not seem to constitute a 
contraindication to non-surgical ablative procedures for insulinoma, with the potential 
exception of RFA due to deep layer of abdominal adipose tissue separating the source of 
RFA from the pancreatic tumor. In our 10-year index case experience, TAE provided a 
favourable rescue treatment in a severely obese patient with life-threatening 
complications. The overall reported recurrence/persistence rate was 16%, but the time to 
recurrence remains unknown in most cases, and longer follow-ups could help to better 
profile the true success rates. Adverse events were only noted in 23% of cases, and these 
were usually self-limiting and medically manageable. While surgery remains a therapeutic 
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mainstay in eligible patients because definitive cure is a treatment target for insulinoma 
(Falconi 2016), we are inclined to suggest that non-surgical ablation of symptomatic well-
defined insulinoma is a feasible, inimally invasive, safe and repeatable procedure in 
patients if they are elderly, or poor candidate to surgery, or if they refuse surgery. Clinical 
trials and longer follow-ups are warranted to define the role of these procedures in the 
treatment algorithm for insulinoma. 
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Tables 
 
Table 1. Summary of the main case reports related to minimally invasive therapeutic procedures of benign insulinomas. 
Author N° of cases Age Gender 
Tumor 
Size (mm) 
Location 
of Tumor 
Reason for the choice 
of treatment N° of treatments 
Post-procedure 
complications 
Follow up 
(months) Recurrence 
Time of 
Recurrence 
(months) 
Ethanol Ablation 
Jürgensen 2006 1 78 F 13 Body Refusal of surgery Comorbidities 1 
- Abdominal pain 
- Mild acute pancreatitis 34 No - 
Deprez 2008 1 78 F 20 Head Comorbidities 1 - Mild pancreatitis - Ulcer of the duodenal wall 24 No - 
Vleggaar 2011 1 82 F 9.5 Body Comorbidities 1 None 6 No - 
Levy 2012 8 
67 M 11 Head Refusal of surgery 1 None 16 No - 
72 F 17 Head Refusal of surgery 3 None 13 Yes 13 
60 M 14 Head Refusal of surgery 1 - Fluid collection - Pseudocyst 35 No - 
82 M 23 Tail Comorbidities 2 None 13 Yes 13 
80 F 21 Body Comorbidities 2 None 12 No - 
57 F 9 Head Refusal of surgery 2 None 38 Yes 38 
34 M 16 Head Previous abdominal surgery 2 None 5 No - 
79 F 15 Head Intraoperative surgery complications 1 
- Pancreatitis 
- Pseudocyst 7 No - 
Lee 2013 1 26 F 17 (multiple lesions) Head, body, tail Elective 1 None 12 No - 
Qin 2014 4 
48 F 10 Head Refusal of surgery 1 None 6 No - 
56 F 5.4 Head Refusal of surgery 1 None 4 No - 
56 M 11.8 Junction of head and body Refusal of surgery 1 None 5 No - 
66 F 10 Body Refusal of surgery 1 None 2 No - 
Yang 2015 4 
59 
(mean  
age) 
N/A N/A N/A Comorbidities Surgical failure 
2 (n=1) 
1 (n=3) N/A 
17.3 (mean) 
(range, 2-30) 1 N/A 
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Paik 2016 3 
99 M 9 Head Age 1 None Not specified No - 
20 M 11 Head Not specified 1 None Not specified No - 
32 M 14 Head Surgical failure 2 Abdominal pain 6 No - 
Trikudanathan 
2016 1 66 M 14 Head Comorbidities 1 None 1.5 No - 
Burghardt 2017 1 65 F 13 Junction of head and body Comorbidities 1 None 12.5 No - 
Radiofrequency Ablation 
Limmer 2009 1 80 F 15 Tail Surgical risk 1 None 7 No - 
Procházka 2012 1 75 F 17 Body Comorbidities 1 Transitory diabetes 3 No - 
Waung 2016 1 70 F 18 Uncinate Comorbidities 3 None 10 No - 
Lakhtakia 2016 3 
42 M 14 Body Comorbidities 1 None 12 No - 
41 M 17 Genu Comorbidities 1 None 12 No - 
52 M 22 (multiple lesions) Head, body, tail Surgical risk 1 None 12 No - 
Bas-Cutrina 2017 1 63 F 10 Body Comorbidities 1 None 10 No - 
Arterial Embolization 
Moore 1982 1 38 F 20 Head Surgical failure 1 
- Low-back pain 
- Nausea 
- ↑ iŶ liǀeƌ eŶzǇŵe ǀalues 
11 No - 
Uflacker 1992 2 
56 M 18 Head Refusal of surgery 2 - Abdominal pain - Hyperamylasaemia 18 No - 
49 M 20 Body Emergency 1 None 40 No - 
Rott 2008 1 84 F 14 Head Refusal of surgery 1 
- Abdominal pain 
- Mild pancreatitis 
- Transitory mild diabetes 
12 No - 
Peppa 2009 1 30 M 30 Peripancreatic Post-surgical recurrence 1 Abdominal pain 12 Yes 12 
Our case 1 72 F 17 Head Comorbidities 2 - Abdominal pain - Mild pancreatitis 108 Yes 48 
Percutaneous Microwave Ablation 
Chen 2015 1 60 M 32 Neck 
Comorbidities and 
limited life 
expectancy 
1 None 3 No - 
 
MEN 1, Multiple Endocrine Neoplasia type 1; OSA, Obstructive Sleep Apnea; COPD, Chronic Obstructive Pulmonary Disease 
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Table 2. Summary of anthropometric and biochemical data relating to pre-treatment and 
post-treatment period and during the last follow up evaluation. 
 
Parameters Before embolization (2007) 
After embolization 
(2009) 
Last follow up 
(2017) 
Weight (kg) 119.4 82.5 104 
Height (cm) 154 154 154 
BMI (kg/m2) 50.3 34.8 43.8 
Waist (cm) 138 116 123 
Hip (cm) 125 120 123 
WHR 1.10 0.96 1.00 
FM (%) 52.3 47.4 48.2 
FFM (Kg) 57.1 46.5 53.9 
REE (kcal/24 hour) 1575 1428 na 
Fasting Glucose (mg/dL) 49 67 78 
Fasting Insulin (mU/L) 40.5 6.7 18.1 
 
BMI body mass index, WHR waist-to-hip ratio, FM fat mass, FFM free fat mass, REE resting energy 
expenditure 
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Figures 
 
Figure 1. Index case of pancreatic head insulinoma. Pre-treatment CT scan (a), post-
treatment CT scan (markedly reduction in size with necrotic behaviour can be observed) 
(b); late arterial phase of gastroduodenal artery angiogram before embolization (c) and 
complete devascularisation 5 min after embolization (d). 
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TYPE 2 DIABETES: FROM MOLECULES FOR ITS TREATMENT TO 
MEDICATIONS PREDISPOSING TO ITS ONSET 
 
Introduction 
 
The rise in type 2 diabetes mellitus (T2DM) parallels the global increase in the prevalence 
of obesity. Ninety percent of patients with T2DM are overweight or obese, and over 60% 
of cases of type 2 diabetes can be attributed directly to excess body weight (Hu 2001). 
Outcomes are significantly worse in type 2 diabetic patients who are also obese, including 
an increased risk of cardiovascular disease and all-cause mortality of 44% and 71%, 
respectively (Eeg-Olofsson 2009). The etiology of type 2 diabetes is complex, and is the 
product of a combination of genetic predisposition and often, excess body weight 
(Pedersen 2013). Excess adipose tissue increases the risk of T2DM by increasing resistance 
to insulin-mediated peripheral glucose uptake. The mechanisms by which this occurs are 
complex, involving a host of adipokines and inflammatory mediators. 
Developing peptides to treat obesity and/or diabetes is a relatively recent advance, but of 
importance, the clinical success of this concept has been evidenced by the usefulness of 
intestinal peptide glucagon-like peptide-1 (GLP-1) in controlling obesity as well as 
diabetes (Briones 2006). The human GLP-1 analogues, besides improving glico-metabolic 
homeostasis and promoting weight loss, are able to explicate extraglycemic effects on 
renal function. 
In the same time, some therapies used in the treatment of conditions associated with 
diabetes, could increase the risk of development of diabetes. 
 
This section aims to explore: 
- The effects of liraglutide on renal function in type 2 diabetes. 
- Glucose abnormalities and new-onset diabetes (NOD) in statins users. 
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Abstract 
 
Background. Unlike GLP-1, liraglutide is not cleared by the glomerulus and its 
pharmacokinetic is not altered in patients with mild renal impairment. The aim of our 
study was to analyze the effects of liraglutide on renal function in patients with type 2 
diabetes. 
 
Methods. A twelve-month longitudinal prospective post-marketing study was performed. 
According to eGFR (estimated glomerular filtration rate) calculated with CKD-EPI 
equation, 84 consecutive patients were divided in Group A (eGFR>90 ml/min) and Group 
B (eGFR<90 ml/min). BMI, glucose, HbA1c, serum creatinine, microalbuminuria, and eGFR 
were evaluated at baseline and after 12 months of treatment.  
 
Results. A reduction in fasting plasma glucose (p<0.01), HbA1c (p<0.003), BMI (p<0.01), 
and systolic (p<0.01) and diastolic blood pressure (p<0.006) was recorded irrespective of 
eGFR category. Concerning renal function, creatinine levels had a trend to decrease in 
both groups. eGFR did not change in Group A, while it increased in Group B (p<0.05) 
independently from the concomitant changes of other parameters. Moreover, seven out 
of 41 patients of Group B had increased eGFR levels which reached the normal values 
(>90 ml/min). At baseline, five patients had pathological microalbuminuria, but at 12 
months three of them returned to normal albuminuria (p<0.006). Total microalbuminuria 
levels improved in both groups (p<0.02).  
 
Conclusion. According to preliminary data in animals, our study shows that liraglutide is 
effective in preserving eGFR in diabetic patients, increasing it in those with reduced renal 
function. This was associated with a decrease of frequency of patients positive to 
microalbuminuria. Further studies are needed to confirm these data. 
  
94 
 
Background 
 
Liraglutide is a human GLP-1 long-acting analog approved for once daily treatment for 
patients with type 2 diabetes.  
Liraglutide, which shares 97% structural homology with human GLP-1, has a longer half-
life than the native hormone and similar pharmacokinetics, with no single organ 
responsible for its major removal (Malm-Erjefalt 2010). After a single dose of liraglutide, 
no intact molecules of the GLP-1 analog were found in urine or feces, suggesting slow 
degradation into small peptides, aminoacids, and fatty acid fragments eliminated through 
the liver or the kidney. Pharmacokinetic studies failed to identify a specific excretory 
organ, suggesting that liraglutide could be metabolized in a way similar to that of large 
proteins (Malm-Erjefalt 2010). 
Unlike GLP-1, liraglutide is not cleared by the glomerulus and its pharmacokinetic is not 
altered in patients with mild renal impairment (Davidson 2011). Those properties may 
offer advantages in using liraglutide in patients with impaired renal function. In fact, dose 
adjustment is not required in these patients, while the use of liraglutide in patients with 
moderate or greater renal dysfunction is not recommended because of lack of clinical 
experience (Russell-Jones 2010). 
Several studies demonstrated that liraglutide effectively lowers glycosylated hemoglobin 
(HbA1c) as monotherapy or in combination with oral anti-diabetic drugs (Madsbad 2009). 
A metaanalysis showed that mild renal impairment did not significantly affect the 
reduction of HbA1c or the percentage of patients reaching glycemic targets. Moreover, 
Liraglutide was not associated with acute changes in renal function as measured by serum 
creatinine supporting data on its safety in patients with mild renal impairment (Madsbad 
2009). 
However, there is a lack of data about the renal effects of liraglutide, especially in the 
daily clinical practice, despite evidence supporting a role of GLP-1 in modulation of renal 
function (Gutzwiller 2004). Different studies showed that GLP-1 is able to induce diuresis 
and natriuresis, but the mechanisms that regulate those effects are still unknown. GLP-1 
receptor has been recently detected in porcine proximal tubular cells, where it reduces 
sodium reabsorption (Schlatter 2007). Moreover, the infusion of GLP-1 activates an 
intracellular pathway mediated by cAMP/PKA which causes an increase in glomerular 
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filtration rate (GFR), renal plasma flow, and bicarbonate and fractional potassium 
excretion (Crajoinas 2011) in addition to its diuretic and natriuretic effects. The evidence 
that this peptide increases both GFR and renal plasma flow suggests that GLP-1 might 
exert a direct effect on renal vasculature, most likely by decreasing the resistance of the 
pre-glomerular capillaries (Moreno 2002, Nystrom 2005).  
Based on the above, the aim of our study was to analyze the effects of 12-month therapy 
with liraglutide on renal function in a group of patients with type 2 diabetes. 
 
Methods 
 
We performed a longitudinal, prospective, observational study. Study quality was 
assessed using the checklist ͞STROBE͟ ;foƌ ͚“TƌeŶgtheŶiŶg the Reporting of OBservational 
studies iŶ EpideŵiologǇ͛; additioŶal file ϭͿ ;“uppleŵeŶtal Table 1). We consecutively 
recruited patients with type 2 diabetes, referred to the Diabetes and Endocrine Unit of 
the ͞Maggiore della Carità͟ hospital in Novara from August 2010 to April 2013, and all 
patients were evaluated at baseline and after 12 months of treatment. 
We considered all eligible patients with type 2 diabetes not on target with common oral 
anti-diabetic drugs (HbA1c>7 % or >53 mmol/mol), to which we added a daily injection of 
liraglutide. Patients were excluded from the study whether they (1) had poor compliance 
to treatment with liraglutide (fear of daily subcutaneous injection, elderly people unable 
to self-administer the drug, people suffering from senile dementia and/or 
neurodegenerative diseases); (2) had renal failure requiring dialysis; (3) had a history of a 
renal disease different fromthat due to diabetes or hypertension (kidney stones, 
metabolic diseases, glomerulonephritis, etc.); and (4) did not gave theirconsent to 
undergo a regular and periodic follow-up, as required by the Italian Agency of Drugs 
(AIFA). 
We evaluated at baseline and after 12 months of therapy BMI, glucose, HbA1c, serum 
creatinine, microalbuminuria, and estimated glomerular filtrate rate (eGFR), calculated 
with the MDRD (Florkowski 2011) and CKD-EPI equation (Levey 2009). All the formulas are 
reported in Supplemental Table 2.  
Patients were subdivided in Group A and Group B according to eGFR estimated with CKD-
EPI, because MDRD equation has a low accuracy for an eGFR>90 ml/min/1.73 m2 
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(Florkowski 2011, Levey 2009). Patients were included in Group A if they had a normal 
renal function (eGFR>90 ml/min) and in Group B if it was impaired (eGFR<90 ml/min). 
However, nine patients were discordant for eGFR if evaluated with MDRD equation, eight 
in group A and 1 in group B, respectively. 
Height was measured by the Harpenden stadiometer to the nearest mm with the subject 
head in Frankfurt plane and weight using electronic scale both taken in triplicate. 
Averaged BMI was calculated as body weight divided by squared height (kg/m2).  
Plasma glucose levels (mg/dl; 1 mg/dl: 0,05551 mmol/l) were measured by the 
glucooxidase colorimetric method (GLUCOFIX, by Menarini Diagnostici, Florence, Italy). 
HbA1c levels were measured by the high-performance liquid chromatography (HPLC), 
using a Variant machine (Biorad, Hercules, CA); intra- and inter-assay coefficients of 
variation are, respectively, lower than 0.6 and 1.6%. Linearity is excellent from 3.2 (11 
mmol/mol) to 18.3% (177 mmol/mol). Serum creatinine levels were assessed with the 
enzimatic method of creatinine deamidase/GLDH (Adivia Chemistry-Bayer). 
 
Statistical analysis 
 
All data are expressed as mean ± standard deviation (SD), absolute or delta values. A 
sample of 60 individuals has been estimated to be sufficient to demonstrate a difference 
of 10.0 ml/min in eGFR with an SD of 16 with 90% power, a significance level of 95% using 
the Student t test, and a drop out of 10%. Distributions of continuous variables were 
examined for skewness and were logarithmically transformed as appropriate. Analysis of 
covariance was used to determine differences in subjects with and without renal 
impairment. Analysis of repeated measures was used to determine differences in subjects 
before and after the treatment with liraglutide. Covariates were sex, age, BMI, disease 
duration, number of drugs for hypertension, use of ACE-inhibitors, angiotensin receptor 
blockers (ARBs), or diuretics (yes/no). A stepwise regression was used to determine the 
association of changes (expressed as delta values) among each variable and delta of the 
others. The v2 test was used to determine difference in distribution. Statistical 
significance was assumed at p<0.05. The statistical analysis was performed with SPSS for 
Windows V.17.0 (SPSS Inc., Chicago, IL, USA). 
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Results 
 
A population of 243 patients was firstly selected, but 159 subjects failed to respect the 
inclusion criteria and were excluded. In particular, (a) 58 subjects did not gave the 
informed consent; (b) 41 did not performed the evaluation of creatinine at baseline or 
after 12 months of therapy; (c) 37 showed no compliance to therapy; (d) 20 had 
discrepant data between our database and that of AIFA; and (e) three drop out for 
gastrointestinal adverse events. Of the 84 patients (age 59.9±11.1 years) who met 
inclusion criteria and completed the 12-month follow-up and were definitively studied, 73 
of them were on therapy with 1.2 mg/day of liraglutide, ten with 1.8 mg/day, and only 
one with 0.6 mg/day. Liraglutide treatment was associated with metformin (42 patients), 
sulphonylurea (two patients), metformin plus sulphonylurea (37 patients), or repaglinide 
(three patients). Sixty-six patients had hypertension, of which 18 took ACE-inhibitors, 30 
ARBs, and 22 diuretics (19 of them in co-administration with ACE-inhibitors or ARBs). 
Complete clinical characteristics of Group A and B are listed in Table 1 (pag. 103). Group A 
and B were composed by 43 and 41 patients, respectively. The liraglutide dose was 1.2 ± 
0.1 and 1.2 ± 0.2 mg/day in Group A and B, respectively. In Group B, 30 patients had a 
mild renal impairment (eGFR 60–89 ml/min), meanwhile 11 of them had a moderate 
renal impairment (eGFR 31–59 ml/min). In the whole population, 12-month therapy with 
Liraglutide induced a reduction in fastiŶg plasŵa gluĐose ;Δ -2.39±4.08 mmol/l; p<0.01), 
HďAϭĐ ;Δ -ϭ.Ϭϱ±ϭ.ϳϭ%; Δ -11.20±17.74 mmol/mol; p=Ϭ.ϬϬϯͿ, BMI ;Δ -2.13±6.39 kg/m2; 
p<Ϭ.ϬϭͿ, aŶd sǇstoliĐ ;Δ -13.51±27.20 mmHg; p<0.01) and diastolic blood pƌessuƌe ;Δ -
5.42±13.91 mmHg; p=0.006). Similar results were recorded for both GroupA and GroupB 
(Table 1). The reduction of systolic and diastolic blood pressure remained significant also 
when weighted for changes inBMI, glucose levels, and HbA1c in the whole population and 
in both subgroups. The number of hypertensive patients did not change (31 and 35 
patients in Group A and B, respectively); however, five out of 66 patients (all of Group B) 
reduced the number of drugs for the treatment of hypertension. The liraglutide dose was 
1.2 mg/day in all of them. 
Concerning renal function, creatinine levels had a trend to decrease without reaching 
significance, without any differences between the two groups (Table 1, pag. 103). After 12 
months of treatment, eGFR irrespective of the formula used did not change in Group A, 
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while increased in Group B (p<0.05) (Figure 1, pag. 104). The variation of eGFR 
irrespective of the formula 
used was found to be independent from the concomitant changes of the other 
parameters (BMI, glucose, HbA1c, and blood pressure values) and by the number of the 
type of drugs for hypertension or renal impairment. Moreover, at the end of the study 
period, three patients of Group A showed a reduction in eGFR values below the normal 
range (<90 ml/min), while seven patients of Group B had increased eGFR levels which 
improved and reached the normal values (>90 ml/min). The liraglutide dose was 1.2 
mg/day in all of these seven patients. All the three patients of Group A with a worsening 
in eGFR had basal eGFR<100 ml/min (respectively 94, 96, and 99 ml/min), a BMI>30 
kg/m2, dyslipidemia, and hypertension under specific treatment, but not albuminuria. The 
liraglutide dose was 1.2 mg/day in two of them and 1.8 mg/day in the last one. No 
complications or worsening of comorbidities occurred during the 12 months of 
observation in these three subjects. 
At baseline, five patients had pathological microalbuminuria (three from Group A and two 
from Group B, respectively). At 12 months, three of them presented albuminuria in the 
normal range (p=0.006) and the other two of them (both from group A) showed an 
improvement in microalbuminuria levels. Total microalbuminuria levels improved in both 
gƌoups ;Δ -2.54 ± 10.32 mg/24 h; p=0.02) also when weighted for number of drugs for 
hypertension, or use of potential interfering drugs. 
 
Discussion 
 
Liraglutide is not predominantly eliminated by renal excretion. Some meta-analyses of 
Phase III studies showed that liraglutide is safe and effective in patients with type 2 
diabetes at different stages of renal function (Madsbad 2009, Marre 2009, Neumiller 
2010, Rigato 2014). 
Our study confirmed the efficacy of liraglutide in improving glycemic control in patients 
with type 2 diabetes, by reducing fasting plasma glucose and HbA1c levels, irrespective of 
eGFR, but more strikingly showed that liraglutide did not deteriorate serum creatinine 
levels and eGFR in patients with normal renal function and improved eGFR in those with a 
mild or moderate renal impairment. 
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First of all, we confirmed data of the registration studies on the efficacy of liraglutide 
about the reduction of fasting glucose, HbA1c, and BMI in a single-center daily clinical 
practice, where the compliance to treatment is frequently poor, number of visits each 
Ǉeaƌ is less, aŶd patieŶts͛ characteristics are more heterogeneous with respect to 
registration studies (Neumiller 2010, Rigato 2014, Aimaretti 2009). The reduction of 
parameters was comparable to Phase III studies (Davidson 2011, Aimaretti 2009, Henry 
2011) and also with the ABCD nationwide post-marketing study conducted in UK which 
included patients also with mild or moderate renal impairment (Thong 2013). Moreover, 
the degree of clinical improvement is irrespective of renal function at baseline. It has to 
note that ABCD study referred to first 6 months of treatment, meanwhile our data 
confirmed the efficacy of liraglutide in renal impairment over 12 months of therapy. 
We also observed a reduction in both systolic and diastolic blood pressure irrespective of 
the renal function. Data derived by previous studies (Vilsboll 2007, Wang 2013, Robinson 
2013, Katout 2014) showed positive effects of liraglutide on the reduction of diastolic 
and, more strongly, systolic blood pressure irrespective of the combined therapy for the 
treatment of diabetes, as also an improvement of the cardiac function (Okada 2014). The 
main hypothesized mechanism for the reduction of blood pressure was the weight 
decrease; however, we observed that this was independent of the changes in glucose, 
HbA1c, and BMI. It has to mention that GLP-1 has been demonstrated to have natriuretic 
and vasodilatatory effects due to inhibition of Na+ reabsorption in the proximal tubule, 
attenuation of angiotensin II-induced phosphorylation of extracellular signal-regulated 
kinase-1/2 in renal cells, and NO-dependent and independent mechanism in endothelium 
(Gutzwiller 2004, Crajoinas 2011, Wang 2013, Hirata 2009, Anagnostis 2011). The fact 
that the magnitude of changes in blood pressure was identified also in mild or moderate 
renal impairment and that five patients with this alteration reduced the number of drugs 
for hypertension leads to hypothesize that the treatment could have a further role in this 
condition where lower blood pressure levels are recommended and, frequently, difficult 
to achieve. 
Furthermore, we did not observe any significant changes in serum creatinine levels, 
independently by daily dosing of liraglutide, even if a trend to decrease was observed. 
These data are in agreement with those pooled by meta-analysis and systematic reviews 
of clinical trials on patients with mild-to-severe renal impairment (Davidson 2011, 
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Jacobsen 2009, Giorda 2014). This is in line with those reported in the ABCD study where 
significance, maybe due to the higher sample size, was reached (Thong 2013). However, a 
direct effect on kidney with a following improvement of nephropathy cannot be excluded, 
by considering that the activation of GLP-1 receptor was associated with the reversion of 
nephropathy in diabetic rats (Liu 2012). 
Accordingly, with this hypothesis and with data in animals, our observation of a reduction 
of percentage of patients with albuminuria is in agreement with other pilot studies with 
exenatide (Zhang 2012) or DPP-4 inhibitors (Haluzik 2013). Finally, we observed stable 
eGFR levels in those with normal renal function, and, more strikingly, an improvement in 
those patients with a mild or moderate renal impairment with a tendency towards 
normal levels in a subgroup of them. To evaluate this aspect, we used two formulas, the 
MDRD and the CKD-EPI equations. This was done because the Cockcroft-Gault formula for 
calculation of eGFR has some limitations. The MDRD equation overtakes the limits due to 
body weight or height in patients with chronic kidney diseases. Although helpful, poorer 
performance of the MDRD formula was reported at low plasma creatinine concentrations 
(corresponding to higher levels of renal function) and tends to underestimate renal 
function in those with a normal eGFR>90 mL/min/1.73 m2 (Florkowski 2011). The CKD-EPI 
equation was validated to match the accuracy of the MDRD equation at GFR<60 
mL/min/1.73 m2 and to offer a greater accuracy at higher GFR, minimizing the over-
diagnosis of chronic kidney diseases with the MDRD equation, being accurate as MDRD in 
the subgroup of patients with an eGFR<60 ml/min/1.73 m2 and substantially more 
accurate in the subgroup of them with an eGFR>60 ml/min/1.73 m2 (Levey 2009). Our 
results on eGFR were evaluated with both equations and were unrelated to which 
formula was used to estimate the eGFR. Since the increase in eGFR levels in patients with 
reduced renal function is independent of the changes in other variables considered, this 
could address a direct effect of Liraglutide on the kidney. As discussed above, this 
hypothesis is supported by a few studies in animals, which showed that GLP-1 is 
responsible for a natriuretic effect, by reducing sodium reuptake in proximal tube and 
aldosterone levels in mice (Hirata 2009). Moreover, the infusion of native GLP-1 activates 
an intracellular pathway mediated by cAMP/PKA which also causes an increase in eGFR, 
renal plasma flow, and bicarbonate and fractional potassium excretion (Crajoinas 2011), 
suggesting a direct effect on renal vasculature, most likely by decreasing the resistance of 
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the pre-glomerular capillaries (Moreno 2002, Nystrom 2005). This is reinforced by a 
recent re-evaluation of tissue GLP-1 receptor distribution which showed that in the 
kidney GLP-1 receptor was exclusively expressed in smooth muscle cells of arteries and 
arterioles (Pyke 2014). Since the presence of microalbuminuria in diabetes implies either 
dysfunction of the glomerular filtration barrier and/or dysfunction in tubular reabsorption 
(Haluzik 2013, Lazzara 2007), the improvement of eGFR could partially explain also the 
reduction in frequency and total amount of microalbuminuria we showed. 
The results on creatinine and eGFR should be interpreted with caution since the study is 
of relatively short duration. However, the population is less homogenous of that selected 
for Phase III studies and better mirror conditions of unknown potential risks. However, 
the heterogeneity of patients included and the small number of those who had a mild 
deterioration in Group A and, foremost, of those who had a restoration of eGFR in Group 
B did not allow to phenotype these two subgroups which need further studies over the 
next few years in addition to the ongoing LEADER study (Marso 2013). Since our study 
had relatively small numbers of patients with moderate renal impairment or under the 
maximal daily dosing of 1.8 mg of liraglutide, there is a need for other investigations to 
evaluate the safety in these specific conditions. Moreover, particular attention has to be 
paid to extend our data to all the class of drugs acting on the GLP-1 system, by 
considering that other derived GLP-1 drugs are mainly eliminated through the kidney, first 
of all exenatide. Another limitation of our study is the unavoidable loss of data from 
patients being lost to follow up or with incomplete data in real-life clinical practice. This 
has the potential to introduce bias of results for those patients attending visits more 
frequently. Nevertheless, the high concordance of our data with the results on glucose, 
BMI, and blood pressure of published meta-analysis on registration studies (Davidson 
2011, Robinson 2013) is a reassuring finding. It should also be considered that the sample 
size was calculated for eGFR changes but not for microalbuminuria and that we weighted 
the analyses for the number or the type of potential interfering drugs, but the specific 
dose was not considered. Wider studies are warranted to better investigate these 
aspects. 
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Conclusions 
 
Our study firstly showed that liraglutide is effective in preserving GFR in diabetic patients, 
increasing glomerular filtration rate in those with reduced renal function, independently 
by the changes in glucose levels or BMI. This effect was associatedwith a trend to 
decrease serumcreatinine levels and number of patients positive to microalbuminuria. 
Further real-life studies are needed to confirm these data. 
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Tables 
 
Table 1. Characteristics of the population as a whole and according to subgroups. 
 
 Population (n=84) Group A (n=43) Group B (n=41) 
 Baseline 12 months Baseline 12 months Baseline 12 months 
Age (years) 59.9±11.1 60.7±10.9 52.9±9.2 53.8±9.1 66.3±8.4 67.3±8.5 
Disease duration (years) 8.5±7.6 9.5±7.4 6.8±4.6 7.7±4.5 10.2±9.6 11.1±9.5 
BMI (kg/m2) 33.8±5.8 32.5±5.4c 35.4±6.7 33.7±6.1c 32.2±4.3 31.1±4.4b 
SBP (mmHg) 154.6±24.3 142.8±20.0c 148.9±22.9c 139.8±20.2c 160.6±24.7 146.0±19.6c 
DBP (mmHg) 88.1±12.2 83.7±11.2c 88.4±11.5 84.7±10.1a 87.8±13.1 82.6±12.2b 
FPG (mmol/L) 10.7±3.4 8.4±2.3c 10.9±3.9 8.2±2.1c 9.8±2.7 8.6±2.5a 
HbA1c (mmol/mol and%) 70.0±13.9 8.6±1.4 
60.2±11.6c 
7.7±1.1c 
73.4±17.3 
8.9±1.6 
58.9±13.0c 
7.5±1.2c 
68.5±12.4 
8.4±1.1 
62.3±9.9a 
7.8±0.9a 
Serum creatinine (µmol/L) 72.2±20.2 70.4±22.0 60.7±12.3 59.8±13.2 83.6±21.1 81.8±23.8 
Microalbuminuria (mg/24 h) 5.8±14.0 3.0±7.2a 7.4±18.0 4.1±9.5a 3.9±7.2 1.7±2.3a 
eGFR (MDRD; mL/min) 87.4±27.1 91.9±30.6 107.7±20.6 110.3±26.5 66.1±13.7 72.5±21.3a 
eGFR (CKD-EPI; mL/min) 87.5±20.8 89.4±21.6 104.3±8.5 103.8±12.4 69.9±14.1 74.4±18.7a 
 
Group A: patients with a normal renal function (eGFR>90 ml/min with CKD-EPI). Group B: patients with impaired renal function (eGFR>90 ml/min with CKD-
EPI). Data are expressed as mean±SD. 
BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HbA1c hemoglobin A1c, SBP systolic blood 
pressure. 
ap<0.05; bp<0.005; cp<0.0005 

105 
 
Baseline glucose homeostasis predicts the new 
onset of diabetes during statin therapy: 
a retrospective study in the real life 
 
 
Maria Chantal Ponziani1, Ioannis Karamouzis1, Chiara Mele1,2, Luisa Chasseur1, Marco 
Zavattaro1, Marina Caputo1, Maria Teresa Samà1, Arianna Busti1, Loredana Pagano1, Luigi 
Castello1, Paolo Marzullo1,2, Gianluca Aimaretti1, Flavia Prodam3 
 
 
1Department of Translational Medicine, University of Piemonte Orientale, via Solaroli 17, 
28100 Novara, Italy 
2Division of General Medicine, Istituto Auxologico Italiano, Ospedale S. Giuseppe, via 
Cadorna 90, 28824 Piancavallo (VB), Italy 
3Department of Health Sciences, University of Piemonte Orientale, via Solaroli 17, 28100 
Novara, Italy 
 
 
 
Published in: Hormones 2017; 16(4):396-404 
  
106 
 
Abstract 
 
Objective. We evaluated the risk of altered glucose levels and new-onset diabetes (NOD) 
associated with statins according to glucose levels at baseline in a population treated for 
dyslipidemia on primary prevention for >5 years. 
 
Design. The retrospective study included 308 subjects (265 on statins and 43 controls on 
diet) with a follow-up of 5-15 years. The cohort was classified according to glucose 
tolerance at both baseline and follow-up. 
 
Results. The cumulative incidence of NOD was 13.6% (9.3% in controls and 13.5% in 
treated patients). NOD was diagnosed after 3.4±1.8 years. In the group with normal 
glucose levels at baseline, the family history of diabetes (OR: 3.4, 95% CI 1.3-8.9), BMI >30 
kg/m2 (OR: 8.5, 95% CI 2.0-35.8), treatment with thiazide (OR: 21.9, 95% CI 1.2-384.2) 
and no alcohol consumption (OR: 0.3, 95% CI 0.1-0.8) reduced  the risk to develop altered 
glucose levels or NOD. No effects of statins were seen. In the group with altered glucose 
levels at baseline, hypertension (OR: 5.0, 95% CI 1.0-25.3) and hypertriglyceridemia (OR: 
3.5, 95% CI 1.0-11.8) increased the risk of remaining with altered glucose levels or 
develop NOD. Treatment with statin (OR: 7.5, 95% CI 1.5-37.4), in particular atorvastatin, 
was associated with the increased risk. In the whole population, the statin therapy (OR: 
4.0, 95% CI 1.1-14.1, p<0.020), and in particular simvastatin and atorvastatin were 
associated with increased risk of altered glucose levels or NOD. Patients who developed 
or maintained altered glucose levels or NOD had a poor metabolic phenotype at baseline. 
 
Conclusions. Statins were associated with an increased risk of NOD or altered glucose 
levels, mainly in subjects with altered glucose levels before the beginning of therapy. Poor 
metabolic phenotype and habits, or family history of diabetes contributed to that risk. 
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Background 
 
Due to the high morbidity and mortality related to cardiovascular (CV) diseases, 
prevention is a priority. In Europe, around 50% of deaths are caused or are related to 
these pathologies (mainly coronary disease, responsible for 20% of deaths, followed by 
stroke (WHO 2015)). 
Statins represent one of the most important improvements in the treatment of patients 
with high CV risk, as documented by many studies in both primary and secondary 
prevention (CTT 2008, 2010). However, there is an association between statin therapy 
and new onset of type 2 diabetes mellitus (NOD) (Sattar 2010, Preiss 2011, Ridker 2012, 
Waters 2012, Carter 2013) which is a major CV risk factor (Sarwar 2010).  
In February 2012, the US Food Drug Administration (FDA) issued a warning related to 
statin therapy and an increased risk of NOD (US-FDA 2016). However, it is useful to 
remember that most of the evidence arises from post-hoc analyses of studies not 
specifically designed to investigate NOD. 
The objective of the present study was to evaluate the long-term effect of statin therapy 
on glucose metabolism in a heterogeneous group of dyslipidemic primary prevention 
patients referred to a tertiary center. 
The primary objective was the evaluation of NOD in patients treated with statin therapy 
for at least 5 years. The secondary objective was the detection of alterations in markers of 
pre-diabetes during statin treatment on the basis of anthropometric and biochemical 
parameters, concomitant treatment, family history, habits, and risk factors as described in 
the Treating to New Target (TNT), Incremental Decrease in End Points Through Aggressive 
Lipid Lowering Trial (IDEAL) and the Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels (SPARCL) studies (Waters 2013, Waters 2004, La Rosa 2005, Pedersen 
2005, Waters 2011). 
 
Methods 
 
We performed a retrospective longitudinal study from 2000 to 2014 in patients referred 
to the LipidologǇ outpatieŶt ĐliŶiĐ of the ͞Ospedale Maggioƌe della Caƌità͟, Noǀaƌa, ItalǇ. 
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Study quality was assessed using the STROBE checklist (STROBE 2016). Patients were 
selected based on the following criteria: males and females aged 18-90 years, naïve to 
statin use before the baseline sample followed by continuous statin (cases) or diet 
therapy (controls) for at least 5 years. We selected patients on primary prevention; those 
with a known diagnosis of type 2 diabetes and/or cardiovascular diseases different from 
hypertension, dyslipidemia secondary to kidney failure or cystic fibrosis, family history of 
type 1 diabetes or active neoplasia were excluded. Patients with impaired fasting glucose 
or impaired glucose tolerance at baseline were allowed. Changes of statin dosage or 
molecule were allowed, and patients were scheduled as treated with the last dosage or 
molecule at the end of the study. To be included in the study, patients and controls 
should be checked and scheduled at baseline and at the last visit for family history (type 2 
diabetes and dyslipidemia), habits (smoke and alcohol consumption), other diseases or 
treatments. They also should have evaluations of the following clinical and biochemical 
parameters: weight, height, waist circumference, systolic blood pressure (SBP), diastolic 
blood pressure (DBP), fasting glucose, HbA1c, total cholesterol (T-c), High Density 
Lipoprotein-cholesterol (HDL-c), Low Density Lipoprotein-cholesterol (LDL-c), triglycerides 
(TG), serum creatinine, aspartate aminotransferase (AST) and alanine aminotransferase 
levels (ALT). 
The initial cohort was composed of 1879 subjects, of whom 1571 were excluded because 
failed inclusion criteria. A total of 308 subjects were included in the study. The cohort was 
classified according to the glucose tolerance at both baseline and follow-up. They were 
firstly divided into 2 groups, subjects with normal (A) and altered glucose levels (B). The 
subjects were further divided in patients who maintained (AA) or switched back to normal 
glucose levels (BA), patients who developed (AB) or maintained altered glucose levels 
(BB) and patients who developed NOD (AC, BC).  
Height was measured by the Harpenden stadiometer to the nearest mm and weight by 
using electronic scale, both taken in triplicate. BMI was calculated as body weight divided 
by squared height (kg/m2). SBP and DBP were measured using a mercury free 
sphygmomanometer (UM-102A, A&D Medical, Japan) with an appropriate cuff size after 
participants were seated quietly for at least 15 min, with their right arm supported at the 
level of the heart and feet flat on the floor, prior to other physical evaluations. 
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NOD was diagnosed according to the American Diabetes Association (ADA) criteria for 
fastiŶg plasŵa gluĐose ;шϭϮϲ ŵg/dl, ϳ.Ϭ ŵŵol/lͿ, post-glucose challenge (2-h plasma 
gluĐose шϮϬϬ ŵg/dl, ϭϭ.ϭ ŵŵol/lͿ duƌiŶg aŶ oƌal gluĐose toleƌaŶĐe test ;OGTTͿ oƌ HďAϭĐ 
leǀels шϲ.ϱ%. Alteƌed gluĐose leǀels used foƌ iŶdiǀiduals ǁith iŵpaiƌed fastiŶg gluĐose 
(IFG; fasting plasma glucose 100 mg/dL or 5.6 mmol/L to 125 mg/dL, 6.9 mmol/l) and/or 
impaired glucose tolerance (IGT; 2-h PG in the 75g OGTT 140 mg/dl/7.8 mmol/l to 199 
mg/dl/11.0 mmol/l) according to the ADA criteria (ADA 2015). LDL-c was determined 
either by laboratory test or with the Friedewald formula; non HDL-c, LDL- to HDL-c ratio 
and T-c to HDL-c ratio were also calculated. Prediction risk factors for NOD were 
evaluated according to the TNT, SPARCL and IDEAL studies (Water 2013, Waters 2004, La 
Rosa 2005, Pedersen 2005, Waters 2011), as fasting glucose >100 mg/dl (5.6 mmol/l), 
blood pressure levels >140/90 mmHg or treatments for hypertension, BMI >30 kg/m2, 
and TG >150 mg/dl. 
BioĐheŵiĐal aŶalǇses ǁeƌe peƌfoƌŵed usiŶg staŶdaƌdized ŵethods iŶ the Hospital͛s 
Laboratory. Plasma glucose levels (mg/dl; 1 mg/dl: 0.05551 mmol/l) were measured by 
the gluco-oxidase colorimetric method (GLUCOFIX, by Menarini Diagnostici, Florence, 
Italy). HbA1c levels were measured by the high-performance liquid chromatography 
(HPLC), using a Variant machine (Biorad, Hercules, CA); intra- and inter-assay coefficients 
of variation are respectively lower than 0.6 and 1.6%. Linearity is excellent from 3.2% (11 
ŵŵol/ŵolͿ to ϭϴ.ϯ% ;ϭϳϳ റŵŵol/ŵolͿ. “eƌuŵ ĐƌeatiŶiŶe leǀels ǁeƌe assessed usiŶg the 
enzymatic method of creatinine deamidase/GLDH (Adivia Chemistry -Bayer). Plasma T-c 
(mg/dl; 1 mg/dl: 0.0259 mmol/l) concentration was measured by esterase and oxidase 
conversion (Advia 1650, Bayer Diagnostics, Newbury, UK); coefficient of variation 1.9%. 
Plasma TG (mg/dl; 1 mg/dl: 0.0113 mmol/l) and HDL-c (mg/dl; 1 mg/dl: 0.0259 mmol/l) 
concentrations were measured by enzymatic determination (Advia 1650, Bayer 
Diagnostics, Newbury, UK); coefficient of variation 1.7%. AST and ALT levels were 
measured by enzymatic methods (Roche Diagnostics, Mannheim, Germany).  
The study was conducted in accordance with the declaration of Helsinki, was approved by 
the Local Inter-Hospital Ethic Committee (Maggiore Hospital Ethical Committee) and 
written informed consent was obtained from all subjects. 
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Statistical analysis 
 
Results are expressed as mean, standard deviation (SD), or 95% confidence interval (95% 
CI). Distributions of continuous variables were examined for skewness and were 
logarithmically transformed as appropriate. Analysis of variance was used to determine 
differences between groups. Logistic regression analysis was used to determine the 
association of altered glucose levels/NOD with the odd ratio (OR, 95% CI) of the following 
risk factors: diet/treatment with statin , alcohol, thiazide therapy, and risk factors derived 
from TNT, IDEAL and SPRCL studies (model 1). Model 2 also included the family history of 
type 2 diabetes or dyslipidemia. All the models were corrected for age, sex, PUFA-n3 or 
treatment with ezetimibe, smoking habit and years of follow-up. Statins were also 
classified according to molecules (fluvastatin + pravastatin; simvastatin, atorvastatin, 
rosuvastatin). Logistic regression analysis was performed in the whole population or in 
the two subgroups (controls on diet/patients on statins) to refine the risk. Diet/statin 
therapy was evaluated in both main effect and custom models (interaction of all fixed 
factors and covariates).  
Cox regression models were fitted to the time of observation to the outcome of NOD. The 
ascertainment of the year of diagnosis of NOD was derived from the files of all patients 
who had obtained an exemption from payment for drugs, syringes, and glucose 
monitoring strips because of a diagnosis of diabetes mellitus. Cox regression models were 
not performed for the outcome NOD + altered glucose levels because the year of 
diagnosis of altered glucose levels was uncertain. 
Statistical significance was defined as p <0.05 (2-sided models). The statistical analysis 
was performed with SPSS for Windows version 17.0 (SPSS Inc., Chicago, IL, USA). 
 
Results 
 
The first dataset included 1879 subjects of whom 1571 patients were excluded because 
they did not satisfy the inclusion criteria: 1206 subjects for a follow-up <5 years, 26 for 
incomplete clinical or biochemical data, 20 for statin withdrawal before 5 years and 319 
for the presence of type 2 diabetes at baseline. The final dataset of 308 subjects (130 
males, 178 females, age: 53.9±12.6 years), with 265 patients on statin therapy and 43 on 
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diet (controls), included 216 patients in group A (normal glucose levels) and 92 of group B 
(altered glucose levels). Moreover, 123 patients had a family history of type 2 diabetes 
and 164 of dyslipidemia.  
With respect to therapy, 65 patients had been treated with atorvastatin, 85 with 
simvastatin, 62 with rosuvastatin, 37 with pravastatin and 16 with fluvastatin, 
respectively. Moreover, 16 patients had been further treated with ezetimibe, 25 patients 
and 6 controls with PUFA-n3, 9 patients had been taken thiazide diuretics and 2 patients 
beta-blockers for hypertension. No patients had been on chronic corticosteroid 
treatments. 
 
Clinical and metabolic characteristics of patients with normal and altered glucose levels 
at baseline 
 
Age, weight, BMI, waist circumference, SBP, DBP, fasting glucose, HbA1c and AST levels 
were higher (p<0.020), while T-c, LDL-c, HDL-c and non-HDL-c (p<0.030) were lower in 
group B than A, respectively, in the cohort as a whole or divided according to cases and 
controls (Table 1, pag. 117). 
Altered glucose levels at baseline were associated with family history of type 2 diabetes 
(OR: 2.81, 95% CI 1.58-4.98, p<0.001) and dyslipidemia (OR: 0.3, 95% CI 0.168-0.536; 
p<0.001). No associations with smoking or alcohol consumption were shown. 
 
Clinical and metabolic characteristics of patients with normal and altered glucose levels 
at follow-up 
 
At the last visit of follow-up, those in group B had higher weight, BMI, waist 
circumference, glucose, HbA1c, blood pressure, TG, ALT, and lower T-c, LDL-c, HDL-c, and 
T-c to HDL-c ratio levels than those in group A (table 2, pag. 118). 
By considering subjects with normal glucose levels at the follow-up (AA and BA), those 
treated with statins had higher BMI (24.6±3.7 vs 23.4±5.0 Kg/m2, p=0.050), while lower T-
c (199.6±43.1 vs 227.3±48.1 mg/dl, p<0.001), LDL-c (114.1±41.3 vs 139.0±38.4 mg/dl 
p<0.001), non-HDL-c (129.1±55.6 vs 164.2±44.2 mg/dl, p<0.001), LDL-c to HDL-c ratio 
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(2.0±1.1 vs 2.4±1.2, p<0.048), T-c to HDL-c ratio (1.9±0.2 vs 4.0±1.5; p<0.047) than 
controls. 
By considering subjects with altered glucose levels at the follow-up (AB, AC, BB and BC), 
those treated with statins had lower T-c (190.9±35.5 vs 211.8±38.4 mg/dl, p<0.020), LDL-c 
(108.1±32.1 vs 128.4±39.0 mg/dl p<0.022), non-HDL-c (133.7±37.0 vs 161.4±35.8 mg/dl, 
p<0.004), LDL-c to HDL-c ratio (2.0±0.7 vs 2.6±0.8, p<0.006), T-c to HDL-c ratio (1.9±0.2 vs 
3.8±1.3; p<0.004), and AST levels (22.6±8.3 vs 25.9±7.0 U/L, p<0.009) than controls. 
 
Baseline clinical and metabolic characteristics of patients according to glucose levels at 
the follow-up  
 
The median time of observation was 6.0±1.6 years (5-15 years). In group A, 169 patients 
(AA: 146 on therapy, 23 controls) maintained normal glucose levels, 42 (AB: 38 on 
therapy, 4 controls) developed altered glucose levels and 5 (AC: 1 on therapy, 4 controls) 
had NOD. Conversely, in group B, 18 patients (BA: 13 on therapy, 5 controls) switched 
back to normal glucose levels, 37 (BB: 30 on therapy, 7 controls) maintained altered 
glucose levels and 37 (BC: 36 on therapy, 1 control) developed NOD. The cumulative 
incidence of NOD during the follow-up was 13.6% (11.6% in controls and 13.9% in treated 
patients). NOD was diagnosed after a median time of 3.4±1.8 years after the first visit. 
All the AA subjects presented lower BMI (24.1±3.3 vs 26.1±3.4 Kg/m2; p<0.001), waist 
circumference (81.2±10.7 vs 97.8±9.0 cm; p<0.001), SBP (126.5±16.8 vs 134.4±13.3 
mmHg; p<0.001), DBP (78.0±8.1 vs 80.9±8.6 mmHg; p<0.020), glucose (86.1±7.9 vs 
91.1±6.8 mg/dl; p<0.001), and higher HDL-c levels (61.1±17.5 vs 55.9±15.7 mg/dl 
p<0.038) than in group AB. AA subjects also had lower BMI (24.1±3.3 vs 28.4±3.5 Kg/m2; 
p<0.004), and higher T-c (274.8±54.7 vs 242.2±102.1 mg/dl; p<0.041) and HDL-c levels 
(61.1±17.5 vs 47.0±12.3 mg/dl, p<0.038) than AC subjects at baseline. Furthermore, the 
AA group as a whole and as treatment group presented a lower prevalence of obesity 
(p<0.003), thiazide diuretics assumption (p<0.033) and family history of type 2 diabetes 
(p<0.021), and a higher prevalence of family history of dyslipidemia (p<0.014) than AB 
plus AC subjects.  
The BB group had lower BMI (26.3±4.8 vs 28.5±4.0 Kg/m2; p<0.004) waist circumference 
(91.3±11.7 vs 103.8±5.4 cm; p<0.006), glucose levels (109.7±6.7 vs 115.5±9.1 mg/dl; 
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p<0.001), HbA1c (5.8±0.3 vs 6.2±0.4%; p<0.001), LDL-c to HDL-c ratio (3.0±1.0 vs 3.7±1.8; 
p<0.020), T-c to HDL-c ratio (4.6±1.2 vs 5.6±2.6; p<0.009), and higher HDL-c (57.1±19.5 vs 
48.2±12.5 mg/dl; p<0.004) than BC. The BB group had higher SBP (135.3±18.0 vs 
125.5±12.4 mmHg; p<0.029), glucose (109.7±6.7 vs 106.1±4.5 mg/dl; p<0.014), TG 
(177.6±98.6 vs 144.4±109.5 mg/dl; p<0.040), AST (24.9±6.6 vs 20.4±5.7 IU/L; p<0.010), 
and ALT levels (28.8±9.2 vs 20.9±9.1 IU/L; p<0.001), than BA at baseline.  
Moreover, the AB group had lower weight (p<0.020), BMI (p<0.001), SBP (p<0.002), 
glucose (p<0.0001), HbA1c (p<0.018), ALT (25.8±11.8 vs 32.7±10.9 UI/L p<0.001), and 
higher T-c (274.5±53.5 vs 258.5±50.9 mg/dl p<0.041) and HDL-c levels (p<0.011) than BC. 
 
Risk factors associated with the development of altered glucose levels 
 
Risk factors associated with altered glucose levels and NOD 
By evaluating the whole population, the family history of type 2 diabetes (OR: 3.1, 95% CI 
1.3-7.2, p<0.006), BMI >30 kg/m2 (OR: 5.2, 95% CI 1.5-17.8, p<0.006), glucose levels > 100 
mg/dl (OR: 22.6, 95% CI 8.5-59.6, p<0.006), treatment with  statins (OR: 4.0, 95% CI 1.1-
14.1, p<0.029) increased, and no alcohol assumption (OR: 0.4, 95% CI 0.2-0.9, p<0.025) 
decreased the risk to maintain/develop altered glucose levels or develop NOD. Thiazide 
assumption was marginal significant (OR: 14.1, 95% CI 0.9-210.4, p=0.052). The 
assumption of statins (OR: 4.0, 95% CI 1.1-14.1, p<0.029), and in particular simvastatin 
and atorvastatin were associated with the increased risk in the full custom models (Table 
3). By using the number of TNT factors in spite of each of them, the presence of 
increasing TNT risk factors increased the risk (p<0.0001).  
In group A, a family history of type 2 diabetes (OR: 3.4, 95% CI 1.3-8.9, p<0.010), BMI >30 
kg/m2 (OR: 8.5, 95% CI 2.0-35.8, p<0.003), thiazide therapy (OR: 21.9, 95% CI 1.2-384.2, 
p<0.034), increased, and no alcohol consumption (OR: 0.3, 95% CI 0.1-0.8, p<0.010) 
reduced  the risk to develop altered glucose levels or NOD. No effects for statins (OR: 1.1, 
95% CI 0.4-3.4, p=0.753) were seen in all models. In group B, hypertension (OR: 5.0, 95% 
CI 1.0-25.3, p<0.049), and hypertriglyceridemia (OR: 3.5, 95% CI 1.0-11.8, p<0.040) 
increased the risk to maintain altered glucose levels or develop NOD. Treatment with 
statin (OR: 7.5, 95% CI 1.5-37.4, p<0.012), and in particular atorvastatin were associated 
with the increased risk in the full custom models (Table 3, pag. 119). 
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Risk factors associated to NOD 
The analysis was performed in group B due to the relative few cases of NOD in group A by 
the end of follow-up (4 controls and 1 treated patient). 
In group B, to have a BMI >30 Kg/m2 (HR: 2.7, 95% CI 1.2-6.0, p<0.009) and hypertension 
(HR: 2.5, 95% CI 1.1-5.3, p<0.021) increased the risk to develop NOD. Statin therapydid 
not reach significance with respect to diet possibly due to the sample size (37 events 
censored on statin and 1 event censored on diet therapy). 
 
Discussion 
 
In our retrospective study on a cohort of dyslipidemic patients treated with statins or diet 
and with a follow-up longer than 5 years, those who developed or maintained altered 
glucose levels or NOD had a poor metabolic phenotype at baseline. Statin therapy, in 
particular atorvastatin, was associated with altered glucose levels or NOD in those who 
had altered fasting glucose at baseline, suggesting that this population should be carefully 
monitored. The cumulative incidence of NOD was 13.6%, 11.6% in controls and 13.9% in 
those treated with statins. A meta-analysis of 13 randomized controlled trials with 
>90,000 participants found a 9% risk for incident NOD after 4 years of statin treatment, 
particularly in those who were older (Sattar 2010) and on intensive-dose statin therapy 
(Preiss 2011). The higher incidence in our cohort could be explained by the longer follow-
up (median: 6 years, range 5-15 years). Furthermore, because our patients were referred 
to a tertiary referral center for dyslipidemia, a selection bias due to a higher risk 
metabolic phenotype cannot be excluded. In addition, our patients were subjected to a 
careful staging of CV risk factors and an OGTT was also performed for a slight increase in 
fasting plasma glucose. Moreover, the incidence of NOD in patients treated with diet was 
higher than other studies in European countries (Harding 2008, Cederberg 2015). This 
difference could be due to difficulties in the ascertainment of the incidence of NOD in the 
general population and dyslipidemic patients could be a population at higher risk when 
diet adheƌeŶĐe is Ŷot good, as shoǁŶ iŶ the ͞PƌiŵaƌǇ pƌeǀeŶtioŶ of ĐaƌdioǀasĐulaƌ disease 
ǁith pƌaǀastatiŶ iŶ JapaŶ͟ ;MEGAͿ study (Mizuno 2013). Cederberg et al. (Cederberg 
2015) published similar data based on the follow-up of the METabolic Syndrome In Men 
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(METSIM) study conducted in men randomly selected from the Kuopio population 
register. They observed an increased risk of NOD in those treated with statins, but also a 
worsening of hyperglycemia at OGTT that represented a progressive pre-diabetic state. 
We confirm this observation in a selected population of dyslipidemic patients of both 
sexes on primary prevention and with a longer follow-up. The most important result of 
our study is that the glucose phenotype at baseline was crucial in the risk to develop 
altered glucose levels with statins, whereas the risk was not present when fasting glucose 
levels are <100 mg/dl (5.6 mmol/l). A post hoc analysis of the patients without diabetes at 
baseline from both the TNT and IDEAL trials reported similar findings (Kohli 2015). 
Our analysis of anthropometric and metabolic parameters show that patients who 
developed altered glucose levels or NOD had an insulin resistance phenotype at baseline. 
In particular, they had more central obesity, hypertension, and lower HDL-c levels and 
maintained these characteristics over time. These findings suggest that statins could more 
quickly worsen a metabolic phenotype already known to predict the risk of NOD (Mizuno 
2013, Alberti 2009, O'Neill 2015). Because we also observed that a higher number of TNT 
risk factors increased the risk, clinicians should carefully monitor patients with this 
phenotype because a synergistic action of statins with other diabetes risk factors is likely. 
A family history of type 2 diabetes is recognized as a risk factor for NOD development. It 
has been proven that the risk is 3 times higher in people who have a relative affected by 
type 2 diabetes and 6 times higher in people who have both parents affected (Meigs 
2000, Valdez 2007). In our series, family history of type 2 diabetes should be another 
factor to consider in the global management of patients treated with statins. 
Alcohol abuse has been identified as a possible risk factor for NOD since it results in an 
extreme intake of carbohydrates, obesity, increasing pancreatitis incidence and 
worsening of hepatic function with an alteration of glucose metabolism (Nakanishi 2003). 
Interestingly, although we were unable to stratify daily alcohol intake due to the 
retrospective nature of the study, no alcohol consumption was protective. This factor 
should be considered in the follow-up of patients treated with statins. Studies with dose-
response analyses are needed, especially since it was recently observed that a moderate 
reduction risk of NOD is present but confined to women with moderate levels of alcohol 
consumption (Knott 2015). 
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Furthermore, we showed that statins, mainly atorvastatin, are linked to a higher risk of 
NOD or altered glucose levels in agreement with the majority of the literature. 
Pravastatin and pitavastatin even showed a protective effect on glucose alteration 
development (Mita 2007, Ray 2013, Vallejo-Vaz 2015). The reason why some, but not all 
statins, have detrimental effects on glucose metabolism remains unresolved. Beyond 
molecule-dependent mechanisms, other possible explanations include residual 
confounding factors, including a different lifestyle and an aggressive statin treatment.  
We also reported a lower risk of having altered glucose levels at baseline, before any 
treatment with statins, in those with a family history of dyslipidemia. These results are in 
line with several observational studies that reported an inverse association between 
familial hypercholesterolemia and the risk of type 2 diabetes with a certain genotype-
phenotype correlation (Yu 2017). Moreover, the SAFEHEART cohort study showed that 
statins do not increase the risk of type 2 diabetes mellitus in patients with familial 
hypercholesterolemia (Fuentes 2015). These data open the intriguing hypothesis that LDL 
ƌeĐeptoƌ ;LDL‘Ϳ ŵutatioŶs ĐaŶ iŵpƌoǀe the fuŶĐtioŶ of paŶĐƌeatiĐ β Đells (Yu 2017). 
The current study has some limitations. First, due to its retrospective nature, we could 
not control for adherence to treatment. Secondly, because the cases of altered glucose 
levels could not be ascertained on registries or with medical prescriptions, cox regression 
models for this condition were not performed. Furthermore, we studied only few controls 
but this is linked to the nature of a population followed in a tertiary referral center. 
Conversely, the study included a number of patients with a follow-up >5 years. 
Furthermore, many risk factors including family history of type 2 diabetes were 
considered. 
 
Conclusions 
 
In conclusion, this study confirmed that statins were associated with an increased risk of 
NOD or altered glucose levels, mainly in subjects with fasting glucose >100 mg/dl before 
initiating treatment. A worse metabolic phenotype, lifestyle risk factors and family history 
of type 2 diabetes contributed to the risk.  
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Tables 
 
Table 1. Clinical and metabolic characteristics of patients with normal and altered glucose 
levels at baseline. 
 
Variable Group A Group B p 
Subjects (M/F) 216 (88/128) 92 (42/50) 0.760 
Age (years) 54.0 ± 12.6 57.2 ± 11.1 0.004 
Weight (Kg) 67.7 ± 12.2 75.2 ± 17.0 0.0001 
BMI (Kg/m2) 24.6 ± 3.5 27.6 ± 6.2 0.0001 
WC (cm) 83.4 ± 12.1 97.1 ± 12.1 0.0001 
SBP (mmHg) 128.1± 16.3 134.8 ± 16.8 0.0001 
DBP (mmHg) 78.6 ± 8.3 80.8 ± 7.8 0.016 
FPG (mg/dl) 87 ± 8 111 ± 9 0.0001 
HbA1c (%) 5.5 ± 0.3 6.0 ± 0.5 0.0001 
T-c (mg/dl) 273.9 ± 55.8 255.8 ± 53.3 0.006 
HDL-c (mg/dl) 60 ± 17 55 ± 18 0.013 
LDL-c (mg/dl) 183 ± 55 168 ± 53 0.014 
Non HDL-c (mg/dl) 215 ± 54 201 ± 58 0.023 
LDL-c/HDL-c 3.23 ± 1.16 3.23 ± 1.46 0.654 
T-c/HDL-c 4.87 ± 1.41 4.99 ± 1.96 0.792 
TG (mg/dl) 165 ± 139 176 ± 105 0.258 
Creatinine (mg/dl) 1.0 ± 0.2 1.0 ± 0.2 0.243 
eGFR (ml/min) 75.4 ± 15.9 70.0 ± 14.4 0.520 
AST (U/L) 23 ± 8 24 ± 6 0.191 
ALT (U/L) 24 ± 12 28 ± 11 0.002 
 
Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: Body Mass Index; 
DBP: Diastolic Blood Pressure; eGFR: estimated Glomerular Filtration Rate; FPG: Fasting Plasma Glucose; 
HbA1c: Haemoglobin A1c; HDL-c: HDL cholesterol; SBP: Systolic Blood Pressure; T-c: total cholesterol, Group 
A: patients with normal glucose levels; TG: triglycerides. Group B: patients with altered glucose levels. Data 
are expressed as mean ± SD. 
  
118 
 
Table 2. Clinical and metabolic characteristics of patients with normal (Group A) and 
altered glucose levels (Group B) at the follow-up. 
 
Variable Group A Group B p 
Subjects (M/F) 187 (71/116) 121 (59/62) - 
Weight (Kg) 67.3 ± 13.7 74.8 ± 14.7 <00001 
BMI (Kg/m2) 24.4 ± 3.9 27.6 ± 4.8 <0.001 
WC (cm) 90.7 ± 13.5 100.3 ± 11.3 <0.001 
SBP (mmHg) 124.2 ± 18.4 133.3 ± 16.2 <0.001 
DBP (mmHg) 78.0 ± 7.2 80.1 ± 8.2 0.010 
FPG (mg/dl) 89.4 ± 7.7 116.6 ± 15.5 <0.001 
HbA1c (%) 5.5 ± 0.2 6.3 ± 0.5 <0.001 
T-c (mg/dl) 204.0 ± 45.0 193.5 ± 36.4 0.010 
HDL-c (mg/dl) 62.3 ± 21.0 54.2 ± 14.5 <0.001 
LDL-c (mg/dl) 118.1 ± 41.8 110.7 ± 33.6 0.040 
Non-HDL-c (mg/dl) 134.4 ± 55.4 137.1 ± 37.8 0.366 
LDL-c/HDL-c 2.1 ± 1.1 2.1 ± 0.7 0.051 
T-c/HDL-c 3.5±1.3 3.7 ± 0.9 0.004 
TG (mg/dl) 129.1 ± 87.7 147.7 ± 67.3 0.001 
Creatinine (mg/dl) 0.8± 0.2 0.8 ± 0.1 0.351 
eGFR (ml/min) 86.9 ± 16.8 84.9 ± 17.5 0.141 
AST (U/L) 21.9± 6.8 23.1 ± 8.2 0.163 
ALT (U/L) 22.6 ± 11.2 31.2 ± 18.2 0.003 
 
Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: Body Mass Index; 
DBP: Diastolic Blood Pressure; eGFR: estimated Glomerular Filtration Rate; FPG: Fasting Plasma Glucose; 
HbA1c: Haemoglobin A1c; HDL-c: HDL cholesterol; SBP: Systolic Blood Pressure; T-c: total cholesterol; WC: 
Waist Circumference; Group A: patients with normal glucose levels; TG: triglycerides. Group B: patients with 
altered glucose levels. Data are expressed as mean ± SD. 
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Table 3. Risk to maintain altered glucose levels or to have new onset diabetes in logistic regression. 
 
 All subjects Group A Group B 
 OR CI 95% p OR CI 95% p OR CI95% p 
Diet 1.000 - - 1.000 - - 1.000 - - 
Prava+Fluva 2.045 0.417-10.023 0.378 0.566 0.205-2.383 0.698 1.750 0.385-7.951 0.469 
Simvastatin 5.797 1.434-23.438 0.010 0.898 0.318-2.534 0.898 5.625 0.894-35.389 0.067 
Atorvastatin 4.343 1.024-18.422 0.042 0.975 0.314-3.027 0.966 7.812 1.262-48.356 0.023 
Rosuvastatin 3.851 0.807-18.365 0.911 0.886 0.300-2.616 0.827 1.875 0.396-10.463 0.474 
 
Abbreviations. CI, confidence interval. OR, odds ratio. Group A: subjects (216) with normal glucose levels at baseline. Group B: subjects (92) with altered glucose levels at 
baseline. 65 patients had been treated with atorvastatin (38 A, 27 B), 85 with simvastatin (61 A, 24 B), 62 with rosuvastatin (49 A, 13 B), 37 (24 A, 13 B) with pravastatin and 
16 (7 A, 9 B) with fluvastatin The models also included the following fixed factors and covariates: age, sex, BMI > 30 Kg/m2, hypertension, hypertriglyceridemia, thiazide, 
PUFA-n3 or ezetimibe use, alcohol consumption, smoking, years of follow-up for Group A and B, and also for glucose >100 mg/dl for all subjects. Table 3 represents OR only 
for statin assumption (independent variable). 
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CHAPTER 2 
 
The spectrum of thyroid disorders:  
dysfunctions and cancer 
 
PRIMARY HYPOTHYROIDISM: 
TREATMENT AND MANAGEMENT 
 
Introduction 
 
Primary hypothyroidism is an insidious condition with a significant morbidity and often 
subtle and nonspecific symptoms and clinical signs (Roberts 2004, Vaidya 2008). The 
earliest biochemical abnormality is an increase in serum (TSH) concentration associated 
with normal serum free thyroxine (T4) and triiodothyronine (T3) concentrations 
(subclinical hypothyroidism), followed by a decrease in serum free T4 concentration, at 
which stage, most patients have symptoms and benefit from treatment (overt 
hypothyroidism) (Roberts 2004, Vaidya 2008, Cooper 2012). The cause is either chronic 
autoimmune disease [atrophic autoimmune thyroiditis or goitrous autoimmune 
thyroiditis (Hashimoto's thyroiditis)] or destructive treatment for hyperthyroidism with 
either radioiodine or surgery which may account for up to one-third of cases of 
hypothyroidism in the community (Tunbridge 1977). Less frequent causes include surgery 
and radioiodine ablation for benign nodular thyroid disease and thyroid cancer, external 
beam irradiation of malignant tumours of the head and neck and drugs including lithium, 
amiodarone and interferon (Roberts 2004). 
Since the 1970s levothyroxine (LT4) has become the standard of care for thyroid hormone 
replacement in subjects unable to produce their own thyroid hormones due to 
congenital, autoimmune or iatrogenic causes. LT4 has become one of the most widely 
used drugs worldwide, it is the most commonly prescribed drug in the United States (US), 
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the third most in the United Kingdom (UK), and there is evidence that its use is steadily 
increasing (Rodriguez-Gutierrez 2016, Taylor 2014). 
LT4 oral formulation has been mainly marketed as tablets whose absorption occurs in the 
upper intestinal tract by means of a mechanism not yet fully understood (Visser 2011). 
Absorption increases linearly over the first 60–90 min, and varies in the range of 60 and 
80% of the administered dose (Benvenga 1995). Traditionally, a dose of 1.6–1.8 mcg is 
considered satisfactory in order to treat hypothyroid patients (Biondi 2014). However, a 
non-negligible rate of patients requires increased doses up to 30–40% of that estimated, 
whereas inappropriately high dose is cause of definite side effects (Biondi 2014, Biondi 
2008, Mercuro 2000). 
In the last years, alternative LT4 formulations have become available in some countries 
and they have rapidly gained attention in clinical practice: softgel capsule and liquid 
solution. The softgel capsule contains LT4 dissolved in glycerin and surrounded by a layer 
of gelatin, while in liquid solution LT4 is dissolved in glycerol and ethanol. 
Pharmacokinetic studies revealed that the latter formulation might have a better in vivo 
bioavailability as compared to classic LT4 tablet (Yue 2012). Softgel formulation has 
instead been proven bioequivalent in rate and exposure extent as compared to tablet 
formulations (Colucci 2011). 
 
This section aims to explore the management of newly diagnosed hypothyroidism in Italy 
as compared to the recommendations of the recent guidelines and to evaluate the 
patieŶts͛ adheƌeŶĐe to LTϰ theƌapǇ.  
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Abstract 
 
Background. The adherence by endocrinologists to guideline regarding levothyroxine 
(LT4) therapy and the compliance of patients may impact the management of 
hypothyroidism. The aim of this study is to compare the adherence of Italian 
endocrinologists to the ATA/AACE and ETA  guidelines on the management of newly 
diagnosed primary hypothyroidism and to validate the Italian version of Morisky-Green 
Medical Adherence Scale-8 items (MMAS-8) questionnaire as applied to the evaluation of 
the adherence of patients with hypothyroidism to LT4 treatment. 
 
Methods. This was an observational, longitudinal, multicenter, cohort study, involving 12 
Italian Units of Endocrinology. 
 
Results. 1039 consecutive outpatients were enrolled (mean age 48 years; 855 women, 
184 men). The concordance of Italian endocrinologists with AACE/ATA and ETA 
recommendations was comparable (77.1% and 71.7%) and increased (86.7% and 88.6%) 
after the recommendations on LT4 dose were excluded, considering only the remaining 
recommendations on diagnosis, therapy and follow-up. The MMAS-8 was filled out by 293 
patients. The mean score was 6.71; with 23.9% low (score <6), 38.6% medium (6 to <8), 
37.5% highly (=8) adherers; an internal validation coefficient of 0.613 was found. Highly 
adherent patients were not more likely to display a good control of hypothyroidism 
compared with either medium (69% versus 72%, p=0.878) or low (69% versus 43%, 
p=0.861) adherers. 
 
Conclusions. Clinical management of hypothyroidism in Italy displayed an observance of 
international guidelines by Italian endocrinologists. Validation of Italian version of MMAS-
8 questionnaire provides clinicians with a reliable and simple tool for the assessment of 
adherence of patients to LT4 treatment. 
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Background 
 
Levothyroxine (LT4) oral mono-therapy is the treatment choice for primary and secondary 
hypothyroidism. In the last 40 years, two main developments changed the clinical 
practice. First, the development of the serum thyroid-stimulating hormone (TSH) 
radioimmunoassay discovered a high percentage of overtreatment (Jonklaas 2014). First 
TSH assays, indeed, showed lower sensitivity compared to recent radioimmunoassay, 
with particular challenges in lowest limit of normal range. Second the identification of 
peripheral deiodinase-mediated conversion of T4 to three-iodiothyronine (T3) led to a 
suggestive combined association of these hormones in a sample of selected patients 
(Gullo 2011). 
The American Association of Clinical Endocrinologists (AACE), the American Thyroid 
Association (ATA) and the European Thyroid Association published specific guidelines 
dealing with primary hypothyroidism (PH) in 2013 and 2014, showing few differences, 
although these were of substantial magnitude (Jonklaas 2014, Pearce 2013). New 
research suggests the need of personalized clinical management of hypothyroidism, 
aimed to improve diagnostic tests, therapeutic options, treatment adherence (Hamburg 
2010) and the knowledge of underlying pathogenetic mechanisms. Three surveys 
evaluated the approach to PH in France and elsewhere (Burch 2014, Delemer 2012, 
McDermott 2001) but little is known about the management of PH in Italy and its 
concordance with clinical guidelines. Moreover, a valid, reliable and cost-effective 
method for evaluating the LT4 adherence is not currently available. The Morisky 
Medication Adherence Scale questionnaire (Morisky 2008), in its more recent 8-items 
version (MMSA-8) shows a higher sensitivity and specificity than the previous 4-items 
version (MMSA-4). MMAS-8 is an easy and fast, self-reported tool, useful and reliable in 
the outpatient clinical setting. No previous studies validating the MMAS-8 in the context 
of hypothyroidism have been published. 
Therefore, we performed an observational study aimed to determine the management of 
newly diagnosed hypothyroidism in Italy as compared to the recommendations of the 
ATA/AACE and the ETA guidelines. The second objective of the present study was to 
validate the Italian version of the MMAS-ϴ ƋuestioŶŶaiƌe foƌ the patieŶts͛ adheƌeŶĐe to 
LT4 therapy. 
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Methods 
 
Study design 
 
An Italian survey regarding the diagnosis and clinical management of PH (Endotrial SIE: 
DIagnosis and clinical management of Primitive hypothyrOidism in Italy-EDIPO) was 
performed. 
The institutional review board of the University of Modena and Reggio Emilia and the 
local institutional review boards of the 12 Endocrinological Italian Centers (Bari n=35, 
Brescia n=86, Cagliaƌi Ŷ=ϰϲ, Chieti Ŷ=ϰϴ, L͛AƋuila Ŷ=ϲϴ, MessiŶa Ŷ=ϲϴ, Mestƌe Ŷ=ϴϱ, 
Modena n=112, Naples Ŷ=ϯϴ, Noǀaƌa Ŷ=ϭϮϲ, ‘oŵe ͞“apieŶza͟ Ŷ=ϮϮϳ aŶd ‘oŵe ͞“aĐƌo 
Cuoƌe͟ Ŷ=ϭϬϬͿ appƌoǀed the protocol and all subjects gave their written informed 
consent. This observational, longitudinal, multicenter, cohort study, led by the young 
Italian endocrinologists group (EnGioI) of the Italian Society of Endocrinology (SIE), used 
the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) and 
STAndards for the Reporting of Diagnostic accuracy studies (STARD) checklists flow 
diagram and was carried out from September 2015 to March 2016. 
The adherence to treatment was evaluated through the MMAS-8, created for the 
evaluation of anti-hypertensive drug adherence (Morisky 2008). This is a self-reported 
questionnaire, which measures medication taking behaviour, starting from previous four-
items scale further with additional items addressing the circumstances surrounding 
adherence behaviour (Morisky 2008). Response categories were yes/no for each item 
with a dichotomous response and a 5-point Likert response for the last item. The total 
score of questionnaire was 8, divided in seven points for each of first seven items and one 
point divided in the last Likert question. 
 
Participants 
 
Outpatients were enrolled using the following inclusion criteria: age between 18 and 75 
years and newly diagnosed PH (Pearce 2013, Garber 2012). PH diagnosis was made when 
TSH serum levels were above the upper limit of the normal range, irrespective of fT4 and 
fT3 serum levels. Thus, both clinical (elevated TSH with low fT4 serum levels) and 
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subclinical (elevated TSH with normal fT4 serum levels) hypothyroidisms were included. 
Exclusion criteria were: (i) previous thyroidectomy for thyroid cancer, (ii) secondary 
hypothyroidism, (iii) hypothyroidism already treated with LT4 and (iv) pregnancy. 
 
Setting and Variables 
 
Patients were enrolled at Visit 1 (time 0). Visit 2, 3 and 4 coincided with any further 
follow- up visit. Socio-demographic, clinical, therapeutic management and laboratory data 
were collected by the clinician using electronic case report forms (eCRF) at baseline and 
at follow-up visits. When available, thyroid ultrasonography (US)-detectable 
abnormalities such as goiter and/or thyroiditis (US-thyroiditis) were recorded, according 
to standard criteria (Rago 2008). In particular, US-thyroiditis was defined by a diffusely 
heterogeneous echotexture and a marked diffuse reduction of the gland echogenicity, 
together with admixed hypo- and hyperechoic not-nodular areas, all often associated 
with decreased volume of the gland. 
Each endocrinologists used a therapeutic approach based on their clinical practice. The 
recruitment of the Centers was performed by the Coordinating center before starting the 
trial, considering the possibility to cover all Italian regions. 
The treatment to treatment was evaluated by MMAS-8 questionnaire, which was not yet 
published in Italian language. For this study, the questionnaire was adapted for LT4 
therapy evaluation and the Mapi company (Lyon, France) conducted the linguistic 
validation in Italian. 
 
Statistical Methods 
 
All data were collected in eCRF and a database was created at the Coordinating center. 
Hormonal data were converted to the same units of measurement, given the 
methodological differences among the reports of the laboratories. Since inclusion criteria 
depended on the PH diagnosis, each result was referred to the correspective laboratory 
reference range. Statistical analyses were performed at the Coordinating center. 
The descriptive analyses were performed considering all patients enrolled in the trial, 
whereas the evaluation of clinical practice was performed considering both AACE/ATA 
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and ETA recommendations. The variables regarding LT4 treatment that were evaluated 
included formulations, brands, doses and dosing regimen. In addition patient who 
received a constant daily dose and those receiving different daily doses were considered 
separately in some analyses. The distribution of each variable was evaluated through the 
Kolmogorov-Smirnov test. The prevalence of patients in each subgroup was compared by 
Fisher-Yates test. Comparison of variables among different groups was performed by 
ANOVA univariate when they showed normal distribution, whereas Mann-Whitney or 
Kruskal-Wallis tests were applied for not-normally distributed parameters. Post-hoc tests 
were performed by Dunnet test. Parameters were compared through “peaƌŵaŶ͛s 
correlation coefficient. For all comparisons, p values < 0.05 were considered statistically 
significant.  
The validation of the Italian version of the MMAS-8 questionnaire was performed 
following different steps. First, the MMAS-8 was translated in Italian. Second, it was 
administered to patients included in the study and data were collected. Third, the internal 
validity was considered, using standard statistical procedures described by Cronbach 
(Cronbach 1951). The Cronbach alpha is an adjusted proportion of total variance of the 
item scores explained by the sum of covariance between scores (Cronbach 1951, Bland 
1997). Thus, it ranged between 0 and 1 if all covariance elements were not negative, such 
as for MMAS-8 (Cronbach 1951, Bland 1997). Items with higher coefficient alpha were 
preferred to measure target outcome (Heo 2015). Internal validity was considered when 
the Cronbach alpha is >0.6. Fourth, the MMAS-8 reliability was considered following 
CƌoŶďaĐh͛s ĐoeffiĐieŶt. FiŶallǇ, the suƌǀeǇ͛s iŶfoƌŵatioŶ ǁeƌe revised according to the 
internal validity obtained. In particular, the validity of the 8-item scale was assessed 
through associations with TSH serum levels and according to sub-grouping of patients. 
“tatistiĐal aŶalǇsis ǁas peƌfoƌŵed usiŶg the ͚“tatistiĐal PaĐkage foƌ the “oĐial “ĐieŶĐes͛ 
software for Macintosh (version 21.0; SPSS Inc., Chicago, IL). 
 
Results 
 
Twelve Italian Units of Endocrinology were involved in the survey. 1039 patients were 
enrolled according to inclusion and exclusion criteria, for a total of 1430 records 
considering also the follow-up visits. 
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Study population 
 
The baseline characteristics of the study population are reported according to gender 
groups in Table 1 (pag. 138). The mean age was 47.84+15.32 years, with a significant 
difference among Centers (p<0.001), and the majority of patients (82.3%) were females. 
Comorbidities were present in 161 patients (5.5%) with a higher prevalence of 
cardiovascular diseases (13.6% of the total) in male patients (23.4% vs 11.1%). 
Hypothyroidism was incidentally discovered in 349 patients (43.1%). Other reasons for 
thyroid function evaluation were the presence of symptoms in 246 patients (30.4%), 
positive familial history in 190 (23.5%) and previous thyroid disease in 130 (16.1%). Less 
frequently, patients underwent thyroid function evaluation for infertility (6.4%), 
overweight (3.3%), tachycardia (1.8% and osteoporosis (1.7%). Overall, the 64.4% of our 
cohort (609 patients) had subclinical hypothyroidism. 
During the follow-up, a significant decrease of serum TSH levels together with a 
significant increase in fT4 levels was observed (Table 1, pag. 138). 
 
Treatment 
 
At baseline, LT4 monotherapy was prescribed in 76.1% of patients, with a comparable 
distribution between sexes (76.5% in females versus 72.8% in males).The brand was 
specified in the 79.1% of the entire cohort according to the following reasons: 
consolidated personal clinical ďehaǀiouƌ ;Ŷ=ϱϬϵ, ϳϮ.ϳ%Ϳ, patieŶt͛s alleƌgǇ oƌ iŶtoleƌaŶĐe 
;Ŷ=ϳϴ, ϭϭ.ϭ%Ϳ, patieŶt͛s ĐhoiĐe ;Ŷ=ϭϬϮ, 14.7%), factors interfering with the LT4 absorption 
(n=5, 0.7%) or difficulties in swallowing pills (n=3, 0.4%), availability of specific LT4 doses 
(n=3, 0.4%). LT4/LT3 combined therapy was chosen in 6 patients (0.8%), whereas a 
preparation containing only selenium and/or iodine integration was recommended in 114 
patients (11%). 
 
Follow-up 
 
A follow-up visit was recommended in 876 patients (84.3%) with serum thyroid function 
testing in 699 patients (67.3%) and thyroid US to 368 patients (35.4%). During the entire 
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duration of the trial, a modification of the initial therapeutic dose was recommended in 
143 patients (16.3%). 
 
Adherence to AACE/ATA Guidelines (see table 2, pag. 139) 
 
Diagnosis 
In our cohort, serum autoimmunity against thyroid gland was evaluated in 437 patients 
(71.7%) with subclinical hypothyroidism, even though AACE/ATA guidelines do not 
recommend autoimmunity evaluation in all hypothyroid patients. 
 
Therapy 
LT4 treatment was started in almost all patients (n=237 [95.9%], 186 females – 78.5% and 
males 21.5%) with TSH > 10 mIU/L. The therapy was postponed in 10 patients and a re-
evaluation of hormone levels was suggested. 
A concordance to guidelines regarding the LT4 mono-therapy and the description of 
correct modality of assumption was evident. 
 
LT4 dose 
Only seven patients (5.3%, 6 females and 1 male) received the full replacement dose (1.6 
µg/Kg daily), as suggested by AACE/ATA guideline, while the mean dose of LT4 suggested 
was 0.91 µg/kg daily. The 85.4% (n=158, 127 females and 31 males) of patients older than 
50 years was treated with LT4 although the regimen provided a gradual restore of 
euthyroidism only in 53.4% of those patients (n=29, 22 females and 7 males). The 43.2% 
(n=66) of those patients without coronary heart disease and 40% (n=2) with coronary 
heart disease was treated as suggested by guidelines. 
LT4 was prescribed in 73.9% (n=450) of patients with subclinical hypothyroidism, and in 
particular the recommended dose of 50-75 µg daily was suggested in 361 patients 
(80.2%). 
 
Follow-up 
Guideline suggests evaluation of TSH 4-8 weeks after starting or adjusting LT4 treatment, 
however 876 patients (84.3%, 724 females and 152 males) were evaluated after the first 
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visit within a mean interval of 4.29+3.36 months. Therefore, among treated patients, the 
guideline was strictly followed only by 146 patients (20.3%), suggesting a poor adherence 
to follow-up recommendations of the guidelines. 
In conclusion, the adherence of Italian endocrinologists to AACE/ATA guidelines was high, 
on average, with a mean concordance of 77.1%. However the final percentage of 
concordance increased to 88.6% excluding the low adherence to dose-related items (i.e. 
R22.7.1: Young adult patients with overt hypothyroidism should be treated with a full 
replacement dose (1.6 µg/kg daily). R22.7.2: Patients >50 years with overt 
hypothyroidism and without coronary disease should be treated with 50 µg daily. 
Gradually restore euthyroidism in patients older than 50-60 years of age. R22.8: Patients 
with subclinical hypothyroidism should be treated with 25–75 µg, depending on the 
degree of TSH elevation). 
 
Adherence to ETA Guidelines (see Table 3, pag. 140) 
 
Therapy 
Considering the entire cohort of patients with subclinical hypothyroidism, the treatment 
proposed and the description of the correct assumption modality was high. 
 
LT4 dose 
The starting LT4 dose was higher in younger than older subjects (p=0.002), without 
significant difference when patients were divided considering the degree of subclinical 
hypothyroidism. The mean LT4 daily dose adjusted for weight was 0.93±0.70 µg/Kg. Only 
2 patients (0.5%) of those without cardiac disease were treated with the exact 
recommended dose of 1.5 µg/Kg daily of LT4. 
On the contrary, 50 patients (12.5%) were accordingly treated, considering the suggested 
dose correction of 0.1 µg/Kg daily. 
Patients older than 70 years were treated with a mean LT4 dose of 48.81+24.02 µg, with a 
high concordance with guidelines recommendations, even though only one male patient 
was treated with a gradual increase LT4 therapy. 
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Considering patients with age less than 70 years, almost all patients with TSH > 10 mIU/L 
(n=63, 92.6%) were treated with LT4 (mean dose of 73.70+39.08 µg). Conversely, 504 
patients with TSH value < 10 mIU/L were treated in 71.4% of cases (n=360). 
 
Follow-up 
The follow-up visit was proposed in 313 treated patients, with a mean interval of 
4.43±3.87 months, with a low concordance to guideline recommendations. 
In conclusion, the adherence of Italian endocrinologists to ETA guidelines was 71.7% in 
average. However, the final percentage of concordance increased to 86.7% excluding the 
low adherence to dose-related items (45.5%) (i.e. recommendation 17: For patients 
without cardiac disease, a dose of 1.5 µg/kg daily should be use. Recommendation 18: For 
patients with cardiac disease or in the elderly is recommended a dose of 25 or 50 µg daily 
and a dose increase by 25 µg daily every 14–21 days until a full replacement dose is 
reached). 
 
PatieŶt’s adhereŶce to the treatŵeŶt 
 
MMAS-8 questionnaire was obtained from 293 patients, with a mean score of 6.71±1.42. 
The internal validation of the MMAS-8, evaluated by Cronbach coefficient alpha (13) was 
0.613. Moreover, the item-total correlations were greater than 0.30 for all items, 
suggesting that MMAS-8 could be applied to evaluation of adherence to LT4 treatment, as 
well (Table 4, pag. 141). 
A stratification of patients according to adherence to LT4 therapy was performed and 
compared with thyroid function assessment. Highly adherent patients were specified 
based onscore of 8 on MMAS-8, medium adherers by a score of 6 to <8, and low adherers 
with a score of <6 (Table 5, pag. 142). TSH serum levels did not differ among high, 
medium and low adherent patients (p=0.139). Forty seven patients (14.7%) had at least 
one agent and/or condition possibly having an impact on LT4 therapy and consequently 
on serum TSH levels. 
The MMAS-8 scores did not differ between sexes (p=0.348). The total MMAS-8 score was 
significantly directly related to the age (r=0.155, p=0.008). The age was significantly 
different among MMAS-8 categories (p=0.036), and post-hoc tests showed that low 
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adherent patients were significantly younger than highly adherent patients (p=0.031). The 
MMAS-8 score did not relate to the number of concomitant medications (p=0.098) except 
that highly adherent patients were more frequently treated with 3 or more concomitant 
medication compared to low adherent patients (p=0.016). MMAS-8 score did not differ 
among LT4 dosing regimens (p=0.142) and formulation (p=0.331) in the three adherence 
categories. Considering the time intercurrent between LT4 and breakfast, even though a 
post-hoc test showed a significantly longer interval in patients on LT4 tablets compared to 
liquid formulations (p<0.001) and soft gel (p<0.001), MMAS-8 score did not correlate with 
the fasting time. 
 
Discussion 
 
This is the first prospective, multicenter study designed to evaluate the approach to the 
management of PH in Italy. The study demonstrated a variable or somewhat variable 
approach of Italian endocrinologists towards PH, albeit in the context of a good 
percentage of adherence to AACE/ATA and ETA recommendation, although not complete. 
The second key result of the study was that it validates the Italian version of the MMAS-8 
questionnaire for the adherence to LT4 treatment. 
A similar adherence of the Italian endocrinologists to AACE/ATA and ETA 
recommendations was found (77.1% vs 71.7%). Noteworthy, these percentages must 
consider a low adherence to the guidelines recommendations concerning the ideal timing 
of follow-up visit. 
Moreover, the concordance to guidelines increases to 86.7 and 88.6%, respectively, after 
the exclusion of the recommendations regarding the LT4 dose. This result confirms the 
personalized medicine approach of Italian endocrinologists, who engage to establish case 
by case the LT4 daily dose needed to treat PH, confirming once again the importance of 
the customized therapy (Hamburg 2010). Indeed, the exact TSH threshold for the 
treatment start, the LT4 starting dose, the dosage adjustment in respect to clinical 
variables (i.e. age, sex, the presence of cardiovascular diseases) (Pearce 2013, Garber 
2012, Rodondi 2010), and the origin of hypothyroidism (iatrogenic, congenital or 
acquired) remain still topic of debate. 
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The starting LT4 daily dose depends on different factors, such as age, sex and body weight 
(Roti 1993, Mandel 1993, Toft 1994, Sawin 1983). These variables influence each other 
and they could mask the real effect of the treatment (Devdhar 2011), limiting the ability 
to design fully accepted recommendations. Both AACE/ATA and ETA guidelines do not 
recommend a fixed LT4 starting dose, suggesting a hypothetical starting dose, adjusted 
for anthropometrical features, clinical response, follow-up and laboratory determination 
(Jonklaas 2014, Pearce 2013, Garber 2012). As in different clinical conditions, the 
personalization of treatment, doses and regimen seems to be the best applicable 
approach in PH (Hamburg 2010). This approach often requires small LT4 doses and 
adjustment (Brajkovich 1983), thus, the availability of intermediate doses of LT4 
preparations could influence the ĐliŶiĐiaŶ͛s deĐisioŶ to iŵpƌoǀe patieŶts͛ adheƌeŶĐe aŶd 
endpoint achievement. The difficulty on the LT4 starting dose definition was already 
demonstrated worldwide (Burch 2014). 
Serum TSH represents the most reliable therapeutic endpoint for the treatment. Despite 
the discrepancies between LT4 starting dose chosen and recommended, the 
normalization of TSH  serum levels is achieved in the vast majority of our patients at the 
first follow-up visit. Previously, a similar reduction in TSH serum levels was observed in a 
French population, despite the average LT4 dose was lower than the full-recommended 
replacement dose (Delemer 2012). These results confirm once again the difficulty to 
define an exact LT4 starting dose universally acceptable. Alongside finding the exact dose, 
the correct time interval for follow-up visits remains a challenge in drawing and following 
guidelines. A relevant percentage of Italian endocrinologists do not strictly respect the 
recommended time interval proposed by AACE/ATA and ETA guidelines for the follow-up. 
This discrepancy could be explained by the difficulty in clinical practice to evaluate 
outpatients frequently in the setting of the Italian health care system. Our survey should 
be considered only a snapshot of the Italian approach to PH and the presence of biases 
should be carefully evaluated. For example, considering the study design and the 
enrolment of clinicians, and not of patients, it is not possible to completely rule out a 
Hawthorne effect (Campbell 1995) in the evaluation of Italian endocrinologists clinical 
habits. This effect explains the altered behaviour or performance of a clinician, resulting 
from awareness of being in an experiment, corresponding to the placebo effect in 
randomized clinical trial (Campbell 1995, McCambridge 2014). Enrolled endocrinologists 
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were asked to fulfil the eCRF during the 6 months of survey and, although a direct control 
was not provided, their decisions could be influenced by the awareness of being 
observed. 
The evaluation of LT4 treatment adherence represents the key point in the management 
of PH, since it seems to be the major reason for treatment inefficacy. This questionnaire is 
validated in several chronic treatment so far, such as osteoporosis (Reynolds 2014), type 2 
diabetes mellitus (Sakthong 2009), and PaƌkiŶsoŶ͛s disease (Fabbrini 2013), but not for 
LT4 therapy adherence. EDIPO was the first attempt to use the MMAS-8 questionnaire in 
the setting of PH, finding a high internal consistency of the Italian version of MMAS-8 also 
iŶ this field, usiŶg the CƌoŶďaĐh͛s ĐoeffiĐieŶt. This ĐoeffiĐieŶt ƋuaŶtifies how faithfully the 
questionnaire items represent the outcome construct of the instrument is aiming to 
measure (Cronbach 1951). Here, we validate for the first time the Italian version of 
MMAS-8 in the evaluation of LT4 treatment adherence in PH. Up to now, MMAS-8 could 
be considered a new reliable tool that could be further applicable both in clinical and 
research practice in the setting of levothyroxine therapy, although a validation in other 
languages is necessary to allow an international use. However, event though the 
validation of the MMAS-8 is acquired, a significant relationship between the 8-items score 
to TSH serum levels were not found. Thus, we are not able to use the MMAS-8 score to 
predict the response to LT4 treatment, even if several pitfalls should be considered. First 
of all, the TSH serum levels change slowly (Wiersinga 2001), whereas the mean follow-up 
interval was around four months in our study. Second, the adherence to LT4 therapy does 
not necessarily reflect TSH serum levels, which, in turn, could be influenced by several 
other factors, such as concomitant medication influencing the adsorption and the LT4 
dose used. This latter represents the most important challenge in the evaluation of 
MMAS-8 score and TSH relationship, considering the difficulty to find a precise LT4 dose 
applicable to all patients, as discussed above. 
However, a subdivision of patients in low, medium and highly adherent categories was 
previously suggested (Morisky 2008). Although this classification is useful in our cohort of 
patients, no differences in TSH serum levels were found, confirming that other 
parameters, besides adherence, are able to influence TSH modifications. However, we 
found that highly adherent patients were older and treated with at least 3 concomitant 
medications than low adherents. These results suggest that adherence to LT4 treatment 
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is influenced by age and the presence of concomitant medications, whereas no 
correlation was found with sex, the complexity of the LT4 regimen chosen, the LT4 
formulation and the time to follow-up. Thus, specific studies should be drawn to better 
describe the factors influencing the LT4 adherence. 
In 43% of cases, hypothyroidism was discovered incidentally, whereas the majority of 
remaining patients underwent TSH examination because of suggestive symptoms. Thus, 
hypothyroidism in Italy is generally detected before the onset of clinical symptoms, 
allowing the start of appropriate management, limiting the occurrence of overt 
hypothyroidism. Moreover, chronic autoimmune thyroiditis was found in about half of 
our cohort. This result is in line with the previous survey in the French population 
(Delemer 2012), confirming that in iodine-deficient areas this represents the most 
frequent cause (Vanderpump 1995). The majority of our patients (64%) showed a 
subclinical hypothyroidism, with a prevalence of a mild (87%) rather than a severe form. 
This finding appeared different compared to previously data acquired in the French 
population, in which subclinical hypothyroidism prevalence was about 35% (Delemer 
2012). Moreover, a different gender incidence of the disease is discovered, although the 
management was similar between males and females. Despite the observational design 
of this trial, the short time-interval chosen for the observation could represent a 
limitation, considering the chronic feature of the natural history of hypothyroidism. 
 
Conclusion 
 
The EDIPO study provides a valuable snapshot of the approach to clinical management of 
hypothyroidism in Italy. The wide number of Italian endocrinology centers enrolled and of 
hypothyroid patients included makes our findings robust and probably representative of 
the entire Italian population. This study showed different approaches to define the LT4 
starting dose by the clinicians, confirming the weight of personalization in chronic 
treatment. Thus, specific studies are needed to better establish the correct LT4 starting 
dose. The definition of a specific algorithm could be considered in order to detect the 
correct dose, connecting all factors known to influence the response to hypothyroidism 
treatment. In line with this, a high adherence of endocrinologists to both American and 
European guidelines is demonstrated, with the exception of the LT4 starting dose. Finally, 
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it is the first time the MMAS-8 questionnaire was used in patients with hypothyroidism. 
We validated the Italian version of the MMAS-8 questionnaire for the adherence to LT4 
treatment. Although the final score does not predict the TSH response to the therapy, the 
subdivision in low, medium and high adherents patients is helpful to better understand 
new factors influencing the treatment adherence. 
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Tables 
 
Table 1. Characteristics of treatment chosen and hormones between baseline visits and 
follow-up. 
 
 Baseline Follow-up visit p-value 
TSH (mIU/mL) 12.54+20.95 4.57+7.54 <0.001 
Free T4 (pg/mL) 8.72+3.14 10.54+8.82 <0.001 
Free T3 (pg/mL) 3.19+1.03 3.05+0.99 0.533 
TgAbs measurement 568 (54.7) 297 (22.7) - 
TPOAbs measurement 658 (63.3) 297 (22.7) - 
Autoimmune thyroiditis 482 (46.4) - - 
Thyroiditis at ultrasonography 660 (63.5) - - 
Nodular goiter 268 (25.8) - - 
Therapy 
LT4 started 709 (76.1) - - 
LT4 dose changed - 143 (16.3) - 
LT4 formulation chosen in the entire cohort of patients 
Tablets 614 (76.2) - - 
Liquid formulation 114 (14.1) - - 
Drops 6 (5.3) - - 
Vials 108 (94.7) - - 
Soft gel capsules 78 (9.7) - - 
 
Footnotes to table 1: vials indicate a LT4 liquid formulation packaged in ampoules. 
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Table 2. Concordance to AACE/ATA guidelines. 
 
 
Recommendation n. Recommendation 
Survey 
Concordance 
(%) 
Diagnosis 
R1 TPOAb measurement should be considered in subclinical hypothyroidism 71.7 
R10 T3 or fT3 should not be use to diagnose hypothyroidism 100 
Therapy R22.1 Use LT4 oral mono-therapy 99.6 
R22.2 Do not use LT4/LT3 combinations to treat hypothyroidism 99.6 
R22.4 Do not use desiccated thyroid hormone to treat hypothyroidism 100 
R32.1 Do not use iodine supplementation in iodine-sufficient areas 99.5 
R33 Selenium should not be used to prevent or treat hypothyroidism 89.6 
R15 Patients with TSH above 10 mIU/L should be considered for treatment with LT4 95.9 
R23 
LT4 should be taken on an empty stomach: with 
water 30–60 minutes before breakfast or at 
bedtime 4 hours after the last meal. 
Concomitant intake of substances or medications 
interfering with its absorption should be avoided. 
98.4 
LT4 dose 
R22.7.1 
Young adult patients with overt hypothyroidism 
should be treated with a full replacement dose 
;ϭ.ϲ μg/kg dailǇͿ 
5.3 
R.22.7.2 Patients > 50 years with overt hypothyroidism and without coronary disease: 50 μg daily. 43.2 
R 22.8 
Patients with subclinical hypothyroidism, 
initial LT4 dose is generally lower: 25–ϳϱ μg, 
depending on the degree of TSH elevation. 
80.2 
R.22.7.2 Gradually restore euthyroidism in patients older than 50-60 years of age 53.4 
Follow-up 
R8 Measure both TSH and fT4 to monitor LT4 treatment 100 
R13 Measure TSH 4-8 weeks after starting or adjusting LT4 20.3 
 
fT3: free triiodothyronine; fT4: free thyroxine; LT3: liothyronine; LT4: levothyroxine; n: number; T3: 
triiodothyrodinine; TPOAb: antithyroid peroxidase antibodies; TSH: serum thyroid-stimulating hormone 
  
140 
 
Table 3. Concordance with ETA guidelines. 
 
 
Recommendation n. Recommendation Survey concordance (%) 
Diagnosis 1 Measure TPOAbs 71.7 
Therapy 16 Use monotherapy with oral LT4 100 
16 Do not use LT3 alone or LT4 and LT3 combinations to treat hypothyroidism 100 
7 
Treat patients with persistent subclinical 
hypothyroidism and diffuse or nodular 
goiter to normalize TSH levels 
77.4 
13 
LT4 is recommended in younger patients, 
with serum TSH >10 mIU/L, with or without 
symptoms 
92.6 
19 
LT4 should be taken on an empty stomach, 
in the morning, an hour before food, or at 
bedtime, 2 h or more after the last food. 
Avoid or take 4 h or more after its 
ingestion medications interfering with LT4 
absorption 
97.8 
LT4 dose 
17 For patients without cardiac disease, a dose of ϭ.ϱ μg/kg dailǇ should ďe use 12.5 
18 For patients with cardiac disease: 25 or 50 μg daily 83.3 
18 In the elderly: 25 or 50 μg daily 77.8 
18 
For patients with cardiac disease and in the 
elderly: increase the dose of LT4 by 25 μg 
daily every 14–21 days until a full 
replacement dose is reached 
8.3 
Follow-up 20 Measure TSH 2 months after starting LT4 67.7 
 
fT3: free triiodothyronine; fT4: free thyroxine; LT3: liothyronine; LT4: levothyroxine; n: number; TPOAb: 
antithyroid peroxidase antibodies; TSH: serum thyroid-stimulating hormone. 
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Table 4. Morisky Medical Adherence Scale (MMAS)-8 inter-items variability, evaluated by 
Cronbach coefficient alpha. The Italian version of the questions and the respective 
translation is reported. 
 
Item Cronbach 
Coefficient 
alpha 
1. Do you ever forget to take medications for hypothyroidism? 
 
;Le Đapita ŵai di diŵeŶtiĐaƌe di pƌeŶdeƌe i faƌŵaĐi peƌ l͛ipotiƌoidisŵo?Ϳ 
0.540 
2. Sometimes people do not take the drugs for reasons other than forgetfulness. In 
the last two weeks, there have been days when you did not take the drugs for 
hypothyroidism? 
 
(A volte le persone non prendono i farmaci per motivi diversi dalla dimenticanza. In 
riferimento alle ultime due settimane, ci sono stati giorni in cui non ha preso i farmaci per 
l͛ipotiƌoidisŵo?Ϳ 
0.577 
3. Have you ever reduced or stopped taking the drugs without telling the doctor, 
taking them because you felt worse? 
 
;Ha ŵai ƌidotto o iŶteƌƌotto l͛assuŶzioŶe dei faƌŵaĐi seŶza ĐoŵuŶiĐaƌlo al ŵediĐo, peƌĐhĠ 
prendendoli si sentiva peggio?) 
0.613 
4. Do you ever forget to take your medications for hypothyroidism when they 
are away from home or traveling? 
 
;Le Đapita ŵai di diŵeŶtiĐaƌe di poƌtaƌsi i faƌŵaĐi peƌ l͛ipotiƌoidisŵo ƋuaŶdo ğ fuoƌi Đasa o 
in viaggio?) 
0.572 
5. Yesterday took medication for hypothyroidism? 
 
;Ieƌi ha pƌeso i faƌŵaĐi peƌ l͛ipotiroidismo?) 
0.612 
6. Do you ever stop taking the medication when you consider that 
hypothyroidism is under control? 
 
;Le Đapita ŵai di iŶteƌƌoŵpeƌe l͛assuŶzioŶe dei faƌŵaĐi ƋuaŶdo ƌitieŶe Đhe l͛ipotiƌoidisŵo sia 
sotto controllo?) 
0.587 
7. For some people take daily medications is a real hassle. Do you ever resent the fact 
that they have to stick to the treatment plan for hypothyroidism? 
 
(Per alcune persone prendere ogni giorno i farmaci è una vera seccatura. Le capita mai di 
provare fastidio per il fatto di doǀeƌsi atteŶeƌe al piaŶo teƌapeutiĐo peƌ l͛ipotiƌoidisŵo?Ϳ 
0.550 
8. How often do you have trouble remembering to take any 
medications? 
 
(Quanto spesso ha difficoltà a ricordare di prendere tutti i farmaci?) 
0.576 
 
Cronbach coefficient alpha was considered significant in each item when it was greater than 0.3. 
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Table 5. Characteristic of participants who fulfil the Morisky Medical Adherence Scale 
(MMAS)-8 score. Data are expressed as mean±SD. MMAS-8 Score: low adherence <6; 
medium adherence from 6 to 8; high adherence >8. The p-value referred to the 
differences among three categories of adherence. 
 
 
Total 
(n=293) 
High 
adherent 
(n=110) 
Medium 
adherent 
(n=113) 
Low 
adherent 
(n=70) 
p 
Age (years) 47.54±14.97 50±14.09 47.112±15.55 44.34±14.92 0.036 
Gender 
 Male: n (%) 42 (14.3) 14 (12.7) 17 (15) 11 (15.7) 0.887 
 Female: n (%) 251 (85.7) 96 (87.3) 96 (85) 59 (84.3) 0.887 
Formulation 
 tablets 234 (79.7) 81 (75.0) 95 (84.1) 58 (80.0) 0.131 
 liquid 38 (13.1) 18 (16.7) 14 (12.4) 6 (8.6) 0.131 
 soft gel capsules 21 (7.2) 9 (8.3) 4 (3.5) 8 (11.4) 0.131 
Weekly regimen 
 stable 280 (96.2) 103 (95.4) 109 (95.4) 68 (97.1) 0.561 
 variable 11 (3.8) 5 (4.6) 4 (3.5) 2 (2.9) 0.561 
Concomitant medications: n (%) 
0 181 (61.8) 71 (64.6) 65 (57.5) 45 (64.3) 0.117 
1 57 (19.4) 14 (12.7) 28 (24.8) 15 (21.5) 0.021 
2 24 (8.2) 10 (9.1) 9 (8) 5 (7.1) 0.117 
шϯ 31 (10.6) 15 (13.6) 11 (9.7) 5 (7.1) 0.016 
Serum TSH 
 mean (microIU/L) 4.55±8.13 4.56±5.74 5.03±11.30 3.76±4.36 0.139 
 within range: n (%) 186 (63.3) 69 (62.7) 72 (63.7) 45 (64.3) 0.947 
MMAS-8 score 6.72±1.42 8±0.00 6.76±0.50 4.62±1.05 <0.001 
 
Footnotes to table 5: n: number; TSH: serum thyroid-stimulating hormone. 
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THYROID CANCER PHENOTYPES IN RELATION TO 
METABOLIC SETTING AND RISK FACTORS 
 
Introduction 
 
Most epidemiological studies concerning differentiated thyroid cancers (DTC) indicate an 
increasing incidence over the last two decades. This increase might be partially explained 
by the better access to health services worldwide, but clinicopathological analyses do not 
fully support this hypothesis, indicating that there are carcinogenetic factors behind this 
noticeable increasing incidence (Marcello 2014). Environmental/lifestyle factors (e.g., 
radiation, iodine intake, and nitrates), insulin resistance, inflammation, and perhaps a 
complex multiplication of these factors are considered possible causes for a true increase 
in thyroid cancer incidence (Yihao 2017). 
 
Radiation Exposure. After the nuclear power accident of Chernobyl in 1986, a large 
increase in childhood thyroid cancer incidence was reported in contaminated areas 
(Williams 2008) and after acute exposure before age 20, the excess relative risk of thyroid 
cancer has been found to persist for over 50 years (Furukawa 2013). Radiation-induced 
papillary thyroid cancer (PTC) is unique in its molecular profile that most cases were 
found to have RET-PTC chromosomal rearrangements, while BRAF or RAS point 
mutations, commonly found in sporadic PTCs, rarely occurred (Williams 2008). While 
radiation exposure may have contributed a few extra cases of thyroid cancer diagnosed 
every year, it could not have explained the sharp increase in thyroid cancer incidence. 
 
Iodine Intake. Iodine is an essential element for the synthesis of thyroid hormones. Since 
universal salt iodization was introduced in the 1990s, whether iodine contributes to the 
increasing cancer incidence has been a topic of controversy and public concern. 
Level of iodine intake affects thyroid functions, but mechanisms linking with thyroid 
cancer are not clear. Chronic stimulation of the thyroid-stimulating hormone (TSH) and 
BRAF mutations in PTC are possible pathways (Fuziwara 2014, Guan 2009). Also, some 
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studies suggested that iodine intake may influence the distribution of thyroid cancer 
subtype, rather than the overall incidence. There may be more follicular and fewer 
papillary carcinomas in iodine-deficient areas and more papillary subtype in iodine-rich 
areas (Bubenhofer 1977, Williams 1977). 
 
Obesity, Diabetes and Insulin Resistance. The trend of rising thyroid cancer incidence 
over the past few decades also coincides with the growing trend of obesity and diabetes 
(Schmid 2013), but whether or how they are correlated is largely unknown. Mechanisms 
for a possible link between obesity, diabetes, and thyroid cancer include elevated levels 
of insulin resistance and TSH. Insulin resistance may activate insulin and the IGF pathway, 
which are important to cell proliferation and apoptosis (Aschebrook-Kilfoy 2011, Pazaitou-
Panayiotou 2013). The chronically elevated circulating insulin levels may influence thyroid 
cancer risk mediated by insulin receptors overexpressed by cancer cells. However, the 
specific effects of hyperinsulinemia and insulin resistance on promoting thyroid cancer 
risk are not well understood. 
 
Estrogen and Reproductive Factors. Estrogen has historically been proposed as a 
potential mechanism mediating the risks of different types of cancer (Santen 2015, 
Ashton 2009, Gallo 2010). Given that women account for over three-fourth of the 
prevalence of thyroid cancer, estrogen is regarded as a possible risk factor (Magri 2012). 
The exposure to exogenous estrogen has also seen an increasing trend due to various 
medical and environmental sources. Evidence linking these to thyroid cancer risk is, 
however, nonconclusive. Cellular studies have shown that estrogen and its receptors play 
an important role in the proliferation, migration, and invasion of thyroid cancer (Kamat 
2011, Rajoria 2011, Rajora 2010). It exerts its growth-promoting effect via a membrane-
bound estrogen receptor (ER) (Lu 2016). However, such effects or pathways have not 
been successfully demonstrated in human studies. 
 
Hashimoto's Thyroiditis and inflammation. The incidence of chronic autoimmune 
Hashimoto's thyroiditis (HT) has increased in the past two decades, paralleling the trend 
of increased thyroid cancer incidence (Lun 2013). Yet the link between HT and PTC has 
long been a topic of controversy. Some plausible mechanisms have been proposed. 
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Elevated levels of TSH found in hypothyroid patients with autoimmune thyroid disease 
may stimulate follicular epithelial proliferation, promoting the development of papillary 
carcinoma. Autoimmune thyroiditis might also induce thyroid tumorigenesis via the 
production of proinflammatory cytokines and oxidative stress (Khatami 2009). 
 
This section aims to explore the role of metabolic setting and other risks factor in 
determining  thyroid tumorigenesis and thyroid cancer phenotypes, in particular: 
- the clinical and histopathological characteristics of 2 Italian populations with DTC 
exposed to different risk factors, in order to evaluate the differences in DTC 
phenotype. 
- the role of inflammation and autoimmunity in determining the thyroid cancer 
phenotype 
- the relationship between insulin resistance, adipokines levels and the presence of DTC 
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Abstract 
 
The aim was to retrospectively analyse the clinical-histopathological characteristics of 
patients with newly diagnosis of differentiated thyroid cancer (DTC) referred to two 
Italian centres, one in Northern and the other in Southern Italy, between 2000 and 2013. 
1081 patients were included and subdivided into two groups: group A (474 patients from 
Novara) and group B (607 patients from Naples). The group A came from the industrial 
area of Novara, while the Group B came from the areas around Vesuvius and Campi 
Flegrei. The two groups were comparable for iodine levels, body mass index, diagnostic 
timing and clinical procedures. For all patients, demographic and clinical data were 
collected. No difference was found in gender, whereas the age at diagnosis was later in 
the group A (group A 53.1±15.16 years, group B 41.9±14.25 years, p<0.001). In both 
groups, the most frequent histotype was papillary thyroid cancer (PTC) with prevalence of 
follicular variant in group A (p<0.0001) and classical variant in group B (p<0.0001). 
Aggressive histological features were mainly seen in group A (bilaterality p<0.0001, 
multifocality p<0.0001 and thyroid capsular invasion p<0.0001). Microcarcinomas were 
more frequent in group A (p<0.0001) but mostly characterized by bilaterality (p<0.001) 
and multifocality (p<0.04). In both groups, tumour-associated thyroiditis showed a 
significant increase over the years (group A p<0.05, group B p<0.04). Environmental 
factors could justify the differences found in our study. These preliminary data should 
stimulate the need for an Italian Cancer Registry of DTC in order to allow an 
epidemiological characterization, allowing the identification of specific etiological factors 
and an improvement in the management of the disease. 
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Background 
 
The incidence of the differentiated thyroid carcinoma (DTC) has been increasing in many 
countries over the last 30 years (Howlader 2013, Davies 2014, Kent 2007, Simard 2012, 
Enewold 2009, Ascherbrook-Kilfoy 2011, Colonna 2007, Reynolds 2005, Netea-Maier 2008, 
Lise 2012, Elisei 2010). 
The most recent data about this massive increase in the incidence come from the U.S. 
SEER (Surveillance, Epidemiology, and End Results) which shows that the age- adjusted 
incidence rate has increased from 4.85/100,000/year in 1975 to 14.93/100,000/year in 
2011 (Howlader 2013). 
In Italy, a marked increase occurred over the last three decades, both in men (+9.1% per 
year) and in  women (+8.7% per year), according to AIRTUM (Italian Association of Cancer 
Registries), AIOM data (Italian Association of Medical Oncology) and literature (Elisei 
2011); in particular, more than 16,000 new cases were seen in 2013 (4100 men and 
12,200 women), representing about 4.5 % of all new cases (AIRTUM 2013). 
The reported incidence increase in all countries is almost exclusively due to an increase in 
the papillary thyroid carcinomas variant (PTC), with no significant changes in the follicular 
(FTC), medullary and anaplastic form (Davies 2014). Despite the most part of PTC consists 
in indolent micro/small carcinomas (Davies 2014), the mortality rate has not decreased, 
standing around 0.5 per 100,000 per year in both sexes in almost all countries (Ferlay 
2004, Ferlay 2010). 
Therefore, even if the increased incidence could be attributed to a better diagnostic 
accuracy (Elisei 2010, Lee 2012, Grodski 2008), we cannot exclude environmental and 
lifestyle causative factors (Pellegriti 2013, Morris 2010, Li 2013). 
Major data about epidemiology and risk factors for DTC come from geographical areas, 
such as United States, where the vastness, the presence of different ethnic groups and 
different lifestyles make difficult to evaluate the environmental carcinogens (Davies 2014, 
Simard 2012, Enewold 2009, Ascherbrook-Kilfoy 2011). In Italy, this limit could be avoided 
thanks to the territorial limited extension, the more homogeneous population and the 
comparable lifestyle in all regions (Malandrino 2013, Pellegriti 2009, Biondi 2012, 
Marcello 2014). 
149 
 
The aim of our study was to retrospectively analyse the clinical and histopathological 
characteristics of Italian caucasic patients with DTC referred to two Italian centres, the 
UŶiǀeƌsitǇ Hospital ;AOUͿ ͞Maggiore della Carità͟ in Novara, in Northern Italy and the 
University Hospital (AOU), Federico II in Naples, in Southern Italy, in order to evaluate the 
possible differences of DTC in these populations compared to data reported in the 
national literature. 
 
Methods 
 
We retrospectively analysed clinical and pathological features of patients with newly 
diagnosis of DTC referred to 2 clinical centres: ͞Maggiore della Carità͟ University Hospital 
(Novara) in Northern Italy aŶd ͞FedeƌiĐo II͟ University Hospital (Naples) in Southern Italy, 
from January 2000 to December 2013. All cases were collected from the Pathology 
archive of each centre. 
Patients were subdivided into two groups, according to the centre of origin (Group 
A=Novara; Group B=Naples). The group A patients came from the eastern province of 
Novara, a typical industrial area, while the Group B population came from the areas 
around the volcano Vesuvius and Campi Flegrei, an active sunken volcanic area. 
According to ARPA (Regional Agency for Environmental Protection) data, there are some 
differences in exposure between these two Italian regions: Novara population is exposed 
to industrial chemicals, such as formaldehyde and benzene (ARPA Piedmont 2014), while 
Naples area is exposed to minerals of volcanic origin such as nitrates, vanadium, 
manganese and other heavy metals (ARPA Campania 2014). 
 The two groups were comparable for iodine levels, body mass index (BMI), diagnostic 
timing and clinical procedures. 
Patients data were collected through retrospective medical record review regarding 
demographics and clinical aspects (age, gender, BMI, ioduria, type of surgery) and 
histological reports including information about tumour size, extrathyroidal extension, 
multifocality, lymph-nodal (LN) metastasis and presence of peritumoural thyroiditis. 
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Environmental and occupational exposures were identified through a direct interview for 
each patient. Smoking habits, hormonal and genetic factors were not investigated 
because the evaluation of this clinical outcome was not a purpose of the study. 
Patients with history of medical irradiation, poorly differentiated, anaplastic, medullary 
thyroid carcinomas and secondary tumours or living for less than 5 years in the analysed 
areas were excluded. 
Our data relating to ioduria were extrapolated from a new document, which contains 
information about ioduria in 16 Italian regions including Piedmont and Campania. This 
document was published by ItaliaŶ ͞Istituto Superiore di Sanità͟ in 2014 (ISS 2014). 
Histological diagnoses were blindly determined by two independent pathologists, 
specialized in thyroid pathology, belonging to the two centres. Pathologic staging was 
redefined according to the Tumour, Lymph Node, and Metastasis classification system 
based on the 6th edition of the UICC/AJCC TNM classification (Edge 2010). 
Moreover, we evaluated the frequency and histopathological characteristics of 
microcarcinomas (defined as tumours 1 cm or less in size (LiVolsi 2004)) in both the 
groups. 
For all cases, tumour-associated thyroiditis was assessed. The histological criteria used to 
make this diagnosis included diffuse lymphoplasmacytic infiltration, germinal centres and 
enlarged epithelial cells with large nuclei and eosinophilic cytoplasm (Hurthle cells), which 
aƌe speĐifiĐ foƌ Hashiŵoto͛s thǇƌoiditis ;HTͿ aŶd also polǇŶuĐleaƌ ŵaĐƌophage-like and 
fibroblastic-like population specific for non-specific lymphocytic thyroiditis, which might 
represent perineoplastic inflammation, when occurring immediately adjacent to a tumour 
(Liotti 2012). 
The results were expressed as mean ± standard deviation (SD) or percentage with 95 % 
confidence intervals. The association between factors was assessed with the multinomial 
logistic regression for dichotomous or categorical variables. Continuous variables were 
analysed using student t test. 
P values less than 0.05 were considered significant. The analyses were performed using 
SPSS 17.0 (SPSS Inc., Chicago, Ill., USA). 
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Results 
 
1081 patients were included in this study: group A=474 patients and group B=607 
patients. The clinical and histopathological characteristics of all patients are reported in 
Table 1 (pag. 158). 
  
Group A (474 cases) 
 
In this population, the majority of patients were female (76.4 %) with a M:F ratio of 1:3. 
The mean age at diagnosis (mean±SD) was 53.1±15.16 years (range: 13.0–88.0 years); in 
particular, 68.6% was aged >45 years. The mean BMI (mean±SD) was 26.6±4.52 kg/m2. 
Total thyroidectomy was performed in 99.2% of cases and 28.1% of patients also 
underwent lymphadenectomy. The most frequent histotype was PTC (90.0%), and the 
most widespread variant was the follicular one (37.3% of all PTCs), followed by the 
classical variant (36.9%). FTC was detected in 9.0% of cases. Only 5.5% of tumours were  
sized >4.0 cm, while microcarcinomas represented the majority of cases (44.1%). 
The 75.3% of tumours were classified as stage I, followed by stage III tumours (11.4%), 
with high frequency of thyroid capsular invasion (19.2%). Tumours were bilateral in the 
25.3% of cases and multifocal in the 31.2% of cases. Among patients who underwent 
lymphadenectomy, 50.8% had lymph node metastasis. 
Finally, tumour-associated thyroiditis was histologically found in 24.5% of cases. 
 
Group B (607 cases) 
 
In this group, the disease was more frequent in females with M:F ratio of 1:3. 
The mean age at diagnosis (mean ± SD) was 41.9±14.28 years (range: 8.0-84.0 years); in 
particular, 58.3% of the patients were aged <45 years. The mean BMI (mean±SD) was 
27.1±5.57 kg/m2. 
99.7% of patients underwent total thyroidectomy with lymphadenectomy in 46.9% of 
cases. The most frequent histotype was PTC (89.0%), and the most widespread variant 
was the classical (63.8% of total PTCs), followed by follicular (19.9%). The 11.0% of 
patients was affected by FTC. 
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Tumours  sized >1.0 cm  and <2.0 cm represented the majority of cases (43.9% of cases). 
Stage I tumours represented more than three-quarters of the cases (88.4%), followed by 
stage II (5.5%), stage III (4.1%) and stage IV (2.0%) tumours. 
Tumours were bilateral in 13.2% of cases and multifocal in 21.1% of cases, and the 
thyroid capsular invasion was found only in 8.7% of cases. Among patients who 
underwent lymphadenectomy, 50.2% had lymph node metastasis. 
Finally, the tumour-associated thyroiditis was histologically found in 29.7% of cases. 
 
Group A vs Group B 
 
With regard to the clinical characteristics, the age at diagnosis was earlier in  group  B  
than  in  group A (p<0.001) (Figure 1, pag. 159). 
Moreover, no significant difference was found in BMI (26.6±4.52 kg/m2 in group A and 
27.1±5.57 kg/m2 in group B). 
In both populations, we observed an upward trend over time of PTC cases (Figure 2, pag. 
159). Regarding histotype, the most frequent was PTC in both the groups; the follicular 
variant was more represented in group A, while the classical variant in group B (p<0.0001) 
(Figure 3, pag. 159). Furthermore, most aggressive variants were observed more in group 
A than in group B, although without statistical significance. Histopathological differences 
were found between the two populations: bilaterality (group A vs. group B, 25.3% vs. 
13.2%, p<0.0001), multifocality (group A vs. group B, 31.2% vs. 21.1%, p<0.0001) and 
thyroid capsular invasion (group A vs. group B, 19.2% vs. 8.7%, p<0.0001) (Figure 4, pag. 
160). 
Regarding smaller tumours, microcarcinomas were significantly more frequent in group A 
(p<0.0001) with respect to group B, and, similarly to macroscopic tumours, in Noǀaƌa͛s 
group they were mostly characterized by bilaterality (group A vs. group B, 20.5% vs. 8.3%,   
p<0.001), multifocality (group A vs. group B, 25.9% vs. 16.6%, p<0.04) and, without 
reaching significance, thyroid capsular invasion (group A vs. group B, 6.3 % vs. 4.1 %). 
Therefore, stage I tumours were more represented in group B than in group A (p<0.0001), 
considering the earliest age of discovery of the disease (Figure 5, pag. 160). 
With regard to the presence of lymph node metastasism (N) and distance metastasis (M) 
at the time of diagnosis, no difference was found between the two groups, nor about the 
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presence of thyroiditis, considering both thyroid peroxidase antibodies (TPOAb) positivity 
and the presence of lymphocytic and non-specific lymphocytic peritumoral inflammation; 
however, this tumour-associated thyroiditis showed a significant progressive increase 
over the years, in both the populations (p<0.05 in group A, p<0.04 in group B) (Figure 6, 
pag. 160). 
 
Discussion 
 
The study of clinical, histopathological and epidemiological characteristics directly 
influences diagnostic and therapeutic decisions in the field of oncology (Sipos 2010). 
In recent years, the literature reported a significant increase in the incidence of PTC 
worldwide and in particular in Italy (Howlader 2013, Davies 2014, Kent 2007, Simard 
2012, Enewold 2009, Ascherbrook-Kilfoy 2011, Colonna 2007, Reynolds 2005, Netea-Maier 
2008, Lise 2012, Elisei 2010). 
In our study, we observed the same upward trend in incidence of thyroid cancer cases in 
both the cohorts studied; however, considering the clinical and histopathological 
characteristics at the time of diagnosis, some differences emerge, leading to hypothesize 
that environmental and carcinogens factors could change the DTC tumourigenesis. 
First, we observed a difference in age at diagnosis between the two populations. In fact, 
in the Neapolitan population, thyroid cancer seems to be diagnosed earlier than in 
Novara population, in agreement with other national and international studies reported 
in literature (Elisei 2010, Shi 2016). Interestingly, in group B, we observed a high 
percentage of subjects younger than 25 years. This anticipation in the age at diagnosis 
was also found in the Italian study by Malandrino and co-workers (Malandrino 2013) 
involving populations living in volcanic areas. As a matter of fact, Neapolitan patients 
mainly came from the areas around the volcano Vesuvius and Campi Flegrei, which are 
exposed to volcanic minerals, according to ARPA data (ARPA Campania 2014). Therefore, 
this phenomenon of age anticipation could be related to the exposure to one or more 
volcanic carcinogens (in particular heavy metals) (Pellegriti 2009, Biondi 2012, Marcello 
2014, Duntas 2009, Arnbjornsson 1986, Kolonel 1990, Curado 2007, Truong 2007). It has 
already been reported that high heavy metal concentration in the soil or water would act 
as endocrine disruptors, increasing the risk for thyroid cancer in younger age because 
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their effects may manifest in utero, in children and in adulthood (Patrick 2009). 
Moreover, considering only thyroid cancers larger than 1.0 cm, in this group, we found a 
significantly higher incidence of larger thyroid cancers, even papillary types, according to 
other studies regarding populations living in volcanic areas (Pellegriti 2009, Truong 2007). 
In these areas, there seems to be a significant inverse relationship between tumour size 
and age at diagnosis (the mean tumour size was significantly higher in younger patients in 
a Sicilian cohort around Etna volcano) (Malandrino 2013). 
OŶ the otheƌ haŶd, iŶ Noǀaƌa͛s gƌoup, ǁe fouŶd oldeƌ age at diagŶosis, diffeƌeŶtly from 
what reported in literature (Davies 2014, Elisei 2010, Shi 2016). It has to be considered 
that also Fugazzola and co-workers (Abstract no. 20. Abstract book from 9° Congresso 
Associazione Italiana della Tiroide) recently showed an increased age at diagnosis in their 
population living in Milan and surrounding areas, close to Novara region. 
This increase in thyroid cancer incidence in elderly population could be due to the 
combined effect of radiations and natural changing of hormonal status in this age (Fuzik 
2013, Prysyazhnyuk 2014). Therefore, considering that Northern Italy was more exposed 
to CheƌŶoďǇl͛s ŶuĐleaƌ ƌadiatioŶs thaŶ “outheƌŶ Italy, as shown in the European map 
from Chernobyl, 22 years later, CBS News (Plante 2008), we could speculate that in 
Noǀaƌa͛s gƌoup, ǁe aƌe Ŷoǁ oďseƌǀiŶg the seĐoŶd peak of tuŵouƌs afteƌ aďout ϮϬ Ǉeaƌs 
of latency. 
Another interesting observation coming from our data concerns the histopathological 
featuƌes. IŶ Noǀaƌa͛s gƌoup, ǁe fouŶd a higheƌ peƌĐeŶtage of folliĐulaƌ ǀaƌiaŶt of PTC 
(FVPTC) compared to Neapolitan group and other Italian cohorts (De Leo 2013). The 
FVPTC is a heterogeneous disease that includes two different groups of tumours: one 
similar to the classical PTC in its behaviour and another more similar to FTC in its invasive 
features and molecular profile (Liu 2006). Certainly, the re-classification of FVPTC in these 
2 subgroups and the genetic characterization of tumours in our population might be 
helpful to explain their higher incideŶĐe iŶ Noǀaƌa͛s gƌoup. 
Fuƌtheƌŵoƌe, iŶ Noǀaƌa͛s Đohoƌt, CDT shoǁed ŵoƌe histopathologiĐal aggƌessiǀe featuƌes 
already at diagnosis, such as thyroid capsular invasion, bilaterality and multifocality. The 
same was seen in microcarcinomas, especially with regard to bilaterality and 
multifocality, even if in literature these two characteristics do not seem to adversely 
affect survival (Elisei 2010). This result corroborates the data available in the literature 
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(Tzvetov 2009) showing that microscopic thyroid cancer at presentation can be as 
aggressive as macroscopic disease, regardless of whether the tumour is incidentally 
discovered or not. Molecular studies would be able to differentiate, at an early stage, 
microcarcinomas with an aggressive behaviour from microcarcinomas with an indolent 
clinical course. The increased aggressiveness could correlate with and another risk factor, 
of ǁhiĐh Noǀaƌa͛s populatioŶ is eǆposed, chemical pollutants in atmosphere (Fincham 
2000, Carstensen 1990). As a matter of fact, Novara is placed in a predominantly 
industrial area and the population is exposed to chemical pollutants such as 
formaldehyde and benzene (ARPA Piedmont 2014). Most of the population came from 
the Eastern part of the Novara province, where the industries are predominantly placed, 
especially in the textile and engineering fields; about 30.0% of our patients were 
employed in the textile sector and about 25.0% in the engineering industry. According to 
ARPA data collected from 2003 to 2009 (ARPA Piedmon 2014), environmental exposure to 
formaldehyde and benzene in this area was recognized to be higher than in the rest of 
Italy. The correlation between thyroid cancer and exposure to formaldehyde and benzene 
emerges in several studies reported in literature (Wong 2006, Kuzmickiene 2009, Lope 
2009). In particular, a study conducted on a cohort of Chinese women working in the 
textile industry in Shanghai showed a strong association between thyroid cancer and 
exposure to formaldehyde (Wong 2006). Even exposure to benzene has been shown to 
be related to thyroid cancer, but with a lower extent than formaldehyde. To date, few 
studies focused on the role of these substances in thyroid cancer and on the mechanisms 
of inducing tumourigenesis, but all agree with the hypothesis that these chemicals can 
determine both the tumour onset and its more aggressive behaviour (Wong 2006, 
Kuzmickiene 2009, Lope 2009). 
We can speculate that in the Northern area both environmental factors (radiation or 
chemical pollutants exposure), together or alone might play a role in thyroid 
tumourigenesis. From a recent review by Marcello and co-workers (Marcello2014), 
radiation exposure seems to be the cause of a high percentage of RET/PTC 
rearrangements, while chemical pollutants seem to be associated with BRAF mutations, 
and more specifically BRAFV600E point mutation. Thus, the study of the underlying 
biological and molecular pathways in our population could help us to understand which 
etiopathogenetic hypothesis is most probable. 
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Finally, no significant difference was found in iodine level, being median urinary iodine 87 
lg/L in Naples (Mazzarella 2009) and 98 lg/L in Piedmont (ISS 2014), as both populations 
belong to region with mild iodine deficiency. In both the groups, we found a similar 
distribution of associated thyroiditis with an increasing trend over time in term of both 
tumour- associated inflammation and TPOAb positivity. This could be explained by 2 
hypothesis: 1) the increase in the iodine intake as a result of programmes of iodine 
prophylaxis (Aghini-Lombardi 1997); 2) external factors (still unknown) probably 
triggering both thyroid disorders, inflammation and tumour (Malandrino 2015). However, 
if the increased frequency of thyroiditis would be an additional factor contributing to the 
continuous increase in incidence of thyroid cancer, it is still debated (Latina 2013, Cunha 
2011). 
The present study has some potential limitations. It was retrospective and cases were 
collected from the Pathology archives, so we cannot supply complete information about 
the reasons of all the thyroid surgical interventions and about the incidental nature of all 
microcarcinomas. Moreover, we do not have a control group, and thus, we compared our 
data with others coming only from Italian studies. 
The role of these potential chemicals and environmental factors in inducing thyroid 
cancer is only conceivable. A greater number of studies are required to classify the role of 
these substances, in order to accurately understand their physiopathological mechanisms 
of induction of tumourigenesis and the clinical and histopathological characteristics, they 
are responsible for. 
 
Conclusions 
 
The more sensitive and widespread diagnostic procedures can only partially justify the 
progressive increase in DTC. More studies are necessary to investigate the role of 
environmental factors, which include both volcanic elements and industrial chemical 
pollutants. In this scenario, a national cancer registry could be a mirror of the different 
territories and could provide a better understanding of the different risk factors and 
mechanisms involved in tumourigenesis. It could also allow to carry out comparative 
studies, through which it would be possible to outline the characteristics of the 
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populations at risk and then to perform screening programmes and prevention, 
improving the management of DTC. 
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Tables 
 
Table 1. Clinical and histopathological characteristics of all patients divided into two study 
groups: group A (Novara) and group B (Naples). 
 
  Group A (Novara) (474 cases) 
Group B (Naples) 
(607 cases) 
Age at diagnosis 
< 45 years (%) 31.4 58.3 
ш 45 years (%) 68.6 41.7 
Mean ± SD (years) 53.1±15.16 41.9±14.28 
Gender Male (%) 23.6 22.2 Female (%) 76.4 77.8 
Body Mass Index (BMI) Mean ± SD (years) 26.6±4.52 27.1±5.57 
Type of surgery 
Total or near total 
thyroidectomy (%) 99.2 99.7 
Lobectomy (%) 0.8 0.3 
Lymphadenectomy No (%) 71.9 53.1 Yes (%) 28.1 46.9 
Histotype 
PTC (%) 90.0 89.0 
FTC (%) 9.0 11.0 
PTC + FTC (%) 1.0 0.0 
PTC variant 
Classic (%) 36.9 63.8 
Follicular (%) 37.3 19.9 
Classic and Follicular (%) 9.1 7.6 
Other (%) 16.7 8.7 
Size 
< 1.0 cm (%) 44.1 30.4 
2.0 cm (%) 27.8 43.9 
2.0-4.0 cm (%) 22.6 21.9 
> 4.0 cm (%) 5.5 3.8 
Multifocality Absent (%) 68.8 78.9 Present (%) 31.2 21.1 
Bilaterality Absent (%) 74.7 86.8 Present (%) 25.3 13.2 
Capsular Invasion Absent (%) 80.0 91.3 Present (%) 19.2 8.7 
Staging (TNM 2010) 
Stage I (%) 75.3 88.4 
Stage II (%) 8.9 5.5 
Stage III (%) 11.4 4.1 
Stage IV(%) 4.4 2.0 
Histological associated 
thyroiditis 
Absent (%) 75.5 70.3 
Present (%) 24.5 29.7 
Lymph Node Metastasis Absent (%) 49.2 49.8 Present (%) 50.8 50.2 
TPOAba Absent (%) 70.0 67.0 Present (%) 30.0 33.0 
 
aTPOAb assays has a functional sensitivity of 25.0 U/mL and the analysis was automatically performed using 
͚͚ADVIA CeŶtauƌ ATPO͛͛ ;“ieŵeŶs HealthĐaƌe DiagŶostiĐ iŶĐ., TaƌƌǇtoǁŶ, NY, U“AͿ 
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Figures 
 
Figure 1. Age at diagnosis in groups A and B. 
 
 
 
 
Figure 2. PTC and FTC in groups A and B: trend over the years. 
 
 
 
 
Figure 3. Histotype variants of PTC in groups A and B. 
 
 
160 
 
Figure 4. Focality, laterality and thyroid capsular invasion in groups A and B. 
 
 
 
 
Figure 5. Staging in groups A and B. 
 
 
 
 
Figure 6. Tumour-associated thyroiditis in groups A and B: trend over the years. 
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Abstract 
 
Thyroid cancer represents the most frequent endocrine neoplasm and is 
epidemiologically linked to a growing incidence worldwide, which is only, in part, 
explained by the increased detection of small cancers in the preclinical stage. 
Understanding the molecular pathogenesis of well-differentiated and poorly-
differentiated thyroid cancers has prompted interest into the identification of crucial 
signaling pathways and molecular derangements related to genetic and epigenetic 
alterations. Increasing attention has been recently focused on inflammation and 
immunity as major culprit mechanisms involved in thyroid tumorigenesis, through the 
detection of activated immune cells, pro-inflammatory cytokines, as well as signal 
integrations between inflammatory and proliferative pathways within the thyroid tumor 
micro-environment (TME). In addition to playing important roles in tumor surveillance 
and rejection, the presence of tumor-associated macrophages (TAM) and the activation 
of NF-κB sigŶalliŶg pathǁaǇ aƌe Ŷoǁ ƌeĐkoŶed as hallŵaƌks aŶd ĐƌuĐial ŵediatoƌ of 
inflammation-induced growth and progression of thyroid cancer. Thorough 
understanding of this immunological link and identification of novel molecular targets 
could provide unprecedented opportunities for research and development of diagnostic, 
prognostic and treatment strategies for thyroid cancer. 
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Background 
 
Thyroid cancer is the most frequent endocrine neoplasia and its incidence rates are on 
the rise (Lim 2017). Thyroid cancers are usually follicular or para-follicular in their origin, 
and lesions developing from follicular cells include well differentiated thyroid cancers 
(DTC), poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinomas (Kondo 
2006). DTCs, which encompass papillary cancers (PTC) and follicular cancers (FTC), usually 
show a good prognosis after surgery and radioiodine therapy, yet 5–10% of cases 
progress to radioiodine refractory-disease. On the other hand, PDTCs and ATCs are 
therapy-resistant and prognosis is unfavorable (Rosai 1992). Medullary thyroid carcinoma 
(MTC), which originates from the para-follicular C-cells, is either sporadic or familial and, 
by the time of diagnosis, shows high rate of lymph node metastases, which can elude 
detection pre-operatively or even intra-operatively (Wells 2015). 
The role of inflammation in DTCs has been the focus of several studies published in the 
last 10 years, which have demonstrated positive association between chronic 
inflammation and increased risk of developing DTC, and suggested that the inflammatory 
microenvironment is an essential component of cellular transformation and tumour 
progression (Guarino 2010, Melillo 2010, Cunha 2014). In support of this inference, there 
has been demonstration that local activities engaged in thyroid tumorigenesis and thyroid 
cancer progression are positively influenced by two major inflammatory components: 
inflammatory cells along with their humoral mediators presenting within the cancer site, 
and activation of oncoprotein-mediated signalling present in epithelial cancer cells. 
Inflammatory cells and mediators enrich the tumour stroma and partake in several 
processes such as tissue remodelling, tissue repair and neo-angiogenesis (Hanahan 2000). 
Cancer stroma englobes both inflammatory cells engaged in antitumour effects and 
activated immune cells capable of pro-tumor immune responses, and the balance of 
antitumour/protumour immune responses culminates in the regulation of cancer 
suppression vs cancer progression (Cunha 2014, Poschke 2011). Cancer stroma thus plays 
a dominant role in the development and progression of DTCs (Modi 2003, Yano 2007, 
French 2012), as well as it shows a potential role in MTC and PDTCs. The aim of this article 
is to provide an overview on the relationship between inflammation and thyroid cancers 
in relation to the immune mechanisms regulating thyroid cancer progression. To this 
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purpose, our at-a-glance description will mainly focus on DTCs, where essential evidences 
related to different histotypes and relative clinical aspects have been collected, whereas 
information resumed in MTC and ATC will be presented separately. 
 
Inflammation and DTC 
 
In general, two pathways have been proposed to explain the link between inflammation 
and DTC (Mantovani 2008): the extrinsic (microenvironment-driven) and the intrinsic 
(oncogene-driven) pathways. 
 
Extrinsic pathway 
 
Tumour-infiltrating inflammation 
The extrinsic pathway is triggered by tumour-infiltrating inflammation that includes 
leukocyte infiltration, tumour-associated macrophages (TAM), cytokines, chemokines and 
VEGF (Liotti 2012). TAM and immature dendritic cells accumulate both in tumoral stroma 
and at the invasive front of PTC, and the strength of their infiltrate positively correlates 
with capsular invasion, extra-thyroidal extension and aggressive behaviour (Ryder 2008). 
According to a classical view, tumours are encircled by extracellular matrix (ECM) with its 
structural and specialized proteins, as well as by stromal cells, which comprises cancer-
associated fibroblasts (CAFs), innate and adaptive immune cells, specialized mesenchymal 
cells, endothelial cells and pericytes. CAFs impact cancer progression by remodelling the 
ECM, inducing angiogenesis, recruiting inflammatory cells, and redirecting cancer cell 
proliferation via secretion of growth factors, immune suppressive cytokines, and 
mesenchymal-epithelial cell interactions (Kalluri 2006). Cancer stroma contributes to 
create the so-called tumour microenvironment (TME), which enfolds a significant 
inflammatory cell infiltrate capable of acting pleiotropically (Xing 2013). While some cells 
are engaged in antitumour effects (i.e., dendritic cells, tumour infiltrating lymphocytes, 
M1 macrophages), others instigate a pro-tumour immune response (i.e., neutrophils, 
mast cells, NK cells, tumour infiltrating lymphocytes, M2 macrophages), such that the 
(un)balance of antitumour/protumour immune responses intervenes to regulate cancer 
suppression vs cancer progression (Cunha 2014, Poschke 2011). Per se, TME acts as a 
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reservoir of pro-tumorigenic and pro-angiogenic cytokines, which are either produced by 
tumour cells, CAFs, innate or adaptive immune cells. The resulting inflammatory 
microenvironment is associated with the production of reactive oxygen species and 
oxidative stress initiated by the transcription of NF-kB and perpetuated by activation of 
the MAPK pathway (Xing 2013). Several lines of evidence state that TAMs promote cancer 
cell survival, proliferation, metastases, angiogenesis and immune suppression (Noy 2014). 
Likely, the impact of TAMs on tumour progression depends on their specific 
reprogramming within the tumour, a process influenced by factors of the local 
microenvironment such as hypoxia, locally released mediators (e.i. cytokines, growth 
factors), as well as metabolic products either released by cancer cells or other immune 
and stroma-related cells (Galdiero 2016). Pathways and mechanisms involved in TAMs 
reprogramming are not completely understood, yet activation of the AKT/mTOR pathway 
has been hypothesized to influence the inflammatory phenotype of DTC-induced 
macrophages (Arts 2016). 
Furthermore, Melillo et al (Melillo 2010) demonstrated the complex relationship between 
mast cells and thyroid cancer cells. PTC displayed an increased density of mast cells with 
respect to normal tissues, and this would be associated with a worse prognosis. In vitro, 
papillary thyroid cells recruited mast cells through tumour-derived VEGF-A; in turn, mast 
cells surrounding the tumour secreted histamine and chemokines (ex. CXCL-1, CXCL10) 
that induced cancer proliferation, survival and migration by an autocrine and a paracrine 
loop (Melillo 2010). Likewise, TAMs and mast cells have been experimentally and clinically 
shown to promote progression of PTC (Ryder 2013). 
 
Obesity-dependent inflammation 
Obesity enhances the risk of at least 13 different cancers, and is a risk factor for tumour 
recurrence after curative surgery, poor survival, non-cancer-related as well as cancer-
related mortality (Steele 2017, Calle 2003). Epidemiological linkage between excess body 
weight and thyroid cancers has been highlighted in cross-sectional studies (Samanic 2004, 
Engeland 2006) and confirmed in meta-analyses of cross-sectional (Del Maso 2000) and 
prospective studies (Samanic 2004, Engeland 2006, Renehan 2008). In a pooled scrutiny 
of five U.S prospective studies, BMI was associated with thyroid cancer risk in both men 
and women, independent of tumour histology (Kitahara 2011). Several lines of evidence 
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suggest a potential role for adipose tissue (AT) accumulation in regulating TME 
pathophysiology, supported by associations found between obesity-dependent 
inflammation and cancer (Marcello 2014). As such, there is demonstration that hypoxia, 
chronic inflammation and oxidative stress, which are typical of obese subjects, could 
favour the development of a subgroup of DTC characterized by resistance to both 131I 
treatment and chemotherapy (Marcello 2014, Ilie 2013, Santini 2014). The relevance of 
AT biology in thyroid tumorigenesis is mainly related to its ability to intervene both as a 
reservoir and as a regulator of key elements of the immune system, which involve 
production of immunomodulatory molecules and expression of their receptors within the 
AT (Frühbeck 2006, Schäffler 2010). 
It is known that AT englobes different cell populations, e.g. preadipocytes, mature 
adipocytes as well as immune and stromal cells. Pre-adipocytes have functional 
characteristics and transcriptional patterns of multipotent cells that are similar to 
immune cells, and can transdifferentiate into macrophages both in vitro and in vivo 
(Cousin 1999, Charriere 2003). Mature adipocytes share the ability to secrete cytokines 
acting as pro- or anti-inflammatory factors related to AT accumulation. Immune cells 
englobed in AT include pro-inflammatory T lymphocytes (predominantly CD8+), which 
contribute to local inflammatory cell activation by attracting macrophages, which 
perpetuate the inflammatory response within the AT (Nishimura 2009, Kintscher 2008). 
Both M1 and M2 macrophages can be found in AT (Haase 2014). While resident M2 
macrophages play dominant roles in AT physiology and are able to produce anti-
inflammatory cytokines, M1-like macrophages are recruited and clustered within the AT 
as crown-like stƌuĐtuƌes ;CL“sͿ aŶd, upoŶ stiŵulatioŶ ďǇ IFNγ oƌ lipopolǇsaĐĐhaƌide, theǇ 
are able to produce pro-inflammatory cytokines, thus contributing to inflammatory 
pathways relating to insulin resistance (Hill 2014, Cinti 2005, Weisberg 2003, Xu 2003). AT 
hypoxia may promote the M2 to M1 switching (Fujisaka 2013), and these macrophages 
aƌe ƌespoŶsiďle foƌ AT eǆpƌessioŶ of TNFα, as ǁell as pƌoduĐtioŶ of disĐrete amounts of 
iNOS and IL6 (Weisberg 2003). TNFα is a ĐǇtokiŶe Đapaďle of aŶti-proliferative actions in a 
human PTC line, through a receptor-mediated mechanism (Pang 1996). Nevertheless, the 
high TNFα eǆposuƌe ƌelated to oďesitǇ seeŵs to iŶduĐe a state of TNFα resistance, which 
ultimately facilitates thyroid tumour progression (Marcello 2014, Pang 1996) and 
metastatic diffusion (Coperchini 2016). IL-6 is a cytokine involved in tumorigenesis 
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(Lumachi 2010), but its role in thyroid cancer is still confusing. Although results linking 
directly thyroid cancer to IL-6 are scant (Couto 2012, Chang 2003), IL-6 could be 
important for the inflammation microenvironment in thyroid carcinogenesis, influencing 
DTC development and progression (Cunha 2014, Lumachi 2010). Recently, Kobawala et al 
(Kobawala 2016) demonstrated that IL-6 mRNA expression is higher in the primary 
tumour tissues of PTC patients as compared to the corresponding adjacent normal 
tissues, and that serum IL-6 correlates with larger tumour size, presence of distant 
metastasis, extra-thyroidal extension and poor overall survival. 
The obesity-related adipocytokine network also accounts for the biological activity of AT 
in relation to the development of thyroid cancer (Cunha 2014, Marcello 2014, Santini 
2014, Dalamaga 2012). Mature adipocytes produce leptin, which is involved in activation 
of monocytes and macrophages, stimulation of VEGF and angiogenesis, and suppression 
of anti-inflammatory cytokines. Leptin promotes cell migration of PTC, while inhibiting the 
migration of follicular cells (Cheng 2010a). Studies in vitro demonstrated that leptin is 
able to stimulate a more aggressive PTC phenotype by activating the PI3K/AKT pathway 
(Uddin 2010), as well as it promotes the de-differentiation of thyroid cancer cells via the 
JAK2/STAT3 signalling pathway (Kim 2013). Recently, Fan et al (Fan 2015) demonstrated 
that leptin had negative prognostic significance in PTC, whereas it may play a protective 
role in FTC. 
On the contrary, adiponectin, an adipocytokine with strong anti-inflammatory properties 
capable of proapoptotic and antiproliferative effects, appears to be inversely correlated 
with DTCs, suggesting a protective effect against tumorigenesis (Mitsiades 2011). 
Accordingly, Cheng et al (Cheng 2013) found that, when tissues were negative for 
adiponectin receptors, tumours were significantly associated with extrathyroidal invasion, 
multicentricity, and higher TNM stage, demonstrating that the expression of adiponectin 
receptors could associate with a better prognosis. Further potential links between 
obesity-related inflammation and DTC are represented by ghrelin and obestatin. In 
particular, a recent review reported that lower levels of ghrelin would favour thyroid cell 
proliferation, whereas supra-physiological levels would have an inhibitory effect (Santini 
2014). 
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Obesity-induced inflammation involves other inflammatory components that could 
contribute to tumorigenesis. These components include matrix metalloproteinases 
(MMPs), which are associated with cancer-cell invasion and metastasis (Egeblad 2002, 
Marecko 2014, Wang 2013, Wang 2014). 
Finally, the possible association between obesity and autoimmune thyroid diseases might 
also play a role because of the link between chronic autoimmune thyroiditis and thyroid 
cancer (Cunha 2011). 
 
Intrisic pathway 
 
Genetic alterations 
The intrinsic via is driven by the most frequent genetic alterations associated with DTC, 
such as RET/PTC rearrangement and BRAF point mutation. Up to 70% of PTCs express 
non-overlapping mutations of RET, TRKA, RAS and BRAF genes, which encode 
transcription of components of the mitogen-activated protein kinase (MAPK) cascade 
(Guarino 2010). Both point-mutations and genetic rearrangements can promote the 
constitutive activation of the tyrosine kinase activity of RET in the absence of ligands. 
Activation of RET by physiological ligands or by oncogenic conversion results in the 
phosphorylation of intracellular tyrosine residues, which serve as docking sites for the 
recruitment of signalling adapters (Takahashi 2001, Kimura 2003, Melillo 2016).  
Local activities engaged in thyroid tumorigenesis and thyroid cancer progression are 
positively influenced by the activation of oncoprotein-mediated signalling present in 
epithelial cancer cells. Studies investigating the role of the RET/PTC3 oncoprotein in the 
recruitment of immune cell populations into the tumour site (Powell 1998, Castellone 
2004, Borrello 2005, Puxeddu 2005) showed that the transplantation of RET/PTC3 
expressing thyrocytes activates an inflammatory transcriptional program both in vitro and 
in vivo, and PTC-like lesions in mice were characterized by a leukocytic infiltrate mainly 
constituted by macrophages, with parallel increase in cytokine production within the 
tumour (Russell 2004). Main humoral components of this program include mediators 
responsible for different pro-tumour effects, such as growth factors implicated in 
leucocyte recruitment and survival (G-CSF; GM-CSF, M-CSF), chemokines (CCL2, CXCL12), 
chemokines receptors (i.e. CXCR4) implicated in monocyte recruitment, angiogenesis and 
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tumour-cell homing to lymph nodes, IL-8, L-selectin and proteases responsible for tumour 
invasion and dissemination. RET/PTC3-positive thyroid cancer were also found to induce 
recruitment of CD11b+, Gr1+ cells capable of mediating tumour escape from the immune 
surveillance (Pufnock 2009), whereas the expression of the RET/PTC3 isoform in a rat 
thyroid cell line (PC Cl3) was demonstrated to increase NF-kB DNA-binding activity with 
consequent increase in the pro-inflammatory cytokine secretion (Russell 2003). 
NF-kB ia a transcription factors laying at the intersection between the intrinsic and 
extrinsic proinflammatory pathways related to tumorigenesis (Mantovani 2008), and high 
constitutive expression of NF-κB is a primary feature of cancer cells but not normal cells, 
indicating a crucial role for NF-κB in regulating tumorigenesis (Karin 2006). NF-κB 
comprises a family of transcription factors involved in transcription of different genes 
controlling apoptosis, immune response and inflammation, as well as cancer 
development and progression. Activation of NF-κB ƌesults fƌoŵ diffeƌeŶt sigŶalliŶg 
pathways triggered by cytokines, growth factors, and tyrosine kinases (Pacifico 2010, 
Gallel 2008). NF-κB is also ƌeĐogŶized to play a major role in the initiation and progression 
of thyroid carcinoma (Bonmarito 2011, Li 2012). In thyroid cancer cells, oncogenic 
proteins RET/PTC, RAS and BRAF can induce NF-κB aĐtiǀatioŶ iŶ PTC, FTC, aŶd MTC, ǁhile 
constitutive de-regulated NF-κB activity has been found in ATC (Pacifico 2010). In a subset 
of PTCs associated with unfavourable outcome, it has been shown that NF-κB-mediated 
anti-apoptotic effects are enhanced by over-activation of Ras-related C3 botulinum toxin 
substrate 1 (RAC-1b), a hyperactive variant of the RAS superfamily of small GTP-binding 
proteins (Faria 2017). 
 
The immune network 
Conflicting reports deal with the association between the prognosis of PTC and the 
degree of lymphocytic infiltration surrounding and/or inside the tumour (Hirabayashi 
1965, Clark 1980, Aguayo 1989, Matsubayashi 1995). Several studies suggest that the 
immune response might be important in preventing metastases and recurrence of thyroid 
cancer, improving disease-free survival (Cunha 2011, Ehlers 2014). On the contrary, other 
studies showed that patients with tumor-associated lymphocytes exhibited higher disease 
stage and increased incidence of invasion and lymph node metastases compared to 
patients without lymphocytes, or with background thyroiditis (French 2012, Quing 2012, 
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Yu 2013). Moreover, recent studies (Muzza 2010, Stassi 2003) showed important clinical 
implication of autoimmunity on tumor behaviour; in particular, Stassi et al (Stassi 2003) 
demostrated that IL-4 and IL-10 activation induce thyroid cancer cells resistance to 
chemoterapeutic agents. 
Autoimmunity stimulates the production of higher levels of proinflammatory cytokines 
with growth factor activity (IL-17, IFN-γ aŶd TNF-αͿ aŶd the aŶgiogeŶesis eŶhaŶĐed ďǇ 
TNF-α aŶd VEGF (Ehlers 2014, Fajardo 1992, Ji 2012, Mardente 2010, Landskron 2014, 
Felicetti 2017); moreover, HMGB1 and nitric oxide, detected in both thyroiditis and PTC 
patients, promote matrix remodelling, inhibit immune response and are able to suppress 
cell cycle regulators, thus increasing the risk of PTC (Mardente 2012). In addition, reactive 
oxygen species contribute to DNA damage and promote the epithelial-to-mesenchymal 
transition (Wang 2014). Two hypotheses may explain the association between 
autoimmune thyroiditis and differentiated thyroid cancer. In both cases, the main actor is 
RET/PTC rearrangement, modulating the autoimmune response (Ehlers 2014, Felicetti 
2017, Borrello 2008). This rearrangement, considered specific for PTC, is also expressed in 
some non-neoplastic conditions such as Hashiŵoto͛s thǇƌoiditis (Wirtschafter 1997). In 
vivo studies showed that RET/PTC seems to be more represented in PTC associated with 
thyroiditis, whereas BRAFV600E in PTC alone (Powell 1998, Muzza 2010). According to the 
first hypothesis, free radicals production, cytokine secretion, cellular proliferation as well 
as other phenomena related to local inflammation might predispose to the 
rearrangement in follicular cells (Gandhi 2006). The second hypothesis is supported by 
the observation that RET/PTC3 rearrangement express high levels of proinflammatory 
cytokines and proteins involved in the immune response (Melillo 2010, Puxeddu 2005, 
Rhoden 2006, Russell 2003). Furthermore, RET/PTC1 rearrangement is able to induce the 
expression of different genes involved in inflammation and tumor invasion, including 
chemokines, chemokine receptors, cytokines, adhesion molecules and matrix-degrading 
enzymes (Borrello 2005). Other gene alterations have been proposed to explain the 
association between thyroid cancer and autoimmune thyroiditis. For example, p63 
protein is commonly expressed in both PTC and Hashimoto thyroiditis (Unger 2003), 
suggesting p63 expression as a potential link between these conditions (Pellegrini 2001). 
Moreover, the increased expression of p-Akt, Akt1, and Akt2 in thyroid cancer and 
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autoimmune thyroiditis suggests PI3K/Akt pathway to be involved in both disorders 
(Larson 2007). 
Finally, recent analysis has focused on immune checkpoints as a prognostic and 
therapeutic tool for DTCs. In a study assessing immunostaining and mRNA levels of 
programmed death-ligand 1 (PD-L1), a macrophage-related cell surface glycoprotein 
regulating local inflammatory responses, more intense expression was observed in 
samples from DTCs than those from benign tumors, and increasing PD-L1 mRNA 
expression was demonstrated in more advanced tumor stages (Cunha 2013). Similarly, an 
increased expression of PD-L1 has been observed in advanced DTCs and ATCs, both at the 
cellular level and on tumour-associated lymphocytes (Bastman 2016). While these 
findings await confirmation in Tregs, TAMs, and immature dendritic cells, it appears 
feasible that studies focusing on immune checkpoint inhibitors in DTCs could lead to way 
to test new therapeutic strategies (Cunha 2017). 
 
Inflammation and MTC 
 
Data regarding the potential link between MTC and cancer-related inflammation (CRI) 
originate from few in vitro studies. 
In MTC, the intrinsic pathway, which is driven by genetic alterations associated with 
thyroid carcinogenesis, seems to play a major role in this link. Germline point mutations 
of proto-oncogene RET are known to be responsible for almost all familial MTC in multiple 
endocrine neoplasia (MEN) type 2A and 2B, and familial medullary thyroid carcinoma 
(FMTC), while somatic point mutations are found in up to 50% of patients with sporadic 
MTC (Haugen 2016). 
RET encodes for the tyrosine kinase receptor of growth factors belonging to the Glial cell-
Derived Neurotrophic Factor (GDNF) family, the stimulation of which activates a variety of 
signalling pathways, such as the RAS/ERK, the PI3-K/AKT and the MAPK pathways, which 
are involved in cell survival and differentiation. Gain-of-function mutations of RET cause a 
constitutive activation of the tyrosine kinase activity of the receptor in the absence of 
ligands, leading to tumour development and progression (Iwahashi 2002). 
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In vitro studies (Iwahashi 2002) demonstrated that GDNF stimulation induced high level 
of interleukin-8 (IL-8) production in TT medullary thyroid carcinoma cells. IL-8 is a pro-
inflammatory, mitogenic and proangiogenic chemokine that is known to be involved 
directly in tumour growth, cell migration, and angiogenesis in an autocrine or paracrine 
ǁaǇ, oƌ iŶdiƌeĐtlǇ ďǇ attƌaĐtiŶg iŶfiltƌatioŶ Đells, iŶĐludiŶg Ŷeutƌophils aŶd ŵaĐƌophages; 
therefore, its expression in tumour cells may affect their biological properties such as 
invasion and metastatic ability (Iwahashi 2002, Liotti 2012). 
Transcription of IL-8 is known to depend on activation of  NF-IL-6 and NF-kB (Iwahashi 
2002, Mukaida 1994). 
Two reports have associated RET-mediated carcinogenesis with NF-κB aĐtiǀatioŶ, so faƌ 
(Gallel 2008, Ludwig 2001). Ludwig et al. (Ludwig 2001) found that NF-κB ǁas stƌoŶglǇ 
expressed in tissue specimens from parafollicular C-cell carcinomas, and in vitro data 
suggested that NF-κB-dependent transcription plays an essential role in the development 
of MTC induced by both oncogenic RET isoforms, i.e. those harboring the mutations 
C634R or M918T, responsible for MEN 2A and MEN 2B, respectively. Gallel et al. (Gallel 
2008) also demonstrated that the expression of mutated RET induces an increase in NF-κB 
DNA-binding activity and a consequent increase in pro-inflammatory cytokine secretion. 
RET-mediated transformation would be dependent on NF-κB deliǀeƌed aŶti-apoptotic and 
mitogenic signals. Since most part of pro-inflammatory molecules are under NF-κB 
transcriptional control, it has been hypothesized that NF-κB Đould ďe iŶǀolǀed iŶ the 
regulation of pro-inflammatory program of thyroid cells, and this event would contribute 
to the onset of thyroid cancer (Pacifico 2010). 
 
Inflammation and ATC 
 
There are studies suggesting that inflammation could also be a key factor involved in the 
development of ATC, one of the most lethal human malignancies. Many characteristics of 
the inflammatory status leading to enhanced tumour growth, invasion, angiogenesis, and 
metastasis, are similar between ATC and PDTC, that is the bridge between DTC and ATC. 
Compared to DTC and normal thyroid, ATC and PDTC show an increased amount of TAMs 
accounting for about more than 50% of immune cells infiltrating ATC. Infiltrate of TAMs is 
higher in PDTCs and ATCs than in PTCs and FTCs, and results positively correlated with the 
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poor prognosis of PDTCs (Ryder 2008). TAMs usuallǇ foƌŵ a ͞ŵiĐƌoglia-like͟ stƌuĐtuƌe that 
is in close contact with cancer cells, and their inter-connection and density correlate with 
invasive features and worse prognosis of the tumor (Caillou 2011, Visciano 2015, Galdiero 
2016), as confirmed by the evidence that TAMs infiltrate promoted the invasiveness of 
ATC cell lines in vitro through production of CXCL8/IL-8 (Galdiero 2016). In contrast to 
TAMs, infiltration of lymphocytes and dendritic cells, which are involved in antitumor 
response (Cunha 2014, Poschke 2011), is reduced or absent in ATC (Ugolini 2007). In ATC 
cell lines, CXCL8/IL-8 plays a central role in cell proliferation both during unstimulated 
conditions and under the effect of pro-inflammatory stimuli, such as IL-1 and TNF-α 
(Galdiero 2016, Rotondi 2015). Recruitment of neutrophils within the thyroid gland, a 
crucial metastasis-promoting factor, is dependent on the amount of CXCL8 produced by 
the tumor cells when exposed to TNF-α ;Rotondi 2015, De Larco 2004). Moreover, there is 
evidence that induction of reduced expression of CXCL8/IL-8 and MCP-1/CCL2 pathways 
by the oncolytic adenovirus dl922-947 is able to impair angiogenesis and macrophage 
infiltration, as well as it promotes ATC cell death in vitro and tumor regression in vivo 
(Passaro 2016). A recent study in a xenograft mouse model showed that cytokines 
expressed in ATC cell lines and tumour tissues, including IL-8, TGF-α, aŶd TNF-α, ǁeƌe all 
down-regulated by suppression of ubiquitin-like containing PHD and RING finger domains 
1 (UHRF1), involved in the DNA base excision repair (BER) pathway. This UHRF1-mediated 
effect was found to be associated with inhibited proliferation of ATC, both in vitro and in 
vivo (Wang 2016). 
Moreover, inflammatory conditions relating to production of INF-y and TNF-a can 
promote the autocrine production of IL4, IL10, CXCL1/GROa, CXCL10/IP-10 in primary 
human ATC cells, as well as in DTCs, and contribute to up-regulate anti-apoptotic 
pathways and chemo-resistance (Stassi 2003, Rotondi 2013). Mast cells are also present 
in ATC and their infiltrate is directly correlated with tumour invasiveness through 
production of soluble factors involved in epithelial-to-mesenchymal transition, with 
CXCL8/IL-8 again acting as main effector of this mechanism (Visciano 2015). Furthermore, 
mast cell-derived CXCL1/GRO-a and CXCL10/IP10 production increased ATC proliferation 
through the engagement of CXCR2 and CXCR3 expressed on thyroid cells (Melillo 2010). 
Interestingly, the activation of the CXCL10-CXCR3 axis was also induced by NK cell 
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migration in ATC cell lines. Prostaglandin-E2 was identified as the main responsible for the 
ATC-mediated NK cell suppression (Wennerberg 2014).  
At odds with results obtained in DTCs, there is no evidence of a connection between the 
oncogenetic background of ATCs and inflammation. Likewise, no associations have been 
fouŶd ďetǁeeŶ Hashiŵoto͛s thǇƌoiditis oƌ thǇƌoid lǇŵphoŵa aŶd ATC incidence.  
It is worth noting that observational studies in humans have investigated different 
inflammatory biomarkers as a tool to assess aggressiveness of different thyroid cancers 
subtypes. The neutrophil-to-lymphocyte ratio, a simple surrogate index of the systemic 
inflammatory response, was shown to be a prognostic factor in some types of cancers. In 
a cohort of 3,870 patients affected by benign or malignant thyroid diseases, the 
neutrophil-to-lymphocyte ratio differed between tumour cancer subtypes and was 3.8.-
fold higher in ATC than in PDTC or PTC patients (Cho 2015). Moreover, also eosinophilia 
refractory to steroids has been recently reported in an ATC patient (Shiraishi 2015). 
Finally, serum levels of IL10 and C-reactive protein in ATC patients were directly 
correlated with higher peripheral blood myeloid cells (MDSSCs), which are known to be 
immunosuppressive and cancer promoting (Suzuki 2013). 
 
Conclusions 
 
The link between inflammation and thyroid cancer involves multiple elements of the 
immune system, ECM, stroma, and AT. The role of these link is complex: the pro-tumoral 
activity of inflammation is opposed to anti-tumor functions favoring protection against 
cancer progression. This paradox may be explained by the specific circuits expressed 
within the tumour microenvironment and by the abundance  and activation state of 
different cell types in the tumour site. 
Within the tumour microenvironment, inflammatory cells, belonging both to innate 
(macrophages) and adaptive (lymphocytes) immune responses, are interconnected with 
fibroblasts, endothelial cells, adipocytes, and ECM through cytokines, chemokines and 
adipocytokines. 
Cancer-related inflammation could represent an important target for innovative 
diagnostic and therapeutic strategies in thyroid cancer. The molecular patterns of 
cytokines and chemokines are key orchestrators and could explain the involvement of the 
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immune system in tumour progression. In fact, anticancer immunotherapy, in particular 
the immune checkpoint inhibitors, act promoting lymphocyte activation in order to 
destroy cancer cells and counteract immune-suppressive signals produced by cancer cells. 
By doing this, they also activate immune memory, leading to a sustained anti-tumour 
response. 
Further informations on the inflammatory microenvironment may help to explain tumour 
aggressive behaviour and identify potential new targets of therapy. 
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Abstract 
 
Background. The associative link relating insulin resistance (IR) and adipokines to the 
occurrence and phenotype of differentiated thyroid cancer (DTC) is unknown. Aim of this 
study was to evaluate the relationship between insulin resistance (IR) and adipokines in 
DTC patients, as compared with carriers of benign thyroid diseases (BTD) and controls 
free of thyroid diseases. 
 
Methods. This observational study enrolled 77 subjects phenotyped as DTC (N=30), BTD 
(N=27) and healthy subjects (N=20). Each subject underwent analysis of anthropometric 
parameters, thyroid function and autoimmunity, insulin resistance (HOMA-IR) and levels 
of unacylated (UAG) and acylated ghrelin (AG), obestatin, leptin and adiponectin . 
Multivariate regression models were used to test the predictive role of metabolic 
correlates on thyroid phenotypes and DTC extension. 
 
Results. The three groups showed similar age, gender distribution, smoking habit, BMI 
and thyroid parameters. Obestatin was significantly higher in DTC group compared to BTD 
(p<0.05) and control subjects (p<0.0001). DTC and BTD groups showed higher levels of 
UAG (p<0.01 for both) and AG (p<0.05 for both). Leptin levels were comparable between 
groups, whereas adiponectin levels were lower in DTC group compared to BTD group 
(p<0.0001) and controls (p<0.01). In parallel, HOMA-IR was higher in DTC than BTS 
(p<0.05) and control group (p<0.01). Stepwise multivariable regression analysis showed 
that obestatin and UAG levels were independent predictor of DTC (p=0.01 for both). In an 
analysis restricted to the DTC group, multinomial regression analysis showed that 
obestatin levels were associated with the absence of lymph node metastases (p<0.05). 
 
Conclusion. Our results highlight a potential association between metabolic setting, 
circulating adipokines, and thyroid tumorigenesis . Further studies are needed to validate 
these findings.  
178 
 
Background 
 
The incidence of differentiated thyroid cancer (DTC) has been rising in many countries 
over the last few decades (Pazaitou-Panayiotou 2013, Pagano 2017) along with a parallel 
increase in obesity and metabolic diseases (Pazaitou-Panayiotou 2013).  
Even if the rising incidence of DTC could be attributed to an improved diagnostic 
aĐĐuƌaĐǇ, ǁhiĐh ƌesults iŶ ͞oǀeƌ-diagŶosis͟ of ŵiĐƌoĐaƌĐiŶoŵas (Pazaitou-Panayiotou 
2013a, Elisei 2010, Lee 2012, Grodski 2008), an increasing prevalence of more aggressive 
forms of DTCs suggests the real existence of a changing pattern of incidence (Gomez 
Segovia 2004, Enewold 2009, Pazaitou-Panayiotou 2013b). Environmental and lifestyle 
factors, such as obesity and insulin resistance (IR), seem to be implicated in the 
pathogenesis of thyroid cancer (Pagano 2017, Marcello 2014, Santini 2014). Although the 
pathways linking obesity or IR to thyroid cancer remain largely unknown, a potential role 
for insulin, growth hormone (GH) secretagogues, and adipokines has been postulated 
(Santini 2014). The insulin-cancer hypothesis assumes that hyperinsulinemia could 
decrease the concentrations of IGF-binding protein 1 (IGFBP1) and IGFBP2, which would 
increase the bioavailable free IGF-1 levels (Almquist 2011). IGF-1 has mitogenic and anti-
apoptotic effects, which favour tumorigenesis (Santini 2014). Other factors potentially 
linking obesity, IR and DTC could be represented by ghrelin, a GH secretagogue, and 
obestatin, which are expressed in tumor cancer tissues albeit with inhomogeneous 
patterns (Karaoglu 2009). There are studies suggesting that the adipocytokine network 
could play a role in thyroid tumorigenesis. Leptin is an adipokine predominantly secreted 
by the adipose tissue (Piya 2013) that is involved in the regulation of food intake and 
resting energy expenditure, as well as activation of monocytes and macrophages, and 
stimulation of angiogenesis and cell proliferation (Kwon 2013). Several studies 
investigated the effect of leptin on thyroid cancer cells (Santini 2014). Leptin was shown 
to promote cell migration in PTC cells (Cheng 2010), to stimulate a more aggressive 
cancer phenotype (Uddin 2010) and to promote the de-differentiation of thyroid cancer 
cells (Kim 2013). Adiponectin is an adipokine with anti-inflammatory properties produced 
by adipocytes. It is able to improve insulin sensitivity, influence cell proliferation, and 
regulate the balance of anti- and pro-inflammatory molecules and cells (Marcello 2014, Li 
2009). Serum adiponectin levels are inversely correlated with the presence of DTC 
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(Mitsiades 2011), and the absence of adiponectin receptors has been shown to be 
associated with extrathyroidal extension, multicentricity and higher TNM stage of DTCs 
(Cheng 2013). 
To date, the causal association relating IR and adipokines to the presence and phenotype 
of DTC is unknown and the associative studies so far published have presented discordant 
data. Therefore, the aim of our observational study was to evaluate the relationship 
between IR and adipokines in DTC patients, as compared with carriers of benign thyroid 
diseases and subjects without thyroid diseases. 
 
Methods 
 
Patients 
 
The study enrolled 77 subjects, consisting of 57 adults undergoing total thyroidectomy 
because of benign thyroid disease (uninodular or multinodular goitre, follicular adenoma) 
or suspected DTC on the basis of cytological examination according to Bethesda criteria 
(Cibas 2017) and classified as TIR3B, TIR4, TIR5. Twenty healthy subjects without thyroid 
disease served as control group. 
Following blood sampling for the purpose of the study, patients who underwent 
thyroidectomy were followingly divided into two groups, according to the post-surgical 
histological diagnosis: 
- DTC group: 30 patients diagnosed with papillary or follicular thyroid cancer 
- BTD Group: 27 patients diagnosed with benign thyroid diseases. 
Subjects with poorly differentiated, anaplastic, medullary thyroid carcinomas, secondary 
tumors, history of medical neck irradiation, hormone therapies and treatments 
interfering with insulin sensitivity were excluded from the analysis. 
The experimental procedure was approved by the ad hoc Ethical Research Committee of 
Novara, Italy. A written informed consent was obtained from all patients and controls. 
The study protocol was conformed to the guidelines of the European Convention on 
Human Rights and Biomedicine concerning biomedical research. 
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Body measurements 
 
All subjects underwent body measurements wearing light underwear, in fasting 
conditions after voiding. Weight and height were measured in the nearest 0.1 kg and 0.1 
cm, respectively, using standard methods. BMI was expressed as body mass (kg)/height 
(m)2. Overweight was defined for any BMI between 25 and 29.9 kg/m2 and obesity for any 
BMI over 30 kg/m2. Waist circumference (WC) was measured midway between the lowest 
rib and the top of the iliac crest after gentle expiration. 
 
Laboratory tests 
 
Blood samples were drawn under fasting conditions, centrifugated, and stored at -20°C or 
-80°C, until assay. 
Undiluited serum samples were assayed for thyroid stimulating hormone (TSH), free-
tyroxine (fT4) and free-triiodothyronine (fT3) using an automated chemiluminescence 
assay system (ADVIA Centaur Systems TSH3/fT4/fT3 Ultra Ready Pack, Siemens 
Healthcare Diagnostics, Milan).  
Serum levels of thyroglobulin (Tg) were determined using an automated 
chemiluminescence method (LIAISON XL, DiaSorin S.p.A, Saluggia). 
Plasmatic levels of anti-Tg and anti-thyroperoxidase (TPO) antibodies were assessed using 
an automated chemiluminescence assay system (Anti-Tg, Anti-TPO Ready Pack, Siemens 
Healthcare Diagnostics, Milan).  
Plasma glucose levels were determined using an enzymatic method (ADVIA 1800 
Chemistry System, Siemens Healthineers, Milan). Serum insulin levels were obtained 
using direct chemiluminescence method (ADVIA Centaur IRI, Siemens, Milan). Insulin 
resistance was calculated by the homeostatic model of insulin resistance (HOMA-IR) 
index: insulin (mIU/mL) x [glucose (mmol/L)/22.5] (Matthews 1985). A HOMA-IR value 
greater than 2.5 was considered indicative of insulin resistance (Muniyappa 2008). 
For hormone assays, assay procedure was performed in accordance with the 
ŵaŶufaĐtuƌeƌ͛s iŶstƌuĐtioŶ aŶd the saŵples ǁeƌe aŶalǇzed iŶ dupliĐate. 
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Serum leptin levels were assessed using a commercially available human ELISA kit 
(Mediagnost, Reutlinger, Germany). Intra-assay CV and inter-assay CV of leptin were less 
than 10%. Minimum detectable concentration was 0.2 ng/mL. 
Serum adiponectin levels were determined using a commercially available human ELISA 
kit (Mediagnost). Intra-assay CV was less than 6.7% and inter-assay CV was less than 
4.7%. Minimum detectable concentration was 0.6 ng/mL. 
Serum obestatin concentrations were assessed using a commercially available human EIA 
kit (Yanaihara Institute Inc, Awakura, Japan). Intra-assay CV was 3.5-9.9% and inter-assay 
CV was 5.6-9.0%. Minimum detectable concentration was 0.231 ng/mL. 
Plasma unacylated ghrelin (UAG) levels were determined using a commercially available 
human ELISA kit (BioVendor Research and Diagnostic Product, Czech Republic). Intra-
assay CV was 3.2-11.8% and inter-assay CV was 3.8-13.2%. Minimum detectable 
concentration was 6 pg/mL. 
Plasma acylated ghrelin (AG) levels were assessed using a commercially available human 
ELISA kit (BioVendor). Intra-assay CV was 2.9-11.8% and inter-assay CV was 3.4-14.4%. 
Minimum detectable concentration was 5 pg/mL. 
 
Thyroid cytology and histology 
 
The cytology specimens were evaluated and classified according to the international 
guidelines (Haugen 2016, Nardi 2014). Histological slides were reviewed by two 
independent pathologists for the purpose of this study. For all cases, tumor-associated 
thyroiditis was assessed. The tumor size, number of foci, focality, extension, presence of 
loco-regional and/or distant metastases were also reported and classified according to 
the 2010 tumor-node-metastases (TNM) system (Edge 2010). 
 
Neck ultrasound (US) 
 
Pre-surgical US was routinely performed in all patients. The study was conducted using a 
͞MǇ Laď Ϯϱ Gold͟ ;E“AOTE “.p.A, GeŶoǀa, Italy) equipped with a linear transducer of 7.5 
MHz. Sonographic features predictive of malignancy were considered according to 
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American Thyroid Association and AACE-AME guidelines (Haugen 2016, Gharib 2016). 
Cervical lymphadenopathies and their US features were also evaluated. 
 
Data analysis 
 
Statistical analysis was performed using SPSS version 21 (Somers, NY, USA) on log 
transformed data to correct for the non-Gaussian distribution obtained by the Shapiro–
Wilk test. Values were expressed as median and interquartile ranges (IQ). For 
Đoŵpaƌatiǀe aŶalǇsis, ANOVA ďetǁeeŶ the ϯ gƌoups ǁas used. “peaƌŵaŶ͛s ĐoƌƌelatioŶ 
analysis was used to identify significant associations between variables of interest. 
ANCOVA multinomial regression analysis was used to evaluate the association of 
adipokines levels with histological characteristics of DTCs. Stepwise multivariate 
regression analysis was used to evaluate the independent association of metabolic, 
anthropometric or biochemical parameters with adipokines and HOMA-I‘. β ĐoeffiĐieŶts 
and related significance values obtained from the models were reported. P<0.05 was 
considered as statistically significant. 
 
Results 
 
Analysis on all study groups 
 
The anthropometric and biochemical data of our population are reported in Table 1 (pag. 
189).  
Anthropometric parameters were comparable between the groups. Obesity 
;BMIര>രϯϬരkg/ŵϮͿ ǁas pƌeseŶt iŶ ϮϬ.ϴ% of Đases ;ϲ patieŶts ǁith DTC, ϴ patieŶts ǁith BTD 
and 2 controls) and overweight in 27.3% (7 patients with DTC, 6 patients with BTD and 8 
controls). Before surgery, hypothyroidism under replacement therapy was present in 14% 
of patients (6 patients with DTC and 2 patients with BTD), while hyperthyroidism under 
methimazole treatment was present in 5.3% (3 patients with BTD). 
Thyroid function parameters were comparable between the groups, whereas TPOAb 
levels were higher in DTC and BTD group with respect to the control group (p<0.05).  
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Compared to controls, we observed higher levels of UAG (p<0.01 for both) and AG 
(p<0.05 for both) in DTC and BTD groups. Obestatin concentrations were higher in DTC 
group as compared both to BTD group (p<0.05) and controls (p<0.0001), as well as in the 
BTD group with respect to controls (p<0.0001). Leptin levels were comparable between 
the 3 groups, whereas adiponectin levels were lower in DTC group compared to BTD 
group (p<0.0001) and controls (p<0.01), and in BTD group with respect to controls 
(p<0.0001). 
Analysis of metabolic parameters showed the occurrence of insulin resistance in 32.5% of 
the entire dataset (14 patients with DTC, 8 patients with BTD and 3 controls). The DTC 
group showed higher insulin levels and HOMA-IR than BTD (Insulin: p<0.01, HOMA-IR: 
p<0.05) and control group (Insulin: p<0.01, HOMA-IR: p<0.01). 
In bivariate correlation analysis across the three groups (Table 2, pag. 190), expected 
positive associations were documented between metabolic parameters, HOMA-IR and 
leptin levels. Both leptin and adiponectin were positively correlated with anti-TG 
antibodies, while adiponectin was also correlated with AbTPO levels. However the above 
mentioned correlations were lost after controlling for age, gender, BMI and thyroid 
phenotypes. 
Stepwise multivariable regression analysis with a model weighted for gender, age, BMI 
and HOMA-IR documented that the presence of DTC (DTC=0, BTD=1, Controls=2) was 
iŶdepeŶdeŶtlǇ pƌediĐted ďǇ oďestatiŶ aŶd UAG leǀels ;ƌespeĐtiǀelǇ β=-Ϭ.ϯϯϵ aŶd β=-
0.357, p=0.01). 
 
Analysis of patients with DTC 
 
Histopathological characteristics of all patients with DTC are summarized in Table 3 (pag. 
191). As expected, the most frequent histotype was PTC (83.3%) and the most 
widespread variant was the classical one (36.0%), followed by other more aggressive 
variants such as tall cell, oncocytic, solid and Warthin-like variants. Capsular invasion was 
present in more than 40.0% of cases, bilaterality and multifocality respectively in 16.7% 
and 26.7% of patients. Overall, 60.0% of tumours were classified as stage I, followed by 
stage IV (16.7%), with high frequency of thyroid capsular invasion (43.3%). Tumors were 
bilateral in 16.7% and multifocal in the 26.7% of patients. Among patients who 
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underwent lymphadenectomy, 38.9% had lymph node metastases. Finally, tumour-
associated thyroiditis was histologically found in 23.3% of cases. 
Bivariate correlation analysis restricted to the DTC group is reported in Table 4 (pag. 192). 
After adjusting for age, BMI and gender, only the negative association between obestatin 
levels and the presence of lymph node metastases (r=-0.862, p<0.05) and the positive 
association between obestatin and TPOAb titer (r=0.856, p<0.05) remained significant. 
Multinomial logistic regression analysis, performed to study the association between 
adipokines levels or HOMA-IR and DTC histological characteristics, showed that obestatin 
levels were significantly associated with the absence of lymph node metastases (Odds 
Ratio (OR)=4.370, CI 95% 1.080-10.964, p<0.05). 
 
Discussion 
 
The present study analysed the relationship between IR, adipokines and DTC 
tumorigenesis and histopathological characteristics. Our results show that the prevalence 
of insulin resistance was higher in patients with DTC and that these subjects harbour 
higher level of obestatin than patient with benign nodules and controls. However in the 
analysis restricted to DTC cases, obestatin levels were inversely associated with the 
metastatic capacity of tumor. While leptin levels were comparable between groups, 
adiponectin levels are lower in patients with DTC in respect to subjects with benign 
nodules and controls. Moreover, in patients with thyroid nodules, either benign or 
malignant, we observed higher concentrations of UAG and AG compared to controls. 
Higher obestatin and UAG levels also represented predictors of the presence of 
malignancy in patients with thyroid nodules. 
In the past few decades, the incidence of DTC has shown a steady increase worldwide 
(Pagano 2017, Enewold 2009). Some evidence suggests that environmental and lifestyle 
factors can play an important role (Pagano 2017, Leenhardt 2011). Among the potential 
risk factors involved in the changing epidemiology of TC, particular attention has been 
drawn to insulin resistance and metabolic syndrome, which have been also rapidly 
increasing worldwide due to widespread dietary and lifestyle changes (Malaguarnera 
2017). On this basis, it has been suggested that insulin resistance is associated with the 
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rising incidence of differentiated  thyroid cancers. A small cross-sectional study detected 
an increased prevalence of insulin resistance in patients with DTC (Rezzonico 2009), and a 
recent study of Bae et al. (Bae 2016) showed a clearcut association relating insulin and 
HOMA-IR index to the risk of PTC and the multifocality of this disease. Our results 
confirmed these findings. In fact, we found that patients with DTC harbour higher insulin 
levels and HOMA-IR index with respect to patients with benign nodules and subjects 
without thyroid diseases. Insulin resistance is known to be an important risk factor 
responsible for carcinogenesis (Inoue 2012). Insulin shares structural homology with IGF-
1, which binds to the IGF-1 receptor and functions as a potent growth factor with key 
roles in malignant transformation, tumor progression, and metastasis in various kinds of 
cell types (Clemmons 1989, Frasca 2008). It has been shown that IGF-1, its receptor, and 
insulin receptors are expressed in thyroid cancers (Vella 2001), suggesting that 
hyperinsulinemia, a consequence of insulin resistance, may play a role in thyroid 
carcinogenesis. However, we failed to demonstrate direct associations between insulin 
levels and DTC, suggesting that the metabolic setting rather than insulin levels could play 
a role in this relationship.This circumstance would agree with the evidence that insulin 
resistance enhances the proinflammatory state by decreasing the production of anti-
inflammatory adipokines, such as adiponectin, and increasing the production of  pro-
inflammatory adipokines, such as leptin, which could interact with molecular pathways 
involved in tumor development (Catalan 2013).  
Adipokines are a subset of cytokines produced by the adipose tissue (Cunha 2014). They  
are  involved  not  only  in  immune responses, but also in the regulation of appetite and 
energy balance, insulin sensitivity, angiogenesis, blood pressure regulation, and lipid 
metabolism (Kwon 2013). In particular, leptin is involved in the control of food intake 
through satiety sensation, regulation of  energy expenditure, the activation of monocytes 
and macrophages, stimulation of VEGF, angiogenesis, cell proliferation, and the 
suppression of anti-inflammatory cytokines. The induction of leptin responses and effects 
involves its binding to leptin receptor b (ObR), leading to the activation of intracellular 
signals through JAK2, STAT3, and AMPK (Kwon 2013). These molecules will then regulate 
several pathways of pivotal importance to cancers, such as the AKT/mTOR/PI3K and 
ERK/MAPK pathways, involved in cell proliferation  and survival (Surmacz 2013). A 
relationship of this molecule with DTC and other cancers has demonstrated (Dutta 2012, 
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Vansaun 2013). As regards DTC, leptin was found to be associated with a high risk of 
lymph node metastases (Cheng 2010) and it seems to be involved in the clinical 
phenotype of the tumours as well as in the migration of thyroid cell, promoting 
metastases formation and diffusion (Cheng 2010, Kim 2013, Cheng 2011, Cheng 2012, 
Zhang 2013). Although in our study failed to detect differences in serum leptin levels 
across the three groups, we observed a significant association between circulating leptin 
and the presence of lymph node metastases, which was lost after controlling for 
confounders (age, BMI and gender). However we have to consider that the serum 
concentration of leptin may not reflect its action on thyroid tissue. Furthermore, the 
higher levels of this adipokine found in subjects with benign nodules, would require 
future analysis to evaluate its modulatory role in the hyperplastic phase of the thyroid 
follicle. Subsequently, in the process of neoplastic transformation of the thyroid follicle, 
the loss of leptin expression could positively regulate the process of oncogenic 
transformation with unknown mechanisms, similarly to what happens in the ovary cancer 
(Jin 2016). 
Adiponectin is an adipokine with strong anti-inflammatory properties. It is able to 
improve insulin sensitivity, influence cell proliferation, and regulate the balance of anti- 
and pro-inflammatory molecules and cells (Yokota 2000, Kumada 2004, Takemura 2007). 
Owing to its complex anti-proliferative and inflammation-restraining functions, 
adiponectin has been suggested to have anti-neoplastic properties in some types of 
cancers (Marcello 2014). Our results showed lower adiponectin levels in patients with 
thyroid cancer. Similar findings were shown by Mitsiades et al. (Mitsiades 2011), who 
demonstrated that serum adiponectin levels are inversely associated with the prevalence 
of DTCs, suggesting a potential protective effect of adiponectin against the development 
of this cancer. The mechanisms by which adiponectin may act on thyroid cancer still 
remain to be identified but it may include a protection against the development of insulin 
resistance (Yadav 2013), in particular through the activation of the adenosine 
monophosphate kinase (AMPK) pathway (Cheng 2013, Yamauchi 2002, Zakikhani 2008). 
Adiponectin has also been shown to directly inhibit angiogenesis and promote apoptosis 
in vivo, through the activation of the caspase cascade (Brakenhielm 2004). Low 
adiponectin has been proposed as a possible mediator in the association between BMI 
and cancer risk (Dalamaga 2012). 
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Ghrelin is implicated in several processes of cancer progression including cell 
proliferation, cell migration and invasion, angiogenesis, and apoptosis, probably via an 
autocrine/paracrine mechanism (Ucan 2017). Some reports demonstrated that ghrelin 
may have an inhibitory effect in the proliferation of some cancer types, including thyroid, 
prostate, breast and small cell lung carcinoma (Chopin 2011). However, the exact role of 
ghrelin in thyroid tumorigenesis is still debated. Ucan and colleagues (Ucan 2017) did not 
found any significant differences in serum ghrelin levels between patients with PTC and 
healthy controls. Our study demonstrated that AG concentration were higher in the 
patients with malignant and benign thyroid nodules with respect to controls. These 
findings seem to confirm the hypothesized role of AG in promoting tumorigenesis 
(Malendowicz 2009, Markowska 2009). In particular, the increased expression of this 
molecule could influence thyroid tumor proliferation through deregulation of GH and IGF-
1 secretion, factors involved in cancer growth (Samani 2007). 
With regard to UAG, our data showed that this hormone was higher in patients with DTC 
and benign thyroid nodules. Moreover, we found that the presence of DTC was 
independently predicted by UAG. Recently, UAG has been hypothesized to be involved in 
various biological activities, including the inhibitory role on AG (Delhanty 2013), the anti-
proliferative and pro-apoptotic capacity on different cell lines in vitro (Cassoni 2006). 
However, these are preliminary results and its role is still debated. Further prospective 
studies investigating ghrelin expression in DTCs and its association with serum ghrelin 
levels could be helpful to clarify this issue. 
Finally, the role of obestatin in promoting thyroid cancer tumorigenesis is still 
controversial. However, this molecule appears very interesting for its probable 
involvement in cell proliferation through AKT-dependent signalling (Chopin 2011, Camina 
2007, Pazos 2007). In previous studies, Volante et al. (Volante 2009) found obestatin 
expression in medullary, papillary, follicular and poorly differentiated thyroid cancer. The 
authors detected obestatin immunoreactivity mostly in ghrelin-positive areas of DTC, 
whereas there was no obestatin expression in normal thyroid tissue (Volante 2009). On 
the contrary, Karaoglu et al. demonstrated obestatin expression in healthy thyroid, 
Hashimoto thyroiditis and PTC without evident differences in the intensity of reaction 
(Karaoglu 2009). In a recent study, obestatin immunoreactivity was observed in benign 
nodules, as well as cancer cells (Gurgul 2015). However, the intensity of 
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immunohistochemical expression was poor and obestatin-positive cells were 
accompanied by regions without any immunoreactivity (Volante 2009). In our study, 
serum obestatin concentrations were, overall, higher in patients with DTC with respect to 
subjects with BTD and controls, thus representing a predictor of the presence of DTC. 
Interestingly, within the DTC group obestatin levels were significantly associated with the 
absence of lymph node metastases. Together, our data suggest a dual role for obestatin, 
such that its circulating levels could reflect thyroid tumorigenesis and represent a 
biomarker of the metabolic setting of DTC, but at the same time this adipokine could 
reflect lower proneness to the metastatic diffusion of DTC. 
 
Conclusions 
 
In conclusion, the role of these metabolic biomarkers in thyroid tumorigenesis appears 
very interesting due to their potential involvement in cell proliferation. We speculate that 
the expression of these factors may be altered in different phases of thyroid cell 
proliferation, and could reflect the influence of these markers on the pathogenesis of 
nodular goitre and thyroid cancer. Furthermore, since the thyroid gland is associated with 
the maintenance of energy balance, the relationship between IR, adipokines network and 
thyroid tumorigenesis is worthy of consideration. 
With the complexity of insulin resistance-related pathways still awaiting full clarification 
in DTC patients, an array of metabolic molecules could represent novel therapeutic 
targets in thyroid health and disease. 
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Tables 
 
Table 1. Anthropometric and biochemical data obtained in the 2 groups and controls. 
 
Parameters [Median (IQ)] Controls BTD Group DTC Group 
GENDER 
   N. males (%) 
   N. females (%) 
 
5 (25.0%) 
15 (75.0%) 
 
4 (14.8%) 
23 (85.2%) 
 
9 (30.0%) 
21 (70.0%) 
AGE (years) 47.0 (37.0-62.5) 56.0 (53.5-65.0) 50.0 (41.0-58.8) 
SMOKE 
   N. No (%) 
   N. Yes (%) 
   N. Ex (%) 
 
24 (70.0%) 
3 (15.0%) 
3 (15.0%) 
 
17 (63.0%) 
5 (18.5%) 
5 (18.5%) 
 
18 (60.0%) 
4 (13.3%) 
8 (26.7%) 
WEIGHT (Kg) 69.5 (58.0-73.3) 62.0 (58.0-80.5) 68.0 (57.5-83.8) 
BMI (kg/m2) 25.1 (22.7-26.4) 25.8 (21.9-30.3) 24.2 (22.1-28.2) 
WC (cm) 86.5 (78.8-90.0) 90.0 (76.0-99.5) 93.0 (80.0-102.8) 
TSH (µIU/mL) 1.6 (1.2-2.1) 1.3 (1.0-2.0) 1.5 (0.9-2.8) 
fT4 (ng/dL) 1.2 (1.1-1.3) 1.1 (1.0-1.3) 1.1 (1.0-1.3) 
fT3 (pg/mL) 3.1 (3.0-3.3) 3.4 (2.8-3.5) 3.1 (2.9-3.4) 
TG (ng/dL) 17.2 (9.4-30.5) 43.3 (15.7-220.9) §1 11.9 (3.6-24.7) § 
TGAb (IU/mL) 34.5 (21.3-52.0) 32.2 (15.0-54.5) 20.8 (13.5-57.5) 
TPOAb (IU/mL) 33.0 (21.0-49.5) 41.2 (32.9-134.9) § 37.3 (13.5-81.5) § 
GLUCOSE (mg/dL) 86.0 (83.5-94.5) 90.0 (81.5-98.0) 89.0 (80.8-97.8) 
INSULIN (mIU/mL) 8.1 (6.5-10.1) 7.5 (5.8-11.5) 11.3 (8.4-18.5) §1,*1 
HOMA-IR 1.6 (1.4-2-2) 1.6 (1.3-2.6) 2.5 (1.8-4.1) §1,* 
UAG (pg/mL) 21.7 (11.8-30.8) 79.2 (39.0-129.8) §1 57.8 (28.9-101.2) §1 
AG (pg/mL) 4.3 (2.4-6.2) 9.0 (5.3-16.5) § 5.7 (2.1-14.4) § 
OBESTATIN (ng/mL) 2.5 (2.2-2.6) 4.6 (4.2-5.0) §2 5.0 (4.4-6.1) §2,* 
LEPTIN (ng/mL) 10.6 (5.7-25.6) 16.8 (13.2-23.1) 11.6 (4.1-19.1) 
ADIPONECTIN (ng/mL) 31.4 (15.2-41.0) 22.2 (17.7-31.1) 7.3 (4.5-17.7) §1,*2 
 
Data are expressed as median (with interquartile range in parentheses) Comparison between populations 
ǁas peƌfoƌŵed ďǇ ANOVA test aŶd χϮ test. “igŶifiĐaŶt diffeƌeŶĐes aƌe shoǁŶ iŶ ďold ĐhaƌaĐteƌs. 
Significant differences between controls and BTD or DTC Group: §p<0.05, §1p<0.01, §2p<0.0001 
Significant differences between BTD and DTC group: *p<0.05, *1p<0.01, *2p<0.0001 
BMI, Body Mass Index; WC, Waist Circumference; TSH, Thyroid Stimulating Hormone; fT4, free Thyroxine; 
fT3, free Triiodothyronine; TG, Thyroglobulin; TGAb, Anti-Thyroglobulin antibodies; TPOAb, anti-
thyroperoxidase antibodies; HOMA-IR, Homeostatic Model of Insulin Resistance; UAG, unacylated ghrelin; 
AG, acylated ghrelin 
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Table 2. “peaƌŵaŶ͛s ĐoƌƌelatioŶ aŶalǇsis ďetǁeeŶ adipokiŶes leǀels, HOMA-IR and 
anthropometric-biochemical parameters in the population as a whole. 1p<0.05, 2p<0.01, 
3p<0.001, 4p<0.0001 
 
Variables (Correlation coefficient) UAG AG Obestatin Leptin Adiponectin HOMA-IR 
Gender 0.069 0.255 0.056 0.3122 -0.042 -0.150 
Age -0.154 -0.125 -0.151 0.3632 0.194 0.2731 
BMI (kg/m2) -0.160 -0.079 -0.098 0.6064 -0.026 0.5614 
WC (cm) -0.037 -0.024 -0.140 0.5854 -0.154 0.5984 
Glucose (mg/dL) -0.017 -0.075 0.079 0.3042 0.210 0.5094 
Insulin (mIU/mL) -0.236 -0.213 -0.178 0.4534 -0,2791 0.9534 
HOMA-IR -0.202 -0.208 -0.138 0.4534 -0.195 - 
TSH (µIU/mL) -0.008 -0.090 0.087 -0.014 -0.049 0.068 
fT4 (ng/dL) 0.101 0.138 -0.125 0.051 0.083 -0.007 
fT3 (pg/mL) -0.161 -0.099 0.007 0.006 0.028 -0.067 
TG (ng/dL) -0.126 -0,080 -0.022 -0.045 0.234 -0.191 
TgAb (IU/mL) 0.032 0.045 -0.031 0.2631 0.3742 0.182 
TPOAb (IU/mL) 0.258 0.241 0.072 0.161 0.2891 0.043 
 
BMI, Body Mass Index; WC, Waist Circumference; HOMA-IR, Homeostatic Model of Insulin Resistance; TSH, 
Thyroid Stimulating Hormone; fT4, free Thyroxine; fT3, free Triiodothyronine; TG, Thyroglobulin; TGAb, Anti-
Thyroglobulin antibodies; TPOAb, anti-thyroperoxidase antibodies 
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Table 3. Histopathological characteristics of all patients with DTC. 
 
  N. of patients (%) (30 cases) 
Cytology 
Not performed 1 (3.3%) 
Thy 2 1 (3.3%) 
Thy 3f 10 (33.4%) 
Thy 4 5 (16.7%) 
Thy 5 13 (43.3%) 
Histotype PTC 25 (83.3%) FTC 5 (16.7%) 
PTC variant 
Classical 9 (36.0%) 
Follicular 5 (20.0%) 
Classical and Follicular 5 (20.0%) 
Other 6 (24.0%) 
FTC variant Minimally invasive 4 (80.0%) 
Invasive 1 (20.0%) 
Tumour size (cm) 
ч ϭ Đŵ 6 (20.0%) 
1.0-2.0 cm 11 (36.7%) 
2.0-4.0 cm 11 (36.7%) 
>4 cm 2 (6.6%) 
Multifocality Present 8 (26.7%) 
Bilaterality Present 5 (16.7%) 
Thyroid capsular invasion Present 13 (43.3%) 
Staging (TNM 2010) 
Stage I 18 (60.0%) 
Stage II 4 (13.3%) 
Stage III 3 (10.0%) 
Stage IV 5 (16.7%) 
Histological associated thyroiditis Present 7 (23.3%) 
Lymph node metastases Present (18 lymphadenectomy) 7 (38.9%) 
 
PTC, Papillary Thyroid Cancer; FTC, Follicular Thyroid Cancer 
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Table 4. “peaƌŵaŶ͛s ĐoƌƌelatioŶ analysis between adipokines levels and tumour 
characteristics and thyroid biochemical parameters in patients with DTC. 1p<0.05, 2p<0.01 
 
Variables (Correlation coefficient) UAG AG Obestatin Leptin Adiponectin HOMA-IR 
Tumour size 0.110 -0.004 0.4971 -0.250 0.303 -0.149 
Histotype* -0.028 0.000 -0.094 -0.175 0.323 -0.109 
PTC variants§ 0.156 0.101 -0.079 -0.011 0.306 -0.142 
Bilaterality -0.254 -0.085 0.158 0.316 -0.022 0.164 
Multifocality -0.089 0.022 0.227 0.194 0.231 0.074 
Thyroid capsular invasion -0.333 -0.210 0.136 0.207 -0.091 0.124 
Lymph node metastases -0.056 -0.280 -0.7792 -0.4391 0.187 0.073 
Histological associated thyroiditis -0.292 -0.280 -0.227 0.5012 0.106 0.308 
Staging -0.314 -0.340 0.272 -0.044 0.180 0.223 
TSH -0.222 -0.105 0.193 0.090 -0.120 0.111 
fT4 0.197 0.128 -0.159 0.145 -0.084 -0.168 
fT3 -0.189 -0.104 -0.095 -0.213 -0.151 -0.275 
Tg -0.089 -0.230 0.210 -0.229 0.043 -0.046 
TgAB 0.017 0.007 -0.202 0.4431 0.281 0.307 
TPOAb 0.279 0.300 -0.256 0.333 0.250 -0.082 
 
*PTC=0, FTC=1; §Classical=0, Follicular=1, Classical and Follicular=2, Other variants=3 
 
PTC, Papillary Thyroid Cancer; FTC, Follicular Thyroid Cancer; TSH, Thyroid Stimulating Hormone; fT4, free 
Thyroxine; fT3, free Triiodothyronine; Tg, Thyroglobulin; TGAb, Anti-Thyroglobulin antibodies; TPOAb, anti-
thyroperoxidase antibodies 
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CHAPTER 3 
 
The crosstalk between obesity and thyroid gland 
 
Introduction 
 
Body fat excess related to obesity results from the interaction between environmental 
and genetic factors, and a positive energy balance. This condition leads to adipocyte 
hypertrophy with resultant dysfunction of white adipose tissue, resulting in the 
development of hypoxia, oxidative stress, and inflammation (Gregor 2011, Rupérez 2014). 
Due to the endocrine role of adipose tissue and its importance in homeostasis, the 
dysfunction of this tissue in obesity contributes to metabolic alterations in various organs 
and systems (Bays 2008, Trayhurn 2013). In this respect, endocrine disorders stand out, 
and changes are observed in plasma levels, secretion patterns, and clearance of various 
hormones in obese individuals (Álvarez-Castro 2011). Alongside a chance association, a 
diƌeĐt ƌelatioŶship ďetǁeeŶ ͞ThǇƌoid aŶd OďesitǇ͟ has ďeeŶ hǇpothesized (Biondi 2010, 
Marzullo 2010, Rotondi 2011, Laurberg 2012, Pearce 2012, Duntas 2013). 
Thyroid hormone is indeed an important determinant of energy expenditure and 
contributes to appetite regulation. On the other hand, secretory products from the 
adipose tissue act on the central nervous system (CNS) to inform on the quantity of 
energy stores, and this may have an impact on the activity of the hypothalamus–
pituitary–thyroid axis (Biondi 2010, Rotondi 2011, Duntas 2013). 
Moreover, research has revealed the existence of a positive correlation between 
adiposity parameters and serum thyrotropin (TSH) and triiodothyronine (T3) in euthyroid 
individuals, suggesting a possible influence of obesity on the functioning of the 
hypothalamus-pituitary-thyroid axis and the activity of deiodinases (Bétry 2015, Kitahara 
2012, Lambrinoudaki 2015, Muscogiuri 2013, Ren 2014). 
Many attempts have been made to treat obese euthyroid subjects with thyroid hormones 
and/or their analogs in the effort to stimulate energy expenditure, especially during 
regimens of dietary restriction (Biondi 2010). The matter is a complex one, and it is 
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further amplified by the fact that obese patients may display alterations in their thyroid 
function tests, thus raising the question of whether a specific substitution treatment is 
advisable. 
Changes in thyroid function, even within the normal range, may contribute to the 
worsening of metabolic complications and the development of diseases in the thyroid 
gland. In this context, it is worth mentioning that high levels of TSH and T3 have been 
positively associated with components of metabolic syndrome, and specifically higher 
serum TSH levels have been linked to increased risk of thyroid cancer (Marcello 2014, Oh 
2013, Roef 2014, Taylor 2013, Wang 2016). 
 
This section aims to explore the crosstalk between obesity and thyroid function, in 
particular: 
-  the association between thyroid function and metabolic phenotype in euthyroid 
obese individuals 
- the effects of early weight loss on the relationship between thyroid function and 
resting energy expenditure in subjects with severe obesity 
- the role of substitution with L-T4 therapy on body composition, REE and glucose-
lipid metabolism hypothyroid in severly obese patients 
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Abstract 
 
Background. Obesity is known to promote mild hyperthyrotropinaemia by unknown 
metabolic mechanisms. This investigation aimed to explore the association between 
thyroid function and metabolic phenotype in euthyroid obese individuals. Retrospective, 
cross-sectional study. Tertiary care center. 
 
Methods. 952 euthyroid obese individuals referred to our Institution for obesity. Serum 
levels of TSH, FT4, glucose, insulin and HbA1c levels, lipid profile, liver function and 
proinflammatory indices were measured. Resting energy expenditure was assessed by 
indirect calorimetry and body composition by bioimpedance analysis. 
 
Results. On admission, 306 patients had previously diagnosed diabetes mellitus on 
treatment with metformin, while 113 patients were diagnosed with incident diabetes 
mellitus. Serum TSH levels were similar between metformin-treated diabetic subjects and 
metformin-untreated subjects, while FT4 was slightly but significantly higher in the 
former. Analysis stratified by TSH categories found no effect of metformin-treated 
diabetes mellitus on TSH levels. Interestingly, obese patients with incident diabetes 
showed lower TSH levels than normoglycaemic ones. In correlation studies on the whole 
dataset, an association related TSH to BMI and total cholesterol levels, which was lost 
upon adjustment for individual confounders. FT4 levels were found to be inversely 
related to BMI, insulin resistance and triglycerides, while being directly associated with 
HDL-cholesterol levels. These correlations remained unaltered after controlling for 
individual confounders. In multivariate linear regression analysis, TSH was associated with 
FT4, total cholesterol and BMI values. Significant predictors of FT4 were constituted by 
previously diagnosed diabetes mellitus, BMI, TSH and age. 
 
Conclusions. In euthyroid obese subjects, FT4 seems more closely related than TSH levels 
to parameters of cardio-metabolic risk. TSH levels did not differ between metformin-
treated and untreated subjects, while they were lower in patients with incident diabetes 
mellitus compared to normoglycaemic ones. 
 
197 
 
Background 
 
Thyroid disorders impact body weight in multiple ways, and hypothyroidism is 
traditionally claimed as a contributor of weight accrual via altered metabolic efficiency, 
water retention, decreased lipolysis (Santini 2014). Nonetheless, case-control studies and 
epidemiological surveys revealed that TSH levels tend to follow body weight accrual as 
well as development of obesity and insulin resistance, independent of hypothyroidism 
(Knudsen 2005, Michalaki 2006, De Pergola 2007, Rotondi 2009, Marzullo 2010, Souza De 
Moura 2011, Kitahara 2012, Taylor 2013). The causal mechanism underlying this link 
remains unidentified, yet a compensatory response operated by the hypotalamo-pituitary 
unit via leptin and directed to counteract weight accrual, is very likely involved (Santini 
2014, Reinehr 2010). 
Obesity, type 2 diabetes mellitus (T2DM) and thyroid diseases are the most frequent 
endocrine disorders and often coexist in the same individual (Duntas 2011). Following an 
original case study (Vigersky 2006), cross-sectional and prospective studies have shown 
that the antidiabetic drug metformin can decrease TSH levels in patients with subclinical 
and/or overt hypothyroidism, while other antidiabetic agents do not yield such effect 
(Isidro 2007, Cappeli 2009, Rotondi 2011, Fournier 2014, Diez 2013). In subsequent 
studies, it has been clarified that metformin can alter TSH levels also in euthyroid subjects 
if TSH levels lay in the mid-high normal range (i.e., >2.5–3.0 mIU/L) (Cappelli 2012, 
Karimifar 2014, Santos-Palacios 2013). 
Considering the metabolic derangement commonly associated with obesity as well as the 
frequent use of metformin in overweight patients owing to its insulin-sensitizing effect 
and potential reduction of body weight (Levri 2005), we aimed at assessing the impact of 
the metabolic phenotype, metformin-treated diabetes mellitus, and incident diabetes 
mellitus on thyroid function in euthyroid obese patients, and thus further investigating 
the potential thyroidal determinants of cardio-metabolic risk in this setting. 
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Methods 
 
This study enrolled 952 obese patients [M/F = 410/542, median age 58 (IQR 52–66) years, 
median BMI 45 (IQR 41.4–49.4) kg/m2] referred to our institution for work-up and 
rehabilitation of obesity and its comorbidities. Subjects included in the current study were 
participants of the TONDO study (T2DM of new diagnosis in obesity), an ongoing study 
initiated in 2012 and designed to investigate the relationship between glucose 
abnormalities and indices of organ damage in subjects with uncomplicated and 
complicated obesity (Bellan 2014), and were included according to inclusion criteria and 
availability of complete thyroid function assessment. Written consent was obtained from 
all patient, after full explanation of the purpose and nature of the study. The investigation 
was approved by the local ethical committee, functioning according to the 3rd edition of 
the Guidelines on the Practice of Ethical Committees in Medical Research. The current 
cohort included: (1) 646 euthyroid obese subjects [group OB-Eu; males/females = 
283/363, median age 55 (IQR 48–65) years, BMI 43.7 (IQR 40–48.9) kg/m2], 113 of whom 
were diagnosed on admission with T2DM based on fasting glycaemia and/or HbA1c 
levels; (2) 306 euthyroid obese subjects with T2DM on treatment with metformin for at 
least 6 months [group OB-EuM; males/females, 127/179; median age 58 (IQR 50–65) 
years; BMI 45.6 (IQR 41.4–49.6) kg/m2; median diabetes duration 8.1 years (IQR 6.9–9.4)]. 
Exclusion criteria were age below 18 or above 90 years; previous or current use of 
medications potentially interfering with thyroid function (such as amiodarone, steroids or 
lithium carbonate therapy); previous or current treatment with levo-thyroxine; known 
autoimmune diseases (including thyroid) and/or hypothyroidism; type 1 diabetes 
mellitus; pregnancy; liver or kidney disease. In case of TSH value >4.5 mIU/L, a condition 
not mandatorily indicative of thyroid dysfunction in obesity, patients underwent a 
preliminary thyroid screening inclusive of re-analysis of TSH and measurement of fT3, fT4 
and anti-thyroid antibody titer, to exclude true thyroid hypofunction. Screening test 
included glucose and insulin levels, lipid profile, indices of liver function and 
proinflammatory state, in fasting conditions. Patients were not prescribed diet therapy, 
dietary supplements, or antiobesity compounds for at least 3 months prior to entering 
the study. 
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Body measurements 
 
All subjects underwent body measurements wearing light underwear, in fasting 
conditions after voiding. Weight and height were measured to the nearest 0.1 kg and 0.1 
cm, respectively. BMI was expressed as body mass (kg)/height (m)2. Obesity was defined 
for any BMI over 30 kg/m2 (WHO 2000). Waist circumference was measured midway 
between the lowest rib and the top of the iliac crest after gentle expiration; hip was 
measured as the greatest circumference around the nates. Anthropometric data were 
expressed as the mean of two measurements. 
Fat mass and free fat mass, expressed as percentage of total body mass, were assessed by 
bio-impedance analysis (BIA, 101/S Akern; Florence, Italy) the morning after overnight 
fasting and after voiding. The two vector components of impedance (i.e. resistance and 
reactance) were obtained by single measurements; before each testing session, the 
external calibration of the instrument was checked with a calibration circuit of known 
impedance value. The mean coefficient of variation was 1% for within-day and 3% for 
weekly intraindividual measurements in the steady-state condition in either site and 2% 
for interoperator variability. 
Resting energy expenditure (REE) was expressed in kilocalories per 24 h and determined 
in a thermoregulated room (22–24°C) by computed open-circuit indirect calorimetry, 
measuring resting oxygen uptake and resting carbon dioxide production by a ventilated 
canopy (Sensormedics, Milan, Italy) at 1-min intervals for 30 min and expressed as 24 h 
value. Predicted REE was calculated by the Harris–Benedict formula and allowed to test 
for metabolic efficiency. 
 
Laboratory tests 
 
Insulin resistance was calculated by the homeostatic model of insulin resistance (HOMA-
IR) index: insulin (mIU/L) × [glucose (mmol/L)/22.5]. A HOMA-IR value greater than 2.0 
was considered indicative of insulin resistance, as obtained in a sample of the Italian 
population (Bonora 2000). The hoŵeostatiĐ ŵodel of β Đell fuŶĐtioŶ ;HOMA-B) was used 
to describe the functionality of pancreatic beta cells and calculated using the following 
formula: 20 [insulin (mIU/L)/gluĐose ;ŵŵol/LͿ − ϯ.ϱ]. HďAϭĐ leǀels ǁeƌe deteƌŵiŶed iŶ 
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290 patients of the metformin-untreated group and all metformin-treated patients. ADA 
recommendations for 2012 (ADA 2012) were used for the definition of glucose 
metabolism and T2DM based on fasting plasma glucose (FPG) and glycated hemoglobin 
(HbA1c), as follows: normal FPG if <5.6 mmol/L; impaired FPG (IFG) if FPG was 5.5–6.9 
ŵŵol/L; TϮDM if FPG ǁas шϳ.Ϭ ŵŵol/L oŶ Ϯ daǇs apart. HbA1c values of 5.7 and 6.5% 
were considered as the threshold of normal glucose metabolism and T2DM, respectively. 
Undiluted serum samples were assayed for fT4 and TSH using an automated 
chemiluminescence assay system (Immulite 2000; DPC, Los Angeles, CA). The principle of 
the method is a two-site, solid-phase chemiluminescent immunometric assay or 
competitive immunoassay. Normal values for TSH are 0.4–4.5 mIU/L, and for fT4 102.9-
244.5 nmol/L. Insulin levels were measured by immulite. Glucose, total cholesterol, high-
density (HDL) and low-density lipoprotein (LDL) cholesterol, and triglycerides were 
measured by enzymatic methods (Roche Diagnostics, Mannheim, Germany). Fibrinogen 
levels were determined with the Clauss methodology by Hemosil assay (IL Coagulation 
System, Instrumentation Laboratory, Bedford, MA). Ultrasensitive C-reactive protein 
(CRP) was measured by CRP (latex) HS Roche kit, having sensitivity of 0.03 nmol/L, 
intraassay and interassay CVs of 2.51–5.35 and 4.25–5.79%, respectively, as reported by 
the manufacturer. Alkaline phosphatase, aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were assayed according to the International Federation of Clinical 
Chemistry (IFCC), without pyridoxal-ϱ′-phosphate, using the Cobas Integra 800 (Roche 
Diagnostics). Gamma-glutamyltranspeptidase (GGT) was measured by enzymatic 
colorimetric test using Roche/Hitachi 904/911/912/917/modular (Roche Diagnostics). 
 
Statistics 
 
Statistical analysis was performed using SPSS version 18 (Somers, NY, USA) on log 
transformed data to correct for the non-Gaussian distribution obtained by the Shapiro–
Wilk test. Values are expressed as medians and interquartile ranges. Mann–Whitney test 
ǁas used foƌ ĐoŵpaƌisoŶ ďetǁeeŶ suďgƌoups. “peaƌŵaŶ͛s ĐoƌƌelatioŶ aŶalǇsis aŶd the 
Chi square were used to identify significant associations between variables of interest. 
The role of non-collinear variables on TSH and fT4 levels was tested by stepwise multiple 
regression analysis using as independent variables age, gender, BMI, use of metformin, 
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total cholesterol and fT4 or TSH, depending on whether TSH or fT4 levels were analyzed, 
respectively. HOMA-IR and waist circumference were employed as additional covariates 
in this model after exclusion of potential collinear variables. Logistic regression analysis to 
test the effect of metformin-treated diabetes mellitus and other variables of interest on 
the levels of thyroid parameters. Statistical significance was set at 5%. 
 
Results 
 
A summary of anthropometric and biochemical data are reported in Table 1 (pag. 206).  
BMI values were comprised between 30–73.6 kg/m2, and were >40 kg/m2 in 78.8% (750 
patients), >35–39.9 kg/m2 in 17.8% (172 patients), and >30–34.9 kg/m2 in 3.1% of cases 
(30 patients). The metformin-treated diabetic subgroup exhibited greater BMI, waist 
circumference and fat mass than their counterpart. Both subpopulations were, however, 
severely insulin resistant and HOMA-IR exceed the normal threshold of 2 (WHO 2000) in 
81.6% of metformin-untreated and 87% of metformin-treated diabetic patients. Ninety-
four metformin-treated diabetic subjects were on statins at the time of the study, which 
likely explained the differences in total and LDL-cholesterol noted between groups. 
Analysis of thyroid function showed a mild increase in TSH levels in a subset of 30 patients 
(5.6%). None of these harbored any increase in anti-thyroid antibody titer or abnormal 
free thyroid hormone levels. Table 1 (pag. 206) illustrates similar TSH levels between 
metformin-treated diabetic patients and metformin-untreated subjects. Based on the TSH 
reducing effects previously found to be elicited by metformin, our attention was mainly 
focused on TSH values in metformin users and non-users, yet data dichotomization by 
median TSH levels o 1.72 mIU/L showed a comparable distribution of metformin users 
between top and bottom TSH bearers (24.3 and 23.2%, respectively), with results being 
equivalent if TSH was stratified by quartiles (Figure 1, pag. 209) or logistic regression 
analysis (Table 2, pag. 207).  
Oppositely, analysis of fT4 levels showed significantly higher fT4 levels in metformin-
treated diabetic subjects compared to metformin-untreated ones. Interestingly, when a 
subset of 113 metformin-untreated obese patients with incident diabetes mellitus was 
considered separately, these patients exhibited lower TSH [1.50 (IQR 1.12–2.01) vs. 1.80 
(IQR 1.24–2.51) mIU/L; p=0.02] and greater abdominal obesity [waist, 132 (IQR 121–141) 
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vs. 114.7 (IQR 100.4–132.5) cm; p<0.001] than the normoglycaemic counterpart, devoid 
of differences in fT4 levels [11.1 (IQR 10.2–12.4) vs. 11.3 (IQR 10.2–12.6) pg/mL] or BMI 
values [44.5 (IQR 40.3–49.3) vs. 43.5 (IQR 39.5–48.2) kg/m2]. Gender stratification 
showed no differences in TSH and fT4 levels (data not shown). 
Bivariate regression analyses on the whole dataset depicted a significant negative 
correlatioŶ ďetǁeeŶ T“H aŶd fTϰ leǀels ;ƌho=−Ϭ.Ϭϵϭ, p=Ϭ.ϬϬϱͿ, ǁith eaĐh ďeiŶg ǁeaklǇ 
Đoƌƌelated iŶ opposite diƌeĐtioŶ ǁith BMI ;T“H: ƌho=Ϭ.Ϭϳϴ, p=Ϭ.ϬϮ; fTϰ: ƌho=−Ϭ.Ϭϳϰ, 
p=Ϭ.ϬϮͿ aŶd ǁaist ĐiƌĐuŵfeƌeŶĐe ;T“H: ƌho=Ϭ.Ϭϲϯ, p=Ϭ.Ϭϲ; fTϰ: ƌho=−Ϭ.Ϭϲϲ, p=Ϭ.ϬϰͿ. The 
relationship between TSH and fT4 persisted after controlling for age, BMI, gender, HOMA-
IR and the use of metformin (r=0.088, p=0.008). No correlation was observed between 
TSH and age. In sub-group analysis, patients aged >70 year (103 cases, 10.8%) showed 
comparable TSH levels with the remainders (1.68 mUI/L [IQR 1.25–2.46] vs 1.72 mUI/mL, 
[IQR 1.21–Ϯ.ϰϳ]Ϳ; the possiďilitǇ that this ƌepƌeseŶted a ͚suƌǀiǀoƌ͛ saŵple of patieŶts ǁas 
hinted by the finding of a slightly healthier metabolic profile when compared to the 
younger counterpart, i.e. lower levels of total and LDL cholesterol, triglycerides, and 
HbA1c (data not shown). When thyroid function was plotted against serum parameters of 
cardiovascular risk in the population as a whole, TSH was only associated with total 
cholesterol (rho=0.080, p=0.01). Of note, fT4 levels were inversely related to triglycerides 
;ƌho=−Ϭ.Ϭϵϭ, p=Ϭ.ϬϬϱͿ, iŶsuliŶ ;ƌho=−Ϭ.Ϭϳϵ, p=Ϭ.ϬϮͿ aŶd HOMA-I‘ ;ƌho=−Ϭ.Ϭϴϯ, p=Ϭ.ϬϭͿ, 
and directly to HDL-cholesterol (rho=0.106, p=0.001). In testing the relationship between 
thyroid function and cardio-metabolic variables after controlling for potential 
confounders (i.e. age, gender, BMI, incident diabetes mellitus, use of metformin, use of 
statins, smoking), only fT4 remained correlated with age, BMI and HDL-cholesterol, while 
the correlation with triglycerides approached statistical significance (Table 3, pag. 208). 
No relationship was seen between thyroid function and C-reactive protein, fibrinogen and 
liver function tests, but with alkaline phosphatase (TSH: ƌho=−Ϭ.Ϭϵϴ, p=Ϭ.ϬϬϮ; fTϰ: 
rho=0.070, p=0.03). Likewise, no association related thyroid function to REE and 
metabolic efficiency, as well as BIA-derived parameters of body composition (data not 
shown). 
In multivariate linear regression analysis, TSH was best predicted by fT4 (standardized 
β=−Ϭ.Ϭϳϵ, p=Ϭ.ϬϭϱͿ, total Đholesteƌol ;staŶdaƌdized β=Ϭ.Ϭϳϰ, p=Ϭ.ϬϮͿ aŶd BMI 
;staŶdaƌdized β=Ϭ.Ϭϲϱ, p=Ϭ.ϬϰͿ. ‘eplaĐeŵeŶt of BMI ǁith ǁaist ĐiƌĐuŵfeƌeŶĐe did Ŷot 
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reach statistical significance. When FT4 levels were tested as the dependent variable, 
theǇ ǁeƌe pƌediĐted ďǇ T“H ;staŶdaƌdized β=−Ϭ.ϴϰ, p=Ϭ.ϬϭͿ, ŵetfoƌŵiŶ-treated diabetes 
ŵellitus ;staŶdaƌdized β=Ϭ.Ϭϴϳ, p=Ϭ.ϬϬϴͿ, BMI ;staŶdaƌdized β=−Ϭ.ϴϯ, p=Ϭ.ϬϭϮͿ aŶd age 
;staŶdaƌdized β=−Ϭ.ϴϬ, p=Ϭ.ϬϭϱͿ. WheŶ ǁaist ĐiƌĐuŵfeƌeŶĐe replaced BMI, it also entered 
the ƌegƌessioŶ eƋuatioŶ ;staŶdaƌdized β=−Ϭ.Ϭϳϳ, p=Ϭ.ϬϮϭͿ. HOMA-IR did not enter the 
regression equation both when TSH and fT4 levels were tested. 
 
Discussion 
 
Obesity is conventionally regarded as the result of unbalanced calorie intake and 
impaired energy expenditure acting on a predisposed genetic setting. A common 
explanatory model encompasses the lipostatic regulation system, in which energy stores 
generate signals that are compared with targets encoded in the brain, and differences 
between these drive our food intake levels, activity patterns, and resting and active 
metabolisms (Speakman 2004). Although obesity predisposes to hyperthyrotropinaemia 
and reductions in fT4 levels (Santini 2014, Knudsen 2005), TSH levels can still provide a 
peripheral index of thyroid activity also in the obese state (Tagliaferri 2001). So far, 
analyses on the metabolic correlates of thyroid function in obesity have provided little 
evidence, or were conducted in small cohorts so as to draw definitive conclusions (Santini 
2014, Knudsen 2005). In this regard, a potential confounder is constituted by the 
antidiabetic agent metformin, based on its ability to reduce TSH levels in subjects with 
hypothyroidism and in those with euthyroidism harboring normal-high TSH levels (Duntas 
2011, Vigersky 2006, Isidro 2007, Cappelli 2009, Rotondi 2011, Cappelli 2012, Karimifar 
2014, Santos-Palacios 2013). Metformin acts as insulin-sensitizer in multiple ways, such as 
by decreasing hepatic glucose production through inhibition of the mitochondrial 
respiratory-chain complex 1, by activating the cellular metabolic sensor AMPK, by 
increasing glucagon-like peptide 1 (GLP-1) levels, as well as by inducing islet incretin 
receptor gene expression (Zhou 2001, Gunton 2003, Maida 2011, Lim 2010). The exact 
mechanisms linking metformin effects to variations in pituitary TSH secretion are 
currently unknown, but possibly involve inhibition of hypothalamic AMPK, counteraction 
of central T3 effects, dopaminergic effects and/or inhibition of pituitary TSH secretion 
(Duntas 2011, Lopez 2010, Labuzek 2010). In the current study, first of all we documented 
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comparable TSH levels between obese patients treated and not treated with metformin. 
This result was confirmed by multiple statistical approaches. Oppositely, a slight yet 
significant increase in fT4 levels was seen in metformin-treated subjects compared with 
their untreated counterpart. This latter finding contrasts with the observation that 
metformin leaves unaltered free thyroid hormone levels (Lupoli 2014), and possibly 
reflects an effect played by obesity on thyroid hormone metabolism either mediated by 
type 2 deiodinase activity, TH binding to TBG, or thyroxine degradation. However, we do 
not exclude that such finding simply results from metabolic differences existing between 
subgroups, since metformin-treated subjects were slightly older and mildly more insulin 
resistant, showed a more central distribution of body fat and higher BMI compared to the 
metformin-untreated counterpart. Along this line of reasoning, the positive correlation 
between fat mass and fT4 found by others (Roef 2012) supports the hypothesis that 
abdominal adiposity may increase free thyroid hormone. In addition, diabetes mellitus 
can increase per se fT3 inactivation to rT3 and decrease T4 conversion to T3 due to lower 
type 2 deiodinase activity (Moura Neto 2013), while metabolic syndrome can lead to 
higher fT4 levels in obese subjects (Tarcin 2012). Our obese patients with incident 
diabetes mellitus were found to harbor lower TSH compared with their metformin-
untreated counterpart. In this subgroup, individual analysis found no potential case of 
subclinical dysfunction and no significant metabolic impact was documented in 
correlation analyses likely due to the sample dimension and the overall high rate of 
severe obesity in our study (nearly 80%). Further investigations in larger datasets are 
warranted to verify the clinical significance of this observation. 
Together, our results pinpoint potentially different metabolic roles for TSH and fT4 in the 
obese setting. In general, TSH was associated with increasing BMI and total but not HDL 
Đholesteƌol leǀels. These assoĐiatioŶs disappeaƌed afteƌ ĐoŶtƌolliŶg foƌ iŶdiǀiduals͛ 
confounders. Oppositely, fT4 levels showed an inverse relation with BMI, insulin, HOMA-
IR, triglycerides, in conjunction with a direct association with HDL-cholesterol. fT4 
associations with the metabolic phenotype remained significant after adjustment for 
potential confounders. This leads us to speculate that fT4 reflects better than TSH the 
cardio-metabolic risk of obesity: according to this view, TSH levels mirror the obese 
phenotype, while fT4 levels act as a proxy of the metabolic status related to the obese 
phenotype. Previous studies in morbidly obese patients found an association of increasing 
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TSH, and less significantly decreasing FT4, with insulin and insulin resistance (Michalaki 
2006, Iacobellis 2005, Ambrosi 2010), yet none was controlled for individual confounders. 
On the other hand, population studies related low fT4 more tightly to cardio-metabolic 
indices (BMI, insulin resistance, lipid profile and intima media thickness) than high TSH 
levels (Roos 2007, Dullaart 2007, Kim 2009, Mehran 2014). In a Korean study on 6241 non 
diabetic euthyroid subjects, those with the lowest fT4 quartile had twice the risk for 
insulin resistance as compared to those in the highest quartile after adjustment for age, 
sex, metabolic, and life style factors (Shin 2014). Nevertheless, the NHANES 2007–2008 
analysis on 3114 euthyroid healthy men and women found that only TSH levels, and to a 
lesser degree fT3, were correlated with BMI and waist circumference, while fT4 levels 
were not (Kitahara 2012). Likewise, the Asklepios Study on 2315 healthy euthyroid 
middle-aged men and women found that a higher fT3–fT4 ratio (index of conversion from 
fT4 to fT3) was predictive of an unfavorable metabolic profile (Roef 2014). Differences in 
prevalence and degree of obesity, fat partition, genetic background, and insulin sensitivity 
may contribute to explain the observed discrepancies. 
 
Conclusions 
 
In conclusion, fT4 levels appeared to be related to the overall metabolic phenotype of 
obese patients, while the metabolic impact of TSH was less prominent. Incident diabetes 
seems associated with a reduction in TSH results, yet further studies in larger samples of 
euthyroid obese patients are needed to detail the individual clustering of TSH and fT4 
levels with metabolic features in this setting. 
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Tables 
 
Table 1. Summary of anthropometric and biochemical data obtained in the whole study 
population, in the euthyroid metformin-treated obese diabetic subpopulation (OB-EuM) 
and the euthyroid obese metformin-untreated subpopulation (Ob-Eu). 
 
Variables Whole population (n = 952) OB-EuM (n = 306) Ob-Eu (n = 646) p 
Males/females 410/542 127/179 283/363 0.5 
Age (years) 56 (49–65) 58 (50–65) 55 (48–65) 0.07 
BMI (kg/m2) 44.4 (40.5–48.9) 45.6 (41.4–49.6) 43.7 (40.0–48.7) 0.003 
Weight (kg) 117.8 (102.8–133.5) 118.3 (106.0–134.0) 117.3 (101.6–133.1) 0.09 
Height (cm) 161.8 (155–171) 161 (155–170) 162 (155–171) 0.3 
Waist (cm) 129 (119–138) 131 (122–140) 127 (116–137) <0.001 
Waist-to-hip ratio 0.96 (0.89–1.92) 0.97 (0.91–1.04) 0.94 (0.88–1.02) <0.001 
REE (kcal/day) 1909 (1651–2247) 1963 (1740–2280) 1884 (1598–2233) 0.003 
Fat mass (%) 46.3 (41.0–51.8) 47.3 (41.9–52.6) 45.7 (40.4–51.3) 0.009 
Body water (%) 39.7 (36.2–44.2) 39.5 (36.3–43.9) 39.8 (36.2–44.4) 0.7 
TSH (mIU/L) 1.72 (1.21–2.47) 1.72 (1.19–2.45) 1.72 (1.22–2.47) 0.7 
fT4 (nmol/L) 146.3 (132.5–162.1) 151.9 (135.1–163.5) 145.4 (131.3–162.2) <0.001 
Insulin (pmol/L) 100.7 (65.9–145.8) 98.6 (62.5–150.0) 102.1 (68.1–143.1) 0.5 
Glucose (mmol/L) 5.77 (5.05–7.21) 7.38 (6.05–8.99) 5.38 (5.38–6.22) <0.001 
HbA1c (%) 6.6 (6.0–7.9) 7.5 (6.5–8.7) 6.1 (5.7–6.7) <0.001 
HOMA-IR 4.0 (2.5–6.1) 4.7 (2.9–7.2) 3.7 (2.3–5.6) <0.001 
HOMA-B 125.2 (72.1–214.1) 76.3 (42.6–133.1) 152.0 (97.1–248.3) <0.001 
Cholesterol (mmol/L) 5.10 (4.38–5.80) 4.79 (4.01–5.44) 5.26 (4.66–5.98) <0.001 
LDL (mmol/L) 3.12 (2.49–3.76) 2.75 (2.16–3.39) 3.30 (2.70–3.93) <0.001 
HDL (mmol/L) 1.09 (0.91–1.35) 1.04 (0.85–1.27) 1.11 (0.93–1.37) <0.001 
Triglycerides (mmol/L) 1.59 (1.23–2.18) 1.73 (1.31–2.37) 1.55 (1.20–2.09) <0.001 
AST ;μkat/LͿ 0.35 (0.28–0.48) 0.35 (0.28–0.50) 0.35 (0.30–0.48) 0.8 
ALT ;μkat/LͿ 0.45 (0.32–0.70) 0.43 (0.32–0.70) 0.45 (0.32–0.70) 0.8 
γGT ;μkat/LͿ 0.48 (0.32–0.75) 0.50 (0.33–0.87) 0.47 (0.30–0.72) 0.07 
ALP ;μkat/LͿ 1.64 (1.14–3.02) 1.25 (1.04–1.65) 2.27 (1.25–3.35) <0.001 
CRP (nmol/L) 5.71 (2.86–10.48) 5.71 (2.86–11.43) 5.71 (3.81–10.48) 0.5 
FiďƌiŶogeŶ ;μŵol/LͿ 11.64 (10.17–13.38) 11.44 (9.91–13.17) 11.76 (10.29–13.52) 0.04 
 
HbA1c levels in Ob-Eu refer to measurement in a subgroup of 290 patients. Data are expressed as medians 
(with interquartile range in parentheses). Comparison between populations was performed by Mann–
Whitney test on log-tƌaŶsfoƌŵed data aŶd χϮ test 
 
BMI body mass index; REE resting energy expenditure; HOMA-IR homeostatic model of insulin resistance; 
HOMA-B hoŵeostatiĐ ŵodel of β Đell fuŶĐtioŶ; LDL loǁ deŶsitǇ lipopƌoteiŶ; HDL high deŶsitǇ lipopƌoteiŶ; A“T 
aspaƌtate aŵiŶotƌaŶsfeƌase; ALT alaŶiŶe aŵiŶotƌaŶsfeƌase; γGT gaŵŵa glutaŵiltƌaŶsfeƌase; ALP alkaliŶe 
phosphatase; CRP C-reactive protein 
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Table 2. Logistic regression analysis on values of TSH and BMI dichotomized by median 
values (0 = bottom values; 1 = top values) in the population as a whole. 
 
Variables TSH BMI 
Age 0.98 (0.96–0.99) 0.99 (0.98–1.01) 
Female gender 1.08 (0.59–1.73) 5.67 (3.61–8.90)  
TSH – 1.05 (0.89–1.24) 
BMI 0.97 (0.94–1.01) – 
REE 1.00 (0.99–1.00) 1.003 (1.002–1.003) 
HOMA-IR 1.01 (0.99–1.02) 0.99 (0.98–1.01) 
Use of metformin 1.09 (0.78–1.52) 1.29 (0.90–1.85) 
 
Odds ratio and 95 % confidence intervals are displayed. BMI body mass index; REE resting energy 
expenditure; HOMA-IR homeostatic model of insulin resistance. Use of metformin was categorized as 0 = no 
use of metformin, 1 = use of metformin. Significant values are in italics. 
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Table 3. Correlation analysis between thyroid function and phenotypic variables of 
interest in the obese group as a whole, after controlling for age, gender, BMI and use of 
metformina. 
 
Variables TSH fT4 
 r p r p 
Age −Ϭ.Ϭϱ 0.1  −Ϭ.Ϭϴ  0.01  
BMI 0.05 0.09  −Ϭ.Ϭϵ  0.006  
Waist 0.04 0.3  0.02 0.5  
Percent fat mass 0.09 0.02  0.07 0.06  
Cholesterol 0.506 0.09  −Ϭ.ϬϮ 0.5  
HDL 0.03 0.3  0.13  0.001  
LDL 0.04 0.3  −Ϭ.Ϭϱ 0.1  
Triglycerides 0.05 0.2  −Ϭ.Ϭϳ 0.06  
Insulin 0.01 0.7  −Ϭ.Ϭϯ 0.3  
HOMA-IR 0.01 0.8  −Ϭ.Ϭϰ 0.2  
HOMA-B 0.02 0.5  0.01 0.7  
AST 0.03 0.4  −Ϭ.Ϭϳ 0.06  
ALT −Ϭ.ϬϬϯ 0.9  −Ϭ.ϬϬϯ 0.9  
γGT 0.004 0.2  −Ϭ.Ϭϯ 0.4  
Alkaline phosphatase −Ϭ.ϭϯ  0.001  0.09  0.02 
 
Italic values indicate p-values 
Underlined values indicate significance 
Italic underlined values indicate statistically significant p-values 
Age and BMI were omitted as covariates when measured as independent variables 
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Figures 
 
Figure 1. Comparison of TSH quartiles between obese euthyroid obese patients with 
diabetes and treated with metformin (Met) and those without diabetes and not treated 
with metformin (No Met). Medians (diamonds) and interquartile ranges (lines) are 
displayed. 
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Abstract 
 
Purpose. The effects of early weight loss on the relationship between thyroid function 
and resting energy expenditure (REE) in subjects with severe obesity is unknown. 
 
Methods. To explore the early effects of weight loss on this association, 100 severely 
obese euthyroid inpatients underwent a 4-wk multidisciplinary moderately hypocaloric 
dieting program inclusive of measurements of thyroidal parameters, REE and body 
composition. 
 
Results. No association related thyroid function to REE at baseline. After 4-wk dieting, 
weight loss was modest but significant (-5.5%, p<0.0001 vs. baseline) and paralleled by 
reductions in REE (-4.1%, p<0.001), fat-free mass (-3.7%, p<0.001) and fat mass (-1.6%, 
p<0.05). Early thyroidal changes after weight loss were marginal but significant for TSH (-
6.3%), FT3 (-3.3%) and FT4 levels (+3.9%, p<0.001 for all). After weight loss, REE resulted 
associated with FT3 (r=0.24, p<0.05) and FT4 (r=0.42, p<0.001) via interactions with fat-
free mass (F=13.4 and 9.03, respectively; p<0.001 for both). In multivariate analysis, no 
thyroidal variable entered the regression equation for REE response to weight loss. 
 
Conclusions. Early weight loss reactivates the relationship between thyroid and energy 
balance. This prompt, and likely non-adaptive, response may physiologically act to 
regulate long-term management of severe obesity depending on starting body 
composition.  
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Background 
 
Physiological and environmental factors are known to influence the normal function of 
the hypothalamo-pituitary thyroid (HPT) axis, including iodine intake (Rasmussen 2002), 
aging (Surk 2007), reproductive stages (Negro 2014), ethnic and geographical 
determinants (Spencer 2007), several medications (Aoki 2007) and smoking (Makepeace 
2008). Increasing attention has been dedicated to the ability of obesity to promoting a 
shifting of serum TSH concentrations toward normal-high or slightly supra-normal levels, 
while influencing subtle increments in T3 levels and reductions in FT4 levels (Biondi 2010). 
The mechanisms linking adipose tissue expansion to a change thyroidal parameters likely 
originate from a compensatory response operated by the hypotalamo pituitary unit to 
counteract adiposity via leptin-mediated effects (Santini 2014). In addition to assessing 
the coexistence of thyroid disorders, analysis of thyroid function in the severely obese 
setting can be useful to rule out the possible impairment of resting energy expenditure 
(REE) as a potential contributor of obesity (Tagliaferri 2001). This inference is based on 
the evidence that regulating thermogenesis is one of the major tasks of THs in adult 
humans, which involves direct and indirect effects on cellular processes controlling 
triiodothyronine-responsive energetic processes (Kim 2008). Opposed to the classical 
view that most effects of THs on energy homeostasis are peripheral, current perspectives 
indicate that THs can centrally affect energy metabolism by interacting with global energy 
sensors (López 2013). Upon body weight loss, it has long been acknowledged that REE 
decreases as a consequence of a reduction of fat free mass (FFM) (Ravussin 1985). 
Likewise, weight loss blunts serum TSH concentrations, 24-hr TSH fluctuations and the 
TSH response to thyrotropin releasing hormone (TRH), as well it promotes a decrease in 
FT3 concentrations and the increment of FT4 levels (Santini 2014). The functional 
combination of these changes is meant to be primarily adaptive, and is  partly leptin-
mediated (Rosenbaum 2002). Age, clinical setting, type and duration of intervention, and 
individual confounders can influence the adaptive modifications of the relationship 
between the HPT axis and energy homeostasis during weight loss (Froidevaux 1993, 
Reinehr 2002, Sari 2003, Kok 2005, Agnihothri 2014). 
Because non-adaptive effects of caloric restriction on such relationship have been 
scarcely characterized, the current study was undertaken to explore the potentially early 
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mechanisms relating changes in thyroid function to REE in function of short-term weight 
loss by using an inpatient approach. To this aim, a 4-week timeframe was used for the 
current investigation, based on the demonstration that 6-8 weeks are required to reset 
the HPT axis (Fish 1987, Garber 2012). We thus aimed to profile early thyroidal and REE 
modifications in euthyroid individuals with severe obesity, with the intention of shedding 
new light on non-adaptive associations between weight loss, thyroid function and energy 
homeostasis, and possibly to inform on long-term obesity management decisions. 
 
Methods 
 
The study population was constituted by 100 euthyroid obese patients (BMI >30 kg/m2), 
classified as severely obese (52 females/48 males; mean age, 40.4±12.7 yr; mean BMI, 
45.1±4.8 kg/m2, BMI range, 40-61 kg/m2), who were recruited after signing an informed 
consent upon admission to our Institution for diagnostic workup and rehabilitation for 
severe obesity. Following baseline assessment, all participants underwent a 4-week 
inpatient study consisting of multidisciplinary weight loss program entailing the following: 
a) personalized diet, daily monitored by a dietician,  formulated according to the Italian 
recommended daily allowances (Italian Society for Human Nutrition), entailing an energy 
intake corresponding to the 75% of the measured REE; b) aerobic physical activity 
program, including two 30 min sessions/day of cycle erogometer pedaling, treadmill 
walking and stationery rowing, carried out for 5 days/week. The intensity of exercise was 
set at aŶ aǀeƌage heaƌt ƌate ďetǁeeŶ ϲϬ% aŶd ϴϬ% of the iŶdiǀidual͛s ŵaǆiŵuŵ heaƌt 
rate; c) psychological and nutritional counselling. To reduce potential for selection bias, 
an effort was made to maintain equal distributions in gender, individualized dietary 
intake, energy expenditure and counseling. Each part of the study was conducted under 
skilled medical surveillance and nursing. To reduce differences in performance, medical 
and nursing staff in charge were unaware of patients participation to the study, and the 
ancillary treatment and diagnostic investigations received by the study group paralleled 
that of regular inpatients. The study was approved by the Ethic Committee of the Istituto 
Auxologico Italiano. Study procedures were performed in accordance with the Helsinki  
Declaration of 1975 as revised in 1983. To reduce detection bias, none of the study 
participants suffered from thyroid disease or had been previously treated with 
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medications potentially interfering with thyroid function. Exclusion criteria included 
endocrine obesity, autoimmune or chronic inflammatory disorders, type 1 diabetes 
mellitus (T1DM) and T2DM, chronic obstructive pulmonary disease, history of neoplasms 
or degenerative diseases, previous chronic steroid treatment, kidney or cardiac disorders, 
liver disease. No patient was undergoing pharmacological therapies at the time of the 
study, and body weight had been stable for at least three months prior to study entry. 
Baseline testing was performed at 08.00 h in fasting conditions and after voiding, 3 d after 
admission while patients were fed a balanced diet (30% lipids, 50% carbohydrates, and 
20% proteins). Neither supplements nor anti-obesity therapies were used during the 
study period. 
 
Anthropometry, energy expenditure and thyroid ultrasonography 
 
The study protocol included metabolic profiling and thyroid ultrasonography (US) at study 
entry, while hormonal assessment as well as anthropometry data, body composition and 
energy expenditure were determined at baseline and at the end of the study. For each 
patient, three main trajectories of body weight increase were included: child-hood onset 
obesity, adult-onset obesity and weight oscillations. 
All subjects underwent body measurements wearing light underwear, in fasting 
conditions after voiding. Weight and height were measured to the nearest 0.1 kg and 0.1 
cm, respectively. BMI was expressed as body mass (kilograms)/height (meters)2. Obesity 
was defined for BMI over 30 kg/m2. Waist circumference was measured midway between 
the lowest rib and the top of the iliac crest after gentle expiration; hip was measured as 
the greatest circumference around the nates. Anthropometric data were expressed as the 
mean of two measurements. 
Respiratory quotient (RQ; VO2/VCO2) and REE (kcal/24 h) were determined in a thermo-
regulated room (22–24°C) by computed open-circuit indirect calorimetry, measuring 
resting oxygen uptake and resting carbon dioxide production by a ventilated canopy 
(Sensormedics; Milan, Italy) at 1-min intervals for 30 min and expressed as a 24-h value. 
Predicted REE (pREE; kcal/24 h) was calculated by the Harris-Benedict formula and was 
employed to calculate the REE/pREE ratio as a proxy of metabolic efficiency, set as 100% 
(Marzullo 2004). Fat mass and free fat mass were assessed by bio-impedance analysis 
215 
 
(BIA, 101/S Akern; Florence, Italy) the morning after overnight fasting and after voiding. 
The two vector components of impedance (i.e. resistance and reactance) were obtained 
by single measurements; before each testing session, the external calibration of the 
instrument was checked with a calibration circuit of known impedance value. The mean 
coefficient of variation was 1% for within-day and 3% for weekly intra-individual 
measurements in the steady-state condition in either site and 2% for inter-operator 
variability. 
Thyroid ultrasonography (US) was performed by one certified operator (AM) using a real-
time US device equipped with a linear transducer operating at 7.5 MHz for morphologic 
study (MyLab Class C, Esaote Biomedica, Genova, Italy). US pattern of thyroid 
parenchyma was defined for echogenicity based on comparison with neck muscles on 
transverse section, after excluding the potentially reflecting echoes from isthmus due to 
the tracheal cartilage. The volume of the thyroid gland was calculated according to the 
ellipsoid model [length (cm) × width (cm) × depth (cm) × 0.5], and the size of nodules, if 
present, was measured. Vascularization of the gland and of the nodules was 
semiquantitatively assessed, as well as the occurrence of micro-calcifications and the 
spongiform aspect. Combinations of diagnostic signs for thyroid nodules included size >1 
cm, microcalcifications, a taller-than-wide shape, irregular borders, hypoechogenicity, 
and intranodular vasculature. 
 
Laboratory determinations 
 
Thyroid function was tested by analysis of FT4, FT3, TSH, anti-Tg antibodies (TgAb) and 
anti-TPO antibodies (TPOAb) levels. Undiluted serum samples were assayed using an 
automated electrochemiluminescence assay system (Cobas 6000; Roche Diagnostics 
GmbH, Mannheim, Germany). The principle of the method is a two-site, solid-phase 
chemiluminescent sandwich immunoassay. Normal values were as follows: FT3, 1.8–4.4 
ng/L; FT4, 8.0–19.0 ng/L; TSH, 0.27–ϰ.Ϯ ŵIU/L; TPOAď, less thaŶ ϯϱ μU/L; TgAď, less than 
ϰϬ μU/L. BaseliŶe eǀaluatioŶ ϭϯϬ iŶĐluded aŶalǇsis of the lipid paŶel, gluĐose aŶd iŶsuliŶ 
levels. Glucose homeostasis was based on fasting blood glucose and/or glycated 
hemoglobin (HBa1c) levels according to ADA guidelines (Cunningham 1991), as well as 
insulin resistance calculated by the homeostatic model (HOMA-IR) index: insulin (mIU/L) x 
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[glucose (mmol/liter)/22.5]. Blood glucose, lipids and C reactive protein levels were 
measured by enzymatic methods; a two-site solid-phase electrochemiluminescent 
sandwich assay was used for insulin levels (Cobas 6000). 
 
Statistical analysis 
 
Data were tested for normality of distribution by the Kolmogorov-Smirnov test and log-
transformed when needed, to correct for skewness. Study outcomes were constituted by 
the interactions relating percent modifications of body weight and biochemical, 
anthropometric, and body composition variables measured at the end of the 4-wk study 
period. Parameters of interest were thus considered as values at study entry, at the study 
end and as percent delta vaƌiatioŶs oǀeƌ ďaseliŶe ǀalues ;ΔͿ. Foƌ Đoŵpaƌatiǀe aŶalǇses, 
paired T test for intra-individual comparisons and ANOVA between subgroups were used. 
Correlation between analyzed parameters and their deltas were tested by bivariate 
regression analyses, partial correlation analysis, and ANCOVA by the general linear model 
to control for interactions. Females were categorized as 0 and males as 1. Stepwise 
multivariate regression analysis was used to evaluate the independent association of 
variations in REE, TSH and THs with metabolic or anthropometric variables. Regression 
models were built on the results of simple and partial regression analyses, and included 
age, gender (0=female, 1=male), and baseline and deltas values of FT3, FT4, TSH, REE and 
BMI. β ĐoeffiĐieŶts, ƌelated sigŶifiĐaŶĐe ǀalues aŶd adjusted ‘Ϯ ǀalues oďtaiŶed fƌoŵ the 
models are reported. P<0.05 was considered as statistically significant. 
 
Results 
 
Results obtained at baseline and study end are summarized in Table 1 (pag. 220). 
At the study entry, 17 patients showed impaired glucose tolerance and 11 others showed 
incidental T2DM. Gender-stratified analysis (Table 2, pag. 221) displayed older age, 
stronger metabolic impairment, and higher alcohol intake in men than women. REE 
correlated with FFM (r=0.68, p<0.001), male gender (r=0.54, p<0.0001), BMI (r=0.31, 
p<0.01) and percent FM (r=-0.25, p<0.05). Baseline TSH levels were above normal in two 
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patients free of thyroid antibodies or abnormal US pattern. There was at this stage no 
relationship between thyroidal parameters and REE or its derived measures. 
At US, thyroid hypoechogenicity was found in 11% of cases, and thyroid nodules were 
detected in 60% of cases. One of 8 patients undergoing fine-needle biopsy harbored a 
medullary thyroid carcinoma. Thyroid nodules were associated with TSH (r=-0.33, 
p<0.001) and age (r=0.31, p<0.01). An association was seen between REE and thyroid 
volume (r=0.33, p<0.01), which disappeared after controlling for age, BMI and gender. 
At the end of the 4-week weight loss program, significant changes in most 
anthropometric, hormone and metabolic parameters were observed (Tables 1-2, pag. 
220, 221). Particularly, variations of thyroidal parameters (Figure 1, pag. 223) were 
interindividually skewed but overall significant and each associated with respective values 
recorded at the study entry (Table 3, pag. 222). Marginal associations were observed 
ďetǁeeŶ ΔT“H aŶd ΔBMI afteƌ adjustŵeŶt foƌ ďaseliŶe FFM ;ƌ=Ϭ.ϮϬ, p<Ϭ.ϬϱͿ, as ǁell as 
ďetǁeeŶ ΔFTϯ aŶd ďaseliŶe BMI aŶd FFM ;ƌ=Ϭ.Ϯϭ aŶd ƌ=Ϭ.ϮϬ, p<Ϭ.Ϭϱ foƌ ďothͿ, ǁhile 
stƌoŶgeƌ assoĐiatioŶs ǁeƌe oďseƌǀed ďetǁeeŶ ΔFTϰ aŶd ΔBMI ;ƌ=-0.38, p<0.001), and 
ďetǁeeŶ ΔFTϰ aŶd ďaseliŶe ǀalues of FFM ;ƌ=Ϭ.ϯϮ, p<Ϭ.ϬϬϭͿ aŶd peƌĐeŶt FM ;ƌ=-0.22, 
p<0.05). 
At odds with the null association found at study entry, weight loss disclosed a positive 
correlation between REE and FT4 (r=0.42, p<0.001) as well as FT3 levels (r=0.24, p<0.05), 
via significant interaction with the initial FFM (REE and FT3: F=13.4, p<0.0001; REE and 
FT4: F=9.03, p<0.001). After weight loss, REE was also associated with male gender 
(r=0.55, p<0.0001), as well as final values of FFM (r=0.71, p<0.0001), BMI (r=0.24, p<0.05) 
and percent FM (r=-Ϭ.ϯϯ, p<Ϭ.ϬϭͿ. Δ‘EE ǁas oŶlǇ ŵaƌgiŶallǇ assoĐiated ǁith ΔBMI 
(r=0.22, p<0.05). 
IŶ stepǁise ŵultiǀaƌiate ƌegƌessioŶ aŶalǇses, Δ‘EE ǁas ďest pƌediĐted ďǇ its ďaseliŶe 
ǀalues ;β=-0.59, p<Ϭ.ϬϬϭͿ aŶd ŵale geŶdeƌ ;β=Ϭ.Ϯϴ, p<Ϭ.ϬϱͿ, ǁith aŶ adjusted ‘Ϯ of Ϭ.Ϯϯ. 
AŶalǇsis of thǇƌoidal paƌaŵeteƌs fouŶd that ΔT“H ǁas ďest pƌediĐted ďǇ its ďaseliŶe 
ǀalues ;β=-Ϭ.ϯϬ, p=Ϭ.ϬϬϯͿ aŶd ΔBMI ;β=Ϭ.ϮϬ, p=Ϭ.ϬϯͿ; ΔFTϰ ǁas pƌediĐted ďǇ its ďaseliŶe 
ǀalues ;β =-Ϭ.ϱϭ, p<Ϭ.ϬϬϭͿ, ŵale geŶdeƌ ;β =Ϭ.ϯϲ, p<Ϭ.ϬϬϭͿ aŶd ΔBMI ;β =-0.17, p<0.05); 
ΔFTϯ ǁas pƌediĐted ďǇ its ďaseliŶe ǀalues ;β =-Ϭ.ϱϴ, p<Ϭ.ϬϬϭͿ aŶd ŵale geŶdeƌ ;β =Ϭ.ϯϯ, 
p<Ϭ.ϬϬϭͿ. Adjusted ‘Ϯ ǀalues foƌ the ΔT“H, ΔFTϰ aŶd ΔFTϯ ƌegƌessioŶ ŵodels ǁeƌe Ϭ.ϭϬ, 
0.41 and 0.33, respectively. 
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Discussion 
 
Growing attention has recently focused on the ability of weight loss to restore thyroidal 
parameters previously disrupted by significant accumulation of adipose tissue (Santini 
2014). It remains unclear if changes in REE, a measure of obligatory thermogenesis that 
promptly decreases upon dieting, may interact with early thyroidal modifications 
determined by reductions in bodyweight. In the present study, short-term weight loss 
was found to modify thyroidal parameters in severe obesity and reactivate a relationship 
between THs and REE via significant interaction with the fat-free mass. 
From the standpoint of energy balance and weight control, these results expand to severe 
obesity the link between thyroid, fat accumulation and energy homeostasis, and further 
add early improvements of the association between THs and REE to the extensive list of 
beneficial effects of weight loss in obesity. It has long been known that obesity can 
disrupt the HPT axis due to compensatory mechanisms likely directed at increasing 
energy expenditure, while weight loss promotes reductions of TSH and FT3 levels, and, 
more debatedly, increases in FT4 concentrations (Santini 2014). In dieting obese women, 
it was previously found that at least 10% weight loss, obtained in 6 months, was needed 
to significantly reduce TSH levels (Sari 2003). While our results show that a short-term 
5.5% weight loss can reduce TSH as well as FT3 and increase FT4 levels, they especially 
underscore the favorable role  of early weight loss on the relationship between REE and 
thyroid hormones via significant interaction with fat-free mass. This particular 
circumstance agrees with the established role of fat-free mass as the single best predictor 
of REE, as well as inter-individual variability in REE, over a broad range of body weights 
(ADA 2016), while THs may explain 20-25% of REE variability (al-Adsani 1997). In judging 
the sensitivity of REE to thyroidal changes herein observed, we are inclined to consider 
our short-term results as non-adaptive, based on the inference that 6-8 weeks are 
needed to reset the HPT axis (Fish 1987, Garber 2012). Therefore, we hypothesize that 
even a short-term and overall modest bodyweight loss may act to reactivate the 
relationship between THs and REE. Moreover, the stronger relationship between several 
anthropometric parameters as well as REE with changes in FT4 as compared to FT3 
confirms previous observations on the predictive metabolic role of FT4 levels obtained in 
populations with wide BMI ranges (Johnstone 2005) as well as with severe obesity 
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(Marzullo 2016). Responses of REE to small thyroidal variations have not, to our 
knowledge, been reported before in severe obesity, which affects a minor proportion of 
the population but accounts for a disproportionate amount of medical illnesses and 
health care services. 
As small reductions in body weight, i.e. 5%, have the potential to significantly influence 
health of patients with obesity (Magkos 2016), our findings may help to explain the 
health-related effects of small reductions in bodyweight. 
Although our obese patients were selected as euthyroid, 60% showed incidental thyroid 
nodules, and individuals with thyroid nodules harbored lower TSH, were generally older 
and had larger thyroids than patients without. However, the observed prevalence of 
incidental thyroid nodules overlaps that found in the general population (Russ 2014). 
Because our report provides no mechanistic information, long-term data are needed to 
better profile the relationship between thyroid function, energy homeostasis and weight 
loss maintenance. Similarly, as study participants were selected as euthyroid and severely 
obese, our findings may not apply to people with normal bodyweight or mild obesity, as 
well as those with thyroid dysfunctions. Nevertheless, we consider the homogeneous 
study sample and the controlled weight management schedule as points of strength of 
this study. 
 
Conclusions 
 
In conclusion, a short-term weight loss seems capable of reactivating the favorable 
relationship between REE and thyroid hormones in severe obesity, via interactions with 
fat-free mass. How body composition effectively controls thyroid hormone effects on 
energy expenditure during long-term calorie restriction warrants further investigation, as 
it could frustrate weight loss attempts of obese individuals. 
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Tables 
 
Table 1. Baseline data in the obese population obtained at baseline and at the end of the 
4-ǁeek studǇ, aŶd eǆpƌessed as peƌĐeŶt ǀaƌiatioŶ oǀeƌ ďaseliŶe ǀalues ;ΔͿ. “igŶifiĐaŶĐe 
between the two time points was obtained by paired T test and is depicted as: a, p<0.05; 
b, p<0.01; c, p<0.001. 
 
Variables Baseline (n=100) After 4 weeks (n=100) Δ 
Age (years) 40.4±12.7 - - 
BMI (kg/m2) 45.1±4.8c 42.5±4.4 -5.5±1.8 
Waist (cm) 128±12.2c 122.6±11.6 -4.3±1.2 
FPG (mg/dL) 99.2±26.9 - - 
Insulin (mIU/L) 22.2±30.3 - - 
HbA1c (%) 5.9±1.2 - - 
HOMA-IR 5.2±6.9 - - 
CRP (mg/dL) 0.9±0.8 - - 
CHO (mg/dL) 201.7±39.1 - - 
HDL (mg/dL) 44.9±11.8 - - 
LDL (mg/dL) 134.1±35.1 - - 
Triglycerides (mg/dl) 153.8±78.9 - - 
TSH (mIU/L) 2.09±0.92c 1.87±0.91 -6.3±32.2 
Free T3 (ng/L) 3.22±0.36c 3.10±0.33 -3.3±9.7 
Free T4 (ng/L) 11.7±1.59c 12.0±1.52 3.9±12.7 
FT3/FT4 ratio 0.28±0.06b 0.26±0.03 -5.7±13.4 
REE (Kcal/24h) 2038±372c 1936±322 -4.1±10.8 
REE/pREE (%) 94.1±11.0a 91.8±10.2 -0.12±0.5 
RQ (VO2/VCO2) 0.78±0.08 0.80±0.07 3.1±12.6 
FM (%) 46.7±6.8a 45.8±6.9 -1.6±6.7 
FFM (kg) 67.2±13c 64.5±12.5 -3.7±7.7 
 
For abbreviations: BMI, body mass index; FPG, fasting plasma glucose; FI, fasting insulin; HbA1c, glycated 
haemoglobin; HOMA-IR, homeostatic model of insulin resistance; CRP, C-reactive protein; CHO, cholesterol; 
HDL, high density lipoprotein; LDL, low-density lipoprotein; REE, resting energy expenditure; pREE, predicted 
REE; REE/pREE, metabolic efficicncy; RQ, respiratory quotient; FM, fat body mass; FFM, fat-free body mass. 
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Table 2. Data summary obtained at baseline and at the end of the 4-week study in the 
obese population subgrouped by gender. Significance for between-gender ANOVA at 
baseline and at the study-end time-points is depicted as: a, p<0.05; b, p<0.01; c, p<0.001. 
Significance for within-gender paired T test between baseline and study-end time-points 
is depicted as: d, p<0.05; e, p<0.01; f, p<0.001. 
 
Variables Men (n=48) Women (n=52) 
 Baseline At study end Delta (%) Baseline At study end Delta (%) 
Age (yrs) 43.1±12.2a - - 38±12.8 - - 
BMI (kg/m2) 44.7±4.2f 41.9±4 -6.2±1.9c 45.3±5.1f 43.1±4.8 -4.9±1.5 
Waist (cm) 133.6±9.2cf 128±8.5c -4.1±2.5 123.5±12.6f 117.9±11.9 -4.5±1.9 
FPG (mg/dl) 104.5±32.5 - - 94.4±19.9 - - 
FI (mIU/L) 25.5±40.7 - - 19.1±15.5 - - 
HbA1c (%) 6.1±1.5 - - 5.6±0.8 - - 
HOMA-IR 6.2±9.1 - - 4.3±3.4 - - 
CRP (mg/dl) 0.8±0.9 - - 1.03±0.8 - - 
CHO tot (mg/dl) 203.1±37.8 - - 200.5±40.6 - - 
HDL CHO (mg/dl) 39.3±8.2 - - 49.9±12.3 - - 
LDL CHO (mg/dl) 138.1±32.4 - - 130.6±37.2 - - 
TG (mg/dl) 177.4±89.4 - - 133±62.1 - - 
TSH (mIU/L) 2.12±0.36e 1.82±0.94 -10.5±29.9 2.06±0.89 1.91±0.89 -2.6±39.2 
Free T3 (ng/L) 3.33±0.36b 3.26±0.28c -1.6±9.1 3.12±0.33e 2.96±0.31 -4.8±10.2 
Free T4 (ng/L) 11.96±1.92f 12.76±1.41c 8.3±14.8b 11.38±1.17 11.37±1.30 0.2±9.0 
FT3/FT4 ratio 0.28±0.05e 0.26±0.03 -7.6±13.9 0.27±0.05 0.26±0.04 -3.9±12.8 
REE (Kcal/24 h) 2247±337ce 2122±307c -4.7±12.3 1841±298e 1768±233 -3.6±9.4 
REE/pREE (%) 91.2±10.0a 88.2±10.9b -0.12±0.5 96.7±11.3 95±8.5 -0.11±0.5 
RQ (VO2/VCO2) 0.78±0.08 0.79±0.07 3.0±13.1 0.78±0.07 0.81±0.07 3.3±12.2 
FM (%) 41.5±6.2ce 39.7±4.3c -3.6±8.7b 51.3±3.1 51.4±3.1 0.1±3.3 
FFM (kg) 77.9±9.7ce 75.5±8c -2.4±10.5 57.5±6.5f 54.6±5.8 -4.9±3.5 
 
For abbreviations: BMI, body mass index; FPG, fasting plasma glucose; FI, fasting insulin; HbA1c, glycated 
haemoglobin; HOMA-IR, homeostatic model of insulin resistance; CRP, C-reactive protein; CHO, cholesterol; 
HDL, high density lipoprotein; LDL, low-density lipoprotein; TG, Tryglicerides; REE, resting energy 
expenditure; pREE, predicted REE; REE/pREE, metabolic efficiency; RQ, respiratory quotient; FM, fat body 
mass; FFM, fat-free body mass. 
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Table 3. Bivariate correlation analysis between main hormone and anthropometric study 
variables recorded at baseline and at the study end. 
 
Variables r p 
BMI (kg/m2) 0.984 0.0001 
Waist (cm) 0.970 0.0001 
TSH (mIU/L) 0.709 0.0001 
FT3 (pg/L) 0.543 0.0001 
FT4 (pg/L) 0.608 0.0001 
FT3/FT4 ratio 0.521 0.0001 
REE (kcal/24h) 0.791 0.0001 
REE/pREE (%) 0.475 0.0001 
RQ (VO2/VCO2) 0.189 0.06 
FM (%) 0.879 0.0001 
FFM (kg) 0.941 0.0001 
 
For abbreviations: BMI, body mass index; REE, resting energy expenditure; pREE, predicted REE; REE/pREE, 
metabolic efficiency; RQ, respiratory quotient; FM, fat body mass; FFM, fat-free body mass. 
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Figures 
 
Figure 1. Percent variations recorded at the study end over baseline values for TSH 
;ΔT“HͿ, FTϯ ;ΔFTϯͿ, FTϰ ;ΔFTϰͿ, aŶd the FTϯ/FTϰ ƌatio ;ΔFTϯ/FTϰͿ. IŶdiǀidual deltas, ŵeaŶ 
and standard deviations are displayed. 
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Abstract 
 
Background. The general prevalence of inadequate L-T4 replacement therapy approaches 
40%. Obesity carries a high disease burden, and biochemical control of hypothyroidism is 
essential to avoid the harmful health consequences of suboptimal thyroid hormone 
replacement. There is no information on obesity-related metabolic homeostasis in 
relation to L-T4 therapy and its adequacy. 
 
Methods. Of 4950 obese patients, 690 hypothyroid subjects were selected as treated 
with L-T4 (L-T4 Group) and 773 euthyroid subjects were included as matched controls 
(Eu-Thyr Group). Analysis included TSH and fT4 levels, gluco-lipid homeostasis, fat-free 
mass (FFM) and percent fat mass (%FM), resting energy expenditure (REE). 
 
Results. Inadequate replacement was observed in 171 patients (24.8%), comprising 7.5% 
over-replaced and 17.2% under-replaced. Compared to adequately treated patients, over-
replaced patients took a higher L-T4 dose/kg/die, were younger and had lower BMI 
(p=0.001 for all) and waist circumference (WC) (p<0.05), whereas under-replaced patients 
took a lower L-T4 dose/kg/die (p<0.05), were younger (p=0.001), had higher FFM 
(p<0.0001), REE (p<0.05), WC (p=0.01), insulin levels (p<0.05) and HOMA-IR (p=0.01) and 
lower FM (p=0.01). Multinomial logistic regression analyses showed that under-
replacement was associated with male gender (p<0.05), while over-replacement was 
associated with younger age (p=0.001), higher L-T4 dose/Kg/die (p<0.01) and lower BMI 
(p=0.01). 
 
Conclusions. Obesity has complex effects on the metabolic outcome of hypothyroid 
patients in replacement therapy. However, there are potential confounders to consider 
for the management of hypothyroidism in obesity. 
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Background 
 
Obesity and hypothyroidism are common clinical conditions linked together closely. The 
link has become more relevant in the context of an unprecedented rise in the prevalence 
of obesity worldwide (Sanyal 2016). 
Body composition and thyroid hormones appear to be closely related (Marzullo 2016). In 
fact, thyroid hormones regulate basal metabolism, thermogenesis and play an important 
role in lipid and glucose metabolism, food intake and fat oxidation (Rosenbaum 2000). 
Therefore, thyroid dysfunction is associated with changes in body weight and 
composition, body temperature and resting energy expenditure (REE) independent of 
physical activity. In particular, the alteration in body weight associated with 
hypothyroidism may reflect both the accumulation of body fat (Seppel 1997, Wolf 1996), 
due to decreased REE, and the increased the body water content (Smith 1989), 
consequent to a reduced capacity of excreting free water (Skowsky 1978). 
Replacement therapy with thyroid hormone is indicated as a treatment when the 
diagnosis of persistent thyroid hormone deficiency is confirmed (Singer 1995, Surks 2004, 
Garber 2012). Levothyroxine (L-T4) is considered to be the treatment of choice in 
hypothyroid patients (Roti 1993). The daily dosage of L-T4 is dependent on age, sex and 
body size (Roti 1993, Woeber 2002). Ideal body weight is best used for clinical dose 
calculations because lean body mass is the best predictor of daily requirements (Santini 
2005). With little residual thyroid function, replacement therapy requires approximately 
fƌoŵ ϭ.ϲ μg/kg to ϭ.ϴ μg/kg of L-T4 daily (Fish 1987, Devdhar 2011). Patients who are 
athyreotic after total thyroidectomy may require higher doses (Kabadi 1995), while 
patients with subclinical hypothyroidism may require less (Teixeira 2008, Meier 2001). 
Adequacy of L-T4 treatment is generally monitored by measurements of serum fT4 and 
TSH. Restoration of euthyroidism is followed by an increase in REE and even small 
variations in serum TSH, induced by L-T4 substitution, are associated with opposite 
changes in REE (al-Adsani 1997, Boeving 2011, Santini 2014). However, in spite of 
adequate substitution with L-T4, hypothyroid patients may experience only a modest 
and/or transient loss of weight during hormone treatment (Santini 2014, Karmisholt 
2011). Excretion of excess body water, rather than reduction in fat mass, accounts for this 
change of body weight (Santini 2014). 
227 
 
Although management of L-T4 therapy has been considered relatively straightforward, 
several studies in the past 2 decades have indicated aspects of previously unrecognized 
complexity despite the improvement in TSH and thyroid hormone assay (Roti 1993, Biondi 
2008, Cooper 2012). Epidemiological studies have reported that inadequate thyroid 
hormone replacement is present in over a third of L-T4-treated hypothyroid patients 
(Canaris 2000, Somwaru 2009) despite frequent biochemical monitoring (Okosieme 2011, 
Liwanpo 2009). 
In obesity, the prevalence of adequate substitution with L-T4 and its association with bio-
anthropometric and metabolic parameters is, to date, unknown. This study was therefore 
designed to investigate the prevalence of adequate substitution with L-T4 therapy in 
obese patients, and to analyze its role in influencing body composition, REE and glucose-
lipid metabolism. 
 
Methods 
 
Patients 
 
Of 4950 obese patients admitted to our center between 2011-2014, this study enrolled 
1463 patients, consisting of 690 hypothyroid obese subjects treated with tablet L-T4 (L-T4 
Group) [605F/86M, age: 59 (IQR 50-69) years, BMI 43.9 (IQR 40.1-48.4) Kg/m2] and 773 
euthyroid obese subjects (Eu-Thyr Group) [667F/106 M, age: 56 (IQR 48-65) years, BMI 
43.5 (IQR 39.8-48.2) Kg/m2], referred to our institution for work-up and rehabilitation of 
obesity and its comorbidities. Written consent was obtained from all patient, after full 
explanation of the purpose and nature of the study. The investigation was approved by 
the local ethical committee, functioning according to the 3rd edition of the Guidelines on 
the Practice of Ethical Committees in Medical Research. Exclusion criteria included age 
below 18 or above 85 years, previous or current use of medications potentially interfering 
with thyroid function (such as amiodarone, steroids or lithium carbonate therapy), 
pregnancy, liver or kidney disease. Screening test included thyroid function tests (TSH, 
fT4), lipid profile, glucose and insulin levels, in fasting conditions. Patients were not 
prescribed diet therapy, dietary supplements, or antiobesity compounds for at least 3 
months prior to entering the study. 
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Body measurements 
 
All subjects underwent body measurements wearing light underwear, in fasting 
conditions after voiding. Weight and height were measured to the nearest 0.1 kg and 0.1 
cm, respectively. BMI was expressed as body mass (kg)/height (m)2. Obesity was defined 
for any BMI over 30 kg/m2. Waist circumference (WC) was measured midway between 
the lowest rib and the top of the iliac crest after gentle expiration; hip was measured as 
the greatest circumference around the nates. Anthropometric data were expressed as the 
mean of two measurements.  
Fat mass (FM) expressed as percentage of total body mass and free fat mass (FFM) 
expressed in kilograms, were assessed by bio-impedance analysis (BIA, 101/S Akern; 
Florence, Italy) the morning after overnight fasting and after voiding. The two vector 
components of impedance (i.e. resistance and reactance) were obtained by single 
measurements; before each testing session, the external calibration of the instrument 
was checked with a calibration circuit of known impedance value. The mean coefficient of 
variation was 1% for within-day and 3% for weekly intraindividual measurements in the 
steady-state condition in either site and 2% for interoperator variability. 
Resting energy expenditure (REE) was expressed in kilocalories per 24 h an determined in 
a thermoregulated room (22-24°C) by computed open-circuit indirect calorimetry, 
measuring resting oxygen uptake and resting carbon dioxide production by a ventilated 
canopy (Sensormedics, Milan, Italy) at 1-min intervals for 30 min and expressed as 24 h 
value.  
 
Laboratory test 
 
Undiluted serum samples were assayed for fT4 and TSH using an automated 
chemiluminescence assay system (Immulite 2000; DPC, Los Angeles, CA). The principle of 
the method is a two-site, solid-phase chemiluminescent immunometric assay or 
competitive immunoassay. Normal values for TSH are 0.27-4.20 mU/L, and for fT4 9.0-
17.0 ng/L. 
Routine laboratory data including glucose, total cholesterol (CHO), high-density (HDL) and 
low-density lipoprotein (LDL) cholesterol and triglycerides (TG) were measured by 
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enzymatic methods (Roche Diagnostics, Mannheim, Germany). Insulin levels were 
measured using a Cobas Integra 800 Autoanalyzer (Roche Diagnostics, Indianapolis, IN, 
USA).  
Insulin resistance was calculated by the homeostatic model of insulin resistance (HOMA-
IR) index: insulin (mIU/L) × [glucose (mmol/L)/22.5] (Matthews 1985). A HOMA-IR value 
greater than 2.0 was considered indicative of insulin resistance, as obtained in a sample 
of the Italian population (Bonora 2000). The hoŵeostatiĐ ŵodel of β Đell fuŶĐtioŶ ;HOMA-
B) was used to describe the functionality of pancreatic beta cells and calculated using the 
folloǁiŶg foƌŵula: ϮϬ [iŶsuliŶ ;ŵIU/LͿ/gluĐose ;ŵŵol/LͿ − ϯ.ϱ] (Matthews 1985). 
 
Statistics 
 
Statistical analysis were performed using SPSS version 21 (Somers, NY, USA) on log 
transformed data to correct for the non-Gaussian distribution obtained by the Shapiro-
Wilk test. Values are expressed as median and interquartile ranges. Univariate Anova test 
was used for comparisoŶ ďetǁeeŶ gƌoups. “peaƌŵaŶ͛s ĐoƌƌelatioŶ aŶalǇses ǁeƌe used to 
identify significant associations between variables of interest. Stepwise multivariate 
regression analysis was used to evaluate the independent association of variations in FM 
and FFM with metabolic, anthropometric or biochemical parameters. The multilinear 
model included age, gender, L-Tϰ dose, T“H aŶd fTϰ leǀels as iŶdepeŶdeŶt ǀaƌiaďles. β 
coefficients and related significance values obtained from the models are reported. 
Multinomial logistic regression analyses were performed to test the effect of under- and 
over-replacement L-T4 therapy and other variables of interest on the metabolic 
parameters. Statistical significance was set at 5%. 
 
Results 
 
A summary of anthropometric and >40 kg/m2 in 75.2% (1100 patients), >35.0-39.9 kg/m2 
in 18.4 % (269 patients), and >30.0-34.9 kg/m2 in 6.4% (94 patients). 
Anthropometric and metabolic parameters differed between groups (Table 1, pag. 234). 
LT4 Group exhibited lower FFM (p<0.01) and higher %FM (p<0.0001) than Eu-Thyr Group. 
Nevertheless, cholesterol levels were lower in the former. Excluding over- and under-
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treated patients from the L-T4 Group, we substantially found the same differences 
between the two groups as regard anthropometric and biochemical parameters. 
L-T4 Group showed higher TSH and fT4 levels than Eu-Thyr Group. Inadequate 
replacement therapy was observed in 171 patients (24.8%), comprising 52 over-replaced 
(7.5%) and 117 under-replaced (17.2%). Compared to adequately treated patients, over-
treated patients took a higher L-T4 dose/kg/die, were younger and had lower BMI 
(p=0.001 for all) and WC (p<0.05) (Table 2, pag. 235), whereas under-replaced patients 
took a lower L-T4 dose/kg/die (p<0.05), were younger (p=0.001), had higher FFM 
(p<0.0001), REE (p<0.05), WC (p=0.01), insulin levels (p<0.05) and HOMA-IR (p=0.01) and 
lower FM (p=0.01) (Table 3, pag. 236). 
Analysis of thyroid function in Eu-Thyr Group showed a mild increase in TSH levels in a 
subset of 30 patients (3.9%). None of these harbored any increase in anti-thyroid 
antibody titer or abnormal free thyroid hormone levels.  
Correlation analysis in the L-T4 Group showed opposite relationships between TSH and L-
T4 dose/kg/die (rho=-0.20, p<0.0001), fT4 levels (rho=-0.34, p<0.0001) autoimmune 
origin of hypothyroidism (rho=-0.103, p<0.01), and positive relationships between TSH 
and BMI (rho=0.13, p=0.001), WC (rho=0.15, p<0.0001), FFM (rho=0.20, p<0.0001) and 
REE (rho=0.12, p<0.0001). These correlations remained after controlling for age, gender 
and smoking habit. Inversely, fT4 was opposely associated with BMI (rho=-0.08, p<0.05), 
WC (rho=-0.09, p<0.05), CHO (rho=-0.09, p=0.01), LDL (rho=-0.09, p<0.05), TG (rho=-0.11, 
p<0.01), insulin levels (rho=-0.11, p<0.01) and FFM (rho=-0.10, p<0.01), and positively 
associate with L-T4 dose/kg/die (rho=0.29, p<0.0001). Except for correlation with L-T4 
dose and TG levels, other correlations were lost after controlling for potential 
confounders. 
Stepwise multivariate regression analyses performed on the LT4 Group, documented that 
FM was independently predicted by LT-ϰ dose/kg/die ;staŶdaƌdized β=-0.13, p<0.0001) as 
ǁell as ďǇ feŵale geŶdeƌ ;staŶdaƌdized β=-0.54, p<0.0001), whereas FFM was 
independently predicted by LT-ϰ dose/kg/die ;staŶdaƌdized β=-0.08, p<0.01) and TSH 
leǀels ;staŶdaƌdized β=-Ϭ.ϭϭ, p<Ϭ.ϬϬϬϭͿ as ǁell as ďǇ ŵale geŶdeƌ ;staŶdaƌdized β=Ϭ.ϱϲ, 
p<Ϭ.ϬϬϬϭͿ aŶd age ;staŶdaƌdized β=-0.26, p<0.0001). 
However, when we performed this analysis on the whole population, we found that FM 
was independently prediĐted ďǇ the ĐoŶditioŶ of hǇpothǇƌoidisŵ ;staŶdaƌdized β=-0.114, 
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p<Ϭ.ϬϬϬϭͿ, feŵale geŶdeƌ ;staŶdaƌdized β=-0.11, p<0.0001) and age (standardized 
β=Ϭ.Ϭϲϯ, p<Ϭ.ϬϭͿ, ǁheƌeas FFM ǁas iŶdepeŶdeŶtlǇ pƌediĐted ďǇ the ĐoŶditioŶ of 
hǇpothǇƌoidisŵ ;staŶdaƌdized β=-Ϭ.ϭϮ, p<Ϭ.ϬϬϬϭͿ, ŵale geŶdeƌ ;staŶdaƌdized β=-0.51, 
p<Ϭ.ϬϬϬϭͿ aŶd age ;staŶdaƌdized β=Ϭ.Ϭϲ, p<Ϭ.ϬϭͿ. 
Multinomial logistic regression analyses (Table 4, pag. 237) showed that under-
replacement was associated with male gender (OR 2.373, 95% CI 1.101-5.111, p<0.05), 
while over-replacement was associated with younger age (OR 0.963, 95% CI 0.941-0.986, 
p=0.001), higher L-T4 dose/Kg/die (OR 2.976, 95% CI 1.442-6.144, p<0.01) and lower BMI 
(OR 0.930, 0.878-0.985, p=0.01). 
 
Discussion 
 
Most of the studies evaluating appropriate thyroid replacement in hypothyroid patients 
were performed on normal weight or overweight individuals (Okosieme 2011, Glymph 
2016). The recommended dose of L-T4 currently used has been largely studied and 
validated in non-obese subjects (Fish 1987, Roos 2005, Jonklaas 2010) and there is a lack 
of clinical evidence demonstrating safe and effective thyroid hormone replacement 
strategies in obese patients (Glymph 2016). The therapeutic goal in hypothyroidism is to 
aĐhieǀe patieŶts͛ ǁell-being and restore serum TSH levels within the reference range 
(Vaidya 2008). However, inadequate replacement is common in patients receiving L-T4. 
Cross-sectional studies demonstrated that 30-50% of patients treated with levothyroxine 
remain biochemically under-treated or over-treated (Canaris 2000, Somwaru 2009, 
Okosieme 2011, Hollowell 2002, Hannemann 2010). Our results showed that 
hypothyroidism in severe obesity seem to be associated with a better adequate 
replacement with lower L-T4 doses compared to normal weight patients. Moreover, L-T4 
daily requirement was able to negatively predict both FFM and FM. In agreement with 
our results, Glymph et al demonstrated that obese hypothyroid females tended to require 
a lower L-T4 dose per kg compared with non-obese females (Glymph 2016). However, 
these findings contrast with results reported by Santini et al, who demonstrated that 
excessive fat accumulation would imply higher doses of L-T4 to attain the same TSH 
reduction as in lean subjects (Santini 2005). It is likely that the variations in their study 
design and ours, such as therapy with TSH-suppressive doses of L-T4, could explain the 
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contrasting results. Lean body mass has been found to be an important determinant of 
body weight in normal weight and obese subjects (Wesche 1998). Therefore, the 
requirements for T4, either secreted by the thyroid or therapeutically administered, may 
depend on lean body mass (Santini 2005). According to the role of lean mass in 
determining L-T4 disposal, the absolute value of L-T4 requirement was higher in males 
than in females, as a consequence of gender-related differences in body weight and body 
composition. Confirming previous studies (Cunningham 1984), the well-known reduction 
of L-T4 needs associated to advancing age appeared dependent on a relative decrease in 
lean body mass. As regards FM, Ortega et al hypothesized that the increased levels of 
iodothyronine deiodinase 1 (D1) in adipose tissue of obese subjects could reflect the 
stimulation of this enzyme by locally formed leptin, and that, in turn, enhanced 
production of T3 involved in adipose tissue metabolism (Ortega 2012). Although the 
lower L-T4 doses required in obesity than normal weight, could be justified by an increase 
in T3 production formed by D1, further studies are required to clarify this issue (Ortega 
2012).  
Despite most of the hypothyroid patients were biochemically adequately replaced with L-
T4, we observed higher %FM and lower FFM than euthyroid subjects. Different studies 
demonstrated that hypothyroid patients may experience only a modest reduction in fat 
mass (Santini 2014) and about 15% of subjects treated with L-T4 do not reach clinical 
euthyroidism (Biondi 2014) and continue to have a metabolic impairment. One 
hypothesis to explain this phenomenon could be that in many tissue, intracellular T3 
levels cannot be predicted based on circulating thyroid hormone levels due to the actions 
of the types 2 and 3 deiodinases. Thus, in some tissues, the relatively higher serum T4 
levels could impair intracellular T3 production via down-regulation of a deiodinase 
pathway (Werneck de Castro 2015). On these bases, several studies evaluated the effect 
of combination treatment with L-T4 and L-T3 vs L-T4 alone (Grozinsky-Glasberg 2006, Ma 
2009). However, the benefits of combination therapy are still unproven (Biondi 2016). 
Hypothyroidism is often associated with lipid abnormalities, especially elevated total and 
LDL-cholesterol (Cappola 2003). However, hypothyroid patients treated with L-T4 showed 
lower levels of total and LDL-cholesterol than euthyroid subjects. In agreement with our 
results, a recent meta-analysis demonstrated an overall beneficial effect of L-T4 
substitution in improving total and LDL cholesterol (Li 2017). Moreover, we confirmed 
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that no significant effect of L-T4 seems to exist in terms of serum HDL cholesterol or TG 
concentrations also in obese subjects (Biondi 2008, Ito 2007, Efstathiadou 2001, Tagami 
2010). 
As far as glucose homeostasis is concerned, the few available studies showed no 
association with subclinical hypothyroidism (Al Sayed 2006, Kowalska 2011, Brenta 2007), 
although different populations were studied. However, our result demonstrated that L-T4 
substitution may reduce basal insulin levels, improving insulin sensitivity. These results 
were in agreement with those reported in the literature (Velija-Asimi 2007, Bilic-Komarica 
2012).  
This study has several limitations including its retrospective nature, the lack of 
iŶfoƌŵatioŶs aďout the patieŶts͛ histoƌǇ L-T4 administration compliance and fT3 assay. 
Moreover, we were unable to determine the source of generic L-T4 preparations, which 
could have affected thyroid hormone bioavailability, and we could not confirm the daily 
schedule of L-T4 administration in each subjects. Overall, the study results reflect a real-
world approach to managing hypothyroidism in obese subjects. 
 
Conclusions 
 
In conclusion, obesity has complex effects on the metabolic outcome of hypothyroid 
patients in replacement therapy. Our study demonstrated that severe obese patients 
required lower L-T4 doses compared to normal weight subjects. However, there are 
potential confounders to consider for the management of hypothyroidism in obesity. 
Further studies are needed to investigate the effects of obesity in the metabolic setting of 
hypothyroidism. 
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Tables 
 
Table 1. Summary of anthropometric and biochemical data obtained in the LT4 Group and 
the Eu-Thyr Group. 
 
Variables LT4 group (n = 690) Eu-Thyr group (n = 773) p 
Males/females 86/605 106/667 0.64 
Age (years) 59 (50-69) 56 (48-65) <0.000 
BMI (kg/m2) 43.9 (40.1-48.4) 43.5 (39.8-48.2) 0.529 
Waist (cm) 123 (114-132) 122 (111-131) 0.067 
REE (kcal/day) 1731 (1557-1940) 1733 (1515-2000) 0.901 
FM (%) 50.9 (46.6-54.2) 48.8 (44.0-52.9) <0.000 
FFM (Kg) 54.0 (48.3-59.8) 55.0 (49.6-63.3) <0.01 
TSH (mU/L) 2.08 (0.96-3.69) 1.80 (1.23-2.73) <0.05 
fT4 (ng/L) 12.1 (10.8-13.6) 11.2 (10.2-12.6) <0.000 
Glucose (mg/dL) 97.0 (88.0-114.8) 95.0 (85.0-110.0) 0.123 
Insulin (mU/L) 13.1 (8.9-18.4) 13.7 (9.9-19.5) <0.01 
HOMA-IR 3.2 (2.1-4.8) 3.3 (2.2-5.2) 0.059 
HOMA-B 136.0 (78.4-209.7) 154.8 (97.0-250.4) <0.000 
CHO (mg/dL) 191 (166-219) 202 (180-231) <0.000 
LDL-CHO (mg/dL) 120 (97-144) 128 (104-152) <0.000 
HDL-CHO (mg/dL) 47 (39-56) 47 (39-54) 0.774 
TG (mg/dL) 130 (100-175) 129 (102-169) 0.533 
 
BMI, body mass index; WHR, Waist-to-hip ratio, REE, resting energy expenditure; FM, fat mass; FFM, free fat 
mass; TSH, thyroid-stimulating hormone; fT4, free thyroxine; HOMA-IR, homeostatic model of insulin 
resistance; HOMA-B, hoŵeostatiĐ ŵodel of β Đell fuŶĐtion; CHO, total cholesterol; LDL, low density 
lipoprotein; HDL, high density lipoprotein; TG, triglycerides. 
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Table 2. Summary of anthropometric and biochemical data obtained in the adequately 
treated and over-replaced patients. 
 
Variables Adequately treated  (n = 519) 
Over-replaced 
(n = 52) p 
Males/females 50/469 6/46 0.660 
Age (years) 60 (51-70) 54 (48-63) 0.001 
Dose ;μg/kg/dieͿ 0.900 (0.617-1.136) 1.157 (0.938-1.371) 0.001 
BMI (kg/m2) 44.1 (40.2-48.5) 40.6 (37.1-43.7) 0.001 
Waist (cm) 123 (113-132) 120 (110-125) 0.021 
REE (kcal/day) 1720 (1549-1920) 1711 (1570-1904) 0.976 
FM (%) 51.0 (47.2-54.5) 50.0 (44.7-53.0) 0.113 
FFM (Kg) 53.7 (47.9-58.8) 51.1 (47.7-56.8) 0.217 
TSH (mU/L) 1.80 (1.02-2.80) 0.07 (0.03-0.15) <0.000 
fT4 (ng/L) 12.1 (11.0-13.6) 14.3 (12.7-16.0) <0.000 
Glucose (mg/dL) 96 (88-113) 95 (88-107) 0.401 
Insulin (mU/L) 12.7 (8.9-17.7) 13.8 (9.6-18.3) 0.202 
HOMA-IR 3.0 (2.1-4.6) 3.2 (2.2-5.0) 0.374 
HOMA-B 131.8 (78.2-205.1) 155.3 (96.8-234.9) 0.064 
CHO (mg/dL) 192 (168-218) 181 (155-213) 0.208 
LDL-CHO (mg/dL) 120 (99-143) 104 (89-140) 0.283 
HDL-CHO (mg/dL) 47 (38-57) 47 (41-53) 0.926 
TG (mg/dL) 127 (102-174) 126 (85-153) 0.278 
 
BMI, body mass index; WHR, Waist-to-hip ratio, REE, resting energy expenditure; FM, fat mass; FFM, free fat 
mass; TSH, thyroid-stimulating hormone; fT4, free thyroxine; HOMA-IR, homeostatic model of insulin 
resistance; HOMA-B, hoŵeostatiĐ ŵodel of β Đell fuŶĐtioŶ; CHO, total Đholesteƌol; LDL, loǁ deŶsitǇ 
lipoprotein; HDL, high density lipoprotein; TG, triglycerides. 
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Table 3. Summary of anthropometric and biochemical data obtained in the adequately 
treated and under-replaced patients. 
 
Variables Adequately treated  (n = 519) 
Under-replaced  
(n = 119) p 
Males/females 50/469 30/89 <0.000 
Age (years) 60 (51-70) 57 (49-64) 0.029 
Dose ;μg/kg/dieͿ 0.900 (0.617-1.136) 0.841 (0.497-1.139) 0.024 
BMI (kg/m2) 44.1 (40.2-48.5) 44.5 (41.0-49.6) 0.105 
Waist (cm) 123 (113-132) 127 (116-139) 0.012 
REE (kcal/day) 1720 (1549-1920) 1809 (1631-2057) 0.029 
FM (%) 51.0 (47.2-54.5) 49.5 (43.6-53.9) 0.012 
FFM (Kg) 53.7 (47.9-58.8) 58.6 (50.9-68.4) <0.000 
TSH (mU/L) 1.80 (1.02-2.80) 5.90 (4.92-8.12) <0.000 
fT4 (ng/L) 12.1 (11.0-13.6) 11.1 (9.9-12.4) <0.000 
Glucose (mg/dL) 96 (88-113) 101 (90-119) 0.175 
Insulin (mU/L) 12.7 (8.9-17.7) 14.3 (8.8-21.8) 0.030 
HOMA-IR 3.0 (2.1-4.6) 3.6 (2.1-6.0) 0.011 
HOMA-B 131.8 (78.2-205.1) 136.8 (77.5-187.3) 0.373 
CHO (mg/dL) 192 (168-218) 189 (166-226) 0.856 
LDL-CHO (mg/dL) 120 (99-143) 121 (95-147) 0.629 
HDL-CHO (mg/dL) 47 (38-57) 46 (40-55) 0.672 
TG (mg/dL) 127 (102-174) 141 (100-183) 0.321 
 
BMI, body mass index; WHR, Waist-to-hip ratio, REE, resting energy expenditure; FM, fat mass; FFM, free fat 
mass; TSH, thyroid-stimulating hormone; fT4, free thyroxine; HOMA-IR, homeostatic model of insulin 
resistance; HOMA-B, hoŵeostatiĐ ŵodel of β Đell fuŶĐtioŶ; CHO, total Đholesteƌol; LDL, loǁ deŶsitǇ 
lipoprotein; HDL, high density lipoprotein; TG, triglycerides. 
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Table 4. Multinomial adjusted Odds Ratios for High TSH level versus Nomal TSH level 
(PANEL A) and for Low TSH level versus Nomal TSH level (PANEL B). 
 
 PANEL A  PANEL B 
Covariates TSH level: High vs Normal  TSH level: Low vs Normal 
 OR (95% CI) P-value  OR (95% CI) P-value 
Age 0.991 (0.974-1.007) 0.258  0.963 (0.941-0.986) 0.001 
Gender      
Female 1 Ref.  1 Ref. 
Male 2.373 (1.101-5.111) 0.027  1.746 (0.545-5.593) 0.348 
BMI 1.012 (0.978-1.047) 0.507  0.930 (0.878-0.985) 0.013 
Dose 1.023 (0.588-1.780) 0.935  2.976 (1.442-6.144) 0.003 
Duration of disease 0.989 (0.958-1.021) 0.488  0.995 (0.952-1.039) 0.819 
Fat free mass 1.012 (0.989-1.036) 0.300  0.981 (0.947-1.016) 0.284 
Cause of disease      
- Autoimmune (0) 1 Ref.  1 Ref. 
- Thyroidectomy (1) 0.562 (0.294-1.270) 0.166  1.375 (0.582-3.250) 0.468 
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CHAPTER 4 
 
Other research interests 
 
PITUITARY DYSFUNCTION: 
HYPOPITUITARISM AND ACROMEGALY 
 
Introduction 
 
Hypopituitarism is deficiency of one or more pituitary hormones. The pituitary gland has 
two lobes. Within the anterior lobe, six hormones are produced: growth hormone, the 
gonadotropins follicle stimulating hormone (FSH) and luteinising hormone, 
adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), and prolactin 
(Higham 2016). The posterior pituitary lobe contains two hormones, oxytocin and 
antidiuretic hormone (ADH), which are produced in the supraoptic and paraventricular 
nuclei of the hypothalamus and transported axonally via the pituitary stalk to be stored 
and released from the posterior lobe (Higham 2016). 
In adults, the most common cause of hypopituitarism is a pituitary adenoma, treatment 
with pituitary surgery or radiotherapy, trauma and vascular injury (Tanriverdi 2014).  
The profile of pituitary hormone deficiencies varies depending on the site within the 
hypothalamic–pituitary axis and the nature of the underlying pathological process 
(Higham 2016). Hypopituitarism is diagnosed based on baseline blood sampling for 
thyroid stimulating hormone, gonadotropin, and prolactin defi ciencies, whereas for 
ACTH, growth hormone, and antidiuretic hormone deficiency dynamic stimulation tests 
are usually needed (Karamouzis 2016). 
Replacement treatment exists in the form of thyroxine, hydrocortisone, sex steroids, 
growth hormone, and desmopressin (Higham 2016). 
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Acromegaly is a rare and underdiagnosed disease that results from the overproduction of 
growth hormone (GH) and insulin-like growth factor 1 (IGF-1) (Melmed 2006). More than 
95% of patients with acromegaly harbor a GH-secreting pituitary adenoma 
(somatotropinoma) arising from somatotroph cells, leading to GH and IGF-1 
hypersecretion (Katznelson 2014). In less than 5% of cases, excess growth hormone 
releasing hormone (GHRH) secretion from a hypothalamic tumor or a neuroendocrine 
tumor (usually from lung or pancreas origin) may lead to somatotroph hyperplasia and 
acromegaly (Borson-Chazot 2012).  
Over 90–95% of GH-secreting pituitary adenomas are sporadic and occur as an isolated 
disorder (Melmed 2006). However, acromegaly can also occur in a familial setting, either 
associated with other endocrine abnormalities or as an isolated disorder (Rostomyan 
2015, Capatina 2015). 
Acromegaly affects both males and females equally and the average age at diagnosis 
ranges from 40 to 50 years (Holdaway 1999, Etxabe 1993). The clinical features of 
acromegaly are due to local effects of an expanding pituitary mass, as well as to the direct 
and indirect effects of excessive secretion of GH and IGF-1, which can lead to systemic 
complications and impaired quality of life (QoL) (Melmed 2016, Molitch 1992). These 
clinical manifestations range from subtle signs of acral overgrowth, soft-tissue swelling, 
arthralgias, jaw prognathism, mild hyperglycemia, menstrual disturbances, erectile 
dysfunction and hyperhidrosis to facial and skeletal disfigurement, florid osteoarthritis, 
severe headache, sleep apnea, severe hypertension, diabetic ketoacidosis, and 
respiratory and cardiac failure (Melmed 2016, Molitch 1992) 
 
This section aims to explore the clinical-diagnostic approach to patients with 
hypopituitarism due to trauma or vascular injury and to estimate prevalence and 
incidence of acromegaly in the Piedmont region, Italy. 
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Abstract 
 
The hypothalamic-pituitary dysfunction attributable to traumatic brain injury (TBI), 
aneurysmal subarachnoid hemorrhage (SAH), and ischemic stroke (IS) has been lately 
highlighted. The diagnosis of TBI-induced-hypopituitarism, defined as a deficient 
secretion of one or more pituitary hormones, is made similarly to the diagnosis of 
classical hypopituitarism because of hypothalamic/pituitary diseases. Hypopituitarism is 
believed to contribute to TBI-associated morbidity and to functional and cognitive final 
outcome, and quality-of-life impairment. Each pituitary hormone must be tested 
separately, since there is a variable pattern of hormone deficiency among patients with 
TBI-induced-hypopituitarism. Similarly, the SAH and IS may lead to pituitary dysfunction 
although the literature in this field is limited. The drive to diagnose hypopituitarism is the 
suspect that the secretion of one/more pituitary hormone may be subnormal. This 
suspicion can be based upon the knowledge that the patient has an appropriate clinical 
context in which hypopituitarism can be present, or a symptom known as caused by 
hypopituitarism. Hypopituitarism should be diagnosed as a combination of low peripheral 
and inappropriately normal/low pituitary hormones although their basal evaluation may 
be not distinctive due to pulsatile, circadian, or situational secretion of some hormones. 
Evaluation of the somatotroph and corticotroph axes require dynamic stimulation test 
(ITT for both axes, GHRH + arginine test for somatotroph axis) in order to clearly separate 
normal from deficient responses. 
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Background 
 
Traumatic brain injury (TBI) is defined as an alteration in brain function, caused by an 
external force, being a major public health problem in nowadays (Tanriverdi 2015). 
Neuroendocrine dysfunction following TBI may occur with a much higher prevalence than 
previously suspected (Tanriverdi 2015). Similarly, subarachnoid hemorrhage (SAH) and 
ischemic stroke (IS) may lead to pituitary dysfunction although the literature in this field 
has largely developed lately as survival rates mainly from SAH have improved, enabling 
pituitary evaluation to be performed on large cohorts of long-term SAH survivors (Hannon 
2011, Bondanelli 2006). 
Pituitary disorders are a frequently overlooked complication of TBI and SAH. Many 
symptoms of TBI and SAH survivors such as fatigue, concentration difficulties, depressive 
symptoms are nonspecific and overlap with symptoms of patients with pituitary disorders 
from other causes with a large amount of hypopituitarism related to brain damage 
remaining undiagnosed (Hannon 2011, Tanriverdi 2011). This can explain why the 
diagnosis of hypopituitarism is often missed or delayed after these conditions with 
potentially serious and sometimes life-threatening consequences for the affected 
patients. Therefore, these patients should undergo routine screening for hypopituitarism 
and each pituitary hormone must be evaluated separately, since there is a variable 
pattern of hormone deficiency among patients with TBI-induced hypopituitarism 
(Tanriverdi 2015). 
 
Epidemiology and pathophysiology 
 
The drive to diagnose hypopituitarism is the suspect that the secretion of one or more 
pituitary hormone may be subnormal. This suspicion has an appropriate clinical context in 
which hypopituitarism can be present, or symptoms known as caused by hypopituitarism 
(Tanriverdi 2015). The knowledge that the patient had a TBI or SAH is robust enough to 
evaluate for hypopituitarism because some patients with hypopituitarism have no 
symptoms (Tanriverdi 2015, Nannon 2011, Bondanelli 2006). On the other hand, 
considering the high number of subjects with TBI, it is crucial to strictly define on a 
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cost/benefit basis which patients should be investigated for hypopituitarism (Tanriverdi 
2011). Evidence shows that pituitary function is impaired at least in 20–30% of patients 
following moderate-to-severe TBI; thus, patients with clinical signs or symptoms 
associated with hypopituitarism should be screened for their pituitary function (Ghigo 
2005). 
There is a wide variation in the frequencies of hormone deficits following TBI and SAH 
(Tanriverdi 2015, Nannon 2011, Bondanelli 2006). Reported prevalence of TBI-induced 
hypopituitarism considerably differs among reported studies ranging from 5.4 to 90% 
(Kokshoorn 2010). Nevertheless, approximately one-third of TBI patients will develop at 
least one anterior pituitary disorder (Lauzier 2014). In particular, a meta-analysis including 
patients with TBI reported a prevalence of anterior hypopituitarism from 15 to 68% and a 
posterior endocrine dysfunction about 6.9% (Schneider 2007). On the other hand, the 
evidences for pituitary dysfunction following SAH and IS are less respect to TBI (Schneider 
2007, Fernandez-Rodriguez 2015, Bondanelli 2010). Among long-term SAH survivors, the 
reported prevalence of anterior and posterior dysfunction was from 37.5 to 55% and 0 to 
2.8%, respectively (Schneider 2007). Similarly, hypopituitarism was detected from 23.5 to 
37.5% in stroke patients (Bondanelli 2006, Bondanelli 2010). These variabilities could be 
attributed to different timings of evaluation, severity of the trauma or stroke, diagnostic 
criteria, methods and assays to test endocrine function (Lauzier 2014). Thus, the timing of 
hormonal assessment of the pituitary disorders at different time frames varied highly 
across studies (Tanriverdi 2015). The transient hypopituitarism has been almost 
exclusively reported in the first 6 months after TBI as hormone alterations mimicking 
pituitary insufficiency can be present in the acute phase after trauma (Kokshoorn 2010). 
An early assessment of pituitary function after the event could lead to overestimate 
prevalence of pituitary dysfunction in these patients, especially if patients with a more 
severe trauma are included. Indeed, the chance to develop hypopituitarism is directly 
related to the severity of trauma. A rational approach to endocrine testing could be with 
an assessment of HPA axis reserve in the acute phase followed by a more comprehensive 
assessment of pituitary function during the chronic recovery phase. Moreover, 
physiologic hormonal changes that can mimic pituitary dysfunction are often observed in 
the early post-traumatic period. The physiologic response to acute and critical illness 
comprises hormonal changes similar for GH deficiency, central hypogonadism, and 
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hypothyroidism. Furthermore, the metabolism of the protein-binding hormones can be 
altered by acute illness or drugs frequently used in severe diseases, resulting in increased 
circulating levels and, consequently, false deficiencies (Fernandez-Rodriguez 2015). 
The reliability of the methodological tools used to assess pituitary function could be 
another important factor (Tanriverdi 2015). Evaluation of the GH and HPA axes requires 
dynamic stimulation test in order to clearly separate normal from deficient responses and 
normative cut-off should be defined using healthy volunteers in each local laboratory 
(Tanriverdi 2015, Kelly 2000, Klose 2014). Therefore, differences in the reported 
frequency may be due to more stringent diagnostic criteria applied by some studies but 
not to others (Tanriverdi 2015, Agha 2004, Kreitschmann-Andermahr 2004, Brandt 2004, 
Aimaretti 2004). Moreover, cut- off levels used for tests and possible different hormone 
assays might have another important influence on the frequency of hypopituitarism 
(Tanriverdi 2015, Kelly 2000, Schneider 2006, Agha 2006). Therefore, the robustness of 
the methodologies used to diagnose hypopituitarism varies between studies but there is 
a broad agreement nevertheless that hypopituitarism is a common complication of TBI 
(Tanriverdi 2015, Hannon 2011, Bondanelli 2006, Tanriverdi 2011, Ghigo 2005, Kokshoorn 
2010, Lauzier 2014, Schneider 2007, Fernandez-Rodriguez 2015, Bondanelli 2010, Kelly 
2000). 
The pathophysiology of hypopituitarism following brain damage is not completely 
understood and several factors implicated in its development have been suggested. 
Different types of lesions could cause from damage to the pituitary capsule, to injury to 
the anterior and posterior lobe and pituitary stalk in the form of hemorrhage, necrosis, 
and fibrosis (Schneider 2007, Richmond 2008). Moreover, vascular damage to the 
pituitary gland can also be caused by venous infarctions of the hypophyseal portal vessels 
or by pituitary stalk transaction (Tanriverdi 2015, Schneider 2007). Finally, recent research 
has indicated a possible interaction between autoimmunity and the development of 
hypopituitarism after TBI. It has been demonstrated that antipituitary and 
antihypothalamic antibodies (Abs) are present in patients with TBI-induced pituitary 
dysfunction and persist even 5 years after diagnosis (Tanriverdi 2008, Tanriverdi 2013). It 
seems that antibodies may form after TBI due to the disruption of the blood–brain 
barrier, which allows brain proteins to leak into the circulation, evoking an immune 
response (Tanriverdi 2008). Moreover, in patients with higher titers of pituitary 
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antibodies, the development of pituitary deficiencies is more frequent whereas the 
recovery of pituitary function is related to negative antibodies titers (Schneider 2011). 
Several studies have highlighted the existing relationship between hypopituitarism and 
TBI-associated morbidity (Tanriverdi 2015, Klose 2008). Serious and life-threatening 
adrenal crises secondary to acute ACTH hormone deficiency in patients with TBI have 
been highlighted in the literature with dramatic improvement following glucocorticoid 
replacement (Agha 2005, Cohan 2005). Increased neuropsychiatric morbidity in patients 
with TBI with GH insufficiency also has been reported (Kelly 2006). It is further expected 
that hypopituitarism significantly impedes recovery and rehabilitation after TBI 
(Fernandez-Rodriguez 2015). In fact, posttraumatic hypopituitarism was independently 
associated with poor quality of life, abnormal body composition, and adverse metabolic 
profile (Klose 2007). In patients with SAH, preliminary data indicate that neuroendocrine 
disturbances contribute to disturbed quality of life, depression, and sleeping disturbances 
(Kreitschmann-Andermahr 2007). These findings indicate that hypopituitarism after both 
TBI and SAH is associated with poor recovery and worse outcome (Table 1, pag. 252). 
 
Diagnostic process 
 
Hypopituitarism should be diagnosed as a combination of low peripheral and 
inappropriately normal/low pituitary hormones. However, the measurement of basal 
hormones alone may be not distinctive due to pulsatile, circadian, or situational secretion 
of some hormones. 
 
Hypothalamic–pituitary–adrenal (HPA) axis 
 
The basal secretion of ACTH must be sufficient to maintain the serum cortisol 
concentration within the normal range. During physical stress, ACTH secretion must 
increase in order to raise serum cortisol concentrations adequately. Thus, normal cortisol 
levels do not exclude the ACTH inability to adequately respond to stress if impaired. ACTH 
and cortisol secretion follow a circadian rhythm with highest levels in the early morning 
hours and lowest levels around midnight. Thus, basal ACTH secretion, and serum cortisol 
should be measured at 8 to 9 AM. 
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In the appropriate clinical context, secondary adrenal insufficiency can be excluded at 
morning cortisol levels greater than 500 nmol/L (>18 mcg/dL) and is indicated below 83-
100 nmol/L (<3 mcg/dL). Intermediate levels require a stimulation test (Tanriverdi 2015, 
Arlt 2003, Lamberts 1998, Snyder 2007). 
Hypoglycemia (blood glucose <2.2 mmol/L, 40 mg/dL) induced by the insulin tolerance 
test (ITT, 0.05, 0.1–0.2 IU insulin per kg body weight given iv as a bolus) is considered as 
the gold standard for assessment of the HPA axis. A cortisol peak level greater than 500 
nmol/L (18 mcg/dL) indicates normal integrity of the axis. This test has some unpleasant 
side effects such as sweating, trembling, fatigue, and hunger, and is contraindicated in 
elderly patients and in those with cardiac, cerebrovascular or epileptic seizures. In the 
under-study population, this test has been used by some authors (Kelly 2000, Agha 2004, 
Brandt 2004, Kreitschmann-Andermahr 2004) without adverse effects, but other authors 
have used alternative tests, suggesting the possible danger of ITT (Ghigo 2005, Aimaretti 
2004). It should be conducted only under close supervision in experienced centers 
(Tanriverdi 2015, Ghigo 2005, Schneider 2006, Landon 1966). 
Corticotropin releasing hormone (CRH, 100 lg as a bolus), given as a stimulus for the 
pituitary ACTH reserve, has proven to be not more predictive of adrenal function than 
morning cortisol levels (Tanriverdi 2015, Dullaart 1999). Therefore, it is of limited value 
for the diagnosis of ACTH deficiency. 
Overnight metyrapone test (MET) has so far been considered a convenient and sensitive 
method, with a good correlation with ITT (Fiad 1994). MET (30 mg/kg administered orally 
with a snack at midnight) inhibits adrenal 11b-hydroxylase and the conversion of 11-
deoxycortisol (11-DOC) to cortisol with a possible risk of precipitating adrenal crisis. 
Shortcomings of the MET test are the limited availability of reliable 11-DOC assays and 
the fact that the drug is not widely available owing to local restrictions (Fiad 1994). 
ACTH deficiency causes adrenal atrophy and ACTH receptor down-regulation. This is the 
rationale for the administration of exogenous ACTH (Tanriverdi 2015, Arlt 2003, Lamberts 
1998). Thus, the 250 µg 1-24 ACTH test could be used to establish secondary adrenal 
insufficiency if performed at least 4 weeks after onset of ACTH deficiency (Tanriverdi 
2015, Arlt 2003, Snyder 2007). It is administered intramuscularly or intravenously 
measuring serum cortisol 30 and 60 min later. A serum cortisol concentration шϱϬϬ 
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nmol/L (>18 mcg/dL) is considered a normal response. “tiŵulated Đoƌtisol leǀels ч500 
nmol/L indicate ACTH deficiency (Tanriverdi 2015, Snyder 2007, Lindholm 1987). 
It has been proposed that the low-dose (1 µg) corticotrophin test represents a more 
physiological stimulus for maximal adrenal stimulation compared to the 250 µg 
(Tanriverdi 2015, Arlt 2003, Snyder 2007). Some studies have suggested a superior 
sensitivity for the 1 µg corticotrophin test whereas a meta-analysis reported comparable 
diagnostic accuracy of both tests (Agha 2006). 
The low-dose test has technical disadvantages (dilution in particular), and the need for 
repetitive blood sampling. This makes the standard test more practical and easy 
performed. Moreover, in a retrospective study where 148 patients with a low-normal 
cortisol response to the 250 lg test were studied over a median time of 4.2 years; only 
two patients developed a clear-cut adrenal insufficiency, another two presented a 
persisting diagnostic uncertainty, and seven had adrenal insufficiency after subsequent 
pituitary surgery or irradiation (Agha 2006). Thus, the 250 µg ACTH test seems an 
appropriate diagnostic tool to exclude clinically significant hypoadrenalism, even though, 
definite conclusion, including a comparison with the ITT, would be desirable. 
In the mean time, glucagon stimulation test (GST, 1 mg glucagon s.c.) has been started to 
be used more frequently in the evaluation of the HPA axis (Simsek 2015, Leong 2001). 
Blood samples for measurement of cortisol were obtained 90, 120, 150, 180, 210, and 
240 min after glucagon injection. The cut-off Đoƌtisol leǀel ш500 nmol/L accepted as 
sufficient responses 
to ITT seems to reveal a low specificity in GST (Berg 2010). In different studies, it was 
demonstrated that the minimum peak cortisol response of an healthy individual could be 
as low as 200, 250, and 295 nmol to GST (Karaca 2011, Tanriverdi 2007) although the 
majority of healthy adults were demonstrated to have peak Đoƌtisol ƌespoŶses ш500 
nmol/L to GST (Rao 1987). It is likely too high and will likely misclassify many healthy 
adults as being adrenally insufficient. Thereby, as suggested by Berg et al., a lower 
cutpoint is likely required in order to avoid many false positives with regard to cortisol 
status during the glucagon test with the threshold of 277 nmol/L being more specify and 
sensitive (Berg 2010). The reproducibility of the GST seems to be about 88% in the 
evaluation of the HPA axis and GST may be a good alternative. In a recent study by Simsek 
et al., comparing ITT, low-dose ACTH test and GST with each other, it has been shown 
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that the peak cortisol responses to all three tests were found to be well correlated with 
each other. The concordance of all 3 tests was found to be only about 44–50% according 
to the cut-off level of 500 nmol whereas higher concordance was detected when new 
cutoff level for peak cortisol response were used. Consequently, any test can be used in 
the evaluation of the HPA axis, but cut-off levels for the insufficiency of HPA axis should 
be individualized for each test (Simsek 2015). Additionally, it has to be borne in mind that 
no test, including the ITT, classifies all subjects correctly while even healthy individuals 
might show abnormal values (Tanriverdi 2015, Arlt 2003, Mayenknecht 1998, Soule 2000, 
Nye 2001, Suliman 2002). Thus, in borderline cases, clinical judgment and careful follow-
up is crucial in the evaluation of HPA axis. 
 
TRH-TSH-thyroid axis 
 
In the appropriate clinical context, central hypothyroidism is easily diagnosed when the 
levels of free T4 are decreased and TSH levels are low or more often normal. Dynamic 
testing is generally not necessary as it does not add to diagnostic reliability. T3 is still 
normal in most cases (Ferretti 1999, Westwood 2000, Hartoft-Nielsen 2004, Mehta 2003). 
 
GnRH-LH/FSH-gonadal axis 
 
In both sexes. Before the diagnosis of GnRH-LH/FSH gonadal axis function, prolactin (PRL) 
excess should be excluded that may be present due to disturbed hypothalamic inhibition 
of prolactin release (Tanriverdi 2015, Ghigo 2005, Lamberts 1998, Snyder 2007). 
Hypogonadism in pre-peripubertal children does not show specific clinical symptoms until 
the onset of puberty. Then it usually presents with delayed or missing onset of puberty 
(Tanriverdi 2015, Mehta 2003, Schneider 2007). 
In a woman of premenopausal age who has pituitary or hypothalamic disease like 
TBI/SAH but normal menses, no tests of LH or FSH secretion are needed because a normal 
menstrual cycle is a more sensitive indicator of intact pituitary–gonadal function than any 
biochemical test. If a-, oligo-menorrhoea is present with low estradiol levels and 
inappropriately low/normal LH and FSH levels secondary hypogonadism in 
premenopausal women is diagnosed. In peri-post menopause, low LH/FSH levels shows 
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central hypogonadism (Figure 1, pag. 253) (Tanriverdi 2015, Ghigo 2005, Lamberts 1998, 
Snyder 2007). 
In man, LH deficiency can best be detected by measurement of the serum testosterone 
concentration. If it is repeatedly low at 8 to 10 AM and the LH concentration is not 
elevated, the patient has secondary hypogonadism. When the serum testosterone 
concentration is low, the serum LH concentration is usually within the normal range, but 
low compared with elevated values in primary hypogonadism. If fertility is an issue, the 
sperm count should be determined (Tanriverdi 2015, Ghigo 2005, Lamberts 1998, Snyder 
2007). 
Dynamic test, GnRH in particular, is generally not necessary in adults because it does not 
add greater diagnostic accuracy. GnRH test could be useful in adolescents when a 
differential diagnosis between hypogonadism and pubertal delay is cumbersome 
(Tanriverdi 2015, Lamberts 1998, Snyder 2007). 
 
Somatotroph axis 
 
The somatotroph (GH-IGF-I) axis needs to be evaluated by stimulation test, unless all 
other pituitary axes are deficient and insulin-like growth factor-1 (IGF-1) is low (Tanriverdi 
2015, Casanueva 2005, Molitch 2011). 
Some studies show that the evidence of low age-related IGF-I level could be diagnostic 
͚͚peƌ se͛͛ oŶlǇ if all otheƌ anterior pituitary hormone are already compromised (Hartman 
2002, Aimaretti 2003). Measurement of basal serum growth hormone concentration does 
not distinguish reliably between normal and subnormal growth hormone secretion in 
adults (Tanriverdi 2015, Aimaretti 1998, 1999, 2003, GHRS 2000). 
For the diagnosis of GH deficiency, the ITT and the GHRH+arginine test are now 
considered as the tests of choice with similar accuracy (Aimaretti 2003). 
For the ITT test a peak GH response levels lower than 3 µg/L indicate severe GH deficiency 
in adults (if hypoglycaemia is adequately reached) (Tanriverdi 2015, Simsek 2015, 
Aimaretti 2003). 
The GH releasing hormone plus arginine test (GHRH+ARG, 1 µg/kg GHRH iv as a bolus plus 
30 g arginine as an infusion over 30 min) is easy to perform, well tolerated, and has been 
shown to reliably detect severe GH deficiency in a lean adult population when a cut-off of 
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9 µg/L is used (Ghigo 1996, Aimaretti 1998). But, the GH response to GHRH+ARG, and to 
all known GH provocative stimuli, significantly declines with increasing body mass index in 
adults (Bonert 2004, Qu 2005); thus the use of cut-off non BMI-related in obese subjects 
causes a high percentage of false positive results (Arlt 2003). The study from Biller and 
coworkers, suggesting for the GHRH+ARG test a cut-off level of 4.2 µg/L is indicative for 
GH deficiency in obese subjects (Biller 2002). Similarly our group (Corneli 2005, 2007) 
using the Roc-analysis defined the BMI-dependent cut-off levels both in adults and in 
transition populations. The cut-off levels suggested for lean (BMI<25), overweight (BMI 
ш25–30), and oďese ;BMI ш30) adults subjects are 11.5; 8.0, and 4.1 µg/L, respectively 
(Corneli 2007). A GH peak below this limit is indicative of GH deficiency in the appropriate 
clinical context. Similar results, considering waist circumference instead of BMI was 
reached by Colao et al. in a collaborative recent study (Colao 2009). Moreover, it is known 
that the response of pituitary GH release as stimulated by multiple individual 
secretagogues is decreased in aging and elevated thyroid hormone concentrations. 
However, somministration of aƌgiŶiŶe eŶhaŶĐes GH‘H͛s stiŵulatoƌǇ effeĐt oŶ GH release 
in the elderly by fourfold, and evokes normal GH secretion acutely (Giustina 1995, 1998). 
Further, there is evidence in patients receiving chronic glucocorticoid treatment that 
arginine is able to normalize the GH response demonstrating that the stimulatory action 
of arginine and the inhibitory action of glucocorticoids on GH secretion are mediated by 
opposite effects on hypothalamic somatostatin tone (Giustina 1992). Another potent and 
validated provocative test is the GHRH+GH releasing peptide-6 test (Leong 2001, 
Aimaretti 1998). It has BMI-dependent cut-off (15 and 5 mcg/L for lean and obese with 
BMI >35 kg/m2, respectively) and possess a great accuracy in distinguish normal subjects 
from patients with GH deficiency (Popovic 2000, Kelestimur 2006). 
Unfortunately GHRH is no longer available in the United States. Other classical stimuli 
such as arginine alone, clonidine, L-DOPA, and the combination of arginine and L-DOPA 
are much weaker and therefore more likely to give false positive results and useless in 
adults patients (Aimaretti 2003). The glucagon test (GST) (1 mg glucagon im, GH 
measurements every 30 min until 240 min after administration) has been proposed as 
alternative because it is able to separate with a sensitivity and specifity of 100% between 
GH deficient and healthy subjects if a peak GH of 3 µg/L is considered (Molitch 2011, 
Gomez 2002). GST is a good alternative when GHRH is unavailable or there is 
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contraindication to ITT However, like the other tests, it is age- and BMIdependent 
(Giustina 1998) and more time-consuming than other stimulation tests (Hartoft-Nielsen 
2004) although revised cut-offs might be taken in consideration in the field of the 
diagnosis of GHD (Diri 2015). 
In all, for the diagnosis of adult GHD in TBI patients we need to consider that no test for 
the assessment of GH deficiency is totally reliable. The likelihood of GH deficiency in TBI 
patients increases with increasing numbers of additional pituitary axes deficiencies 
(Gasco 2012). 
 
Posterior pituitary 
 
Diabetes Insipidus (ADH deficiency) causes polyuria and polydipsia. Diabetes mellitus as a 
common cause of polyuria should be excluded. Diabetes insipidus is likely if polyuria (>40 
mL/kg body weight/day, >2500–3000 cc day) in combination with urine osmolality <300 
mOsm/kg and hypernatriaemia is present. It can be clearly manifested in the acute phase 
and requires treatment acutely. In case of normal plasma sodium levels, a water 
deprivation test will be necessary but it should be effected later (during a clinical stable 
patient phase and recovered). This should be done in an experienced center and signs of 
exsiccosis should be monitored closely. Generally, diabetes insipidus can be diagnosed if 
there is no clear increase in urine osmolality (maximum <700 mOsm/kg) or the ratio of 
peak urine to plasma osmolality is <2. Glucocorticoids may suppress ADH secretion and, 
thus, diabetes insipidus may be precipitated by glucocorticoid replacement (Tanriverdi 
2015, Arlt 2003, Gasco 2012, Moore 2003, Agha 2004, Rajaratnam 2003). 
 
Conclusions 
 
In conclusion, hypopituitarism is a common, potentially serious but treatable 
complication of TBI, and may also occur for a smaller but significant patient number 
affected by of SAH and IS. Increased level of awareness among physicians of all disciplines 
who are involved in the care of patients with TBI, SAH, and SI is required to identify 
affected cases and provide the appropriate and timely hormone therapy, which has the 
potential to improve recovery, rehabilitation, and quality of life for those patients. 
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Figures 
 
Figure 1. Screening recommendations for pituitary function after traumatic brain 
injury/stroke. 
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Abstract 
 
Background. Recent studies from national registries have described changing patterns in 
epidemiology of acromegaly. Our study used administrative databases to estimate 
prevalence and incidence of acromegaly in the Piedmont region, Italy. 
 
Methods. This retrospective study was conducted in Piedmont between 2012-2016 on 
administrative health databases for inpatients and outpatients of any age. Enrollees were 
iŶĐluded if шϮ Đlaiŵs ǁeƌe ideŶtified fƌoŵ the following databases: hospital records with 
acromegaly diagnosis code (ICD-9-CM: 253.0); exemptions from co-payment for 
acromegaly (code: 001); prescriptions of Octreotide LAR, Lanreotide Autogel, 
Pegvisomant, Pasireotide LAR; prescriptions of  pituitary MRI/CT scans.  
 
Results. 369 individuals (M=146, F=223) met our criteria. Overall incidence was 5.3 per 
million population per year (95% CI: 4.2-6.7), and prevalence was 83 cases per million 
inhabitants (95% CI: 75-92). Mean age was 50.9 years. Rates were lowest iŶ чϭϵ Ǉeaƌ olds 
and highest in middle aged individuals. Both incidence and prevalence were slightly 
higher among women (Rate Ratio: 1.08, Prevalence Ratio: 1.43). Age-specific incidence 
was similar between sexes up to 39 years and diverged thereafter, with an increasing 
trend recorded among men. Prevalence was higher in women aged 40-79 years, and 
increased continuously up to 79 years in both sexes. 
 
Conclusions. This is the first population-based study conducted in Italy to estimate 
epidemiology of acromegaly and results show a higher prevalence than previously 
reported. Although our algorithm requires proper validation, it potentially constitutes a 
comprehensive tool to describe the pattern of acromegaly. 
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Background 
 
Acromegaly is a rare entity resulting from a growth hormone (GH)-secreting pituitary 
adenoma (Melmed 2009). The presentation and initial diagnosis of acromegaly can be 
insidious and, despite the advances in this field, there are significant diagnostic delays 
that could prompt adverse sequelae and influence the long-term disease prognosis. 
Hence, a timely diagnosis is desirable. To increase awareness on the disease, the 
Endocrine Society guidelines advised to screen for acromegaly in patients with typical 
clinical manifestations as well as in those without somatic signs but who carry several 
typical comorbidities of acromegaly, like obstructive sleep apnea, type 2 diabetes 
mellitus, debilitating arthritis, carpal tunnel syndrome, hyperhidrosis, and arterial 
hypertension (Katznelson 2014). Similar recommendations were issued in the American 
Association of Clinical Endocrinologists (AACE) guidelines (Katznelson 2011). Another 
relevant issue is represented by therapeutic millstones. GH-secreting pituitary tumors 
display a high prevalence of macroadenomas, which reduces the likelihood of complete 
surgical cure and prompts persistent disease in over 60% of cases (Mestron 2004, Starke 
2013, Giustina 2014). In such instances, multimodal therapies are necessary. Because 
these diagnostic and prognostic factors impact on the health care systems, it is important 
that optimal knowledge exists on chronic care activities related to acromegaly, including 
epidemiology, therapeutics and practices. 
Most epidemiological data currently available are extracted from databases collected in 
specialized referral centers, whose catchment areas may not cover the whole population. 
Published estimates have suggested highly variable figures encompassing prevalence 
rates of 28-137 cases per million and annual incidence rates of 2-11 cases per million 
(Katznelson 2011, Giustina 2014, Alexander 1980, Bengtsson 1988, Ritchie 1990, Daly 
2006, Sesmilo 2013, Burton 2016, Dal 2016, Lavrentaki 2017). To improve accurateness in 
describing the patterns of acromegaly and their impact on healthcare systems (Lavrentaki 
2017), recent US studies have employed a novel analytical approach to derive estimates 
of acromegaly based on data from population healthcare databases and insurance claims 
(Burton 2016, Broder 2016, 2017). These recent epidemiological data collectively suggest 
that incidence and prevalence of acromegaly are rising (Burton 2016, Broder 2016). 
Uncertainty remains on whether this is the result of improved diagnostic tools, stricter 
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clinical surveillance or temporal changes in incidence rates. The aim of our study was to 
estimate the prevalence and incidence data on acromegaly from 2012 to 2016 in the 
Piedmont region through the analysis of routinely collected administrative data.  
 
Methods 
 
Data source 
 
A retrospective cohort study was conducted using the Administrative Health Databases 
(AHDs) of Piedmont Region (about 4.400.000 inhabitants, corresponding to 7.5% of the 
national population), from January 1st, 2012 to December 31st, 2016. Data were obtained 
from four different databases consisting of: a) Drug Claims Registry, including records of 
all outpatient drug prescriptions reimbursable by the National Health Service (NHS); b) 
Hospital Information System, including records of all hospital discharge forms (HDFs) from 
public or private hospitals, containing all clinical data related to hospital discharge and 
day surgeries; c) Co-payment Exemption Registry; d) Outpatient Specialist Service 
Information System, reporting records of endocrine visits and healthcare services related 
to the workup of acromegaly provided by the NHS (laboratory and medical tests, 
outpatient visits, neuro-imaging). These four databases can be linked through a unique 
identifier, which remains unchanged over time. The medical claims in HDFs included 
information on diagnoses reported according to the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis codes. Laboratory and 
radiological data included information reported according to the National Tariff 
Nomenclature (NTN) codes. 
 
Selection of cases 
 
Potential cases were defined as the subjects who had claims suggestive of acromegaly in 
at least two of the four databases during the study period. The claims taken into account 
were:  
1) Hospital discharge records with an acromegaly diagnosis code (ICD-9-CM: 253.0); 
2) Exemptions from co-payment for acromegaly (code: 001); 
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3) Prescriptions for any of the following medications: octreotide (ATC: H01CB02), 
lanreotide (ATC: H01CB03), pegvisomant (ATC: H01AX01), pasireotide (ATC: 
H01CB05); 
4) Prescriptions for any of the following radiological tests: facial bones nuclear 
magnetic resonance (NMR) (codes 88.91.3-88.91.4); cranial (sella turcica, orbit) 
computed tomography (CT) (codes 87.03-87.03.1).  
To further improve the specificity of our approach, we did not take into considerations 
drug prescriptions if:  
1) Patients had received less than three separate drug prescriptions for the 
treatment of acromegaly (occasional drug users); 
2) The medications were not long-acting release (LAR) formulations (octreotide LAR, 
lanreotide Autogel, pasireotide LAR); 
3) Patients taking octreotide or lanreotide had a hospitalization with a diagnosis 
different from acromegaly, among those for which there is an indication for the 
use these drugs, as reported in the summary of product characteristics (malignant 
neoplasms (ICD-9: 140-209; 230-239), liver disorders (ICD-9: 570-573), 
gastrointestinal bleeding (ICD-9: 578), esophageal varices (ICD-9: ϰϮͿ, CushiŶg͛s 
disease (ICD-9: 255; 255.0). 4) Patients had an exemption foƌ CushiŶg͛s disease 
(code: 032). 
 
Statistical analysis 
 
PatieŶts ǁeƌe stƌatified ďǇ age ;чϭϵ, ϮϬ-39, 40-59, 60-ϳϵ, aŶd шϴϬ ǇeaƌsͿ aŶd seǆ. 
Incidence was calculated by dividing the number of new acromegaly cases (i.e., no 
evidence of acromegaly during the two years prior to the index claim) by the size of the 
population total time at risk during each calendar year. Prevalence calculated by dividing 
the number with an acromegaly-related claim, during each calendar year or any time 
prior, by the total number of residents in Piedmont for the entire calendar year. Incidence 
and prevalence estimates were stratified by age decades and sex. Comparisons of 
incidence and prevalence between the two sexes were carried out estimating rate ratios 
and prevalence ratios.  Analyses were performed with the software Stata 12 (StataCorp, 
College Station, TX, USA). 
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Results 
 
In the period 2012-2016, we found 369 individuals in the Piedmont population, 146 males 
and 236 females, who met our combined criteria for diagnosis of acromegaly. Incident 
cases in the period 2014-2016 were 71, of whom 33 were men and 38 were women. 
Mean age was 50.9 years. The observed number of cases translated into an incidence of 
5.3 per million per person year (py) (95% CI: 4.2-6.7) and a prevalence of 83 per million 
inhabitants (95% CI: 75-92) (Table 1, pag. 263). When the index cases were stratified by 
sex, both the incidence and the prevalence were slightly higher among women. 
Compared to men, the Rate Ratio of women was 1.08 (95% CI: 0.67-1.72), while the 
Prevalence Ratio was 1.43 (95% CI: 1.16-1.76). Rates were lowest among subjects with 
less than 19 years old. Age-specific incidence rates were similar in the two sexes up to the 
age of 39 years but seemed to diverge thereafter, with an increasing trend recorded 
among men as compared to women (Figure 1, pag. 264). Prevalence increased in both 
sexes continuously up to 79 years of age, and markedly decreased thereafter. Prevalence 
of acromegaly was substantially higher in women than men between 40 and 80 years of 
age (Figure 2, pag. 265). 
 
Discussion 
 
This is the first population-based study conducted in Italy to estimate the prevalence and 
incidence of acromegaly in a geographically defined population without apparent 
limitations related to catchment area and referral practice. In order to do so, we 
developed an algorithm that identifies acromegaly cases combining information from four 
different administrative databases. This approach is similar to that adopted by Burton et 
al. (Burton 2016) and Broder et al. (Broder 2016), who used two large health insurance 
databases to estimate the incidence of acromegaly in the US. In addition to medical and 
pharmacy claims, however, our algorithm takes also advantage from information included 
the registry of co-payment exemption and hospital discharge records, two reliable 
sources of data that have been previously used for epidemiological research in Italy. Our 
study showed an overall incidence of acromegaly of 5.3 cases per million py, while the 
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prevalence was 83 cases per million inhabitants. While the incidence of acromegaly here 
reported is comprised within the highly variable range of 1.9-7.7 cases per million py 
found in European studies (Bengtsson 1988, Dal 2016, Sesmilo 2010, Bex 2007, Reincke 
2006, Tjörnstrand 2014, Arnardottir 2014, Hoskuldsdottir 2015, Agustsson 2015), two 
recent US surveys have reported a higher incidence rate corresponding to 9.6-11.7 cases 
per million py (Burton 2016, Broder 2016). The discrepancy between these and our 
estimates suggests potential differences in study methodologies, and the implicit 
possibility that acromegaly incidence may differ across the world. Mean age at the 
diagnosis of acromegaly was 50.9 years, we observed a trend toward an increased 
incidence with increasing age, which is aligned with recent reports (Lavrentaki 2017). 
Although the overall incidence was similar between sexes, an age-specific analysis 
showed trends of incidence were similar between sexes up to the age of 39 years but 
slightly increased in men thereafter, as compared to women. These results are consistent 
with those obtained in the Swedish Pituitary Registry, which displayed an increasing trend 
for men and a decreasing one for women after the age of 35 years (Tjörnstrand 2014).  
With regard to prevalence rates, we observed an age-dependent increase in both sexes, 
leading to a prevalence peak in the age group 60-79 years. The prevalence of 83 cases per 
million inhabitants found herein is higher than that of 60 cases per million recorded in a 
large Italian survey (Arosio 2012), as well as that obtained in other retrospective 
European studies (Katznelson 2011, Bex 2007). However, our estimates parallel the 
prevalence rates documented in more recent surveys (Burton 2016, Dal 2016, Broder 
2016), suggesting that the use of combined database could improve the description of 
prevalence figures. Of note, a recent Icelandic survey suggested that prevalence could 
actually be underestimated, reaching in such study a rate of 121 cases per million py 
(Hoskuldsdottir 2015). Our study also showed a higher prevalence of acromegaly in 
women compared to men up to the age of 80 years, whereas the opposite was 
documented thereafter.  
It is still a matter of debate whether incidence rates of acromegaly are increasing over 
time, and whether this is a real phenomenon or it is rather attributable to improved 
diagnostic techniques and disease awareness. Likely, the development of sensitive 
immunoassays for measuring GH and IGF-1 levels, as well as the widespread use of MRI 
for detecting small pituitary tumors, has increased the number of diagnoses of 
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acromegaly over time (Ribeiro-Oliveira 2012). In fact, many of the earlier studies were 
performed when neuroimaging technology could only allow the identification of large 
tumors, while highest resolution and vast use of MRI now enables identification of 
pituitary masses that, previously, would have been too small to detect (Heitkamp 2014). 
For this reason, incidentally discovered pituitary mass can be now identified in patients 
undergoing neuroimaging for unexplained headache, head injury workup, sinus disease, 
cervical spine disease, and vertigo. Once the diagnosis of pituitary mass is made, clinical 
evaluation often include complete assessment of pituitary function to uncover an 
otherwise clinically silent disease (Freda 2011). Also, current diagnostic criteria could have 
contributed to the increase of incidental diagnosis of acromegaly, as they no longer 
require anymore the presence of typical phenotypic features of acromegaly (Katznelson 
2014) or visible pituitary tumors on MRI (Lonser 2010). Finally, increased awareness of 
the condition and its early manifestations may also have contributed to the apparent 
increase in disease prevalence.  
Population-based design, definite regional enrollment, and multiple database sources are 
major strengths of our study. Results from this type of epidemiologic study are more 
generalizable than estimates derived from single-institution studies or case series 
(Lavrentaki 2017), and could compensate for the lack of national registries. Moreover, our 
study included all age groups, as compared to other capturing commercially-insured 
patients under the age of 65 years (Broder 2016). A limitation of using claims data to 
estimate disease incidence is the inability to know with certainty that the first diagnosis 
seen in the data represents the first clinical diagnosis of the condition. Moreover, this 
approach cannot provide information on time from diagnosis and disease status (e.g., 
active vs. inactive disease), as well as it lacks information on adenoma size, hormone 
levels, clinical stratification of subgroups, and cases of multiple endocrine neoplasia-1. 
Finally, but more importantly, our algorithm requires validation to constitute an effective 
tool.  
 
Conclusions 
 
In conclusion, this population-based study provides a novel method to estimate the 
incidence and prevalence rates of acromegaly at the population level. Current results are 
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consistent with the available literature on this topic and show a higher prevalence of 
acromegaly than previously reported. Even if our algorithm requires proper validation 
and larger assessments to detail the epidemiology of acromegaly in Italy, it could 
represent a comprehensive tool to describe the pattern of acromegaly, to assess its 
burden on patients and health care systems, and to provide guidance on resources 
allocation, especially in countries lacking national registries on acromegaly. Future 
developments include the assessment of time trends of the disease and the extension of 
the study to other Italian regions to evaluate geographical homogeneity. 
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Tables 
 
Table 1. Prevalence (period 2012-2016) and incidence (period 2014-2016) of acromegaly 
in Piedmont region (Italy), stratified by sex. Results expressed as cases per million 
inhabitants. 
 
 Men Women 
 N Point estimate (95% CI) N Point estimate (95% CI) 
Incidence 33 5.1 (3.6-7.2) 38 5.5 (4.0-7.6) 
Prevalence 146 68 (58-80) 223 97 (85-111) 
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Figures 
 
Figure 1. Incidence of acromegaly in Piedmont region (Italy) in the period 2014-2016, 
stratified by sex and age groups. 
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Figure 2. Prevalence of acromegaly in Piedmont region (Italy) in the period 2012-2016, 
stratified by sex and age groups. 
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VITAMIN D AND NEUROLOGICAL DISEASES 
 
Introduction 
 
Vitamin D is a secosteroid hormone typically associated with regulation of phosphocalcic 
homeostasis and osteogenesis (Kalueff 2007). The past decade was characterized by an 
increased number of publications which highlighted that vitamin D was not only 
associated with bone disease, but also with non-bone adverse health outcomes, including 
immunosuppression, cancer, infections, and cardiovascular diseases (Kalueff 2007, 
Zitterman 2003). These associations are related to the fact that vitamin D has multiple 
biological targets mediated by the vitamin D receptor (VDR) present in numerous cells 
(Kalueff 2007). 
Vitamin-D-related effects upon the central nervous system (CNS) have been described 
less than other target organs (Kalueff 2007), but it appears that vitamin D deficiency is 
associated with neurological dysfunction (Kalueff 2007, Zitterman 2003). 
 
This section aims to provide an endocrine overview on the relationship between vitamin 
D and neurological diseases.  
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Abstract 
 
Vitamin D system comprises hormone precursors, active metabolites, carriers, enzymes, 
and receptors involved in genomic and non-genomic effects. In addition to classical bone-
related effects, this system has also been shown to activate multiple molecular mediators 
and elicit many physiological functions. In vitro and in vivo studies have, in fact, 
iŶĐƌeasiŶglǇ foĐused oŶ the ͞ŶoŶ-ĐalĐeŵiĐ͟ aĐtioŶs of ǀitaŵiŶ D, ǁhiĐh aƌe assoĐiated 
with the maintenance of glucose homeostasis, cardiovascular morbidity, autoimmunity, 
inflammation, and cancer. In parallel, growing evidence has recognized that a multimodal 
association links vitamin D system to brain development, functions and diseases. With 
vitamin D deficiency reaching epidemic proportions worldwide, there is now concern that 
optimal levels of vitamin D in the bloodstream are also necessary to preserve the 
neurological development and protect the adult brain. The aim of this review is to 
highlight the relationship between vitamin D and neurological diseases. 
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Background 
 
The vitamin D system comprises steroid pro-hormones, their metabolites, carriers and 
enzymes involved in vitamin D metabolism (Norman 1998). Vitamin D occurs in nature as 
two main forms: vitamin D2 (ergocalciferol), which is photochemically synthesized in 
plants, and vitamin D3 (cholecalciferol), which is synthesized in the skin after exposure to 
sunlight,  in particular ultraviolet B radiation at an appropriate wavelength of 280–320 
nm. Vitamin D metabolism is complex and tightly regulated (Norman 1998). The classical 
synthetic vitamin D pathway involves sequential 25-hǇdƌoǆǇlatioŶ [Ϯϱ;OHͿD] aŶd ϭα-
hydroxylation [1,25(OH)2D] of vitamin D2 and D3 precursors in the liver and kidney, 
respectively.   Vitamin D metabolites circulate in the bloodstream as bound to the vitamin 
D binding protein (DBP). Vitamin D catabolism is mostly mediated by 24-hydroxylase 
(CYP24A1), which converts 1,25(OH)2D (calcitriol) in 1,24,25(OH)3D. This catabolite binds 
with significantly lower affinity the vitamin D receptor (VDR), and is further processed 
into excretion products (calcitroic acid). Classically, vitamin D has a recognized role in the 
regulation of bone health physiology and calcium-phosphorus homeostasis, by acting at 
the level of the skeletal bone, intestine and kidney. There is now consistent evidence 
shoǁiŶg that seǀeƌal ͞non-ĐalĐeŵiĐ͟ effeĐts of ǀitaŵiŶ D ŵetaďolites oĐĐuƌ iŶ ǀitƌo aŶd iŶ 
vivo, and increasing consideration is given to vitamin D status as a marker of general 
health, since low vitamin D levels are associated with the development and progress of 
autoimmunity, infectious diseases, diabetes mellitus, cardio-metabolic disorders, obesity, 
neuromuscular disorders, and cancer (Holick 2008). Vitamin D and its congeners yield 
both genomic and non-genomic actions. Genomic actions are mediated by the VDR, a 
member of the steroid hormone superfamily. The VDR is a nuclear receptor present in 
over 30 human tissues, which regulates approximately 3% of the human genome (i.e., 
about 700 genes) (Pertea 2010, Ramagopalan 2010, Pannu 2016). Nuclear VDRs are 
present in the majority of cells of the body and form the basis for the investigations in the 
extra-skeletal benefits of vitamin D. 
VDR, as well as 25-hǇdƌoǆǇlase aŶd ϭα-hydroxylase, the enzymes controlling vitamin D 
activation, along with 24-CYP24A1, the enzyme controlling vitamin D degradation, are 
expressed in the brain (Garcion 2002, Balden 2012, Eyles 2005). The main consequence is 
that the central nervous system (CNS) is able to synthesize its own vitamin D, which yields 
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auto- or paracrine neurosteroid actions at the local level (Eyles 2005). Neurons and glial 
cells, particularly in the temporal, cingulate, and orbital cortices and in the thalamus, 
ŶuĐleus aĐĐuŵďeŶs, stƌia teƌŵiŶalis, aŶd aŵǇgdala, eǆpƌess the VD‘ aŶd ϭα-hydroxylase 
(Kalueff 2007). The distƌiďutioŶ of the VD‘ aŶd ϭα-hydroxylase has also been investigated 
in the adult human brain, and is similar to that found in the rat (Eyles 2005). Calcitriol-
ligand binding to VDR allows heterodimerization with retinoid X receptor (RXR) and its 
ligand (9-cis-retinoic acid), then the VDR/RXR complex binds specific sequences in the 
promoter region of vitamin D responsive genes (vitamin D response elements; VDREs). 
Vitamin D actions on brain development involve effects on cellular proliferation, 
differentiation, calcium signalling, neurotrophism and neuroprotection. It also appears 
that vitamin D plays a role in neurotransmission and synaptic plasticity,  and a link has 
been described between vitamin D and dopaminergic neurotransmission (Cui 2010, Cui 
2013, Kesby 2010). Collectively, the physiological effects of vitamin D in brain functions 
include the promotion of neurotransmission, neurogenesis, synaptogenesis, amyloid 
clearance and the prevention of neuronal death. It is, thus, not surprising that 
observational studies have documented associations between higher serum vitamin D 
concentrations and healthier cognitive performance (Annweiler 2016). 
Another recent field of interest regards VDR gene polymorphisms. Preliminary data 
suggest that single nucleotide polymorphisms (SNPs) in the VDR gene may have roles in 
the development of multiple sclerosis, PaƌkiŶsoŶ͛s disease, aŶd Alzheiŵeƌ͛s disease 
(Tizaoui 2015, Lee 2014). However, recent results on the association between VDR gene 
polymorphisms and different neurological diseases are somewhat contradictory, and the 
role of VDR in the aetiology of neurological diseases is still uncertain. Further 
investigations are needed to obtain more definitive results. 
More than 85% of circulating 25(OH)D and 1,25(OH)2D, the bioactive metabolite of 
vitamin D, are tightly bound to the DBP, which circulates in molar excess with respects to 
its ligands. As little as 5% of all circulating DBP is bound to vitamin D metabolites. DBP can 
also bind globular actin (G-actin) with high affinity and sequesters G-actin released into 
the ĐiƌĐulatioŶ upoŶ tissue/Đell daŵage oƌ ŶeĐƌosis, thus paƌtiĐipatiŶg to the oƌgaŶisŵ͛s 
actin scavenging system (Meier 2006). This peculiar action confers DBP a vital role, since 
circulating free G-actin polymerization into long filaments can initiate disseminated 
intravascular coagulation (DIC) if not rapidly cleared. DBP also intervenes to regulate the 
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chemotactic activity of complement 5a (C5a), and it partakes in the inflammatory cascade 
as a precursor of macrophage activation factor (MAF), which originates from DBP through 
modifications of the glycosylated residues (Nagasawa 2005). The ͞fƌee hormone 
hǇpothesis͟ iŶfeƌs that DBP ǁoƌks as a ƌeseƌǀoiƌ aŶd deliǀeƌǇ sǇsteŵ foƌ fƌee ǀitaŵiŶ D 
metabolites to target tissues at the cellular level (Nagasawa 2005). The free hormone 
hypothesis states that the biological activity of a given hormone is affected by its 
unbound, rather than protein-bound, concentration in the plasma. It has been suggested 
that the free hormone hypothesis could exist occur even if tissue uptake is caused by a 
mechanism involving one or more circulating protein-bound pools of hormone, as well as 
for the hydroxylated metabolites of vitamin D. Nevertheless, endocytic receptors have 
also been identified which are capable of transporting DBP-vitamin D complexes inside 
the target cells (Mendel 1989), and are reckoned as essential for the renal metabolism of 
vitamin D. Of note, DBP-dependent transport mechanisms are also thought to contribute 
to vitamin D access to the CNS (Smolder 2011). Given the multifaceted activities of DBP, 
an alteration of its circulating levels may impact pathophysiology in different ways, one of 
which could imply modifications of vitamin D bioavailability. 
Non-genomic actions of vitamin D have been discovered in many systems, and only 
recently they have been identified in the brain (Cui 2017). Non-genomic pathways 
cooperate with the classical genomic pathway to trans-activate the VDR and exert the 
effects of calcitriol. Non-genomic signalling is rapid, does not depend on transcription and 
may indirectly affect transcription via cross-talk with other signalling pathway. Data 
suggest that non-genomic actions of vitamin D occur at the plasma membrane level and 
involve a non-classical membrane-associated receptor, and a calcitriol-membrane-
associated rapid response steroid binding protein (1,25-MARRS) (Norman 2006, Nemere 
2004). Also, non-genomic actions of calcitriol induce calcium translocation across 
intestinal membranes, and calcitriol binding to membrane receptor activates signalling 
cascades leading to an increase in intracellular calcium flux via opening of voltage-gated 
calcium channels. This may, in turn, activate other growth regulatory pathways (e.g., rat 
sarcoma family of GTPases (RAS), murine leukemia viral oncogene (Raf)-1, mitogen-
activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK), as described 
in skeletal muscle cells). Moreover, ERK can enhance transcriptional activity of the VDR 
and non-genomic activation of protein kinase C (PKC) may stabilize VDR via 
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phosphorylation (Morelli 2001, Wali 1990, Hsieh 1991). There is also evidence that 
1,25(OH)2D modulates l-type calcium channel (LTCC) functions, and these effects can 
influence neuronal function (Cui 2015), such as neuronal maturation during 
developmental stages and/or neuroprotection during adulthood (Zanatta 2012, Bigos 
2010). 
As summarized in Figure 1 (pag. 291), vitamin D deficiency has been mechanistically and 
clinically linked to neurological diseases and neuropsychological disorders, cognitive 
impairment and neurodegenerative diseases (Cui 2017, Groves 2014, FNB 1997, Luque-
Cordoba 2017, McGrath 2010, Vinkhuyzen 2016, Landel 2016). While vitamin D deficiency 
may act as a common risk factor (Groves 2014), it should be borne in mind that the origin 
of these disorders is often complex and involves both genetic and environmental causes. 
Interestingly, animal and human data have suggested that vitamin D status, particularly 
vitamin D deficiency, may intervene during adulthood to modulate the exacerbation of 
inherent brain disorders and/or impair the recovery from brain stressors (Groves 2014). It 
should be mentioned here that vitamin D deficiency has also been related to mood 
disorders and a number of psychiatric conditions. While some cross-sectional and 
epidemiologic studies have found that low levels of vitamin D are significantly associated 
with higher levels of depressive symptoms or with a depression diagnosis, data are 
currently argued for the lack of causality, that is, current evidence does not definitively 
demonstrate that vitamin D deficiency is a cause of or risk for developing depression nor 
that vitamin D is an effective therapy for depression. For these reasons, we reckon that 
this topic should be distinctly addressed in further reviews. 
One key aspect related to vitamin D homeostasis and neurological disorders is the role of 
vitamin D supplementation in 25(OH)D deficient patients. Results of clinical trials 
conducted in patients with neurological disorders have, so far, provided controversial 
findings (Cui 2017, Landel 2016, Avenell 2016, Dong 2016, Rautiainen 2016, Sanders 2016, 
Winzenberg 2016), and the potential confounding effect of baseline vitamin D status and 
supplementation doses exists. It is of note that interventional studies conducted in the 
general population treated with vitamin D have mostly focused on the relationship 
between achieved vitamin D levels and the prevention of falls and fractures (Dawson-
Hughes 1997, Chapuy 2002, Trivedi 2003, Sanders 2010). At present, the Institute of 
Medicine (Ross 2011) recommends attaining 25(OH)D concentrations ranging between 20 
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and 50 ng/mL during vitamin D supplementation, whereas the Endocrine Society, the 
International Osteoporosis Foundation, and the American Geriatric Society suggest that a 
minimum level of 30 ng/mL is needed to minimize the risk of falls and fracture in older 
adults (Holick 2011, Dawson-Hughes 2010, AGS 2014). For concentration purposes: to 
convert ng/mL to nmol/L: 1 ng/mL = 2.5 nmol/L; for dosing purposes: to convert mcg to 
IU: mcg/0.025 = IU. The Institute of Medicine systematic review also voiced concern for 
serum 25(OH)D concentrations above 50 ng/mL (Ross 2011). These concerns were based 
on an increased risk of fractures and certain types of cancer (pancreatic and prostate) in 
people receiving high dose vitamin D supplementation (Sanders 2010). In general, vitamin 
D should be supplemented to reach 25(OH)D level of at least 20 ng/mL, and a level of 30 
ng/mL is recommended by most guidelines (Holick 2011, Dawson-Hughes 2010, AGS 
2014). A critical 25(OH)D threshold of 200 ng/mL should be mandatorily avoided to 
reduce the risk of hypercalcemia and symptoms of vitamin D excess. Expectedly, the 
required dose of vitamin D supplements varies between individuals depending on 
baseline 25(OH)D level, seasonality, latitude, ethnicity, nutrition, adiposity, dosing and 
type of vitamin D analog used for supplementation (Mazahery 2015). The optimal 
approach for supplementation in the general population, and in patients with 
neurological diseases, has not been established yet. 
For many reasons, therefore, vitamin D supplementation in neurological diseases needs 
to be optimized in terms of dosing and timing to generate a therapeutic potential. Recent 
studies suggest that vitamin D supplementation doses should be individualized depending 
on baseline vitamin D status and responsiveness. The potentially interfering activity of 
factors such as adiposity, enzymes catalyzing the different pathways (Cui 2017, Groves 
2014, Luque-Cordoba 2017) and VDR genotypes should be appropriately addressed 
(Carlberg 2016). Large, randomized, well-controlled clinical trials are also awaited to 
provide evidence on the safety and tolerability of vitamin D as adjunct therapy. The aim 
of this review is to provide an unbiased overview on the relationship between vitamin D 
and neurological diseases. 
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Multiple Sclerosis and Vitamin D 
 
Multiple sclerosis (MS) is a debilitating slow progressive disorder of the central nervous 
system, which is characterized by axonal injury and demyelination in the spinal cord and 
brain. Although its etiology is unclear, it seems to be multifactorial, with dysregulation of 
the immune response, environmental factors and genetic determinants all playing a 
contributive role (Van Amerongen 2004). In fact, genetic, epidemiological and 
immunological studies showed that MS is an autoimmune disease (Ebers 1996, Oksenberg 
2001) influenced by environmental risk factors such as infections, cigarette smoking, 
obesity, and inadequate serum levels of vitamin D and/or its metabolites ;O͛GoƌŵaŶ 
2012, Pugliatti 2008, Ascherio 2007). Attention has been recently given to the study of 
the microbiome in MS and its relationship with environmental stressors (Van Amerongen 
2004, Tremlett 2017). Emerging cross-sectional, case-control studies have shown that 
microbiota composition differs between MS subjects and controls (Jangi 2016, Chen 
2016). Nevertheless, human studies supporting the role of microbiota in MS are still 
scarce. 
Of the environmental factors identified in association to MS risk and capable of 
influencing its clinical course, vitamin D is among the strongest and most consistently 
found in connection (Ascherio 2010, Simpson 2010, Ruina 2012, Munger 2006, Mowry 
2010). A direct relationship has been observed between latitude and the prevalence of 
MS, which suggests a role for UV radiation and vitamin D in MS development (Simpson 
2011). Other studies showed that the risk of MS decreases with increasing intake of 
vitamin D (Munger 2004), and serum 25(OH)D levels are significantly lower in patients 
with MS as compared to healthy controls (Mazdeh 2013). Genetic studies found a 
relationship between MS susceptibility and SNPs of enzymes genes relating to vitamin D 
metabolism, namely, CYP27B1 and CYP24A1 (Ramagopalan 2011, IMSGC 2011). Genome-
wide association studies have identified more than 100 non-human leucocyte antigen 
(HLA) genetic risk loci, many acting as cooperative networks. However, each of these 
individual loci exerts modest influence on MS risk, and major histocompatibility complex 
(MHC) remains the key susceptibility locus (Gourraud 2012). Other studies also focused 
on VDR gene polymorphisms in association with increased susceptibility to develop MS, 
or with modulation and progression of MS. As such, significant associations were 
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obtained for the VDR gene polymorphisms Bsm-I in a Japanese cohort, Apa-I in Japanese 
and Australian cohorts, and Taq-I in an Australian cohort (Fukazawa 1999, Niino 2000). 
Further, a trend for the polymorphism Fok-I was described in a UK cohort study (Partridge 
2004), while a Canadian study found no preferential transmission of Apa-I and Taq-1 from 
MS-affected parents to affected offspring, and no association between Taq-I 
polymorphism and MS was found in another UK study (Partridge 2004, Steckley 2000). 
Genetic data also suggest that vitamin D may act on the risk of MS by influencing the 
regulation of vitamin d-responsive genes involved in immunity, such as the HLA-DRB1* 
1501 allele, which has a highly conserved VDR responsive element in its promoter 
(Gourraud 2012, Agliardi 2011). 
Vitamin D influences the cytokine profile and the inflammasome (Smolders 2008). In vitro 
studies support the evidence that vitamin D prevents interleukin (IL) 2, IL12 and 
interferon-gamma production, as well as B cells production (Smolders 2008, Chen 2007, 
Meehan 2002). In addition, vitamin D negatively regulates TH17-mediated autoimmune 
diseases, one example of which is MS (Chang 2010). Activation of the VDR by vitamin D 
stimulates a shift from proinflammatory Th1 responses to anti-inflammatory Th2 
responses in brain (Smolders 2008). Proliferation suppression assays showed an 
association between high 25(OH)D levels and improved regulatory T cell function in 
patients with MS (Correale 2009, Smolders 2009). Interestingly, while the Epstein-Barr 
virus (EBV) infection appears to be a necessary (but insufficient) condition for adult MS to 
develop (Goodin 2009), low vitamin D could act on the immune response to EBV to 
increase the risk of MS (Holmoy 2008, Hayes 2008, Grant 2008). Therefore, a role for 
vitamin D in the immune regulation of MS is, for many reasons, biologically plausible. 
From a clinical viewpoint, several observations suggest a role for vitamin D in MS. 
Evidence relating MS to impaired vitamin D status is prompted by studies conducted both 
in children and adults from Australia (Van der Mei 2007), United States (Munger 2006, 
Mowry 2010, Mahon 2003, Nieves 1004, Weinstock-Guttman 2004) and Europe (Soilu-
Hanninen 2008). Common associations involve circulating 25(OH)D levels, geographic 
distribution of MS, bone mass density in MS patients, seasonal fluctuations of 25(OH)D, 
parameters of MS disease, MS births, MS course in pregnancy, and results of genetic 
analysis on the VDR. As such, a matched case-control study using neonatal dried blood 
spots samples from 521 patients with MS outlined an association between 25(OH)D levels 
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and MS risk as evaluated by odds ratios (ORs), showing a higher MS risk in individuals in 
the bottom 25(OH)D quintile compared to the top quintile (OR, 0.53), whereas a 25 
nmol/L increase in neonatal 25(OH)D resulted in a 30% reduced risk of MS (OR, 0.70) 
(Nielsen 2017). In a Finnish study on vitamin D levels in over 1000 pregnant women who 
were later diagnosed with MS and over 2000 comparable women without MS, a two-fold 
increased MS risk was found among vitamin D–deficient women compared with vitamin 
d-replete women, and each 50 nmol/L increase in vitamin D level was associated with a 
39% lower risk for MS (Munger 2017). Inversely, other studies failed to demonstrate 
direct associations between MS and vitamin D, whereas one study found low 25(OH)D in 
male but not female patients with MS (Orton 2008, Kimball 2007, Tuzun 2003). 
Sun exposure is, indeed, the most important predictor of vitamin D status. In 
retrospective studies, sun exposure during childhood and adolescence was associated 
with a lower risk of adult-onset MS (Van der Mei 2003, Kampman 2007, Islam 2007, 
Dalmay 2010), although these surveys are potentially challenged by the accuracy of recall. 
Studies in individuals migrating from the tropics to temperate regions before or during 
adolescence also found an increased risk of MS (Cabre 2007). Thus, it could be 
hypothesized that low sun exposure at young ages could impair vitamin D status, hence 
increase the risk of MS later in life. However, scant data on the link between 25(OH)D and 
MS exist in world regions where MS is extremely rare, such as peri-equatorial countries, 
Africa, and a few Asian regions. Evidence of vitamin D insufficiency in the rare cases of MS 
diagnosed in these regions would give strength to the hypothetical association between 
vitamin D status and MS. 
Brain imaging studies have shown that vitamin D influences the disease activity in 
patients with MS and relapse risk (Simpson 2010). In relapsing-remitting MS (RRMS), the 
severity of vitamin D insufficiency was related to higher levels of disability measured by 
the Expanded Disability Status Scale (EDSS), and was greater in patients with progressive 
forms of MS as compared with RRMS, suggesting that vitamin D status could have a 
prognostic value in MS (Van der Mei 2007, Smolders 2008). However, this link was not 
confirmed in other studies including fewer patients (Harandi 2012, Hatamian 2013). 
It is also interesting to reckon that some disproportion has been noticed in the 
female/male ratio of MS patients with relapse-onset disease (relapsing remitting (RR) and 
secondary progressive (SP)). An association between skin type and MS-related disability 
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has only been documented in female patients (Woolmore 2007), implying a gender-
related effect in vitamin D metabolism, while a rodent study found an association 
between dietary vitamin D and inhibition of severe experimental autoimmune 
encephalomyelitis (EAE) in female but not male mice (Spach 2005), suggesting a gender-
based difference in vitamin D responsiveness. Oppositely, a recent prospective study on 
101 patients and 107 controls followed during one year with 25(OH)D and 1,25(OH)2D 
measurements in summer and winter (Kragt 2009) documented no difference in vitamin 
D levels between groups, yet an association between high levels of 25(OH)D and lower 
incidence of MS and MS-related disability could only be observed in the female 
population. However, the processes relating to clinical manifestations of MS, such as 
inflammation, demyelination, axonal damage and repair mechanisms, is unequally 
distributed across patients and genders, therefore suggesting the intervention of 
interacting factors relating to the disease and response to treatments (Comabella 2014). 
Despite the extensive literature focusing on cerebro-spinal fluid (CSF) biomarkers in MS, 
only qualitative and quantitative biochemical methods have been used to assess 
intrathecal production of immunoglobulins (Axelsson 2013). Considering the multiple 
roles of DBP, which include actin sequestration and a range of less-defined roles in 
modulating immune and inflammatory responses (Meier 2006, Chun 2012), several 
studies have suggested a potential modulatory role for DBP in the development of MS 
(Qin 2008, Lehmensiek 2007, Stoop 2010, Ottervald 2010, Kroksveen 2012, Disanto 2010), 
although DBP results in CSF or plasma have generated discrepant results (Qin 2008, 
Ottervald 2010, Smolders 2013, Kulakowska 2008, Kulakowska 2010, Yang 2013, Rinaldi 
2015). Recently, Perga et al. proposed a novel biomolecular tool consisting of two 
isoforms of DBP and ApoE in CSF, which may aid monitoring the progression of MS (Perga 
2015). If validated in a larger population, this tool could provide insights on clinical 
management, treatment strategy and long-term prognosis of MS patients. Likewise, 
studies on DBP glycosylation and the activity of the enzymes involved in 
glycosylation/deglycosylation could assist researchers in deciphering the pathogenetic 
pathways associated with the onset, progression and response to treatments in MS 
patients. 
There are studies suggesting that vitamin D supplementation could be used 
therapeutically for subjects with MS or those at a risk for MS. The optimal approach for 
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vitamin D supplementation in the general population, and in patients with MS, has not 
been convincingly established, with controversies relating to dose, time and target levels 
of vitamin D treatment (Ross 2011, Holick 2011, Dawson-Hughes 2010, AGS 2014). The 
relationship between target vitamin D levels and modulation of the risk/progression of 
MS may differ from that used for skeletal health (Rosen 2011), and vitamin D 
supplementation trials in MS have shown inconclusive outcome results (Luque-Cordoba 
2017) due to the lack of long-term follow-up and methodological bias. Preliminary studies 
inferred that high-dose vitamin D supplementation is generally well tolerated in MS 
patients. Phase I and phase II trials using high-dose vitamin D3 supplementation have 
shown that patients with MS can tolerate doses as high as 20,000 IU daily for 12 weeks 
(Smolders 2010), as well as escalating doses of vitamin D3 up to 40,000 IU daily over 28 
weeks (Burton 2010), with barely detectable side effects. However, findings obtained in 
short-term studies await more definitive evidence to prove the safety of long-term, high-
dose vitamin D supplementation. Longer phase II or phase III randomized clinical trials 
(RCTs) are ongoing and will provide more evidence regarding the safety and tolerability of 
vitamin D as an adjunct therapy (Smolders 2011, Dorr 2012, Bhargava 2014). In a recent 
review, Pierrot-Deseilligny et al., (Pierrot-Deseilligny 2017) suggested a pragmatic and 
practical approach for vitamin D3 supplementation using moderate oral doses (between 
2000 and 4000 IU/day) for all types of MS patients, including pregnant women (Wagner 
2017). These authors underlined the advantages of supplementation doses: (1) the 
correction of vitamin D insufficiency existing in the great majority of MS patients, with 
25(OH)D serum levels thus increasing up to the currently recommended range (30–60 
ng/mL) (Pierrot-Deseilligny 2012); (2) the need to prevent osteoporosis, attenuate 
infections, as well as to improve non classical clinical outcomes (Pierrot-Deseilligny 2013) 
in patients with marked vitamin D deficiency; (3) the safety of a moderate 
supplementation in terms of hypercalcemia and other significant adverse events (Pierrot-
Deseilligny 2012, Hathcock 2007); (4) the control of inflammatory components of the 
disease. In temperate countries, the supplementation should never be stopped since 
there is no durable storage of this vitamin in the organism. However, analysis of vitamin D 
and its metabolites should be made prior to supplementation so as to monitor 
responsiveness to treatment at preset times after application (Luque-Cordoba 2017). 
 
279 
 
ParkiŶsoŶ’s Disease aŶd VitaŵiŶ D 
 
PaƌkiŶsoŶ͛s disease ;PDͿ is a pƌogƌessiǀe ŶeuƌodegeŶeƌatiǀe disease ĐhaƌaĐteƌized ďǇ 
slow, selective dopaminergic neuronal loss. Symptoms include dyskinesia, rigidity, and 
tremor, as well as postural instability and gait disorders (Bonnet 1999). Like for MS, 
vitamin D could play a key role in neurological disorders such as PD and dementia (Eyles 
2005, Prufer 1999). 
In the context of PD, potential neuroprotective effects exerted by vitamin D include the 
notion that 1,25(OH)2D indirectly inhibits the synthesis of nitric oxide, a free radical that 
can damage cells (Garcion 2002); secondly, it indirectly stimulates the synthesis of the 
antioxidant glutathione (Garcion 2002), and, thirdly, vitamin D may act as a neurotrophic 
factor, through the stimulation of nerve growth factor (NGF), glial cell line-derived 
neurotrophic factor (GDNF) and neurotrophin 3 (NT3) (Naveilhan 1996, Musiol 1997, 
Neveu 1994). 
Cross-sectional studies have linked vitamin D deficiency and PD incidence (Evatt 2008, 
Sato 2005). The first longitudinal study investigating the association between vitamin D 
status and risk of PD showed that low serum vitamin D levels predicted an elevated risk of 
PD (Knekt 2010), but such findings were not reproduced in a study published later 
(Shrestha 2016). A recent study by Fullard et al. evaluated vitamin D levels in a population 
at risk for developing PD, derived from The Parkinson Associated Risk Syndrome (PARS) 
study cohort. In particular, they found that vitamin D levels did not differ in the high-risk 
group when compared with age- and sex-matched controls, suggesting that sustained 
vitamin D insufficiency is not common before a diagnosis of PD (Fullard 2017). This is in 
line with another recent study of Larsson et al., which used Mendelian randomization 
approach to minimize confounding effects and prevent bias because of reverse causation. 
According to recent findings, their results showed no association between genetically-
predicted lower vitamin D concentration and PD (Larsson 2017). 
In patients with overt PD, however, it has been repeatedly demonstrated that serum 
25(OH)D is significantly lower than in healthy controls (Sato 2005, Topal 2010, Sato 1997, 
Abou-Raya 2009, Evatt 2011, Senel 2011, Van den Bos 2013), and serum 25(OH)D levels 
progressively decrease with increasing severity of PD (Sato 1997, Rimmelzwaan 2016, 
Ding 2013). Intuitively, this link could relate to the reduced sun exposure, hence the 
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dermal synthesis of vitamin D, in patients with progressive motor limitations, whereas no 
significant difference in vitamin D intake was found in patients versus controls (Miyake 
2011). When the relationship between serum 25(OH)D level and functional scores such as 
balance is accounted for, a study by Peterson et al. investigated this association using five 
tests (i.e., the motor control test, sensory organization test, sit and stand test, walk and 
turn test, and the unilateral stance eyes open and closed test) in 40 PD patients and 
showed a significant positive correlation between serum 25(OH)D and automatic postural 
responses (Peterson 2013). 
Interventional studies examined the correlation between vitamin D supplementation and 
PD outcomes. In particular, Suzuki and colleagues (Suzuki 2013) examined the impact of 
vitamin D supplementation (1200 IU per day for one year) on disease progression using 
various PD-related outcomes measured with the modified Hoehn & Yahr (H&Y) scale and 
the Unified Parkinson Disease Rating Scale (UPDRS). In a double-blind placebo-controlled 
trial on 104 patients with PD studied for 12 months, 56 PD patients received 1200 IU 
vitamin D per day and 58 received placebo. The authors found that those on placebo 
experienced worsening PD outcomes, while the deterioration was significantly milder in 
the vitamin D-supplemented group. Analysis of the VDR single nucleotide polymorphisms 
(SNPs) in these patients found that those bearing the FokI VDR genotype (rs10735810) TT 
allele had a more significant and consistent response to vitamin D supplementation than 
individuals with VDR FokI CT, while patients with FokI CC showed no significant effect of 
vitamin D supplementation compared to placebo. Alternatively, the effects of vitamin D 
were not influenced by other VDR variants, that is, rs1544410 (BsmI), rs731236 (TaqI), 
rs7975232 (ApaI), and rs11568820 (Cdx2) (Suzuki 2013). The role of other VDR 
polymorphisms has also been investigated in PD (Peterson 2013, Lin 2014, Han 2012, 
Torok 2013, Suzuki 2012, Tanaka 2017). The rs10735810 (FokI) C allele was present at 
significantly higher frequency in PD patients as compared to controls (Han 2012, Torok 
2013). In a study by Suzuki et al. in a Japanese population, the VDR variant FokI CC was 
associated with milder forms of PD (Suzuki 2012). Tanaka et al. found a significant inverse 
association between VDR SNP rs2228570 and the risk of PD, but this fell below 
significance after adjustment for multiple comparisons (Tanaka 2017). 
Based on the previous, additional studies are warranted to elucidate the effects of 
vitamin D on neuroprotection in PD. 
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Alzheiŵer’s Disease aŶd VitaŵiŶ D 
 
Alzheiŵeƌ͛s disease ;ADͿ is a ŶeuƌodegeŶeƌatiǀe disoƌdeƌ ĐhaƌaĐteƌized ďǇ pƌogƌessiǀe 
and irreversible cognitive deficits and behavioural alterations. Memory impairment and 
loss of spatial memory are hallmarks of the disease, and lead to complete incapacity and 
death within three to nine years since diagnosis (Querfurth 2010). At pathology, AD 
presents with amyloid-β ;AβͿ-rich plaques, neurofibrillary tangles (NFTs), synapse loss, 
and atrophy in brain areas associated with memory and executive functions (Jack 2005, 
Mosconi 2005, Selkoe 2001, Sperling 2011). Aging is a strong risk factor for AD (Perluigi 
2014, Sultana 2013). Other major risk factors for AD include gender, family history, 
genetics, and head trauma, low educational attainment and environmental factors. There 
is accumulating evidence suggesting a significant association between vitamin D and AD 
(Keeney 2015, Moretti 2017, Patel 2017, Littlejohns 2014). In vitro, vitamin D stimulates 
ŵaĐƌophages ǁhiĐh iŶĐƌease the ĐleaƌaŶĐe of Aβ plaƋues (Masoumi 2009, Mizwicki 
2012), reduces amyloid-induced cytotoxicity and apoptosis in primary cortical neurons 
(Dursun 2011), aŶd iŶflueŶĐes Aβ stiŵulatioŶ of iŶduĐed Ŷitric oxide synthase (iNOS), 
which contributes to modulate the inflammatory process related to AD (Dursun 2013). 
Recent genome-wide association studies have focused on the role of VDR polymorphism 
in late onset AD (LOAD) susceptibility (Gezen-Ak 2012). A decreased level of VDR mRNA 
has been reported in hippocampal region by analyzing postmortem AD brain (Sutherland 
1992). Alterations in VDR and 1,25-MARRS genes related to the action and metabolism of 
vitamin D result in the inefficient utilization of vitamin D, making neurons vulnerable to 
neurodegenerative changes (Dursun 2011, 2013, Gezen-Ak 2007, 2012, 2013). 
Associations have been found between AD, VDR gene polymorphisms and megalin to 
support this inference (Dursun 2013, Gezen-Ak 2007, 2011, 2012, 2013, Beydoun 2012). 
Recently, Gezen-Ak et al. focused on the creation of a condition that prevents the 
genomic or non-genomic actions of vitamin D by individually or collectively silencing the 
VDRs (VDR or protein disulfide isomerase A3 (PDIA3)/1,25-MARRS) in primary cortical 
neurons (Gezen-Ak 2011). Using this experimental model, an effect of VDRs disruption 
could be documented on proteins involved in secretases relating to amyloid pathology 
aŶd Aβ ϭ−ϰϮ pƌoduĐtioŶ (Gezen-Ak 2017). The authors then suggested that vitamin D and 
its receptors VDR and PDIA3 could play important roles in amyloid processing pathway 
282 
 
within neurons (Gezen-Ak 2017). The vitamin D carrier, DBP, was also identified at 
decreased levels upon plasma protein profiling of subjects with mild cognitive impairment 
and in AD patients, when compared to healthy controls (Muenchhoff 2015). In a study by 
MooŶ et al., the DBP ǁas fouŶd to iŶhiďit Aβ aggƌegatioŶ aŶd pƌeǀeŶt Aβ ŵediated Đell 
death in cultured hippocampal cells (Moon 2013). Both ŵoŶoŵeƌiĐ aŶd oligoŵeƌiĐ Aβ 
bound to DBP in a dose-depeŶdeŶt ŵaŶŶeƌ. FolloǁiŶg additioŶ of Aβ, DBP treatment 
ƌesulted iŶ ƌeduĐed sǇŶapse loss iŶ ŵouse hippoĐaŵpus aŶd ƌesĐued Aβ-induced memory 
deficits (Moon 2013). Collectively, these results suggest that impairment in vitamin D 
transport is present even at early stages of AD, namely, prior to development of 
dementia. Based on this evidence, it is feasible to hypothesize that AD might be the 
consequence of a hormonal imbalance in which the critical hormone is vitamin D. Vitamin 
D promotes neuroprotection in AD via regulating nerve growth factor and 
neurotransmitters (Brown 2003, Veenstra 1998), increasing the amyloid metabolism 
(Durk 2014, Ito 2011), imposing an anti-inflammatory action (Baeke 2010, Krishnan 2010) 
and promoting calcium homeostasis (Brewer 2001). With this emerging evidence, vitamin 
D has important roles as a neurosteroid in AD. 
Epidemiological studies outlined a strong correlation between deficiency of vitamin D and 
neurodegeneration associated with AD. As many as 70–90% AD patients are vitamin D 
deficient, and AD patients are the most vulnerable group to develop neurodegenerative 
disorder due to additive effect of Vitamin D deficiency along with aging factor (Durk 2014, 
Annweiler 2011, Bischoff-Ferrari 2012, Holick 2007). Although vitamin D status is a crucial 
but non-specific risk factor for AD (Annweiler 2015), Cui et al. suggested that specific 
͞ĐƌitiĐal ǁiŶdoǁs͟ ŵaǇ eǆist duƌiŶg ǁhiĐh ǀitaŵiŶ D defiĐieŶĐǇ ŵight ƌesult iŶ the ŵost 
detrimental brain outcomes. During these timeframes, vitamin D supplementation could 
be the most beneficial factor to prevent long-term damage to the brain (Cui 2015). A 
potential therapeutic window during which vitamin D might provide benefits to reduce 
the risk, or delay the onset, of AD could occur during the pre-clinical and mild cognitive 
impairment ages, wheŶ ŵeasuƌaďle ĐhaŶges iŶ gluĐose utilizatioŶ aŶd Aβ aĐĐuŵulatioŶ 
already occur (Etgen 2011). 
Llewellyn et al. showed an increased risk of losing points on the Mini-Mental State 
Examination (MMSE) in six years in 175 older adults with severe 25(OH)D deficiency (<10 
ng/mL) compared to 157 subjects with sufficient vitamin D (>30 ng/mL) (Annweiler 2011, 
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Llewellyn 2010). Slinin et al. followed up the association between lower 25(OH)D levels 
and cognitive decline in aged individuals (>65 years) for four years (Annweiler 2011, Slinin 
2010). A meta-analysis by Etgen et al. highlighted an increased risk of cognitive 
impairment in patients with vitamin D deficiency (Etgen 2012). Balion et al. compared 
mean MMSE scores with levels of 25(OH)D and showed higher average MMSE scores in 
those with higher 25(OH)D concentrations (Balion 2012). Further, in the Chianti study, a 
large prospective study on 858 adults, cognitive decline was associated with lower 
concentrations of vitamin D, when observed over a period of six years (Llewellyn 2010). 
The association between low vitamin D and increased risk of AD has been confirmed in 
other long-term studies (Annweiler 2012), and over 50% of published prospective studies 
showed an elevated risk of cognitive impairment after four to seven years of follow-up in 
participants with lower 25(OH)D levels compared with participants with higher 25(OH)D 
levels (Annweiler 2015). In parallel, an increased incidence of vitamin D deficiency has 
been documented in AD patients (Annweiler 2011, Balion 2012), while a seven-year 
follow-up study by Annweiler et al. found that higher dietary intake of vitamin D was 
associated with a lower risk of developing AD in older women (Annweiler 2012). Together, 
these studies suggested that low vitamin D poses a serious risk for AD development and 
progression. 
Interventional studies using vitamin D in combination with anti-AD drugs have shown 
fairly encouraging results. A recent six-month trial study by Annweiler et al. observed that 
the combination of memantine, a multi-target therapy for AD-related dementias (ADRD), 
and vitamin D elicited a superior effect than memantine or vitamin D alone in halting the 
cognitive decline among AD patients tested by MMSE (Annweiler 2012). The AD-IDEA trial 
(Annweiler 2011), a randomized placebo-controlled trial initiated in 2011 and completed 
in 2016, further investigated the effect of this combination therapy and awaits 
publication (Annweiler 2011). Fiala and Mizwicki (Fiala 2011) added further evidence that 
combined administration of vitamin D and docosahexaenoic acid (DHA) could enhance 
direct effects and immune protection of neurons against brain amyloidosis and other 
brain insults. As vitamin D targets various pathological processes of ADRDs, it may thus 
increase the effectiveness of standard anti-dementia treatments, or improve at least 
partially the resistance to these treatments. 
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Long-term randomized clinical trials of vitamin D supplements in large populations of 
middle-aged adults from different countries are warranted to study the conversion rate 
to mild cognitive impairment or AD outcome, with the most obvious question remaining 
whether optimizing vitamin D status will reduce the risk AD or be of therapeutic benefit 
following the onset of the disease. 
 
Neurocognitive Disease and Vitamin D 
 
Epidemiological studies outlined an association between 25(OH)D and parameters of 
cognitive function, such as memory, orientation and executive functions (Llewellyn 2009, 
Buell 2009, Lee 2009). Hypovitaminosis D is associated with altered domain-specific 
cognitive and executive functions, particularly information processing speed, mental 
shifting and working memory (Balion 2012), whereas the effect on episodic memory is 
milder (Balion 2012). These functions are required for the cognitive control of behavior 
and the execution of cognitive programs in real time, and are involved in high-level motor 
control (Beauchet 2012). In older adults living independently, low serum 25(OH)D 
concentrations were shown to be significantly associated with cognitive impairment 
(Peterson 2012). In addition, certain variants of human VDR gene are associate with 
increased risk of cognitive decline (Sutherland 1992, Gezen-Ak 2007). A study by Llewellyn 
et al. in 1766 older adults from the Health Survey for England 2000 described an inverse 
association between 25(OH)D levels and cognitive impairment (Llewellyn 2009), and 
patients with 25(OH) levels <20 ng/mL harboured a 230% higher risk of cognitive 
impairment when compared with those having 25(OH)D levels >20 ng/mL. The same 
group of authors showed that impairment of cognitive function during a three- and six-
year follow-up was greater in patients who were initially vitamin D deficient (Llewellyn 
2010). In fact, cognition scores measured by MMSE and Trail-Making Tests A and B were 
poorer in vitamin D-deficient subjects as compared to those whose vitamin D levels were 
sufficient. Having severe vitamin D deficit at baseline increased the likelihood of showing 
cognitive decline of executive functioning (measured by MMSE and Trail B) but not 
attention (measured by Trail A) at the six-year follow-up (Llewellyn 2010). Similar results 
have been obtained in a systematic review and meta-analysis (Balion 2012). Full evidence 
of a causal relationship between low vitamin D and cognitive impairment is far to be 
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demonstrated and the existence of this association has even been challenged in other 
studies (Slinin 2010, Balion 2012, McGrath 2007, Annweiler 2010). Nevertheless, some 
authors concluded that vitamin D deficiency in older adults is associated with dementia 
and that vitamin D supplementation might have a protective effect (Annweiler 2011, 
2012, 2013, Buell 2010, Barnard 2010). Importantly, systematic reviews and meta-
analyses carry several limitations while cross-sectional studies cannot provide causal links, 
that is, answer the question of whether vitamin D deficiency leads to cognitive decline or 
whether people with a cognition disorder have lower exposure to sunlight and/or lower 
vitamin D intake (Van der Schaft 2013). A recent systematic review by Sommer et al. 
evaluated the influence of vitamin D deficiency on dementia risk using longitudinal 
studies (Sommer 2017), and concluded that available findings were consistent with the 
hypothesis that low vitamin D levels could contribute to the development of dementia, 
although methodological issues should be taken in account, such as residual confounders, 
single vitamin D assessments, and sunlight exposure (Sommer 2017). 
Based on these potential links, it appears advisable that normal levels of vitamin D should 
be attained to confer potential protection against the risk and progression of AD. In older 
adults and AD patients, dietary vitamin D intake was associated with better cognitive 
performance (Annweiler 2010), and being in the highest quintile of vitamin D dietary 
intakes was associated with a lower risk of AD after seven years, when compared with the 
lower four quintiles combined (adjusted OR = 0.23; p = 0.007) (Annweiler 2012). This pro-
cognition effect was confirmed in before–after and non-randomized clinical trials on 
vitamin D supplementation, where improved cognitive performance was recorded in the 
older population as well as AD patients (Przybelski 2008, Annweiler 2012, Stein 2011). 
Short-term studies underscored the cognitive benefits elicited by four-week vitamin D 
supplementation (Przybelski 2008), with marked improvements in executive functions 
and information processing speed (Annweiler 2013). The administration of supra-
physiological doses, such as 7000 IU/day, seems to provide no additional benefit (Stein 
2011), while common supplementation dosages around 800–1200 IU/day appear to be 
sufficient and desirable (Annweiler 2013). Because confounding factors could influence 
cognition outcomes (Annweiler 2015), it remains crucial to conduct appropriately 
designed, randomized, placebo-controlled interventional trials to test the effectiveness 
of, and responsiveness to, vitamin D supplementation in AD, once the basal level of 
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vitamin D and other possible confounders are appropriately accounted for (Annweiler 
2016). 
 
Amyotrophic Lateral Sclerosis and Vitamin D 
 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the upper and 
lower human motor system, linked to abnormalities in the glutamate neurotransmitter 
system (Kiernan 2011). With familial ALS accounting for 5–10% of cases, 
neurodegeneration is a hallmark of ALS and results from the complex interaction between 
genetic and molecular pathways, encompassing glutamate excitoxicity, generation of free 
radicals, cytoplasmic protein aggregates, modifications of the superoxide dismutase 
(SOD1) enzymes activity, mitochondrial dysfunction, accumulation of intracellular 
calcium, all leading to disruption of axonal transport through accumulation of intracellular 
aggregates (Vucic 2009, Pasinelli 2006, Neusch 2007, Bruijn 1997, 1998). Challenging the 
͞ŶeuƌoĐeŶtƌiĐ͟ ǀieǁ of AL“, ƌeĐeŶt eǀideŶĐe suggests that ŶoŶ-neural cells such as 
microglia, astrocytes, peripheral blood mononuclear cells (PBMCs) and skeletal muscle 
fibers may partake in motor neuron degeneration and cooperate to exacerbate ALS 
(Pansarasa 2014). Genetic studies have identified several proteins linking vitamin D to 
ALS pathology: MHC class II molecules; toll-like receptors; poly(ADP-ribose) polymerase-1 
and calcium-binding proteins (Long 2013). Genome-wide analysis further identified a 
number of biologically relevant candidate genes with VDR-binding sites within or in close 
proximity (DeLuca 2013), and it has been shown that candidate genes involved in gene 
transcription associated with ALS signaling are modulated by 1,25(OH)2D (Tuohimaa 
2013). Altered calcium homeostasis appears to contribute significantly to selective 
neuronal injury in ALS, with the putative cause of vulnerability being the low levels of the 
calcium-binding proteins calbindin-D28K and of parvalbumin, which can be elevated by 
gene therapy and by vitamin D supplementation (Long 2013, Karam 2013, Gianforcaro 
2013). Calbindin-D28K is a 1,25(OH)2D-induced calcium-binding protein, and is stimulated 
at the protein and gene level by calcitriol in human syncytiotrophoblast cells (Halhali 
2010). Parvalbumin increases in the caudate putamen of rats with vitamin D 
hypervitaminosis (De Viragh 1989), suggesting a link between parvalbumin metabolism in 
the caudate putamen and vitamin D variations in the bloodstream. Also, the injection of 
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80–120 ng calcitriol in the cerebral ventricles of adult rats induced positive 
immunoreactivity for calcium binding proteins in ventral motor neurons (Alexianu 1998), 
implying a potential modulatory effect of calcitriol on the expression of calcium binding 
proteins in the motor system. In mice expressing ALS-linked mutated SOD1, an animal 
model of ALS, vitamin D intake increased muscle strength with no significant effect on 
lifespan (Gianforcaro 2013), whereas vitamin D3-deficient diet delayed disease onset but 
decreased motor performance (Solomon 2011). Treatment of rodent motor neurons with 
1,25(OH)2D promoted efficient binding and nuclear translocation of the VDR, exerted a 
neuroprotective effect against the motor neuron-restricted Fas death pathway, and acted 
by potentiating the trophic activity of neurotrophins (Camu 2014). 
Among the other effects of vitamin D on the proteome linked to ALS, vitamin D has been 
shown to upregulate VEGF by response element in the VEGF promoter, which may delay 
progression of ALS (Cardus 2009). In addition, vitamin D increases neurotrophic factors 
(Oppenheim 1996), and acts to promote the effectiveness of IGF-I by increasing 
expression of IGF-I receptors (Gomez 2006), which promotes survival and motor function 
parameters in SOD1 animals (Lepore 2007). Further, vitamin D exerts pro-differentiative, 
immunomodulatory and anti-inflammatory properties (e.g., by reducing tumor necrosis 
factor (TNF)-α, IL-1B, and cyclooxygenase (COX)-2), which could prove useful to control 
the expression of pro-inflammatory molecules linked to ALS progression (Papadimitriou 
2010, Szodoray 2008), as well as to partake in autophagy-based misfolded SOD1 
aggregates clearance (Von Essen 2010). A direct association has also been demonstrated 
between circulating parathyroid hormone (PTH), which increases in parallel with the 
severity of vitamin D deficiency, and the duration of ALS in males (Yanagihara 1984). 
Finally, the gene encoding DBP (group-specific component, Gc) is a key factor for 
regulating calcium homeostasis through the vitamin D endocrine system. As such, a 
proteomic study of Portuguese patients with familial ALS (FALS), not carrying SOD1 
mutations, isolated an isoform of DBP that was identified as GC2, which was absent in 
healthy controls, and noted a decrease of more acidic isoforms of DBP in FALS; 
collectively, these results suggest that GC2 polymorphism of DBP could constitute a risk 
factor for ALS (Palma 2008). 
An interaction also links vitamin D to muscle morphology and strength (Bischoff-Ferrari 
2012). The VDR is expressed in skeletal muscle and modulates 25(OH)D uptake in 
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myofibers (Girgis 2014) via the cell membrane receptor megalin, and DBP is retained in 
these cells by its specific binding to actin (Abboud 2013). Silencing of the VDR in mice is 
associated with smaller muscle fibres and persistent immature muscle-gene expression 
during adult life (Endo 2003). In C2C12 muscle cells, 25(OH)D and 1,25(OH)2D dose-
dependently exert an auto-regulatory loop to regulate the expression of genes related to 
proliferation, differentiation, and myotube size (Girgis 2014). Tracer studies and 
epidemiological investigations have described a relationship between 25(OH)D levels and 
parameters relating to muscle, such as lean body mass or exercise performance, leading 
to speculate that skeletal muscle cells could act as a reservoir of 25(OH)D capable of 
protecting it from liver uptake, degradation and excretion (Abboud 2013). In their meta-
analysis, Stockton et al. suggested that the beneficial effects of vitamin D on lower 
extremity muscle strength depended on baseline 25(OH)D levels <25 nmol/L, suggesting 
that vitamin D effects on muscle performance are more evident in individuals with lower 
initial 25(OH)D levels (Stockton 2011). Therefore, the association between vitamin D and 
muscle morphology and function could lead to hypothesize that vitamin D effects on the 
muscle contribute to ALS-related function scores (Paganoni 2017). 
These mechanistic associations notwithstanding, conflicting results from clinical studies 
exist on prevalence rates of vitamin D deficiency and the effect of vitamin D 
supplementation in ALS. Using mortality data, a geographic distribution of ALS with a 
northwest to southeast gradient was demonstrated in an American cohort (Sejvar 2005), 
a finding recently mirrored in a study showing higher ALS-associated death rates in more 
northern states (Uccelli 2007). An earlier study suggested a high prevalence of 
hypovitaminosis D in ALS patients (Sato 1997). A subsequent study investigating vitamin D 
levels in 37 consecutive ALS patients found that 81% had vitamin levels below the normal 
range (Karam 2013). In ALS patients, severe vitamin D deficiency was associated with 
four-fold increased rate of functional decline and significantly reduced survival 
expectancy (Camu 2014). In this study, there was an association between low vitamin D 
and a survival time in ALS patients, even after excluding non-ambulatory patients with 
vitamin D deficiency. In 71 sporadic ALS patients, 1,25(OH)2D levels were found 
significantly lower than in controls, with positive correlations between 1,25(OH)2D and 
both ALS functional rating scale (ALSFRS-R) and Manual Muscle Test scoring (MMT) 
(Cortese 2015). Moreover, the levels of 1,25(OH)2D levels were lower in spinal-onset ALS 
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compared to bulbar-onset ALS, and only in spinal-onset ALS 1,25(OH)2D levels positively 
correlated with functional scores and negatively with disease duration, suggesting that 
different impairment of vitamin D signaling pathways in cortical/spinal cord and bulbar 
motoneurons could explain different levels related to ALS site of symptoms onset 
(Cortese 2017). However, divergent conclusions were reached by other studies. In a small 
retrospective study in ALS and controls, lower than expected rates of vitamin D deficiency 
were observed in ALS, and there was a lack of relationship between vitamin D and clinical 
variables related to ALS (Libonati 2017). A prospective study evaluating vitamin D levels in 
106 ALS patients, half of whom were on riluzole, found low vitamin D levels in 69% of 
Đases ;<ϯϬ Ŷg/ŵLͿ, ǁith ϱϬ% falliŶg iŶto the ĐategoƌǇ of ͞iŶsuffiĐieŶt͟ Ϯϱ;OHͿD aŶd ϭϵ% 
ďeiŶg ͞defiĐieŶt͟ (Paganoni 2017). In this cohort, higher vitamin D was associated with 
higher concurrent gross motor ALSFRS-R scores at baseline. However, vitamin D failed to 
predict the future rate of disease progression, suggesting that low vitamin D may be a 
result rather than a cause of worse health in people with ALS, perhaps due to poor 
mobility and/or metabolic confounders (Paganoni 2017). In a study focused on the 
association of clinical disease outcome with bone metabolism, including serum 25(OH)D 
concentrations and bone mineral density, Yang et al. found that 34% of Korean ALS 
patients were severely vitamin D deficient (<10 ng/mL) and 81% were vitamin D deficient 
(<20 ng/mL); nevertheless, 25(OH)D concentration failed to predict survival, and older age 
at onset and bulbar onset were the most predictive factors for survival outcome (Yang 
2016). Emphasizing these contrasting findings even further, Blasco et al. reported that 
high-range vitamin D levels were correlated with a worse rather than with the improved 
prognosis in ALS patients (Blasco 2015). 
The effect of vitamin D supplementation on ALS progression has only been investigated in 
a few studies to date. Daily supplementation with 2000 IU of vitamin D for nine months to 
ALS patients improved the revised ALSFRS-R scores, such that 20 of these patients 
received vitamin D and their functional scores declined less rapidly than those patients 
who did not receive supplements (Karam 2013). Inversely, in their retrospective study 
Libonati et al. reported that cholecalciferol treatment for three and six months (loading 
dose of 100,000 IU every week for four weeks, then maintenance dose of 25,000 IU every 
15 days) did not improve clinical parameters compared to untreated ALS patients 
(Libonati 2017). 
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Based on these results, evidence to support a causative role for low vitamin D in ALS is 
weak, and low levels of vitamin D found in patients with ALS could depend on limited 
mobility, hence sun exposure, in ALS patients. The benefits of vitamin D supplementation 
in ALS patients remain to be elucidated. 
 
Conclusions 
 
Accumulating evidence suggests that vitamin D acts like a neurosteroid (Groves 2014) and 
is required for normal brain development and function (Garcion 2002, Balden 2012, Eyles 
2005, Kalueff 2007, Cui 2010, 2013, Kesby 2010, Groves 2014, McCann 2008). The 
association between low levels of 25(OH)D and a wide spectrum of neurodegenerative 
ĐoŶditioŶs suĐh as ŵultiple sĐleƌosis, Alzheiŵeƌ͛s disease, PaƌkiŶsoŶs͛s disease aŶd 
neurocognitive disorders, is supported by in vitro and in vivo data. Less convincing, on the 
other hand, appears to be the causative link between vitamin D deficiency and the onset, 
progression and clinical burden of amyotrophic lateral sclerosis. Regrettably, most studies 
conducted to date have not controlled for reverse causality, that is, low levels of vitamin 
D possibly being due to impaired mobility or sun-avoidance behavior. As such, there is a 
need for randomized clinical trials on vitamin D treatment in patients at risk of 
neurodegenerative disorders so as to optimize knowledge and precision on the efficiency 
of vitamin D congeners, appropriate dosing, and correct biochemical and clinical 
monitoring. A proper endocrine approach would suggest the use of vitamin D congeners 
related to optimal drug delivery through the brain blood barrier (Hajiluian 2017), using 
gradually increasing doses to avoid the risk of falls in frail populations (Bischoff-Ferrari 
2016). In view of the advantage that vitamin D supplementation is readily available and 
affordable, there is a need for further research in this field. 
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Figures 
 
Figure 1. Schematic overview of neurological disorders and their underlying mechanisms 
relating to impaired homeostasis of the vitamin D system. 
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CONCLUSIONS 
 
The studies reported in this thesis described the complex phenotypes and metabolic 
features of severe obesity and thyroid disorders, conveying to the study of the crosstalk 
between obesity and thyroid function. 
In particular, the data reported in chapter one depict the wide range of metabolic 
features and complications underlying the condition of severe obesity, as well as the 
effects of treatments used for obesity-related comorbidities (i.e., type 2 diabetes mellitus, 
dyslipidaemia) in modifying the metabolic pattern of these patients. 
The results illustrated in chapter 2 underline the fundamental role of metabolic mileau 
and inflammation related to insulin resistance in predisposing patients to the 
development of thyroid disorders and, in particular, thyroid cancer. In fact, the role of 
adipokines and insulin resistance as metabolic biomarkers in thyroid tumorigenesis 
appears very interesting due to their potential involvement in cell proliferation. 
Moreover, with the complexity of IR-related pathways, an array of molecules could 
represent novel therapeutic targets in health and disease. 
Chapter 3 reported new data on the attractive association between obesity and thyroid 
function. In particular, we demonstrated that fT4 levels appeared to be related to the 
overall metabolic phenotype of obese patients and that a short-term weight loss seems 
capable of reactivating the favorable relationship between REE and thyroid hormones in 
severe obesity, via interactions with fat-free mass. Moreover, our data showed that 
obesity has complex effects on the metabolic outcome of hypothyroid patients in 
replacement therapy, who required lower L-T4 doses compared to normal weight 
subjects. 
Finally, it is important to underline that the increased prevalence of obesity worldwide 
may further confound the definition of the normal TSH range in population studies. More 
research is necessary to investigate these aspects and to define the normal range of TSH 
in adult obese subjects. 
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FUTURE PERSPECTIVES 
 
ANGPTL8 and Irisin: new hormones involved in obesity and metabolism  
 
Background. The recently described myokine and adipokine, irisin has been proposed to 
be secreted upon exercise to promote the browning of beige fat cells in white adipose 
tissue that results in enhanced thermogenesis and increased energy expenditure. Initial 
studies suggested a potential role of irisin as treatment option for obesity and associated 
diseases such as type 2 diabetes mellitus (T2D) and stimulated further research. 
Betatrophin is a novel protein predominantly expressed in human liver. Increasing 
evidence has revealed an association between betatrophin expression and serum lipid 
profiles, particularly in patients with obesity or diabetes. However, its precise 
physiological role remains unclear at present. 
 
Aim of the study. The aim of this study is to investigate circulating irisin and ANGPTL8 
concentrations in obese patients stratified as metabolically healthy and unhealthy in 
comparison with lean subjects, in order to characterize their role in glyco-lipid 
metabolism and insulin resistance, hence their potential involvement in multiorgan 
damage process linked to hyperglycaemia of obesity. 
 
Methods. Due to recent controversies about circulating irisin including difficulties of its 
specific detection in human serum, we decided to evaluate firstly the expression of irisin 
by Western Blot. First of all, we detected irisin in serum using a specific antibody, that 
also is used in ELISA assay. The major problem faced in the analysis of human serum is the 
broad range of its protein constituents. So we decided to deplete the serum with 
albumin/IgG depletion kit and further analyzed depleted serum in Western immunoblot. 
In particular with Western Blot we immunodected irisin in human muscle protein, to 
confirm the real presence in muscle and in human serum. We detected a strong band 
around 25 kDa in these sample and also using recombinant irisin, to confirm the 
specificity of the antibody. 
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We enrolled 12 metabolically healthy (MHO) and 12 metabolically unhealthy obese 
subjects (MUO) with type 2 diabetes. These MHO and MUO subjects were comparable for 
anthropometric and body composition data. Biochemical parameters included glucose 
homestasis, lipid panel, adiponectin, leptin, and clinical analyses targeting organ damage. 
Betatrophin and irisin were analyzed using by ELISA. Patients enrolment for the 2 groups 
and lean controls is ongoing. 
 
Preliminary results. Circulating concentrations of irisin were higher in MUO than MHO, 
probably because irisin may act as an adaptive response to decrease insulin resistance. 
Circulating levels of betatrophin were significantly lower in MUO than MHO. The 
decreased levels of betatrophin would seem negatively related to hyperglycemia and to 
the degree of insulin resistance. Because of betatrophin inhibits LPL, and thereby 
suppresses triglyceride clearance and increases serum triglycerides, the decreased serum 
betatrophin levels in diabetes may play a role in explaining the hypertriglyceridemia in 
DMT2. 
 
Future perspectives. Previous studies provided controversial findings on serum irisin and 
betatrophin. We will evaluate their involvement in the development and progression of 
obesity-associated type 2 diabetes, and study the relation with parameters of adiposity, 
muscle mass and adipokines, organ damage, and the effect of short-term weight loss. We 
are currently extending research on irisin and betatrophin actions in obese adult patients 
with Prader Willi Syndrome. 
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Pilot study on metabolomic profiling of metabolically healthy and 
metabolically unhealthy obesity 
 
Background. While obesity is conventionally deemed as a risk factor for the development 
of the metabolic syndrome and its associated comorbidities, it is now recognized that 
individuals in the same BMI category can have substantial heterogeneity of metabolic 
features. Recent interest has focused on a unique subgroup of obese individuals 
described as ͞ŵetaďoliĐallǇ healthǇ oďesitǇ͟ ;MHOͿ, ǁho haǀe Ŷoƌŵal ŵetaďoliĐ featuƌes 
despite their increased adiposity. This trait has attracted growing interest in relation to 
the profiling of clinical determinants and long-term outcomes. Attention has recently 
focused on the metabolome as a tool to screen the complete metabolite composition of a 
system, such as a cell or an organism. In obesity, studies on the metabolome illustrated 
the chemical changes associated with adiposity and regional fat accumulation involving: 
abnormal metabolism of branched-chain and aromatic amino acids; fatty acid synthesis 
and oxidation, as well as serum phospholipids and their degree of saturation; compounds 
involved in carbohydrate metabolism such as fructose, glycerol and mannose; and 
compounds involved in nucleotide metabolism such as uridine. Evidence is also emerging 
from the study of the volatilome, the volatile chemical signature from individuals that is 
capable of providing invaluable information on the physiological status, can contribute to 
expand current knowledge on obesity traits and their trajectories. So far, several 
metabolites and volatiles associated with obesity have been thus identified and 
confirmed to be disturbed extensively in humans. It would be therefore of interest to 
differentiate the metabolomic profile and volatilome of MHO against ͞ŵetaďoliĐallǇ 
unhealthǇ oďesitǇ͟ MUHO to detail how these traits differ or overlap. 
 
Aim of the study. This is a study performed in collaboration with university of Turin and 
university of Nebraska. We aim to explore the metabolic fingerprint of obese patients 
stratified as metabolically healthy and unhealthy individuals. An effort will be made to 
obtain abdominal sc fat tissue biopsies. 
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Patients and Methods. Following a preliminary bio-anthopometric screening of a larger 
group of consecutive patients with severe obesity (BMI >40 kg/m2) admitted to our 
tertiary care center, 50 obese men will be enrolled and subdivided into equal groups of 
MHO and MUHO subjects. MHO subjects will be defined by normal values for all three 
risk factors. Individuals crossing the risk threshold for all three factors will meet ATPIII 
criteria for MUHO. Obesity is defined according to BMI status >30 kg/m2. A group of 
healthy lean subjects will be made available as control for subsequent comparative 
analyses. Obese study participants will undergo full-scale metabolic assessment at 
baseline incorporating: Biochemical analysis, urine analysis, 2h 5-point OGTT with 
determination of glucose, insulin and c-peptide, determination of leptin, adiponectin 
oligomers, irisin and lipasin (ELISA), body composition, indirect calorimetry for 
determination of REE and RQ. At the end of a 4 week diet plus exercise inpatient 
program, the previous assessment will be repeated with the exception of the OGTT. Both 
at study entry and end, participants will undergo withdrawal of plasma samples and 24h 
urine collection for the study of metabolome and volatilome, which will comprise low 
molecular-weight compounds that serve as substrates and products in metabolic 
pathways. 
 
Expected results. Based on the current analysis, future research will concentrate on 
identifying distinct patterns of metabolome and volatilome expression between the 
group of MUO and MUHO, to generate individual fingerprinting, which will be clustered 
according to individual clinical outcomes. Differences in individual fingerprints will be 
mapped to pathway graphs for better understanding of the parts of the pathway that are 
altered due to clinical health. 
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Molecular characterization and biological behaviour of thyroid 
microcarcinomas 
 
Background. The risk of loco-regional relapse and distant metastases of thyroid 
microcarcinomas (mPTC) is less than 2.5% and 0.3%, respectively. Neverthless, BRAF and 
TERT mutations, described in about 36% and 5% of mPTC respectively, seem to correlate 
with histopathological features of aggressiveness and higher risk of relapse. Among mPTC 
followed-up in our Department, we found a more aggressive behaviour with respect to 
literature, with relapse in 9.8% of cases, mainly loco-regional.  
 
Aim of the study. Our study aims are to evaluate the molecular and inflammatory profile 
of mPTCs in our population, and to correlate this profile with the clinical and hysto-
pathological characteristics.  
 
Methods. We retrospectively evaluate the cases of mPTCs followed in the Department of 
EŶdoĐƌiŶologǇ of the ͞Maggioƌe della Caƌità͟ UŶiǀeƌsitǇ Hospital iŶ Noǀaƌa fƌoŵ ϮϬϬϬ to 
2015. Preliminarily, we performed the molecular characterization on tissues of 49 cases, 
analyzing the presence of mutations of BRAF, TERT, NRAS and RET/PTC; moreover, we 
correlated these findings with clinical, histological and follow-up data.  
 
Preliminary results. In 32/49 cases we found one of the searched mutations; in particular, 
29/49 carried mutated-BRAF (28/29 V600E, 1/29 K601E), 2/49 carried the RET/PTC 
translocation and 1/49 TERT mutation. The presence of V600E BRAF mutation positively 
correlated with higher tumour size (p=0.03); RET/PTC trans location correlated with the 
presence of capsular invasion (p<0.05), higher tumour size (p<0.01) and with tumour 
associated thyroiditis (p=0.001). No significant statistical correlation was found between 
mutations and tumour relapse. 
Our preliminary data showed that the main mutation described in mPTCs were associated 
with aggressive histological characteristics, but they were not associated with higher risk 
of relapse, that appared more frequent in our population than in literature.  
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A larger cohorts and a wider molecular characterization will help to clarify the mutation 
associated with higher risk of malignancy and to recognize in a early stage those lesions 
needing for a more invasive treatment, avoiding the overtreatment of indolent lesions. 
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Thyroid function and obesity: a retrospective study in 5000 obese patients. 
 
Background. Obesity is associated with many endocrine dysfunctions, including thyroid 
disorders. An increased interest on the relationship between thyroid function and obesity 
occurred. In particular thyroid hormones are involved in the regulation of basal 
metabolism and thermogenesis, playing an important role in lipid and glucose 
metabolism, fat oxidation and food intake. Although thyroid function is usually normal in 
obese patients, several studies have demonstrated that TSH and BMI are positively 
related, in particular TSH levels are slightly increased (usually below 10 IU/l) in obese 
patients compared to normal weight people. The increased TSH levels could be due to 
hormone resistance. In fact, in obesity T3 receptors are decreased as well as the negative 
feedback between TSH and the peripheral thyroid hormones, leading to increased levels 
of TSH and T3. On the contrary the increase of both TSH and T3 may be an adaptation 
process to increase REE and energy expenditure. To date, studies investigating the 
relationship between obesity, its anthropometric or metabolic features and TSH have 
been investigated in small population samples. Likewise, population studies have 
conventionally included only small severely obese samples.  
 
Aim of the study. We aim to evaluate the relationship between anthropometric 
measures, biochemical parameters and serum thyroid hormones (TSH, fT4) 
concentrations in euthyroid obese subjects across the threshold of severe obesity, in 
order to characterize the modulators of thyroid function in condition of obesity. 
 
Methods. We retrospectively enrolled 5000 obese subjects (BMI > 30 Kg/m2) referred to 
the Division of General Medicine of San Giuseppe Hospital, Piancavallo from 1999 to 
2014. Patients͛ data were collected through retrospective medical records including 
gender, age, smoking status, biochemical analysis (TSH, fT4, glucose, insulin, AST, ALT, 
GGT and lipid panel), anthropometric data (weight, height, body mass index, waist and 
hip circumference, WHR), body composition parameters and calorimetric data. Patients 
with known thyroid disorders and/or under the use of levothyroxine or other medications 
that cause alterations in thyroid function were excluded. 
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Preliminary results. TSH levels in obese patients differ from those reported in the 
international literature for lean subjects (average TSH levels ranging between 1.49-1.79 
µU/mL), with a serum TSH that seems higher in the obese (mean ± SD: 2.1±1.2 µU/mL) 
In our obese population, the study of correlation coefficients showed that TSH levels were 
positively correlated with BMI (r=0.07, p<0.0001), fat mass (r=0.11, p<0.0001), total and 
HDL-cholesterol (r=0.04, p<0.01) and insulin levels (r=0.03, p<0.05), and negatively 
associated with age (r=-0.05, p<0.001), glucose levels (r=-0.05, p<0.001), lean mass (r=-
0.04, p<0.01) and resting energy expenditure (r=-0.05, p<0.001). 
FT4 levels were positively associated with glucose (r=0.03, p<0.05) and HDL-cholesterol 
(r=0.07, p<0.0001), whereas were negatively correlated with age (r=-0.04, p<0.01), BMI 
(r=-0.05, p<0.001), waist circumference (r=-0.06, p<0.0001), triglycerides (r=-0.06, 
p<0.0001) and lean mass (r=-0.04, p<0.01). 
Several studies demonstrated that TSH levels are at the upper limit of the normal range 
or slightly increased in obese children, adolescents, and adults, and they are positively 
correlated with BMI (Biondi 2010). TSH seems to be positively related to the degree of 
obesity. A positive correlation has been identified between serum leptin and serum TSH 
levels in obese individuals, which could reflect the positive association between TSH and 
BMI reported in some individuals. Leptin, adjusted for BMI, was found to correlate with 
TSH, which suggests that the increase in TSH and leptin levels in severe obesity could 
result from the increased amount of fat. Further statistical analyses are in progress. 
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